<SEC-DOCUMENT>0001193125-16-552040.txt : 20160422
<SEC-HEADER>0001193125-16-552040.hdr.sgml : 20160422
<ACCEPTANCE-DATETIME>20160422161309
ACCESSION NUMBER:		0001193125-16-552040
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160531
FILED AS OF DATE:		20160422
DATE AS OF CHANGE:		20160422
EFFECTIVENESS DATE:		20160422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		161586851

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d121496ddef14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Proxy Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section&nbsp;14(a) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities
Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed by the Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed by a Party other than the Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary Proxy Statement</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Proxy Statement</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Additional Materials</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting Material Pursuant to &#167;240.14a-12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></FONT></P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Name of Registrant as
Specified In Its Charter) </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy
Statement if Other Than the Registrant) </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box) </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">No fee required.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title of each class of securities to which transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total fee paid:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee paid previously with preliminary materials.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px;page-break-before:always"></P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount Previously Paid:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filing Party:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date Filed:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2929 Seventh Street, Suite 100 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California 94710 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTICE OF 2016 ANNUAL MEETING OF STOCKHOLDERS
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>May&nbsp;31, 2016 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dear Stockholder: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You are cordially invited to attend the 2016 Annual Meeting of
Stockholders of Dynavax Technologies Corporation, a Delaware corporation, or the Company. The meeting will be held on May&nbsp;31, 2016, at 9:00 a.m. Pacific Time, at the Company&#146;s executive offices at 2929 Seventh Street, Suite 100, Berkeley,
California 94710 for the following purposes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To elect our nominees for Class I directors to hold office until the 2019 Annual Meeting of Stockholders or until their respective successors are duly elected and
qualified. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To amend and restate the Dynavax Technologies Corporation 2011 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock
authorized for issuance under the plan by 3,200,000, and to approve the award limits and other terms applicable to awards intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the Internal Revenue
Code. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To amend and restate the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for
issuance under the plan by 200,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To ratify the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31,
2016. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To conduct any other business properly brought before the meeting or any adjournment(s) thereof. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These items of business are more fully described in the Proxy Statement accompanying this Notice. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The record date for the 2016 Annual Meeting is April&nbsp;6, 2016. Only stockholders of record at the close of business on that date may
vote at the meeting or any adjournment thereof. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#146; Meeting to Be Held at 9:00
a.m., Pacific Time, on May&nbsp;31, 2016 at 2929 Seventh Street, Suite 100, Berkeley, California 94710. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The proxy
statement and annual report to stockholders </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>are available at http://investors.dynavax.com/annuals-proxies.cfm.
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Board of Directors recommends that you vote FOR the proposals identified above.
</B></FONT></P></div> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael S. Ostrach</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;22, 2016 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px; margin-left:2%;margin-right:2%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Your vote is very important, regardless of the number of shares you own. Whether or not
you expect to attend the meeting, please complete, date, sign and return the enclosed proxy as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) is
enclosed for your convenience. Even if you have voted by proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the
meeting, you must obtain a proxy issued in your name from that record holder. </B></FONT></P></div>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2929 Seventh Street, Suite 100 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California 94710 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROXY STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE 2016 ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;31, 2016 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why am I receiving these materials? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have sent you this proxy statement and the enclosed proxy card because the Board of Directors, or Board, of Dynavax Technologies Corporation, or the Company or Dynavax, or we or us, is soliciting your
proxy to vote at the 2016 Annual Meeting of Stockholders, or Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote your
shares. Instead, you may simply complete, sign and return the enclosed proxy card. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to mail this proxy statement and
accompanying proxy card on or about April&nbsp;26, 2016, to all stockholders of record entitled to vote at the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How do I
attend the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Annual Meeting will be held on May&nbsp;31, 2016 at 9:00 a.m. Pacific Time, at our
executive offices at 2929 Seventh Street, Suite 100, Berkeley, California 94710. Directions to the Annual Meeting may be found at <U>http://www.dynavax.com/contact</U>. Information on how to vote in person at the Annual Meeting is discussed below.
For admission to the Annual Meeting, stockholders may be asked to present proof of identification and a statement from their bank, broker or other nominee reflecting their beneficial ownership of our common stock as of April&nbsp;6, 2016, as well as
a proxy from the record holder to the stockholder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who can vote at the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only stockholders of record at the close of business on April&nbsp;6, 2016, will be entitled to vote at the Annual Meeting. On this record
date, there were 38,495,502 shares of common stock outstanding and entitled to vote. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares
Registered in Your Name </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If on April&nbsp;6, 2016, your shares were registered directly in your name with our transfer
agent, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to fill out and return the enclosed proxy card
to ensure your vote is counted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner: Shares Registered in the Name of a Broker or Bank </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If on April&nbsp;6, 2016, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other
similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of
record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. However, since
you are not the stockholder of record, you may not vote your shares in person at the Annual Meeting unless you request and obtain a valid proxy from your broker or other agent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What am I voting on? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are asking you to vote on five (5)&nbsp;proposals: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To elect our nominees for Class I directors to hold office until the 2019 Annual Meeting of Stockholders or until their respective successors are duly elected and
qualified. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To amend and restate the Dynavax Technologies Corporation 2011 Equity Incentive Plan (the &#147;2011 Plan&#148;) to, among other things, increase the aggregate number
of shares of common stock authorized for issuance under the 2011 Plan by 3,200,000, and to approve the award limits and other terms applicable to awards intended to qualify as &#147;performance-based compensation&#148; for purposes of
Section&nbsp;162(m) of the Internal Revenue Code. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To amend and restate the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan (the &#147;2014 ESPP&#148;) to increase the aggregate number of shares of
common stock authorized for issuance under the 2014 ESPP by 200,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in this proxy statement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To ratify the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31,
2016. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To conduct any other business properly brought before the meeting or any adjournment(s) thereof. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What if another matter is properly brought before the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on those
matters in accordance with her or his best judgment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How do I vote? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may either vote &#147;For&#148; all the nominees to the Board or you may &#147;Withhold&#148; your vote for any nominee you specify.
For each of the other matters to be voted on, you may vote &#147;For&#148; or &#147;Against&#148; or abstain from voting. The procedures for voting are fairly simple: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares Registered in Your Name </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a
stockholder of record, you may vote in person at the Annual Meeting or vote by proxy using the enclosed proxy card. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still
attend the Annual Meeting and vote in person even if you have already voted by proxy. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive. Directions to the Annual Meeting may be found at
<U>http://www.dynavax.com/contact</U>. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return
your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the telephone, simply follow the instructions on the enclosed proxy card. Voting by telephone has the same effect as voting by mail. You
may vote by telephone until 11:59 p.m., Eastern Time, May&nbsp;30, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the internet, simply follow the instructions on the enclosed proxy card. You may vote by using the internet until 11:59 p.m., Eastern
Time, May&nbsp;30, 2016. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner: Shares Registered in the Name of Broker or Bank </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a proxy card
and voting instructions with these proxy materials from that organization rather than from Dynavax. Simply complete and mail the proxy card to ensure that your vote is counted. To vote in person at the Annual Meeting, you must obtain a valid proxy
from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px; margin-left:2%;margin-right:2%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We provide internet proxy voting to allow you to vote your shares online, with
procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and
telephone companies. </B></FONT></P></div> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How many votes do I have? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On each matter to be voted upon, you have one vote for each share of common stock you own as of April&nbsp;6, 2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What happens if I do not vote? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares
Registered in Your Name </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a stockholder of record and do not vote by completing your proxy card, by
telephone, through the internet or in person at the Annual Meeting, your shares will not be voted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner:
Shares Registered in the Name of Broker or Bank </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a beneficial owner and do not instruct your broker, bank,
or other agent how to vote your shares, the question of whether your broker or nominee will still be able to vote your shares depends on whether the New York Stock Exchange, or NYSE, deems the particular proposal to be a &#147;routine&#148; matter.
Brokers and nominees can use their discretion to vote &#147;uninstructed&#148; shares with respect to matters that are considered to be &#147;routine,&#148; but not with respect to &#147;non-routine&#148; matters. Under the rules and interpretations
of the NYSE, &#147;non-routine&#148; matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation
(including any advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation), and certain corporate governance proposals, even if management-supported. Accordingly, your broker or nominee
may not vote your shares on Proposals 1, 2, 3 or 4 without your instructions, but may vote your shares on Proposal 5. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What if I return a
proxy card but do not make specific choices? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you return a signed and dated proxy card without marking any voting
selections, your shares will be voted: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 1: &#147;For&#148; election of our nominees for Class I directors. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 2: &#147;For&#148; the approval of an amendment and restatement of the 2011 Plan to, among other things, increase the aggregate number of shares of common
stock authorized for issuance under the 2011 Plan by 3,200,000, and the approval of the award limits and other terms applicable to awards intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the
Internal Revenue Code; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 3: &#147;For&#148; the approval of an amendment and restatement of the 2014 ESPP to increase the aggregate number of shares of common stock authorized for
issuance under the 2014 ESPP by 200,000; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 4: &#147;For&#148; the advisory approval of executive compensation; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 5: &#147;For&#148; ratification of the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for its
fiscal year ending December&nbsp;31, 2016. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any other matter is properly presented at the Annual Meeting, your proxyholder (one of
the individuals named on your proxy card) will vote your shares using his or her best judgment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who is paying for this proxy solicitation?
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will pay for the entire cost of soliciting proxies. In addition to mailing these proxy materials, our directors and
employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other
agents for the cost of forwarding proxy materials to beneficial owners. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What does it mean if I receive more than one proxy card?
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you receive more than one proxy card, your shares are registered in more than one name or are registered in different
accounts. Please complete, sign and return each proxy card to ensure that all of your shares are voted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Can I change my vote after
submitting my proxy? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are
the record holder of your shares, you may revoke your proxy in any one of three ways: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may submit another properly completed proxy card with a later date. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may send a timely written notice that you are revoking your proxy to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh
Street, Suite 100, Berkeley, California 94710. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may attend the Annual Meeting and vote in person. Simply attending the Annual Meeting will not, by itself, revoke your proxy.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your proxy card with the most recent date is the one that will be counted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>When are stockholder proposals due for next year&#146;s Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be considered for inclusion in next year&#146;s proxy materials, your proposal must be submitted in writing by December&nbsp;27, 2016,
to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710. However, if our 2017 Annual Meeting of Stockholders is not held between May&nbsp;1, 2017, and June&nbsp;30, 2017, then
the deadline will be a reasonable time before we begin to print and send our proxy materials. If you wish to submit a proposal that is not to be included in next year&#146;s proxy materials or nominate a director, you must do so no later than
April&nbsp;1, 2017, and no earlier than March&nbsp;2, 2017. However, if our 2017 Annual Meeting of Stockholders is not held between May&nbsp;1, 2017, and June&nbsp;30, 2017, then you must submit your proposal not less than 60 days nor more than 90
days prior to the time we send our proxy materials. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How are votes counted? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count, with respect to the
proposal to elect directors, votes &#147;For&#148; and &#147;Withhold&#148;; and, with respect to other proposals, votes &#147;For&#148; and &#147;Against,&#148; abstentions and broker non-votes. Abstentions will be counted towards the vote total
for each proposal, and will have the same effect as &#147;Against&#148; votes. Broker non-votes will not be counted towards the vote total for any proposal. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How many votes are needed to approve each proposal? </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 1, to elect our nominees for Class I directors, the three nominees receiving the most &#147;For&#148; votes from the holders of shares present
in person or represented by proxy and entitled to vote on the election of directors will be elected. Only votes &#147;For&#148; or &#147;Withhold&#148; will affect the outcome. If a nominee receives a greater number of &#147;Withhold&#148; votes
than &#147;For&#148; votes, such nominee will submit his or her offer of resignation for consideration by our Nominating and Corporate Governance Committee in accordance with our Majority Vote Policy discussed in more detail on page 68 of this proxy
statement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 2, to amend and restate the 2011 Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance
under the plan by 3,200,000, and to approve the award limits and other terms applicable to awards intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the Internal Revenue Code, must receive
&#147;For&#148; votes from the holders of a majority of shares present and cast either in person or by proxy at the meeting. If you return your proxy and select &#147;Abstain,&#148; it will have the same effect as an &#147;Against&#148; vote. Broker
non-votes will have no effect. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 3, to amend and restate the 2014 ESPP to increase the aggregate number of shares of common stock authorized for issuance under the plan by
200,000, must receive &#147;For&#148; votes from the holders of a majority of shares present and cast either in person or by proxy at the meeting. If you return your proxy and select &#147;Abstain,&#148; it will have the same effect as an
&#147;Against&#148; vote. Broker non-votes will have no effect. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 4, advisory approval of the compensation of the Company&#146;s named executive officers, will be considered to be approved if it receives
&#147;For&#148; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter. If you &#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. Broker
non-votes will have no effect. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 5, to ratify the selection of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for our fiscal
year ending December&nbsp;31, 2016, must receive &#147;For&#148; votes from the holders of a majority of shares present in person or by proxy and entitled to vote. If you &#147;Abstain&#148; from voting, it will have the same effect as an
&#147;Against&#148; vote. As Proposal 5 is considered a &#147;routine&#148; matter, we do not expect to receive any broker non-votes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What is the quorum requirement? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A quorum of stockholders is necessary to
hold a valid Annual Meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the Annual Meeting in person or represented by proxy. On the record date, there were
38,495,502 shares outstanding and entitled to vote. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your shares will be counted towards the quorum only if you submit a valid
proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the Annual Meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders of a
majority of shares present at the Annual Meeting in person or represented by proxy may adjourn the Annual Meeting to another date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How can
I find out the results of the voting at the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary voting results will be announced at the Annual
Meeting. Final voting results will be published in a current report on Form 8-K within four business days following the voting. If we are unable to obtain final results in that time, we will announce the preliminary results and subsequently file a
second current report on Form 8-K with the final results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What proxy materials are available on the internet? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2016 proxy statement and 2015 Annual Report on Form 10-K are available at http://investors.dynavax.com/annuals-proxies.cfm.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Householding of Proxy Materials </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Securities and Exchange Commission, or SEC, has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the
delivery requirements for Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to
as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. A number of brokers with account holders who are Dynavax stockholders will be &#147;householding&#148; our proxy materials. A single
set of Annual Meeting materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be
&#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#147;householding&#148; and
would prefer to receive a separate set of Annual Meeting materials, please notify your broker and we will promptly deliver to you a separate set of our Annual Meeting materials. Direct your written request to Dynavax Technologies Corporation,
Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710, (510)&nbsp;848-5100. Stockholders who currently receive multiple copies of the Annual Meeting materials at their addresses and would like to request
&#147;householding&#148; of their communications should contact their brokers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 1 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ELECTION OF DIRECTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board is divided into three classes, and each
class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the
number of directors, shall serve for the remainder of the full term of that class and until the director&#146;s successor is elected and qualified. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Board presently has nine members. There are three directors in the class whose term of office expires in 2016: Dennis A. Carson, M.D., Eddie Gray and Laura Brege, each of whom is a nominee for
director and currently a director of the Company. Dr.&nbsp;Carson was previously elected by the stockholders in 2013. Our Board elected Mr.&nbsp;Gray to the Board in May 2013 when he joined the Company as Chief Executive Officer upon recommendation
of our Nominating and Corporate Governance Committee, based on its review of his experience and qualifications. Our Board elected Ms.&nbsp;Brege to the Board in February 2015 upon recommendation of our Nominating and Corporate Governance Committee,
based on its review of her experience and qualifications. If each nominee is elected at the Annual Meeting, each of these nominees will serve until the 2019 Annual Meeting and until his or her successor is elected and has qualified, or, if sooner,
until the director&#146;s death, resignation or removal. There were two directors in attendance at our 2015 Annual Meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote
on the election of directors. The three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named
below. Although the election of directors at the Annual Meeting is uncontested and directors are elected by a plurality of votes cast, and we therefore anticipate that each of the named nominees for director will be elected at the Annual Meeting,
under our Corporate Governance Guidelines, any nominee for director is required to submit an offer of resignation for consideration by the Nominating and Corporate Governance Committee if such nominee for director (in an uncontested election)
receives a greater number of &#147;Withhold&#148; votes than &#147;For&#148; votes. In such case, the Nominating and Corporate Governance Committee will then consider all of the relevant facts and circumstances and recommend to the Board the action
to be taken with respect to such offer of resignation. For more information on this policy see the section entitled &#147;Corporate Governance.&#148; If any nominee becomes unavailable for election as a result of an unexpected occurrence, your
shares will be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected. Our Board has no reason to believe that any nominee will be unable to serve. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> E<SMALL>ACH</SMALL> N<SMALL>AMED</SMALL>
N<SMALL>OMINEE</SMALL>. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Set forth below is certain biographical information as of April&nbsp;6, 2016, for the nominees
and each person whose term as a director will continue after the Annual Meeting. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairperson of the Board</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer (&#147;CEO&#148;) and Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanley A. Plotkin, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> I D<SMALL>IRECTORS</SMALL> N<SMALL>OMINEES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dennis A. Carson, M.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Carson has been a member of our Board since December 1997. Dr.&nbsp;Carson is a noted researcher in the fields of autoimmune and
immunodeficiency diseases and is co-discoverer with Dr.&nbsp;Eyal Raz of the immunostimulatory sequences (ISS) that form the basis of our technology. He has played key roles in the founding of Vical, Inc., a gene therapy company, IDEC
Pharmaceuticals, a biopharmaceutical company, and Triangle Pharmaceuticals, a pharmaceutical company. Dr.&nbsp;Carson is former director of the Rebecca and John Moores Cancer Center at the University of California, San Diego and has been a professor
in the Department of Medicine at the University of California, San Diego since 1990. The Board believes that Dr.&nbsp;Carson&#146;s significant experience in research and development provides important insights for the strategy of the Company,
particularly with regard to scientific opportunities for development by the Company, and qualifies Dr.&nbsp;Carson to be nominated as a director. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the
Institute of Medicine, as well as the American Association for Cancer Research, the American Society for Clinical Investigation, the American Society of Hematology and the Association of American Physicians. He received his M.D. from Columbia
University and his B.A. from Haverford College. Dr.&nbsp;Carson completed his residency in internal medicine and a postdoctoral fellowship at the University of California, San Diego. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Eddie Gray &#150; CEO and Director </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gray joined Dynavax as Chief
Executive Officer and was appointed to our Board in May 2013. Most recently, Mr.&nbsp;Gray served as the President of Pharmaceuticals Europe and a member of the corporate executive team at GlaxoSmithKline plc (GSK) from 2008 until 2013 and as Senior
Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. Prior to the formation of GSK, Mr.&nbsp;Gray was with SmithKline Beecham from 1988 through 2000 serving in various positions of increasing responsibility, including
Vice President and Director of Anti-Infectives Marketing in the U.S., Vice President and Director of the Vaccines Business Unit in the U.S., and Vice President and General Manager of Pharmaceuticals in Canada. Our Board believes that
Mr.&nbsp;Gray&#146;s more than 30 years of pharmaceutical industry experience, including, most recently, as the President of Pharmaceuticals Europe at GSK, a leading pharmaceutical company, and other senior management roles at GSK and its
predecessor, where he was responsible for the launch, commercialization and strategic development of vaccines and other products, enables him to provide commercial and strategic leadership to the Company and qualifies Mr.&nbsp;Gray to be nominated
as a director. Mr.&nbsp;Gray received a Bachelor of Science degree in Chemistry and Management Studies from the University of London and an MBA from the Cranfield School of Management in the UK. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Laura Brege </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Brege has been a member of our Board since February 2015. Since September 2015, she has served as managing director of Cervantes
Life Science Partners, LLC, a consulting firm providing integrated business solutions to life sciences companies. She has over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. From
September 2012 to July 2015, Ms.&nbsp;Brege was President and Chief Executive Officer of Nodality Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality in 2012, Ms.&nbsp;Brege held several senior-level
positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 until 2012, including positions as Executive Vice President and Chief Operating Officer. While at Onyx she led multiple functions, including
commercialization, strategic planning, corporate development, and medical, scientific and government affairs. Prior to Onyx, Ms.&nbsp;Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage
financing for technology companies. Previously Ms.&nbsp;Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, where she helped build the company from an early stage R&amp;D company through commercial launch of a successful
cardiovascular product. Earlier in her career, she served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. She serves on the board of directors of the following public pharmaceutical companies: Acadia
Pharmaceuticals, Inc., Aratana Therapeutics, Inc., Pacira Pharmaceuticals, Inc. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and Portola Pharmaceuticals. During the past five years, Ms.&nbsp;Brege also served on the boards of directors of Angiotech Pharmaceuticals, Inc., a biotechnology company, and Delcath Systems,
Inc., a pharmaceutical company. Our Board believes that Ms.&nbsp;Brege&#146;s background in finance and management of biotechnology companies provides important strategic insights for the Board in setting strategy and reviewing the operations of the
Company, as well as qualifies Ms.&nbsp;Brege to be nominated as a director. Ms.&nbsp;Brege earned her undergraduate degrees from Ohio University (Honors Tutorial College) and her MBA degree from the University of Chicago. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> II D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL>
<SMALL>THE</SMALL> 2017 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Daniel L. Kisner, M.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Kisner has been a member of our Board since July 2010. From 2003 to 2010, Dr.&nbsp;Kisner served as a partner at Aberdare
Ventures and prior to that as President and CEO of Caliper Technologies, leading its evolution from a start-up focused on microfluidic lab-on-chip technology to a publicly traded, commercial organization. Prior to Caliper, he was the President and
Chief Operating Officer of Isis Pharmaceuticals, Inc., a biomedical pharmaceutical company. Previously, Dr.&nbsp;Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and
Development at SmithKline Beecham Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal
Medicine and Medical Oncology. Additionally, he is currently serving on the boards of Conatus Pharmaceuticals, Inc., a biotechnology company, Lpath, Inc., a biotechnology company and Zynerba Pharmaceuticals, a biotechnology company. Dr.&nbsp;Kisner
previously served as Chairman of the board for Tekmira Pharmaceuticals, a biopharmaceutical company, until March 2015. Our Board believes that Dr.&nbsp;Kisner&#146;s background with larger, complex technology-based organizations as well as his
significant experience with corporate transactions, including investing in venture-backed life science companies provides the Board with insights for setting strategy of the Company. He holds a B.A. from Rutgers University and an M.D. from
Georgetown University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Natale (&#147;Nat&#148;) Ricciardi </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ricciardi has been a member of our Board since June 2013. Mr.&nbsp;Ricciardi spent his entire 39-year career at Pfizer Inc., a biopharmaceutical company, retiring in 2011 as a member of the
Pfizer Executive Leadership Team. While holding the positions of President, Pfizer Global Manufacturing, and Senior Vice President of Pfizer Inc. from 2004 until 2011, Mr.&nbsp;Ricciardi was directly responsible for all of Pfizer&#146;s internal and
external supply organization, a global enterprise that grew to more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products. Mr.&nbsp;Ricciardi maintained
responsibility for global manufacturing activities from 2004 through 2011. Previously, from 1999 to 2004, he had oversight for Pfizer&#146;s U.S. manufacturing operations and from 1995 to 1999 was Vice President of Manufacturing for Pfizer&#146;s
Animal Health Group. Mr.&nbsp;Ricciardi served on the boards of the National Association of Manufacturers and Mediacom Communications Corporation until its privatization in 2011. He is currently a member of the board of the 21st Century Foundation
of The City College of New York. He is also on the Advisory Board of HealthCare Royalty Partners and the board of directors of Asterias Biotherapeutics, Inc., serving as Chair of the Compensation Committee and member of the Audit Committee, and
Rapid Micro Biosystems, Inc. Our Board believes Mr.&nbsp;Ricciardi&#146;s 39-year career at Pfizer Inc., a leading pharmaceutical company, including as a member of the Pfizer Executive Leadership Team and direct responsibility for all of
Pfizer&#146;s internal supply organization, including global manufacturing, provides the Board with insights for reviewing the operations of the Company. Mr.&nbsp;Ricciardi earned a degree in Chemical Engineering from The City College of New York
and an MBA in Finance and International Business from Fordham University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stanley A. Plotkin, M.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Plotkin has been a member of our Board since August 2005. Dr.&nbsp;Plotkin is Emeritus Professor of the University of
Pennsylvania. Until 1991, he was Professor of Pediatrics and Microbiology at the University of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Pennsylvania and Professor of Virology at the Wistar Institute and, at the same time, Director of Infectious Diseases and Senior Physician at the Children&#146;s Hospital of Philadelphia. In
1991, Dr.&nbsp;Plotkin left the University to join the vaccine manufacturer Pasteur-M&eacute;rieux-Connaught (today, Sanofi Pasteur), where for seven years he was Medical and Scientific Director, based at Marnes-la-Coquette, outside Paris. Until
2009, he was an Executive Advisor to Sanofi Pasteur. The Board believes that Dr.&nbsp;Plotkin&#146;s significant experience in development and manufacturing of vaccines provides significant insights for the strategy of the Company with respect to
key technical and operational issues in vaccine development. Dr.&nbsp;Plotkin&#146;s career included an internship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Children&#146;s Hospital of Philadelphia and the Hospital
for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the U.S. Public Health Service. He has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American
Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> III D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL>
<SMALL>THE</SMALL> 2018 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Arnold L. Oronsky, Ph.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Oronsky has been a member of our Board since November 1996 and became Chairman in February 2006. Dr.&nbsp;Oronsky has been a
managing director with InterWest Partners, a venture capital firm, since 2009. Prior to joining InterWest Partners in 1994, Dr.&nbsp;Oronsky was Vice President of Discovery Research for the Lederle Laboratories division of American Cyanamid, a
pharmaceutical company. From 1973 until 1976, Dr.&nbsp;Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr.&nbsp;Oronsky also serves as a senior lecturer in the Department of
Medicine at The Johns Hopkins Medical School. Dr.&nbsp;Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr.&nbsp;Oronsky currently serves on the boards of directors of Tesaro, Inc., an oncology-focused
biopharmaceutical company, and Applied Genetic Technologies Corporation, a biotechnology company. Dr.&nbsp;Oronsky also served on the board of directors of MacroGenics, Inc., a biopharmaceutical company, from 2000 to 2014. The Board believes that
Dr.&nbsp;Oronsky&#146;s significant experience in growing and developing life sciences companies, particularly in the immunology area, provides significant leadership and insights for the Board in defining the strategy of the Company. He received
his Ph.D. from Columbia University, College of Physicians and Surgeons and his A.B. from New York University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Francis R. Cano, Ph.D.
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Cano was appointed to our Board in November 2009. Dr.&nbsp;Cano has been President and Founder of Cano Biotech
Corp., a consulting firm focusing on the vaccine business, since 1996 and also serves on the board of Biomerica, Inc., a developer and manufacturer of diagnostic products. Previously, Dr.&nbsp;Cano served on the board of Arbor Vita Corporation, a
biopharmaceutical company. From 1993 to 1996, Dr.&nbsp;Cano was President and Chief Operating Officer for Aviron, a biopharmaceutical company, which was later acquired by MedImmune in 2001. As a Co-Founder of Aviron, he completed two rounds of
venture financing, a licensing agreement with SmithKline Biologicals and in-licensed Flu-Mist influenza vaccine from the National Institutes of Health. For 21 years, Dr.&nbsp;Cano worked with the Lederle Laboratories Division of American Cyanamid,
most recently as Vice President and General Manager of the Biologicals unit. The Board believes that Dr.&nbsp;Cano&#146;s experience as a founder of and advisor to established vaccine businesses provides significant insights for the strategy of the
Company with respect to key technical and operational issues in vaccine development. He earned a Ph.D. in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in
Microbiology and a B.S. in Biology from St. John&#146;s University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Peggy V. Phillips </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Phillips has been a member of our Board since August 2006. Ms.&nbsp;Phillips served on the board of directors of Tekmira
Pharmaceuticals from February 2014 to March 2015. Ms.&nbsp;Phillips served on the board of directors of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
Portola Pharmaceuticals, a biopharmaceutical company, from 2006 to 2013. From 2003 until 2011, Ms.&nbsp;Phillips served on the board of the Naval Academy Foundation. From 1996 until 2002, she
served on the board of directors of Immunex Corporation, a biotechnology company, and, from 1999, she served as the Chief Operating Officer until the company was acquired by Amgen in 2002. During her career at Immunex, she held positions of
increasing responsibility in research, development, manufacturing, sales and marketing. As Senior Vice President for Pharmaceutical Development and General Manager for Enbrel<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> from 1994 until 1998, she was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining
Immunex, Ms.&nbsp;Phillips worked at Miles Laboratories. The Board believes that Ms.&nbsp;Phillips provides significant experience in development and commercialization of biotechnology products. Her background and experience with larger, complex
organizations provides significant operational and strategic insights in assessing the strategy of the Company. Ms.&nbsp;Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 2 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVAL OF AN AMENDMENT AND RESTATEMENT OF THE 2011 EQUITY INCENTIVE PLAN AND APPROVAL OF THE TERMS APPLICABLE TO AWARDS INTENDED TO QUALIFY AS &#147;PERFORMANCE-BASED COMPENSATION&#148; FOR PURPOSES
OF SECTION 162(M) OF THE INTERNAL REVENUE CODE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board is requesting stockholder approval of an amendment and
restatement of the Dynavax Technologies Corporation 2011 Equity Incentive Plan (the &#147;2011 Plan&#148;). We refer to such amendment and restatement of the 2011 Plan in this proxy statement as the &#147;Amended 2011 Plan&#148;. In addition, we are
requesting that stockholders approve the terms of the Amended 2011 Plan relating to awards intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan contains the following material changes from the 2011 Plan: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the
Amended 2011 Plan will not exceed 8,743,442 shares, which is an increase of 3,200,000 shares over the aggregate number of shares of our common stock that may be issued under the 2011 Plan. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2011 Plan contains a &#147;fungible share counting&#148; structure, whereby the number of shares of our common stock available for issuance under
the 2011 Plan will be reduced by (i)&nbsp;one share for each share issued pursuant to a stock option or stock appreciation right with an exercise price that is at least 100% of the fair market value of our common stock on the date of grant (an
&#147;Appreciation Award&#148;) granted under the 2011 Plan and (ii)&nbsp;1.33 shares for each share issued pursuant to a stock award that is not an Appreciation Award (a &#147;Full Value Award&#148;) granted under the 2011 Plan on or after
May&nbsp;27, 2015. The Amended 2011 Plan retains such fungible share counting structure, except that the number of shares of our common stock available for issuance under the Amended 2011 Plan will be reduced by 1.60 shares for each share issued
pursuant to a stock award that is a Full Value Award granted under the Amended 2011 Plan on or after May&nbsp;31, 2016. As part of such fungible share counting structure, the number of shares of our common stock available for issuance under the
Amended 2011 Plan will be increased by (i)&nbsp;one share for each share that becomes available again for issuance under the terms of the Amended 2011 Plan subject to an Appreciation Award and (ii)&nbsp;1.60 shares for each share that becomes
available again for issuance under the terms of the Amended 2011 Plan subject to a Full Value Award on or after May&nbsp;31, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any stock options or stock appreciation rights granted on or after May&nbsp;31, 2016 under the Amended 2011 Plan will not vest or be exercisable until
at least 12 months following the date of grant of the stock option or stock appreciation right, except that up to 5% of the share reserve of the Amended 2011 Plan may be subject to stock options or stock appreciation rights granted on or after
May&nbsp;31, 2016 under the Amended 2011 Plan that do not meet such vesting and exercisability requirements. The 2011 Plan does not contain any such vesting and exercisability requirements. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The maximum term of stock options and stock appreciation rights granted under the Amended 2011 Plan is seven years. Under the 2011 Plan, such maximum
term is 10 years. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate value of all cash and equity-based compensation granted or paid by us to any individual for service as a non-employee director of the
Board with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total of $200,000 with respect to any such cash compensation and (ii)&nbsp;$800,000 in total value with respect to any such equity-based compensation (including awards
granted under the Amended 2011 Plan and any other equity-based awards), calculating the value of any such awards based on the grant date fair value of such awards for financial reporting purposes. The Board may make an exception to such limits for
any non-employee director in extraordinary circumstances, as the Board may determine in its discretion, provided that any non-employee director who is granted or paid such additional compensation may not participate in the decision to grant or pay
such additional compensation. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan includes certain additional business criteria that may be utilized for performance goals with respect to certain
performance-based awards (as described in the summary below). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2011 Plan includes a list of certain adjustments that may be made by the Board or Compensation Committee of the Board (the &#147;Compensation
Committee&#148;) in the method of calculating the attainment of performance goals with respect to certain performance-based awards. The Amended 2011 Plan retains such list of adjustments, except that the phrase &#147;&#145;extraordinary items&#146;
as determined under generally accepted accounting principles&#148; in the 2011 Plan is replaced with the phrase &#147;items that are &#145;unusual&#146; in nature or occur &#145;infrequently&#146; as determined under generally accepted accounting
principles&#148; in the Amended 2011 Plan. This change is proposed because the concept of &#147;extraordinary items&#148; was recently eliminated from generally accepted accounting principles, but the definitions of &#147;unusual&#148; and
&#147;infrequently&#148; were retained. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan provides that (i)&nbsp;awards granted under the Amended 2011 Plan will be subject to recoupment in accordance with any clawback
policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act
or other applicable law and (ii)&nbsp;the Board may impose other clawback, recovery or recoupment provisions in an award agreement, including a reacquisition right in respect of previously acquired shares or other cash or property upon the
occurrence of cause. The 2011 Plan does not contain any such provision. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why You Should Vote for the
Amended 2011 Plan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity Incentive Awards Are an Important Part of Our Compensation Philosophy </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan is critical to our ongoing effort to build stockholder value by establishing a commercial organization based on our
lead program HEPLISAV-B, advancing a robust pipeline of immuno-oncology clinical stage development programs, and discovering other cutting-edge TLR-based vaccines and immunotherapies. Our success in commercializing products and advancing our
clinical development pipeline in cancer immunotherapy depends on our ability to attract, retain, and motivate key talent with expertise in these areas. Like all biotechnology companies, we actively compete for highly-qualified talent and we continue
to believe that equity compensation is a critical component to attract, retain, and motivate key employees and effectively align employee compensation with stockholder interests. The purpose of the increase in available shares under the Amended 2011
Plan is to provide us with a sufficient reserve of common stock to have competitive equity incentive programs that enable us to compete with our peer group for key talent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Traditionally, stock options have been the primary focus of our equity program. The potential value of stock options is realized only if our share price increases, and so we believe stock options provide
a strong incentive for individuals to work to grow our business and build stockholder value and are most attractive to individuals who share our entrepreneurial spirit. In addition, we have also granted restricted stock unit awards, or RSUs, in
recent years in order to attract and retain exceptional employees. In February 2016, our Compensation Committee granted RSUs that vest solely upon achievement of a clinical development milestone in response to stockholder feedback that a portion of
each NEO&#146;s long-term equity incentives should vest based on achievement of specific performance goals tied to our business strategy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the last three years (from 2013 through 2015), on average approximately 56% of our
equity-based awards were granted to employees other than our named executive officers, or NEOs. The table below shows equity-based awards granted to our Chief Executive Officer, or CEO, and NEOs as a percentage of total grants (the
&#147;Concentration Ratio&#148;) over such three year period, both with and without executive new-hire grants. For purposes of the table below, the number of equity-based awards includes all stock options and RSUs granted in each year. Within the
past three years, our executive new hires consisted of two of our current NEOs: our CEO, Eddie Gray, and our Senior Vice President of Operations and Quality, David Novack. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:16pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>3&nbsp;Year<BR>Average</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grants to CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grants to All NEOs (including the CEO)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">543,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">384,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">233,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">387,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All Grants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,375,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">586,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">899,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concentration Ratio (CEO)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concentration Ratio (CEO <I>without CEO new-hire grants</I>)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concentration Ratio (all NEOs, including the CEO)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concentration Ratio (all NEOs, including the CEO,<I> without NEO new-hire grants</I>)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">In 2015, no new-hire grants were made to our NEOs. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">In 2014, the following new-hire grants were made to our NEOs: 75,001 shares of common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">In 2013, the following new-hire grants were made to our NEOs: 180,000 shares of common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We Manage Our Equity Incentive Award Use Carefully, and Dilution Is Reasonable </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We continue to believe that equity incentive awards such as stock options and RSUs are a vital part of our overall compensation program.
Our compensation philosophy reflects broad-based eligibility for equity incentive awards, and we grant awards to substantially all of our employees. However, we recognize that equity incentive awards dilute existing stockholders, and, therefore, we
must responsibly manage the growth of our equity compensation program. We are committed to effectively monitoring our equity compensation share reserve, including our &#147;burn rate,&#148; to ensure that we maximize stockholders&#146; value by
granting the appropriate number of equity incentive awards necessary to attract, reward, and retain employees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following
table shows our responsible historical dilution and burn rate percentages. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Full Dilution</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross Burn Rate</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Full Dilution is calculated as (shares available for grant + shares subject to outstanding equity incentive awards)/(weighted average common stock
outstanding + shares available for grant + shares subject to outstanding equity incentive awards). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Gross Burn Rate is calculated as (shares subject to options granted + shares subject to other equity incentive awards granted)/weighted average common
stock outstanding. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Size of Our Share Reserve Increase Request Is Reasonable </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our request to increase the share reserve of the Amended 2011 Plan by 3,200,000 shares is approved, we will have approximately
4,100,000 shares available for grant after our Annual Meeting, which we anticipate being a one-year pool of shares and necessary to provide a sufficient amount of equity for attracting, retaining, and motivating employees. We anticipate returning to
stockholders for additional shares in 2017. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The size of our request is also reasonable in light of the equity granted to our
employees and directors over the last three years, which is comparatively lower than the majority of our peer companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overhang </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table provides certain additional information regarding our equity incentive program. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;April&nbsp;6,&nbsp;2016<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock subject to outstanding stock
options</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,743,109</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average exercise price of outstanding stock options</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.96</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average remaining term of outstanding stock
options</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.01</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total
number of shares of common stock subject to outstanding full value awards</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">549,526</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock available for grant under the 2011
Plan</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">862,209</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total
number of shares of common stock available for grant under other equity incentive plans</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock outstanding</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,495,502</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per-share
closing price of common stock as reported on NASDAQ Capital Market</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.78</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This table includes the stock options that were granted under the 2011 Plan in February 2016 subject to stockholder approval of this Proposal 2 that
are described in the table below under &#147;New Plan Benefits under Amended 2011 Plan.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Burn Rate </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides detailed information regarding the activity related to our equity incentive plans for fiscal year 2015.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8px">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total
number of shares of common stock subject to stock options granted</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,338,661</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock subject to full value awards
granted</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,986</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of shares of common stock outstanding</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,881,333</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Burn Rate</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.18</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Amended 2011 Plan Combines Compensation and Governance Best Practices </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan includes provisions that are designed to protect our stockholders&#146; interests and to reflect corporate
governance best practices including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stockholder approval is required for additional shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2011 Plan does not contain an annual
&#147;evergreen&#148; provision. The Amended 2011 Plan authorizes a fixed number of shares, so that stockholder approval is required to issue any additional shares. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repricing is not allowed</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2011 Plan prohibits the repricing of stock options and stock appreciation rights
without prior stockholder approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>No discounted stock options or stock appreciation rights</I>.&nbsp;&nbsp;&nbsp;&nbsp;All stock options and stock appreciation rights must have an
exercise price equal to or greater than the fair market value of our common stock on the date the stock option or stock appreciation right is granted. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Reasonable share counting provisions</I>.&nbsp;&nbsp;&nbsp;&nbsp;In general, when awards granted under the Amended 2011 Plan lapse or are canceled,
the shares reserved for those awards will be returned to the share reserve and be available for future awards. However, shares of common stock received from the exercise of stock options or withheld for taxes will not be returned to our share
reserve. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Minimum vesting requirements</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2011 Plan provides that no stock option or stock appreciation right granted on
or after May&nbsp;31, 2016 will vest until at least 12 months following the date of grant of the stock option or stock appreciation right, except that up to 5% of the share reserve of the
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
Amended 2011 Plan may be subject to stock options or stock appreciation rights granted on or after May&nbsp;31, 2016 that do not meet such vesting requirements. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Limit on non-employee director compensation</I>.&nbsp;&nbsp;&nbsp;&nbsp;The aggregate value of all cash and equity-based compensation granted or
paid by us to any individual for service as a non-employee director of the Board with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total of $200,000 with respect to any such cash compensation and (ii)&nbsp;$800,000 in total
value with respect to any such equity-based compensation (including awards granted under the Amended 2011 Plan and any other equity-based awards), calculating the value of any such awards based on the grant date fair value of such awards for
financial reporting purposes. The Board may make an exception to such limits for any non-employee director in extraordinary circumstances, as the Board may determine in its discretion, provided that any non-employee director who is granted or paid
such additional compensation may not participate in the decision to grant or pay such additional compensation. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Awards subject to forfeiture/clawback</I>.&nbsp;&nbsp;&nbsp;&nbsp;Awards granted under the Amended 2011 Plan will be subject to recoupment in
accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street
Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose other clawback, recovery or recoupment provisions in an award agreement, including a reacquisition right in respect of previously acquired shares or other
cash or property upon the occurrence of cause. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Performance-Based Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approval of the Amended 2011 Plan by our stockholders will also constitute approval of terms and conditions set forth therein that will
permit us to grant stock options, stock appreciation rights and performance-based stock and cash awards under the Amended 2011 Plan that may qualify as &#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m) of the Code.
Section&nbsp;162(m) of the Code disallows a deduction to any publicly held corporation and its affiliates for certain compensation paid to &#147;covered employees&#148; in a taxable year to the extent that compensation to a covered employee exceeds
$1 million. However, some kinds of compensation, including qualified &#147;performance-based compensation,&#148; are not subject to this deduction limitation. For compensation awarded under a plan to qualify as &#147;performance-based
compensation&#148; under Section&nbsp;162(m) of the Code, among other things, the following terms must be disclosed to and approved by the stockholders before the compensation is paid: (i)&nbsp;a description of the employees eligible to receive such
awards; (ii)&nbsp;a per-person limit on the number of shares subject to stock options, stock appreciation rights and performance-based stock awards, and the amount of cash subject to performance-based cash awards, that may be granted to any employee
under the plan in any year; and (iii)&nbsp;a description of the business criteria upon which the performance goals for performance-based awards may be granted (or become vested or exercisable). Accordingly, we are requesting that our stockholders
approve the Amended 2011 Plan, which includes terms and conditions regarding eligibility for awards, annual per-person limits on awards and the business criteria for performance-based awards granted under the Amended 2011 Plan (as described in the
summary below). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2016, our Compensation Committee granted a number of stock options to certain employees
(including our executive officers) under the 2011 Plan subject to stockholder approval of this Proposal 2. The number of shares subject to each such stock option is indicated in the table under &#147;New Plan Benefits under Amended 2011 Plan&#148;
below. Accordingly, approval of this Proposal 2 by our stockholders will also constitute approval of such stock options for purposes of Section&nbsp;162(m) of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe it is in the best interests of the Company and our stockholders to preserve the ability to grant &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code. However, in
certain circumstances, we may determine to grant compensation to covered employees that is not intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the Code. Moreover, even if we grant compensation
that is intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the Code, we cannot guarantee that such compensation ultimately will be deductible by us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of the Amended 2011 Plan </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A summary of the principal features of the Amended 2011 Plan follows below. The summary is qualified by the full text of the Amended 2011
Plan that is attached as Appendix A to this proxy statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Types of Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan provides for the following types of awards: incentive stock options, nonstatutory stock options, restricted stock
awards, restricted stock unit awards, stock appreciation rights, performance stock awards, performance cash awards, and other stock-based awards. We refer to these stock awards in this Proposal 2 collectively as the &#147;stock awards&#148; or
&#147;awards&#148;. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eligibility </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Awards may be granted under the Amended 2011 Plan to employees (including officers) of us or our affiliates and to members of our Board. Pursuant to applicable tax law, we may only grant incentive stock
options to our employees (including officers) and employees of our affiliates. As of April&nbsp;6, 2016, we had approximately 240 employees and eight non-employee directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;162(m) Limits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amended 2011 Plan, subject to
adjustment for certain changes in our capitalization, no participant will be eligible to be granted during any calendar year more than: (i)&nbsp;a maximum of 1,000,000 shares of our common stock subject to stock options, stock appreciation rights
and other stock awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value of our common stock on the date of grant; (ii)&nbsp;a maximum of 1,000,000 shares of our common
stock subject to performance stock awards; and (iii)&nbsp;a maximum of $5,000,000 subject to performance cash awards. Such limitations are designed to help assure that any deductions to which we would otherwise be entitled with respect to such
awards will not be subject to the $1,000,000 limitation on the income tax deductibility of compensation paid to any covered employee imposed by Section&nbsp;162(m) of the Code. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-Employee Director Compensation Limit </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The aggregate value of all cash and equity-based compensation granted or paid by us to any individual for service as a non-employee director of the Board with respect to any fiscal year of the Company
will not exceed (i)&nbsp;a total of $200,000 with respect to any such cash compensation and (ii)&nbsp;$800,000 in total value with respect to any such equity-based compensation (including awards granted under the Amended 2011 Plan and any other
equity-based awards), calculating the value of any such awards based on the grant date fair value of such awards for financial reporting purposes. The Board may make an exception to such limits for any non-employee director in extraordinary
circumstances, as the Board may determine in its discretion, provided that any non-employee director who is granted or paid such additional compensation may not participate in the decision to grant or pay such additional compensation. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Administration </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan is administered by our Board, which may in turn delegate authority to administer the Amended 2011 Plan to a committee. Our Board has delegated administration of the Amended 2011 Plan
to the Compensation Committee, but has retained the authority to concurrently administer the Amended 2011 Plan with the Compensation Committee and may, at any time, revest in itself some or all of the powers previously delegated to the Compensation
Committee. Subject to the terms of the Amended 2011 Plan, the Compensation Committee may determine the recipients, numbers and types of stock awards to be granted, and terms and conditions of the stock awards, including the period of their
exercisability and vesting. Subject to the limitations set forth below, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Compensation Committee also determines the fair market value applicable to a stock award and the exercise price of stock options and stock appreciation rights granted under the Amended 2011 Plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the discretion of the Board, the Compensation Committee may consist solely of two or more &#147;non-employee
directors&#148; within the meaning of Rule 16b-3 of the Exchange Act, or solely of two or more &#147;outside directors&#148; within the meaning of Section&nbsp;162(m) of the Code. The Compensation Committee has the authority to delegate its
administrative powers under the Amended 2011 Plan to a subcommittee consisting of members of the Compensation Committee. The Amended 2011 Plan also permits delegation to one or more officers of the ability to determine the recipients, number of
shares and types of stock awards (to the extent permitted by law) to be granted to employees other than our officers, subject to a maximum limit on the aggregate number of shares subject to stock awards that may be granted by such officers.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Available for Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the Amended 2011 Plan (the &#147;Share Reserve&#148;) will not
exceed 8,743,442 shares, which is equal to the sum of (i)&nbsp;60,889 shares (which is the number of shares subject to the Prior Plans&#146; Available Reserve (as defined below)), (ii)&nbsp;an additional 1,500,000 shares that were approved at our
2011 special meeting of stockholders, (iii)&nbsp;an additional 1,000,000 shares that were approved at our 2013 annual meeting of stockholders, (iv)&nbsp;an additional 2,250,000 shares that were approved at our 2015 annual meeting of stockholders,
(v)&nbsp;an additional 3,200,000 shares that are subject to approval by our stockholders under this Proposal 2, and (vi)&nbsp;an additional number of shares in an amount not to exceed 732,553 shares (which number consists of the Returning Shares (as
defined below), if any, as such shares become available from time to time). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;Prior Plans&#146; Available
Reserve&#148; refers to any available shares that, as of the effective date of the 2011 Plan, were reserved under our 2004 Stock Incentive Plan, 2010 Employment Inducement Award Plan and 1997 Equity Incentive Plan (each, a &#147;Prior Plan&#148;)
but were not subject to stock awards that were granted under the Prior Plans as of the effective date of the 2011 Plan, less any shares that were added to the 2004 Stock Incentive Plan share reserve on the first business day in 2011 by operation of
the evergreen provision in such plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;Returning Shares&#148; refers to any shares subject to outstanding stock
awards granted under the Prior Plans that expire or terminate prior to exercise or settlement or are forfeited because of the failure to vest, to the extent such shares would have otherwise returned to a Prior Plan in accordance with its terms had
such Prior Plan been in active existence at such time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of our common stock available for issuance under
the Amended 2011 Plan will be reduced by: (i)&nbsp;one share for each share issued pursuant to an Appreciation Award granted under the Amended 2011 Plan; (ii)&nbsp;one share for each share issued pursuant to a Full Value Award granted under the
Amended 2011 Plan prior to May&nbsp;27, 2015; (iii)&nbsp;1.33 shares for each share issued pursuant to a Full Value Award granted under the Amended 2011 Plan on or after May&nbsp;27, 2015 but prior to May&nbsp;31, 2016; and (iv)&nbsp;1.60 shares for
each share issued pursuant to a Full Value Award granted under the Amended 2011 Plan on or after May&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
number of shares of our common stock available for issuance under the Amended 2011 Plan will be increased by: (i)&nbsp;one share for each Returning Share or 2011 Plan Returning Share (as defined below) subject to an Appreciation Award; (ii)&nbsp;one
share for each Returning Share or 2011 Plan Returning Share subject to a Full Value Award that returns to the Amended 2011 Plan prior to May&nbsp;27, 2015; (iii)&nbsp;1.33 shares for each Returning Share or 2011 Plan Returning Share subject to a
Full Value Award that returns to the Amended 2011 Plan on or after May&nbsp;27, 2015 but prior to May&nbsp;31, 2016; and (iv)&nbsp;1.60 shares for each Returning Share or 2011 Plan Returning Share subject to a Full Value Award that returns to the
Amended 2011 Plan on or after May&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following shares of our common stock (collectively, the &#147;2011 Plan
Returning Shares&#148;) will become available again for issuance under the Amended 2011 Plan: (i)&nbsp;any shares subject to a stock award that are not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
issued because such stock award expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii)&nbsp;any shares subject to a stock award that are
not issued because such stock award is settled in cash; and (iii)&nbsp;any shares issued pursuant to a stock award that are forfeited back to or repurchased by us because of a failure to vest. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following shares of our common stock will not become available again for issuance under the Amended 2011 Plan: (i)&nbsp;any shares
that are reacquired or withheld (or not issued) by us to satisfy the exercise or purchase price of a stock award granted under the Amended 2011 Plan or a Prior Plan (including any shares subject to such award that are not delivered because such
award is exercised through a reduction of shares subject to such award (i.e., &#147;net exercised&#148;)); (ii)&nbsp;any shares that are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock
award granted under the Amended 2011 Plan or a Prior Plan; and (iii)&nbsp;any shares repurchased by us on the open market with the proceeds of the exercise or purchase price of a stock award granted under the Amended 2011 Plan or a Prior Plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Appropriate adjustments will be made to the Share Reserve, to the other numerical limits described in the Amended 2011 Plan
(such as the limit on the number of shares that may be issued as incentive stock options and the limit on the number of shares that may be awarded to any one participant in any calendar year for purposes of Section&nbsp;162(m) of the Code) and to
outstanding awards in the event of any change in our common stock without the receipt of consideration by us through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash,
large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, other than the conversion of convertible securities.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repricing Prohibition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Amended 2011 Plan, neither the Board nor any committee has the authority to reprice any outstanding stock option or stock appreciation right by reducing the exercise price of the stock option or
stock appreciation right or to cancel any outstanding stock option or stock appreciation right that has an exercise price greater than the then-current fair market value of our common stock in exchange for cash or other stock awards under the
Amended 2011 Plan, unless our stockholders have approved such an action within 12 months prior to such an event. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Terms of
Options </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A stock option is the right to purchase shares of our common stock at a fixed exercise price for a fixed period of
time. Stock option grants may be incentive stock options or nonstatutory stock options. Each option is evidenced by a stock option agreement. The Board determines the terms of a stock option including the exercise price, the form of consideration
paid on exercise, the vesting schedule, restrictions on transfer and the term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, the exercise price of a stock
option may not be less than 100% of the fair market value of the stock subject to the option on the date of grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options
granted under the Amended 2011 Plan will vest at the rate specified in the option agreement; <I>provided, however</I>, that no stock option granted on or after May&nbsp;31, 2016 will vest until at least 12 months following the date of grant of the
stock option, except that up to 5% of the Share Reserve may be subject to stock options or stock appreciation rights granted on or after May&nbsp;31, 2016 that do not meet such vesting requirements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, the term of an option granted under the Amended 2011 Plan may not exceed seven years. Unless the terms of an optionee&#146;s
stock option agreement provides otherwise, if an optionee&#146;s continuous service relationship with us, or any of our affiliates, ceases for any reason other than disability or death, the optionee may generally exercise any vested options for a
period of three months following the cessation of service. The option term may be extended in the event that exercise of the option following such a termination of service is prohibited by applicable
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
securities laws or our insider trading policy, but may not be extended beyond the original seven-year term. If an optionee&#146;s service relationship with us, or any of our affiliates, ceases
due to disability or death, or an optionee dies within a certain period following cessation of service, the optionee or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the
event of death. In no event may any option be exercised beyond the expiration of its term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptable forms of consideration
for the purchase of our common stock issued under the Amended 2011 Plan may include cash, payment pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board, common stock previously owned by the optionee, payment
through a net exercise feature, or other approved forms of legal consideration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, an optionee may not transfer a
stock option other than by will or the laws of descent and distribution or pursuant to a domestic relations order. However, to the extent permitted under the terms of the applicable stock option agreement, an optionee may designate a beneficiary who
may exercise the option following the optionee&#146;s death. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax Limitations on Incentive Stock Options </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to incentive stock options
that are exercisable for the first time by an optionee during any calendar year under all of our stock plans may not exceed $100,000. The options or portions of options that exceed this limit are generally treated as nonstatutory stock options. In
addition, the maximum number of shares that may be issued pursuant to the exercise of incentive stock options under the Amended 2011 Plan is 11,000,000 shares. No incentive stock option may be granted to any person who, at the time of the grant,
owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless the following conditions are satisfied: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the option exercise price must be at least 110% of the fair market value of the stock subject to the option on the date of grant; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the term of any incentive stock option award must not exceed five years from the date of grant. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Terms of Restricted Stock Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Restricted stock awards are awards of shares of our common stock. Each restricted stock award is evidenced by an award agreement that sets forth the terms and conditions of the award. A restricted stock
award may be granted in consideration for cash, the recipient&#146;s services performed for us or an affiliate of ours or other form of legal consideration. Shares of our common stock acquired under a restricted stock award may be subject to
forfeiture in accordance with the vesting schedule determined at the time of grant. Rights to acquire shares of our common stock under a restricted stock award may be transferred only upon such terms and conditions as are set forth in the restricted
stock award agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Terms of Restricted Stock Unit Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A restricted stock unit is a right to receive stock or cash (or a combination of cash and stock) equal to the value of a share of stock at
the end of a set period. No stock is issued at the time of grant. Each restricted stock unit award is evidenced by an agreement that sets forth the terms and conditions of the award. Restricted stock unit awards may be subject to vesting in
accordance with a vesting schedule determined at grant. Dividend equivalents may be credited in respect of shares of our common stock covered by a restricted stock unit award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">When a participant&#146;s continuous service with us or any of our affiliates terminates for any reason, the unvested portion of the restricted stock unit award will be forfeited unless otherwise provided
in the restricted stock unit award agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Terms of Stock Appreciation Rights </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock appreciation rights are granted pursuant to a stock appreciation rights agreement. Each stock appreciation right is denominated in
common stock share equivalents. The Board determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A stock appreciation right granted under the Amended 2011 Plan vests at the rate specified in the stock appreciation right agreement as
determined by the Board; <I>provided, however</I>, that no stock appreciation right granted on or after May&nbsp;31, 2016 will vest until at least 12 months following the date of grant of the stock appreciation right, except that up to 5% of the
Share Reserve may be subject to stock options or stock appreciation rights granted on or after May&nbsp;31, 2016 that do not meet such vesting requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">When a stock appreciation right is exercised, the holder is entitled to an amount equal to the product of (a)&nbsp;the excess of the per share fair market value of our common stock on the date of exercise
over the strike price, multiplied by (b)&nbsp;the number of shares of common stock with respect to which the stock appreciation right is exercised. We may pay the amount of the appreciation in cash or shares of our common stock or a combination of
both. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board determines the term of stock appreciation rights granted under the Amended 2011 Plan, up to a maximum of
seven years. Unless the terms of a holder&#146;s stock appreciation rights agreement provides otherwise, if a holder&#146;s continuous service with us, or any of our affiliates, ceases for any reason other than disability or death, the holder may
generally exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that exercise of the stock appreciation right following
such a termination of service is prohibited by applicable securities laws or our insider trading policy. If a holder&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a holder dies within a certain
period following cessation of service, the holder or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In no event may a stock
appreciation right be exercised beyond the expiration of its term. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Terms of Performance Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan provides for the grant of performance stock awards and performance cash awards. A performance award may vest or be
exercised upon achievement of pre-determined performance goals during a specified period. A performance award may also require the completion of a specified period of continuous service. The length of any performance period, the performance goals to
be achieved during the performance period, and the measure of whether and to what degree such performance goals have been attained will be determined by the Board or, to the extent necessary to comply with Section&nbsp;162(m) of the Code, the
Compensation Committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;162(m) of the Code disallows a deduction to any publicly held corporation and its
affiliates for certain compensation paid to &#147;covered employees&#148; in a taxable year to the extent that compensation to a covered employee exceeds $1 million. However, some kinds of compensation, including qualified &#147;performance-based
compensation,&#148; are not subject to this deduction limitation. While we believe it is in the best interests of the Company and our stockholders to preserve the ability to grant &#147;performance-based compensation&#148; under Section&nbsp;162(m)
of the Code, in certain circumstances, we may determine to grant compensation to covered employees that is not intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the Code. Moreover, even if we
grant compensation that is intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the Code, we cannot guarantee that such compensation ultimately will be deductible by us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In granting a performance award intended to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code,
the Compensation Committee will set a period of time, or a performance period, over </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which the attainment of one or more goals, or performance goals, will be measured. Within the time period prescribed by Section&nbsp;162(m) of the Code, at the time when the achievement of the
performance goals remains substantially uncertain (no later than the earlier of the 90th day of a performance period and the date on which 25% of the performance period has elapsed, and in any event at a time when the achievement of the performance
goals remains substantially uncertain), the Compensation Committee will establish the performance goals, based upon one or more criteria, or performance criteria, enumerated in the Amended 2011 Plan and described below. Prior to the payment of any
compensation under any award intended to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code, the Compensation Committee will certify (in writing) whether the performance goals have been satisfied.
Notwithstanding satisfaction of the achievement of any performance goals, the number of shares of common stock, stock options, cash or other consideration granted, issued, retainable or vested under an award on account of such satisfaction may be
reduced by the Compensation Committee, as determined in its sole discretion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance-based stock and cash awards may be
made subject to one or more of the following criteria: (i)&nbsp;earnings (including earnings per share and net earnings); (ii)&nbsp;earnings before interest, taxes and depreciation; (iii)&nbsp;earnings before interest, taxes, depreciation and
amortization (EBITDA); (iv)&nbsp;total stockholder return; (v)&nbsp;return on equity or average stockholder&#146;s equity; (vi)&nbsp;return on assets, investment, or capital employed; (vii)&nbsp;stock price or stock price performance;
(viii)&nbsp;margin (including gross margin); (ix)&nbsp;net income (before or after taxes); (x)&nbsp;operating income; (xi)&nbsp;operating income after taxes; (xii)&nbsp;pre-tax profit; (xiii)&nbsp;operating cash flow; (xiv)&nbsp;sales or revenue
targets; (xv)&nbsp;increases in revenue or product revenue; (xvi)&nbsp;expenses and cost reduction goals; (xvii)&nbsp;improvement in or attainment of working capital levels; (xviii)&nbsp;economic value added (or an equivalent metric);
(xix)&nbsp;market share; (xx)&nbsp;cash flow; (xxi)&nbsp;cash flow per share; (xxii)&nbsp;share price performance; (xxiii)&nbsp;debt reduction; (xxiv)&nbsp;implementation or completion of projects or processes; (xxv)&nbsp;customer satisfaction;
(xxvi)&nbsp;stockholders&#146; equity; (xxvii)&nbsp;capital expenditures; (xxviii)&nbsp;debt levels; (xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income;
(xxxii)&nbsp;billings; (xxxiii)&nbsp;submission to, or approval by, a regulatory body (including but not limited to the U.S. Food and Drug Administration) of an applicable filing for a product candidate or other product development milestones;
(xxxiv)&nbsp;acquisitions, divestitures, joint ventures, strategic alliances, licenses or collaborations; (xxxv)&nbsp;spin-offs, split-ups, reorganizations, recapitalizations, restructurings, financings (debt or equity) or refinancings;
(xxxvi)&nbsp;manufacturing or process development, clinical trial or research objectives; and (xxxvii)&nbsp;to the extent that an award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of performance selected by the
Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The performance goals may be based on a company-wide basis, with respect to one or more business units, divisions,
affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award agreement at the
time the award is granted or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of performance goals as
follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated goals; (3)&nbsp;to exclude the effects of changes to generally accepted
accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under
generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a
performance period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger,
consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common shareholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based compensation and/or the award
of an annual cash incentive under our Annual Incentive Program; and (10)&nbsp;to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item. In addition, we retain the discretion to reduce or eliminate the
compensation or economic benefit due upon attainment of the goals. The performance goals may differ from participant to participant and from award to award. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Terms of Other Stock Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board may grant other forms of stock awards that are valued in whole or in part by reference to the value of our common stock. Subject
to the provisions of the Amended 2011 Plan, the Board has the authority to determine the persons to whom and the dates on which such other stock awards will be granted, the number of shares of common stock (or cash equivalents) to be subject to each
award, and other terms and conditions of such awards. Such awards may be granted either alone or in addition to other stock awards granted under the Amended 2011 Plan. Such other forms of stock awards may be subject to vesting in accordance with a
vesting schedule determined at grant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Clawback Policy </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Awards granted under the Amended 2011 Plan will be subject to recoupment in accordance with any clawback policy that we are required to
adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In
addition, the Board may impose other clawback, recovery or recoupment provisions in an award agreement, including a reacquisition right in respect of previously acquired shares or other cash or property upon the occurrence of cause. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Transactions; Changes in Control </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Corporate Transaction</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain corporate transactions (as defined below), the Board has the discretion to take one or more of the following actions with
respect to outstanding stock awards under the Amended 2011 Plan: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">arrange for the assumption, continuation, or substitution of a stock award by a surviving or acquiring entity (or its parent company);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award to
the surviving or acquiring corporation (or its parent company); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">accelerate the vesting and exercisability of a stock award followed by the termination of the stock award; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised, in exchange for such cash consideration, if any, as
the Board may determine in its sole discretion; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a)&nbsp;the value of the property the holder of the stock
award would have received upon the exercise of the stock award, over (b)&nbsp;any exercise price payable by such holder in connection with such exercise. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board need not take the same action for all stock awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of
the Amended 2011 Plan, a corporate transaction will be deemed to occur in the event of (i)&nbsp;the consummation of a sale of all or substantially all of our consolidated assets, (ii)&nbsp;the consummation of a sale of at least 90% of our
outstanding securities, (iii)&nbsp;the consummation of a merger or consolidation in which we are not the surviving corporation, or (iv)&nbsp;the consummation of a merger or consolidation in which we are the surviving corporation but shares of our
outstanding common stock are converted into other property by virtue of the transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change in
Control.</I>&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain change in control events (as defined in the Amended 2011 Plan), the Board will have the discretion to take any one or more of the actions described above under &#147;Corporate
Transaction&#148; with respect to outstanding stock awards under the Amended 2011 Plan. A stock award may be subject </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to additional acceleration of vesting and exercisability upon or after a change in control event, as may be provided in the stock award agreement or in any other written agreement between us or
any affiliate and the participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The acceleration of vesting of an award in the event of a corporate transaction or a
change in control event under the Amended 2011 Plan may be viewed as an anti-takeover provision, which may have the effect of discouraging a proposal to acquire or otherwise obtain control of us. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Duration, Suspension, Termination, and Amendment </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board may suspend or terminate the Amended 2011 Plan at any time. Unless sooner terminated by our Board, the Amended 2011 Plan shall automatically terminate on November&nbsp;11, 2020, which is the day
before the tenth anniversary of the date the 2011 Plan was adopted by the Compensation Committee. No awards may be granted under the Amended 2011 Plan while the Amended 2011 Plan is suspended or after it is terminated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board may amend the Amended 2011 Plan at any time. However, no amendment or termination of the plan will adversely affect any rights
under awards already granted to a participant unless agreed to by the affected participant. We will obtain stockholder approval of any amendment to the Amended 2011 Plan as required by applicable law or listing requirement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax Withholding </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board may require a participant to satisfy any federal, state, local, or foreign tax withholding obligation relating to a stock award by (a)&nbsp;causing the participant to tender a cash payment;
(b)&nbsp;withholding shares of common stock from the shares of common stock issued or otherwise issuable to the participant in connection with the award; (c)&nbsp;withholding cash from an award settled in cash or from other amounts payable to the
participant; or (d)&nbsp;by other method set forth in the award agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Federal Income Tax Information </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of the principal U.S. federal income taxation consequences to participants and us with respect to participation
in the Amended 2011 Plan. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Given that the tax consequences to any recipient depend on his or her particular situation, each
recipient should consult the recipient&#146;s tax adviser regarding the federal, state, local, and other tax consequences of the grant or exercise of an award or the disposition of stock acquired as a result of an award. The Amended 2011 Plan is not
qualified under the provisions of Section&nbsp;401(a) of the Code, and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our ability to realize the benefit of any tax deductions described below depends on our generation of taxable income as well as the requirement of reasonableness, the provisions of Section&nbsp;162(m) of
the Code and the satisfaction of our tax reporting obligations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Incentive Stock Options </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2011 Plan provides for the grant of stock options that qualify as &#147;incentive stock options,&#148; as defined in
Section&nbsp;422 of the Code. Under the Code, an optionee generally is not subject to ordinary income tax upon the grant or exercise of an incentive stock option. If the optionee holds a share received on the exercise of an incentive stock option
for more than two years from the date the option was granted and more than one year from the date the option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other
taxable disposition of that share and the holder&#146;s tax basis in that share will be long-term capital gain or loss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If,
however, an optionee disposes of a share acquired on exercise of an incentive stock option before the end of the required holding period, which is referred to as a disqualifying disposition, the optionee generally will recognize
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the share on the date the incentive stock option was exercised over the
exercise price. However, if the sales proceeds are less than the fair market value of the share on the date of exercise of the option, the amount of ordinary income recognized by the optionee will not exceed the gain, if any, realized on the sale.
If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the date of exercise of the option, that excess will be short-term or long-term capital gain, depending on whether the holding period for the share
exceeds one year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock
acquired on exercise of an incentive stock option exceeds the exercise price of that option generally will be an adjustment included in the optionee&#146;s alternative minimum taxable income for the year in which the option is exercised. If,
however, there is a disqualifying disposition of the share in the year in which the option is exercised, there will be no adjustment for alternative minimum tax purposes with respect to that share. In computing alternative minimum taxable income,
the tax basis of a share acquired on exercise of an incentive stock option is increased by the amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the option is exercised.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not allowed an income tax deduction with respect to the grant or exercise of an incentive stock option or the
disposition of a share acquired on exercise of an incentive stock option after the required holding period. If there is a disqualifying disposition of a share, however, we are allowed a deduction in an amount equal to the ordinary income includible
in income by the optionee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nonstatutory Stock Options </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, there is no taxation upon the grant of a nonstatutory stock option if the option is granted with an exercise price equal to the
fair market value of the underlying stock on the grant date. On exercise, an optionee will recognize ordinary income equal to the excess, if any, of the fair market value on the date of exercise of the stock over the exercise price. If the optionee
is employed by us or one of our affiliates, that income will be subject to withholding tax. Generally, the optionee&#146;s tax basis in those shares will be equal to their fair market value on the date of exercise of the option, and the
optionee&#146;s capital gain holding period for those shares will begin on that date. We will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the optionee. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Restricted Stock Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, the recipient of a restricted stock award will recognize ordinary compensation income at the time the stock is received equal to the excess, if any, of the fair market value of the stock
received over any amount paid by the recipient in exchange for the stock. If, however, the stock is not vested when it is received (for example, if the employee is required to work for a period of time in order to have the right to sell the stock),
the recipient generally will not recognize income until the stock becomes vested, at which time the recipient will recognize ordinary compensation income equal to the excess, if any, of the fair market value of the stock on the date it becomes
vested over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service, within 30 days of his or her receipt of the stock award, to recognize ordinary compensation income,
as of the date the recipient receives the award, equal to the excess, if any, of the fair market value of the stock on the date the award is granted over any amount paid by the recipient in exchange for the stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recipient&#146;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from stock awards
will be the amount paid for such shares plus any ordinary income recognized either when the stock is received or when the stock becomes vested. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal
to the taxable ordinary income realized by the recipient of the stock award. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Restricted Stock Units </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, no taxable income is recognized upon receipt of a RSU award. The participant will recognize ordinary income in the year in
which the shares subject to that unit are actually issued to the participant in an amount equal to the fair market value of the shares on the date of issuance. Generally, we will be entitled to an income tax deduction equal to the amount of ordinary
income recognized by the participant at the time the shares are issued. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Appreciation Rights </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, stock appreciation rights are subject to similar tax rules as nonstatutory stock options. This means that, generally, no
taxable income is realized upon the receipt of a stock appreciation right. Upon exercise of the stock appreciation right, the fair market value of the shares (or cash in lieu of shares) received, less any strike price paid for such shares, is
recognized as ordinary income to the participant in the year of such exercise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, with respect to employees, we are
required to withhold from the payment made on exercise of the stock appreciation right or from regular wages or supplemental wage payments an amount based on the ordinary income recognized. We will generally be entitled to an income tax deduction
equal to the amount of ordinary income recognized by the participant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;162(m) </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation of persons who are &#147;covered employees&#148; of the Company is subject to the tax deduction limits of Section&nbsp;162(m)
of the Code. Awards that qualify as &#147;performance-based compensation&#148; are exempt from the limitations of Section&nbsp;162(m), thereby permitting us to claim the full federal tax deduction otherwise allowed for such compensation. The Amended
2011 Plan is intended to enable us to grant awards that will be exempt from the deduction limits of Section&nbsp;162(m). Under Section&nbsp;162(m), compensation attributable to stock options and stock appreciation rights generally may be eligible to
qualify as performance-based compensation if, among other requirements, (i)&nbsp;such awards are approved by a compensation committee composed solely of &#147;outside directors,&#148; (ii)&nbsp;the plan contains a per-employee limitation on the
number of shares for which such awards may be granted during a specified period, (iii)&nbsp;the per-employee limitation is approved by the stockholders, and (iv)&nbsp;the exercise or strike price of the award is no less than the fair market value of
the stock on the date of grant. Compensation attributable to restricted stock, RSUs, performance awards and other stock-based awards generally may be eligible to qualify as performance-based compensation, if, among other requirements, (i)&nbsp;the
award is approved by a compensation committee composed solely of &#147;outside directors,&#148; (ii)&nbsp;the award is granted, becomes vested or is settled, as applicable, only upon the achievement of an objective performance goal established in
writing by the compensation committee while the outcome is substantially uncertain, (iii)&nbsp;a committee of outside directors certifies in writing prior to the granting (or vesting or settlement) of the award that the performance goal has been
satisfied, and (iv)&nbsp;prior to the granting (or vesting or settlement) of the award, the stockholders have approved the material terms of the award (including the class of employees eligible for such award, the business criteria on which the
performance goal is based, and the maximum amount, or formula used to calculate the amount, payable upon attainment of the performance goal). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Awards Granted Under the 2011 Plan </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth, for each of the individuals and various groups indicated, the total number of shares of our common stock
subject to awards that have been granted under the 2011 Plan as of April&nbsp;6, 2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2011 Equity Incentive Plan </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;
Shares<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,001</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">311,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,001</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Vice President, Clinical Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220,750</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">227,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,033,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current directors who are not executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">180,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each nominee for election as a director:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each associate of any executive officers, current directors or director nominees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each other person who received or is to receive 5% of awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">311,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">227,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All employees, including all current officers who are not executive officers, as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,023,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">With respect to certain employees (including our executive officers), this column includes certain stock options that were granted under the 2011 Plan
in February 2016, and such stock options are subject to stockholder approval of this Proposal 2. The number of shares subject to each such stock option is indicated in the table under &#147;New Plan Benefits under Amended 2011 Plan&#148; below.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New Plan Benefits under Amended 2011 Plan </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">280,000</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,000</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,000</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Vice President, Clinical Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,000</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,000</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">592,000</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current directors who are not executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000&nbsp;per&nbsp;calendar&nbsp;year</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All employees, including all current officers who are not executive officers, as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,000</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Awards granted under the Amended 2011 Plan to our executive officers and other employees are discretionary and are not subject to set benefits or
amounts under the terms of the Amended 2011 Plan. However, in February 2016, our Compensation Committee granted a number of stock options to certain employees (including our executive officers) under the 2011 Plan subject to stockholder approval of
this Proposal 2, and the number of shares subject to each such stock option is indicated in this table. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Awards granted under the Amended 2011 Plan to our non-employee directors are discretionary and are not subject to set benefits or amounts under the
terms of the Amended 2011 Plan. However, pursuant to our current compensation program for non-employee directors, each of our current non-employee directors is eligible to receive an annual grant of a stock option to purchase 7,500 shares of our
common stock. On and after the date of the Annual Meeting, any such stock options will be granted under the Amended 2011 Plan if this Proposal 2 is approved by our stockholders. For additional information regarding our current compensation program
for non-employee directors, please see &#147;Director Compensation&#148; below. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Vote Required
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of the holders of a majority of shares present and cast either in person or by proxy at the Annual
Meeting will be required to approve this Proposal 2. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker non-votes are counted towards a
quorum but are not counted for any purpose in determining whether this Proposal 2 has been approved. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL>
B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL>
I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 2. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 3 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVAL OF AN AMENDMENT AND RESTATEMENT OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE 2014 EMPLOYEE STOCK
PURCHASE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board is requesting stockholder approval of an amendment and restatement of the Dynavax Technologies
Corporation 2014 Employee Stock Purchase Plan (the &#147;2014 ESPP&#148;). We refer to such amendment and restatement of the 2014 ESPP in this proxy statement as the &#147;Amended 2014 ESPP&#148;. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2014 ESPP contains the following material change from the 2014 ESPP: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the maximum number of shares of our common stock that may be issued under the Amended
2014 ESPP will be 250,000 shares, which is an increase of 200,000 shares over the maximum number of shares of our common stock that may be issued under the 2014 ESPP. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approval of the Amended 2014 ESPP will allow us to continue to provide our employees with the opportunity to acquire an ownership
interest in the Company through their participation in the Amended 2014 ESPP, thereby encouraging them to remain in our service and more closely aligning their interests with those of our stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Proposal 3 is approved by our stockholders, an additional 200,000 shares of our common stock will be available for issuance under
the Amended 2014 ESPP. As of April&nbsp;6, 2016, a total of 9,330 shares of our common stock remained available for issuance under the 2014 ESPP. We do not maintain any other employee stock purchase plans. As of April&nbsp;6, 2016, a total of
38,495,502 shares of our common stock were outstanding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of the Amended 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A summary of the principal features of the Amended 2014 ESPP follows below. The summary is qualified by the full text of the Amended 2014
ESPP that is attached as Appendix B to this proxy statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purpose </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purpose of the Amended 2014 ESPP is to provide a means by which our employees may be given an opportunity to purchase shares of our
common stock, to assist us in retaining the services of our employees, to secure and retain the services of new employees and to provide incentives for such persons to exert maximum efforts for our success. The rights to purchase common stock
granted under the Amended 2014 ESPP are intended to qualify as options issued under an &#147;employee stock purchase plan&#148; as that term is defined in Section&nbsp;423(b) of the Code. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Administration </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board has the power to administer the Amended 2014 ESPP and may also delegate administration of the Amended 2014 ESPP to a committee comprised of one or more members of the Board. The Board has
delegated administration of the Amended 2014 ESPP to the Compensation Committee, but may, at any time, revest in itself some or all of the powers previously delegated to the Compensation Committee. Each of the Board and the Compensation Committee is
considered to be a Plan Administrator for purposes of this Proposal 3. The Plan Administrator has the power to construe and interpret both the Amended 2014 ESPP and the rights granted under it. The Plan Administrator has the power, subject to the
provisions of the Amended 2014 ESPP, to determine when and how rights to purchase our common stock will be granted, the provisions of each offering of such rights (which need not be identical), and whether employees of any of our parent or
subsidiary companies will be eligible to participate in the Amended 2014 ESPP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Subject to Amended 2014 ESPP
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the maximum number of shares of our common stock that may
be issued under the Amended 2014 ESPP is 250,000 shares, which is equal to the sum of (i)&nbsp;50,000 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shares that were approved at our 2014 annual meeting of stockholders and (ii)&nbsp;an additional 200,000 shares that are subject to approval by our stockholders under this Proposal 3. If any
rights granted under the Amended 2014 ESPP terminate without being exercised in full, the shares of common stock not purchased under such rights again become available for issuance under the Amended 2014 ESPP. The shares of common stock purchasable
under the Amended 2014 ESPP will be shares of authorized but unissued or reacquired common stock, including shares repurchased by us on the open market. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Offerings </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2014 ESPP will be implemented by offerings of rights
to purchase our common stock to all eligible employees. The Plan Administrator will determine the duration of each offering period, provided that in no event may an offering period exceed 27 months. The Plan Administrator may establish separate
offerings which vary in terms (although not inconsistent with the provisions of the Amended 2014 ESPP or the requirements of applicable laws). Each offering period will have one or more purchase dates, as determined by the Plan Administrator prior
to the commencement of the offering period. The Plan Administrator has the authority to alter the terms of an offering prior to the commencement of the offering period, including the duration of subsequent offering periods. When an eligible employee
elects to join an offering period, he or she is granted a right to purchase shares of our common stock on each purchase date within the offering period. On the purchase date, all contributions collected from the participant are automatically applied
to the purchase of our common stock, subject to certain limitations (which are described further below under &#147;Eligibility&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Plan Administrator has the discretion to structure an offering so that if the fair market value of our common stock on the first trading day of a new purchase period within the offering period is less
than or equal to the fair market value of our common stock on the first day of the offering period, then that offering will terminate immediately as of that first trading day, and the participants in such terminated offering will be automatically
enrolled in a new offering beginning on the first trading day of such new purchase period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eligibility </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any individual who is employed by us (or by any of our parent or subsidiary companies if such company is designated by the Plan
Administrator as eligible to participate in the Amended 2014 ESPP) may participate in offerings under the Amended 2014 ESPP, provided such individual has been employed by us (or our parent or subsidiary, if applicable) for such continuous period
preceding the first day of the offering period as the Plan Administrator may require, but in no event may the required period of continuous employment be equal to or greater than two years. In addition, the Plan Administrator may provide that an
employee will not be eligible to be granted purchase rights under the Amended 2014 ESPP unless such employee is customarily employed for more than 20 hours per week and more than five months per calendar year. The Plan Administrator may also provide
in any offering that certain of our employees who are &#147;highly compensated&#148; as defined in the Code are not eligible to participate in the Amended 2014 ESPP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No employee will be eligible to participate in the Amended 2014 ESPP if, immediately after the grant of purchase rights, the employee would own, directly or indirectly, stock possessing 5% or more of the
total combined voting power or value of all classes of our stock or of any of our parent or subsidiary companies, including any stock which such employee may purchase under all outstanding purchase rights and options. In addition, no employee may
purchase more than $25,000 worth of our common stock (determined based on the fair market value of the shares at the time such rights are granted) under all our employee stock purchase plans and any employee stock purchase plans of our parent or
subsidiary companies for each calendar year during which such rights are outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;6, 2016, we had
approximately 240 employees. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Participation in the Amended 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An eligible employee may enroll in the Amended 2014 ESPP by delivering to us, within the time specified in the offering, an enrollment
form authorizing contributions as specified by the Plan Administrator, which may be up to 10% of such employee&#146;s earnings during the offering period. Each participant will be granted a separate purchase right for each offering in which he or
she participates. Unless an employee&#146;s participation is discontinued, his or her purchase right will be exercised automatically at the end of each purchase period at the applicable purchase price. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purchase Price </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The purchase price per share at which shares of our common stock are acquired pursuant to purchase rights on each purchase date during an offering period will not be less than the lower of (i)&nbsp;85% of
the fair market value of a share of our common stock on the first day of the offering period or (ii)&nbsp;85% of the fair market value of a share of our common stock on the applicable purchase date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;6, 2016, the closing price of our common stock as reported on the NASDAQ Capital Market was $21.78 per share.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Payment of Purchase Price; Payroll Deductions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The purchase of shares during an offering period generally will be funded by a participant&#146;s payroll deductions accumulated during the offering period. A participant may change his or her rate of
contributions, if and as permitted in the offering. All contributions made for a participant are credited to his or her account under the Amended 2014 ESPP and deposited with our general funds. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purchase Limits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with each offering made under the Amended 2014 ESPP, the Plan Administrator may specify (i)&nbsp;a maximum number of shares of our common stock that may be purchased by any participant
pursuant to such offering, (ii)&nbsp;a maximum number of shares of our common stock that may be purchased by any participant on any purchase date pursuant to such offering, (iii)&nbsp;a maximum aggregate number of shares of our common stock that may
be purchased by all participants pursuant to such offering, and/or (iv)&nbsp;a maximum aggregate number of shares of our common stock that may be purchased by all participants on any purchase date pursuant to such offering. If the aggregate purchase
of shares of our common stock issuable upon exercise of purchase rights granted under such offering would exceed any such maximum aggregate number, then, in the absence of any action by the Plan Administrator otherwise, a pro rata allocation of
available shares of our common stock will be made in as nearly a uniform manner as will be practicable and equitable. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Withdrawal </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Participants may withdraw from a given offering by delivering a withdrawal form to us and terminating their contributions. Such withdrawal may be elected at any time prior to the end of an offering,
except as otherwise provided by the Plan Administrator. Upon such withdrawal, we will distribute to the employee his or her accumulated but unused contributions without interest, and such employee&#146;s right to participate in that offering will
terminate. However, an employee&#146;s withdrawal from an offering does not affect such employee&#146;s eligibility to participate in subsequent offerings under the Amended 2014 ESPP. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Termination of Employment </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except as required by law, a participant&#146;s outstanding purchase rights under any offering under the Amended 2014 ESPP will terminate immediately upon either (i)&nbsp;termination of the
participant&#146;s employment with us (or any of our parent or subsidiary companies if such company is designated by the Plan Administrator as eligible to participate in the Amended 2014 ESPP) or (ii)&nbsp;any other circumstance or event that causes
the participant to no longer be eligible to participate in the offering. In such event, we will distribute to the participant his or her accumulated but unused contributions without interest. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Restrictions on Transfer </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rights granted under the Amended 2014 ESPP are not transferable except by will, the laws of descent and distribution, or, if permitted by
us, by a beneficiary designation. During the lifetime of the participant, such rights may only be exercised by the participant. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in Capitalization </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of certain changes in our capitalization, the Plan Administrator will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Amended
2014 ESPP; (ii)&nbsp;the class(es) and number of securities subject to, and the purchase price applicable to outstanding offerings and purchase rights; and (iii)&nbsp;the class(es) and number of securities that are the subject of the purchase limits
under each ongoing offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Effect of Certain Corporate Transactions </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a corporate transaction (as defined in the Amended 2014 ESPP and described below), each outstanding purchase right under
the Amended 2014 ESPP will be assumed or continued or a similar right will be substituted for such purchase right by the surviving or acquiring corporation (or its parent or subsidiary), unless the Plan Administrator determines to shorten any
offering periods then in progress by setting a new purchase date prior to the corporate transaction. If the Plan Administrator sets such a new purchase date, then the Plan Administrator will notify each participant in writing at least 10 business
days prior to the new purchase date that the purchase date for the participant&#146;s outstanding purchase rights has been changed to such new purchase date and that either: (i)&nbsp;the participant&#146;s outstanding purchase rights will be
exercised automatically on such new purchase date, unless the participant withdraws from the applicable offering prior to such new purchase date, and such purchase rights will terminate immediately after such exercise; or (ii)&nbsp;in lieu of such
exercise, we will pay to the participant on such new purchase date an amount in cash, cash equivalents, or property as determined by the Plan Administrator that is equal to the difference in the fair market value of the shares of common stock
subject to the participant&#146;s outstanding purchase rights on such new purchase date and the applicable exercise price due had such purchase rights been exercised automatically on such new purchase date, and such purchase rights will terminate
immediately after such payment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Amended 2014 ESPP, a corporate transaction generally will be deemed to
occur in the event of the consummation of: (i)&nbsp;a merger or consolidation in which we are not the surviving entity, except for a transaction the principal purpose of which is to change the state in which we are incorporated; (ii)&nbsp;the sale,
transfer or other disposition of all or substantially all of our assets (including the capital stock of our subsidiary corporations); (iii)&nbsp;our complete liquidation or dissolution; (iv)&nbsp;any reverse merger or series of related transactions
culminating in a reverse merger (including, but not limited to, a tender offer followed by a reverse merger) in which we are the surviving entity but in which securities possessing more than 40% of the total combined voting power of our outstanding
securities are transferred to a person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger but excluding any such transaction or series of related
transactions that the Plan Administrator determines will not be a corporate transaction; or (v)&nbsp;acquisition in a single or series of related transactions by any person or related group of persons (other than us or by an employee benefit plan
sponsored by us) of beneficial ownership of securities possessing more than 50% of the total combined voting power of our outstanding securities but excluding any such transaction or series of related transactions that the Plan Administrator
determines will not be a corporate transaction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Duration, Amendment and Termination </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Plan Administrator may amend, suspend or terminate the Amended 2014 ESPP at any time. However, except in regard to certain
capitalization adjustments, any amendment must be approved by our stockholders if such approval is required by applicable law or listing requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any outstanding purchase rights granted before an amendment, suspension or termination of
the Amended 2014 ESPP will not be materially impaired by any such amendment, suspension or termination, except (i)&nbsp;with the consent of the employee to whom such purchase rights were granted, (ii)&nbsp;as necessary to comply with any laws,
listing requirements or governmental regulations (including Section&nbsp;423 of the Code), or (iii)&nbsp;as necessary to obtain or maintain favorable tax, listing or regulatory treatment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Federal Income Tax Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of the principal
United States federal income taxation consequences to participants and us with respect to participation in the Amended 2014 ESPP. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign
jurisdiction in which a participant may reside. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her
particular situation, each participant should consult the participant&#146;s tax adviser regarding the federal, state, local, and other tax consequences of the grant or exercise of an option or the disposition of common stock acquired under the
Amended 2014 ESPP. The Amended 2014 ESPP is not qualified under the provisions of Section&nbsp;401(a) of the Code and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rights granted under the Amended 2014 ESPP are intended to qualify for favorable federal income tax treatment associated with rights
granted under an employee stock purchase plan which qualifies under the provisions of Section&nbsp;423 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
participant will be taxed on amounts withheld for the purchase of shares of our common stock as if such amounts were actually received. Otherwise, no income will be taxable to a participant as a result of the granting or exercise of a purchase right
until a sale or other disposition of the acquired shares. The taxation upon such sale or other disposition will depend upon the holding period of the acquired shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If the shares are sold or otherwise disposed of more than two years after the beginning of the offering period and more than one year after the shares are transferred to the participant, then the lesser
of the following will be treated as ordinary income: (i)&nbsp;the excess of the fair market value of the shares at the time of such sale or other disposition over the purchase price; or (ii)&nbsp;the excess of the fair market value of the shares as
of the beginning of the offering period over the purchase price (determined as of the beginning of the offering period). Any further gain or any loss will be taxed as a long-term capital gain or loss. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the shares are sold or otherwise disposed of before the expiration of either of the holding periods described above, then the excess
of the fair market value of the shares on the purchase date over the purchase price will be treated as ordinary income at the time of such sale or other disposition. The balance of any gain will be treated as capital gain. Even if the shares are
later sold or otherwise disposed of for less than their fair market value on the purchase date, the same amount of ordinary income is attributed to the participant, and a capital loss is recognized equal to the difference between the sales price and
the fair market value of the shares on such purchase date. Any capital gain or loss will be short-term or long-term, depending on how long the shares have been held. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are no federal income tax consequences to us by reason of the grant or exercise of rights under the Amended 2014 ESPP. We are entitled to a deduction to the extent amounts are taxed as ordinary
income to a participant for shares sold or otherwise disposed of before the expiration of the holding periods described above (subject to the requirement of reasonableness and the satisfaction of tax reporting obligations). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Plan Benefits under 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth, for each of the individuals and various groups indicated, the total number of shares of our common stock
that have been purchased under the 2014 ESPP as of April&nbsp;6, 2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2014 ESPP </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Vice President, Clinical Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">862</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">862</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current directors who are not executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each nominee for election as a director:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each associate of any executive officers, current directors or director nominees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each other person who received or is to receive 5% of purchase rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All employees, including all current officers who are not executive officers, as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New Plan Benefits under Amended 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Participation in the Amended 2014 ESPP is voluntary and each eligible employee will make his or her own decision regarding whether and to
what extent to participate in the Amended 2014 ESPP. In addition, we have not approved any grants of purchase rights that are conditioned on stockholder approval of this Proposal 3. Accordingly, we cannot determine the benefits or amounts that will
be received in the future by individual employees or groups of employees under the Amended 2014 ESPP. Our non-employee directors will not be eligible to participate in the Amended 2014 ESPP. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Vote Required </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of the holders of a majority of shares present and cast either in person or by proxy at the Annual Meeting will be required to approve this Proposal 3. Abstentions will be counted
toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker non-votes are counted towards a quorum but are not counted for any purpose in determining whether this Proposal 3
has been approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL>
R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL>
P<SMALL>ROPOSAL</SMALL> 3. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 4 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with SEC rules,
Dynavax stockholders are being asked to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement, which is commonly referred to as a &#147;say-on-pay vote.&#148; At our 2011 Annual Meeting,
our stockholders voted in favor of holding a say-on-pay vote once every three years. Subsequently, in February 2016, as part of a number of corporate governance reforms made in response to feedback from our stockholders and the proxy advisory firms,
our Board of Directors adopted a policy changing the frequency of our say-on-pay vote from once every three years to every year. Accordingly, we are holding a say-on-pay vote at this year&#146;s Annual Meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive
officers, which results from our compensation philosophy, policies and practices as discussed in this proxy statement. The compensation of our named executive officers subject to the say-on-pay vote is described in the Compensation Discussion and
Analysis, the accompanying tables, and the related narrative disclosure contained in this proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation
Committee is responsible for designing and administering our executive compensation programs. Our Compensation Committee firmly believes that Dynavax&#146;s executive compensation programs should reward our named executive officers for performance,
and that when key performance objectives are not achieved, the compensation of our named executive officers should reflect as much. We believe that the compensation of our named executive officers, as disclosed in this proxy, reflects this
philosophy. In addition, our Compensation Committee believes that the compensation programs for our named executive officers have been instrumental in helping Dynavax be able to attract, retain and motivate our executive team, thereby enabling our
company to be in a position to move forward with our business strategy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors is now asking our stockholders
to indicate their support for the compensation of our named executive officers as described in this proxy statement by casting a non-binding advisory vote &#147;For&#148; the following resolution: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;RESOLVED, that the compensation paid to Dynavax&#146;s named executive officers, as disclosed pursuant to Item&nbsp;402 of
Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although this vote is advisory and the outcome is not binding on our Board of Directors, the views expressed by our stockholders, whether through this vote or otherwise, are important to us. As a result,
the Board of Directors and the Compensation Committee will carefully review the results of this vote, and they will consider these results in making future decisions about our executive compensation programs and arrangements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless our Board of Directors modifies its policy on the frequency of future advisory votes on the compensation of our named executive
officers, the next advisory vote on the compensation of our named executive officers will be held at the 2017 annual meeting of stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Approval of this advisory proposal requires the vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 4. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 5 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>RATIFICATION OF SELECTION OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has selected Ernst&nbsp;&amp; Young LLP, or Ernst&nbsp;&amp; Young, as our independent
registered public accounting firm for the fiscal year ending December&nbsp;31, 2016. Ernst&nbsp;&amp; Young has audited our financial statements since 2001. Representatives of Ernst&nbsp;&amp; Young are expected to be present at the Annual Meeting.
Ernst&nbsp;&amp; Young will have an opportunity to make a statement if it so desires and will be available to respond to appropriate questions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If the stockholders fail to ratify the selection of Ernst&nbsp;&amp; Young, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee
in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the Company and its stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote at the
Annual Meeting will be required to ratify the selection of Ernst&nbsp;&amp; Young. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker
non-votes are counted towards a quorum but are not counted for any purpose in determining whether this matter has been approved; however, Proposal 5 is considered a &#147;routine&#148; matter, and therefore no broker non-votes are expected to exist
in connection with this Proposal 5. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL>
R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL>
P<SMALL>ROPOSAL</SMALL> 5. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>UDIT</SMALL> F<SMALL>EES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the audit of our 2015 financial statements, we entered into an engagement agreement with Ernst&nbsp;&amp; Young which
sets forth the terms by which Ernst&nbsp;&amp; Young will perform audit services for us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table represents
aggregate fees billed to the Company for the fiscal years ended December&nbsp;31, 2015 and 2014 by Ernst&nbsp;&amp; Young, our principal auditors. The Audit Committee pre-approved all service fees described below. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal Year Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,095,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">971,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Related Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All Other Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,097,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">977,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Audit fees include fees for the audit of our consolidated financial statements and interim reviews of our quarterly financial statements, including
compliance with the provisions of Section&nbsp;404 of the Sarbanes-Oxley Act as well as fees related to registration statements, consents and other services related to SEC matters. In each of 2015 and 2014, audit fees included fees related to a
comfort letter in connection with an equity offering. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tax fees include preparation of international subsidiary statutory tax returns. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">All other fees represent subscription fees for an online accounting research tool and related database. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>RE</SMALL>-<SMALL>APPROVAL</SMALL> P<SMALL>OLICIES</SMALL> A<SMALL>ND</SMALL> P<SMALL>ROCEDURES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by our independent
registered public accounting firm, Ernst&nbsp;&amp; Young. Under the policy, the Audit </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Committee pre-approves specified services in the defined categories of audit services, audit-related services, tax services and all other services up to specified amounts. Pre-approval may be
given as part of the Audit Committee&#146;s approval of the scope of the engagement of the independent registered public accounting firm or on an interim basis by the Audit Committee Chair, as needed and on a case-by-case basis before the
independent registered public accounting firm is engaged to provide each service. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has determined that
services rendered by Ernst&nbsp;&amp; Young are compatible with maintaining the principal auditors&#146; independence. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXECUTIVE OFFICERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth certain information with respect to our executive officers as of April&nbsp;6, 2016: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Vice President, Clinical Development</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Please see &#147;Class I Directors Continuing In Office Until the 2019 Annual Meeting&#148; in this proxy statement for more information about
Mr.&nbsp;Gray. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Michael S. Ostrach &#150; Senior Vice President, Chief Financial Officer and Chief Business Officer
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ostrach is our Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr.&nbsp;Ostrach joined
Dynavax in October 2006 as Vice President, Chief Business Officer and General Counsel, and became Principal Financial Officer in September 2013, Chief Financial Officer in March 2015 and Senior Vice President in February 2016. Mr.&nbsp;Ostrach held
the position of Dynavax&#146;s General Counsel from October 2006 to September 2015. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr.&nbsp;Ostrach was
at Kosan Biosciences, most recently as President and Chief Operating Officer. Mr.&nbsp;Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as General Counsel and finally as
Senior Vice President of Corporate Affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr.&nbsp;Ostrach became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from
Stanford Law School. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Robert L. Coffman, Ph.D. &#150; Senior Vice President and Chief Scientific Officer </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Coffman was appointed Senior Vice President and Chief Scientific Officer of Dynavax in February 2014, and prior to that he was
Vice President and Chief Scientific Officer of Dynavax since December 2000. Prior to joining Dynavax in 2000, Dr.&nbsp;Coffman was a founding member of the DNAX Research Institute in Palo Alto, California. Dr.&nbsp;Coffman has authored over 200
scientific publications, is a member of the National Academy of Sciences and the American Academy of Microbiology, and has received a number of prestigious awards for his work. With colleague Dr.&nbsp;Tim Mosmann, he defined the two principal
subtypes of helper T cells, termed Th1 and Th2 cells, and demonstrated the central relationship between their differences in cytokine expression and function. Dr.&nbsp;Coffman defined basic mechanisms of T-cell regulation in asthma and infectious
and parasitic diseases, and demonstrated the central role of regulatory CD4+ T cells in preventing inflammatory bowel disease. At Dynavax, Dr.&nbsp;Coffman has pioneered the development of agonists and antagonists for Toll-Like Receptors
(&#147;TLRs&#148;), key recognition receptors in innate immunity. Dr.&nbsp;Coffman received an A.B. in Microbiology from Indiana University and a Ph.D. in Immunology from the University of California, San Diego. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Robert Janssen, M.D. &#150; Chief Medical Officer and Vice President, Clinical Development </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Janssen was appointed Chief Medical Officer and Vice President, Clinical Development and Regulatory Affairs in July 2013. He most
recently served as Dynavax&#146;s Vice President, Medical Affairs since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through 2012, during which time he was extensively involved with Phase 3 clinical
development of HEPLISAV-B and its U.S. and European licensing applications. Prior to joining Dynavax, Dr.&nbsp;Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health
care provider education focused on </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
HIV and hepatitis B therapies. Until 2008, Dr.&nbsp;Janssen spent 23 years at the U.S. Centers for Disease Control and Prevention (&#147;CDC&#148;), most recently as the Director of the Division
of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV. Dr.&nbsp;Janssen received a
Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology at the University of Pennsylvania. Dr.&nbsp;Janssen has been the
beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific journals. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>David F. Novack &#150; Senior Vice President, Operations and Quality </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Novack joined Dynavax in March 2013 as Senior Vice President, Operations and Quality. Mr.&nbsp;Novack was formerly with Novartis Vaccines&nbsp;&amp; Diagnostics where he served since 2009 as the
Global Head of Technical Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis, Mr.&nbsp;Novack was the Vice President, Business Development for Vaxin,
Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr.&nbsp;Novack worked at MedImmune, formerly Aviron, serving in several capacities including business development, manufacturing, contract operations and most recently as Senior
Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr.&nbsp;Novack was with American Cyanamid Company in various roles. Mr.&nbsp;Novack received a B.S. in Biology from State University of New York and an M.B.A. from Columbia
University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OMPENSATION</SMALL> D<SMALL>ISCUSSION</SMALL> A<SMALL>ND</SMALL> A<SMALL>NALYSIS</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Compensation Discussion and Analysis discusses our executive compensation policies and how and why our Compensation Committee arrived at specific compensation decisions for the year ended
December&nbsp;31, 2015, for the following NEOs whose compensation is set forth in the Summary Compensation Table and other compensation tables contained in this proxy statement: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray, Chief Executive Officer and Director; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach, Senior Vice President, Chief Financial Officer and Chief Business Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D., Senior Vice President and Chief Scientific Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D., Chief Medical Officer and Vice President, Clinical Development; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack, Senior Vice President, Operations and Quality. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We present our Compensation Discussion and Analysis in the following sections: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Executive Summary</I>.&nbsp;&nbsp;&nbsp;&nbsp;In this section, we highlight our
2015 corporate performance, certain governance aspects of our executive compensation program and the Compensation Committee&#146;s response to stockholder feedback.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p.&nbsp;40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><I>Executive Compensation Program</I>.&nbsp;&nbsp;&nbsp;&nbsp;In this section, we
describe the Company&#146;s executive compensation philosophy and process and the material elements of our executive compensation program.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p. 43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><I>2015 Executive Compensation Decisions</I>.&nbsp;&nbsp;&nbsp;&nbsp;In this
section, we provide an overview of the Compensation Committee&#146;s executive compensation decisions for 2015 and certain actions taken before or after 2015 when doing so enhances the understanding of our executive compensation
program.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p. 49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><I>Other Executive Compensation Matters</I>.&nbsp;&nbsp;&nbsp;&nbsp;In this section,
we review the accounting and tax treatment of compensation and the relationship between our compensation program and risk.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p. 56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Executive Summary </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Business Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage biopharmaceutical company that
uses toll-like receptor (&#147;TLR&#148;) biology to discover and develop novel vaccines and therapeutics. Our development programs are focused on vaccine adjuvants and cancer immunotherapy. Our lead product candidates are HEPLISAV-B, an
investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several phase 1/2 studies. Our NEOs are responsible for executing our business strategy of: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transforming the Company into a commercial organization by obtaining FDA approval of HEPLISAV-B and successfully launching this product;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing a robust pipeline of immuno-oncology clinical stage development programs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discovering other cutting edge TLR-based vaccines and immunotherapies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive compensation program is designed to reward achievement of the specific strategic goals that we believe will advance this
business strategy and create long-term value for our stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Performance Highlights </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The highlights of our Company performance for 2015 and early 2016 include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Successfully completing HBV-23, which was a phase 3 trial comparing the safety and immunogenicity of HEPLISAV-B with the currently marketed vaccine,
Engerix-B. In January 2016 we reported preliminary top line results from the study and in March 2016 we submitted a biologics license application (&#147;BLA&#148;) to the FDA. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raising $184 million in net proceeds in an underwritten public offering and through an At Market Issuance Sales Agreement. We used this money to fund
activities associated with completing HBV-23, prepare for the anticipated commercial launch of HEPLISAV-B, including augmenting our manufacturing operations and quality systems, and hire key positions to enhance and support our commercial
infrastructure, as well as support the clinical development of SD-101. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Announcing clinical collaborations with Merck to investigate the combination of our SD-101 with Merck&#146;s KEYTRUDA and MK-1966. In October 2015, a
Dynavax sponsored clinical study was initiated evaluating SD-101 in combination with KEYTRUDA. In December 2015 we reported encouraging data from our clinical trial evaluating SD-101 in patients with lymphoma. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Defining and implementing additional clinical, preclinical and early stage research programs in oncology. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increasing the market value of our common stock by 43% in 2015 and outperforming the following indices: </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Index</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage&nbsp;change&nbsp;for&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ
Biotechnology Index (NBI)</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NYSE
ARCA Biotechnology Index (BTK)</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SPDR
S&amp;P Biotech ETF (XBI)</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ
Composite Index (IXI)</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S&amp;P
500 (SNP)</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-1</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dynavax
(DVAX)</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Governance Highlights </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:40pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What we do</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What we do not do</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Design executive compensation program to align pay with performance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No excessive change in control or severance payments</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Majority of pay is variable and not guaranteed (over 85% for our Chief Executive Officer in 2015)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">No repricing of underwater stock options without stockholder approval</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prohibit hedging and discourage pledging by executive officers and directors (no pledging in 2015)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">No tax gross-ups</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant equity awards with performance-based vesting (starting in 2016)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">No perquisites</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conduct an annual say-on-pay vote (starting in 2016)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">No guaranteed bonuses</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Seek input from, listen to and respond to stockholders</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consideration of Our 2014 Say-on-Pay Vote and Related Stockholder Engagement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We held our first stockholder advisory vote on executive compensation, commonly referred to as a &#147;say-on-pay vote,&#148; at our 2011
stockholder annual meeting. At that meeting, over 99% of the shares that were voted on this proposal were cast in favor of our say-on-pay proposal. At that time, our stockholders also voted in favor of holding a say-on-pay vote once every three
years and subsequently, our Board adopted a policy consistent with that preference. Accordingly, we held our second say-on-pay vote at our 2014 stockholder annual meeting and at that meeting, over 64% of the shares that were voted on this proposal
were cast in favor of our say-on-pay proposal. In the absence of a say-on-pay vote in 2015, we received feedback from our stockholders on our executive compensation program in connection with the reelection of our Compensation Committee members, who
each received support from approximately 69% of the shares cast. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of our 2014 say-on-pay vote and the level of
support for the reelection of our Compensation Committee members in 2015, we increased our efforts to solicit feedback from our stockholders regarding our executive compensation program. Specifically, we sought feedback from our 30 largest
stockholders and obtained feedback from about one-third of them in 2015. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes to Compensation Programs as a Result of Stockholder Engagement and Proxy Advisory Firm Feedback
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our interaction with stockholders and analysis of the feedback from proxy advisory firms prompted changes to our
compensation program. We take seriously the views of our stockholders and based on the feedback we received, as set forth below, we modified certain compensation program and governance practices. We will continue to solicit input from our
stockholders on a regular basis. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;Topic</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What We Heard</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What We Did</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;Annual Incentive Program</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Be more transparent with respect to goals and achievement of goals.</FONT></TD>

<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Below under &#147;Annual Incentive Program&#148;, we provide
transparency with respect to the corporate and individual goals and achievement underlying our annual incentive program and related payments.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;Long-Term Equity Incentives</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acknowledgement that options require an appreciation in stock price from the date of grant in order to
provide economic value to the recipient and that options are prevalent in the biopharmaceutical industry but preference for a portion of each NEO&#146;s long-term equity incentives to vest based on achievement of specific performance goals related
to our business strategy. Specifically, our stockholders acknowledged the value of performance goals associated with clinical development milestones for us as a pre-commercial company.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2016, 20% of each NEO&#146;s long-term equity incentives were granted in the form of
RSUs that vest solely upon achievement of a clinical development milestone.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;Peer Group</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintain a relevant peer group of companies within reasonable size parameters and similar business
focus.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As described below under &#147;2015 Peer Group&#148;, our Compensation Committee updated
our peer group with guidance from its independent compensation consultant to maintain a peer group of companies with which we compete for executive talent that were of similar size to the Company in terms of market capitalization, product portfolio
and pipeline and number of employees.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;Stock Ownership Guidelines</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consider adopting stock ownership guidelines to further align the long-term interests of NEOs and
stockholders.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We encourage our NEOs to hold a significant equity interest in our Company, but we have
not set specific stock ownership guidelines. As of December 31, 2015, our CEO owned stock and the right to exercise vested in-the-money options equal in value to 6.5x his base salary and each of our NEOs owned stock and the right to exercise vested
in-the-money options equal in value to at least 1.6x his base salary.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;Topic</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What We Heard</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What We Did</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;Related Governance Matters</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continue to improve corporate governance, stockholder rights and
transparency.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.50em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As further described above in Proposal 4, our Compensation Committee decided to seek stockholder feedback in the form of a say-on-pay vote annually instead of
triennially as we originally determined in 2011 in response to stockholder support for a triennial vote.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.50em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As further described below under &#147;Corporate Governance&#148;, we
adopted Corporate Governance Guidelines and posted them on our website.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.50em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As further described below under &#147;Corporate Governance&#148;, our Board adopted a majority vote policy so that any nominee who receives a greater number of
&#147;Withhold&#148; votes than &#147;For&#148; votes must submit an offer of resignation to our Nominating and Corporate Governance Committee.</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Executive Compensation Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Philosophy and Objectives </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe our NEOs&#146; compensation should
align our executives&#146; success with that of our stockholders over the long-term through achievement of strategic corporate objectives that are fundamental to our business model and that will create long-term stockholder value. Our executive
compensation programs are designed to be competitive with our peer group to enable us to attract, motivate, reward, and retain outstanding talent. Our compensation programs are based on the following key principles: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant component of pay is linked with performance and the achievement of our strategic goals. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alignment of our executives&#146; interests with those of our stockholders through equity compensation. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overall compensation that is competitive in the industry in which we compete for executive talent. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognition of individual contributions, teamwork and corporate performance. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation-Setting Process </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:6%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Role of the Compensation Committee and Management </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation
Committee oversees and administers our executive compensation programs. The Compensation Committee acts pursuant to a charter adopted by our Board, which can be found at our website, <U>www.dynavax.com</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee approves our corporate goals and the individual goals of our NEOs
after considering the Company&#146;s recommendations on these matters. The Compensation Committee annually reviews the base salaries, cash incentives and equity compensation of our NEOs and periodically reviews other elements of our compensation.
Compensation decisions are based primarily on the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Peer and Industry Data</I> &#150; The Compensation Committee uses peer and industry data provided by its consultant, Arnosti Consulting Inc.
(&#147;Arnosti&#148;), as a reference in setting base salaries and target cash compensation, determining appropriate levels and mix of equity compensation and determining the type and portion of compensation tied to performance goals. <I>
</I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Annual Performance Reviews</I> &#150; The Chair of the Compensation Committee conducts annual performance reviews of our CEO through interviews and
written assessments from the independent members of our Board and the CEO&#146;s direct reports. The feedback from the CEO&#146;s direct reports provides the Chair and the Board with 360 degree feedback, a valuable input in assessing the CEO&#146;s
leadership and overall performance. Our CEO conducts and presents the performance reviews of the other NEOs to the Compensation Committee after the end of each fiscal year. In reviewing and determining the compensation of each NEO, the Compensation
Committee also considers individual factors, such as: potential for future contributions to Company growth, industry experience and retention concerns. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>CEO Recommendations</I> &#150; The Compensation Committee seeks input from our CEO for setting the salary and target cash compensation levels for
the other NEOs, and also for purposes of setting annual performance metrics and target amounts under the Annual Incentive Program. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:6%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Role of Compensation Consultant </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnosti was engaged by the Compensation
Committee in 2010 as its independent compensation consultant. Since then, the Compensation Committee has met regularly with Arnosti, both with and without management present, depending upon the topic being discussed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2015 and again in April 2016, the Compensation Committee reviewed whether the work of Arnosti as a compensation consultant
raised any conflict of interest, taking into consideration the following factors: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provision of other services to the Company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount of fees paid to Arnosti by the Company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnosti&#146;s policies and procedures that are designed to prevent conflicts of interest; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any business or personal relationship of Arnosti or the individual compensation advisors employed by Arnosti with an executive officer of the Company;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any Company stock owned by Arnosti or the individual compensation advisors employed by Arnosti. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the Compensation Committee&#146;s review of this information, it determined the work of Arnosti and the individual compensation
advisors employed by Arnosti as compensation consultants in support of the specific analyses and needs of the Compensation Committee in its efforts for fiscal year 2015, did not create any conflict of interest. The Compensation Committee has the
sole authority to direct, terminate or continue Arnosti&#146;s services, although the Company pays the cost for Arnosti&#146;s services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2015, Arnosti provided advice to the Compensation Committee on several different aspects of its responsibilities related to our compensation programs and practices. Specifically, during 2015, Arnosti
assisted the Compensation Committee as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reviewed and analyzed compensation levels of our NEOs in comparison to those of our peer companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided general information concerning executive compensation trends and developments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided recommendations to the Compensation Committee on refining our peer group; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided an assessment of the annual meeting voting results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided the Board with a review of competitive data from the peer group on Board compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reviewed the Compensation Discussion and Analysis for inclusion in our proxy statement. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2015 Peer Group </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee generally uses a peer group for a general understanding of market compensation practices and our positioning within the peer group with respect to each element of our
compensation program. In some circumstances, our Compensation Committee targets compensation components to meet specific benchmarks, such as targeting a base salary at the 50</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> percentile. However, our Compensation Committee believes that over-reliance on benchmarking can result in compensation
that is unrelated to the value delivered by the NEOs because compensation benchmarking does not take the specific performance of the NEOs, or the performance of the Company, into account. The Compensation Committee also considers various sources of
third party compensation information, such as Radford&#146;s Global Life Science Survey, in connection with its compensation decisions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In November 2014, our Compensation Committee approved a peer group of biotechnology companies at a similar stage of product development with which we compete for executive talent that were of similar size
to the Company in terms of market capitalization, product portfolio, pipeline and number of employees. To align with our strategic plan, which includes commercialization of HEPLISAV-B and expansion of our pipeline with early clinical development in
cancer immunotherapy, our peer group includes companies that are both oncology and non-oncology focused and companies that have their own manufacturing operations. There are only three commercial companies (Anika, Biocryst, and Corcept) in our peer
group. As of October&nbsp;8, 2014, which was shortly before the 2015 peer group was approved, the companies in the 2015 peer group had market capitalizations between $102 million (Vical, Inc.) and $1,630 million (Nektar) and the median market
capitalization of our peer group was $428 million. At that time, our market capitalization was $381 million. The following table summarizes the key statistics of each of the companies in our 2015 peer group: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market<BR>Capitalization</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>on October&nbsp;8,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in millions)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Employees</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company
Description</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>ANIKA
THERAPEUTICS INC</I></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">562</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Develops, manufactures and commercializes therapeutic products for tissue protection,
healing and repair.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARENA
PHARMACEUTICALS INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">844</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">310</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Focused on discovering, developing and commercializing novel drugs that target G
protein-coupled receptors, or GPCRs, to address unmet medical needs.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>BIOCRYST PHARMACEUTICALS INC</I></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">836</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designs, optimizes and develops novel drugs that block key enzymes involved in the
pathogenesis of diseases.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>CORCEPT THERAPEUTICS INC</I></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">280</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Engaged in the discovery, development and commercialization of drugs for the treatment
of severe metabolic and psychiatric disorders.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CYTOKINETICS INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical-stage biopharmaceutical company focused on the discovery and development of
novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="40%"></TD></TR>

<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market<BR>Capitalization</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>on October&nbsp;8,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in millions)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Employees</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company
Description</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEPOMED
INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">873</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">291</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specialty pharmaceutical company initially focused on pain and other conditions and
diseases of the central nervous system.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">GERON
CORP</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">315</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biopharmaceutical company developing first-in-class therapies for
cancer.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NEKTAR
THERAPEUTICS</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,630</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">445</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical-stage biopharmaceutical company developing a pipeline of drug candidates that
utilize PEGylation and advanced polymer conjugate technology platforms.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVAVAX
INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,070</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">213</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical-stage biopharmaceutical company focused on developing recombinant protein
nanoparticle vaccines to address a broad range of infectious diseases.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">OREXIGEN
THERAPEUTICS, INC.</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">448</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biopharmaceutical company focused on the development of pharmaceutical product
candidates for the treatment of obesity.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PEREGRINE PHARMACEUTICALS INC</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">241</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">180</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biopharmaceutical company with a portfolio of innovative monoclonal antibodies in
clinical trials for the treatment and diagnosis of cancer.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPLIGEN
CORP</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">707</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Develops, manufactures and markets high-value, consumable bioprocessing products for
life sciences companies and biopharmaceutical manufacturing companies worldwide.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">RIGEL
PHARMACEUTICALS INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">129</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical-stage drug development company that discovers and develops novel,
small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SANGAMO
BIOSCIENCES INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">716</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical stage biopharmaceutical company focused on the research, development and
commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SYNTA
PHARMACEUTICALS CORP</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">304</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">134</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Focused on discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THRESHOLD PHARMACEUTICALS INC</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">194</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expertise in the tumor microenvironment to discover and develop therapeutic agents that
selectively target tumor cells for the treatment of patients living with cancer.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD></TR>

<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market<BR>Capitalization</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>on October&nbsp;8,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in millions)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Employees</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company
Description</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">VICAL
INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and develop biopharmaceutical products based on patented DNA delivery
technologies for the prevention and treatment of serious or life-threatening diseases.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">XENOPORT
INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">349</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Focused on developing and commercializing a portfolio of internally discovered product
candidates with an initial focus on neurological disorders.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">XOMA
CORP</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">428</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">180</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discovers and develops innovative antibody-based therapeutics.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the companies that were in our 2014 peer group and removed from our 2015 peer
group either because they had market capitalizations below $100 million or because they were acquired. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market<BR>Capitalization</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>on October&nbsp;8,<BR>2014</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in millions)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Employees</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company
Description</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AFFYMAX
INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discovering, developing and delivering innovative therapies that improve the lives of
patients with kidney disease and other serious and often life-threatening illnesses.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALEXZA
PHARMACEUTICALS INC.</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Focused on the research, development and commercialization of novel proprietary
products for the acute treatment of central nervous system conditions.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CYTORI
THERAPEUTICS, INC.</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Developing cell therapies for the treatment of cardiovascular disease, burns and other
soft tissue injuries.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IDENIX
PHARMACEUTICALS INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">acquired</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biopharmaceutical company engaged in the discovery and development of drugs for the
treatment of human viral diseases with operations in the United States and France.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">INTERMUNE INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">acquired</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Focused on the research, development and commercialization of innovative therapies in
pulmonology and orphan fibrotic diseases.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SUNESIS
PHARMACEUTICALS INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Focused on the development and commercialization of new oncology therapeutics for the
treatment of solid and hematologic cancers.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">TARGACEPT INC</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Engaged in the development of novel NNR Therapeutics(TM) for the treatment of diseases
and disorders of the nervous system.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Elements of Executive Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive team continues to manage a changing and increasingly complex business. We strive to recognize these efforts by compensating
our NEOs for the demands and risks associated with our business through three elements that are designed to reward performance in a simple and straightforward manner&#151;base salaries, annual performance-based cash incentives and long-term equity
awards. During our 2015 stockholder outreach, our key stockholders expressed support for the elements of our executive compensation program, including our continued use of stock options as one portion of long-term equity awards. However, several
stockholders also recommended granting a portion of long-term equity awards with performance-based vesting. As reflected in the chart below, we responded to the feedback from our stockholders by introducing performance-based vesting for a portion of
our 2016 long-term equity awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below summarizes the purpose and key characteristics of each of our compensation
elements. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Element</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Purpose</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Key Characteristics</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Base
salary</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provides a fixed level of compensation for performing the essential day-to-day elements of the job; gives executives a degree of certainty in
light of having a majority of their compensation at risk.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fixed compensation that is reviewed annually and adjusted if and when appropriate;
reflects each NEO&#146;s performance, experience, skills, level of responsibility and the breadth, scope and complexity of the position as well as the competitive marketplace for executive talent specific to our industry.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Annual Incentive Program</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve corporate and individual business goals, which we believe increase stockholder value, while providing
flexibility to respond to opportunities and changing market conditions.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual cash incentive based on corporate and individual performance
compared to pre-established goals. Our CEO&#146;s incentive is based entirely on corporate goals.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate goals focus on overarching objectives for the Company, while
individual objectives represent key performance expectations at the departmental or individual level.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate goals are aligned with our business strategy and weighted by
relative importance so that achievement can be objectively measured.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentives (Stock
Option)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve our business objectives by tying incentives to the appreciation of our common stock over the long
term.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options with an exercise price equal to
or greater than the fair market value on the date of grant vesting over four years; the ultimate value realized, if any, depends on the appreciation of our common stock price and if our stock price does not appreciate, there is no value
realized.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the aggregate size of equity grants in any given
year, the Compensation Committee generally considers the same factors described above under &#147;Base Salaries&#148; as well as the criticality of the executive to the long-term achievement of corporate
goals.</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Element</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Purpose</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Key Characteristics</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentives (RSUs)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve our corporate objectives by tying compensation to the performance of our common stock over the long
term and/or the achievement of business and clinical development goals over the long term; motivates our executive officers to remain with the Company by mitigating swings in incentive values during periods when market volatility weighs on our stock
price.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock unit awards may vest based
on continued service over a specified period of time and/or achievement of performance goals; the ultimate value realized varies with our common stock price.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2016, 20% of our executive officers&#146; annual grants were performance-based restricted stock unit awards vesting solely upon achievement of
a clinical development milestone.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other compensation</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive officers participate in the same benefits offered to all other employees, which promote employee health and welfare and assist
in attracting and retaining our executive officers.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indirect compensation element consisting of programs such as medical, vision, dental, life
and accidental death, long-term care and disability insurance as well as a 401(k) plan with a Company matching contribution, and other plans and programs made available to eligible employees.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Severance and Change in Control Benefits</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Serves our retention objectives by helping our named executive officers maintain continued focus and dedication to their responsibilities to
maximize stockholder value, including in the event of a transaction that could result in a change in control of our Company.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provides protection in the event of a termination of employment under specified
circumstances, including following a change in control of our Company as described below under &#147;Potential Payments Upon Change in Control or Involuntary Termination.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2015 Executive Compensation Decisions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Base Salaries </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">When determining base salary
adjustments, the Compensation Committee generally targets a level at or near the 50</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> percentile of our peer group, but also considers each individual&#146;s industry experience and tenure, internal pay equity, and any particular retention concerns. As such, Mr.&nbsp;Gray,
Dr.&nbsp;Coffman and Mr.&nbsp;Ostrach have base salaries at or above the 50</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> percentile because of their broad industry experience, expertise, and tenure with the Company. With respect to Dr.&nbsp;Janssen&#146;s and Mr.&nbsp;Novack, their base salaries are below the 50</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> percentile as a result of the Compensation Committee&#146;s
objective to balance external competitiveness with internal pay equity and the Company&#146;s annual salary budget. The 2015 base salary increases were made after the Compensation Committee considered each individual&#146;s performance and Company
performance. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015&nbsp;Base<BR>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%&nbsp;Increase<BR>from Prior<BR>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">566,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">390,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">453,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">369,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">375,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Annual Incentive Program </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In early 2015, the Compensation Committee established the corporate goals described below. We are a clinical-stage biopharmaceutical company and so our objective corporate goals are directly aligned with
our specific strategic goals, including advancing our development programs, that we believe will create long-term value for stockholders. In February 2016, the Compensation Committee evaluated the accomplishments and performance of the Company
against such corporate goals. We have omitted details about the 2015 goals or achievement of goals in the table below only where we believe disclosing such details would result in competitive harm. After its consideration of the Company&#146;s
performance, as more specifically described in the following chart, the Compensation Committee rated our 2015 corporate achievement at 109% of our 2015 corporate goals. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Goal</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighting</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">HEPLISAV-B Advancement</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Complete HBV-23 study and deliver Complete Response Letter commitments to enable HEPLISAV-B towards a BLA submission</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Complete all activities related to commercialization of HEPLISAV-B</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Successful completion of:</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TheHBV-23 Phase 3 study of HEPLISAV-B and communication of
top line results, enabling HEPLISAV towards a BLA submission</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Activitiesrelated to pre-inspection readiness</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-launchactivities in commercial and
manufacturing</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Improvementsin our manufacturing and quality
systems</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Compensation Committee determined we exceeded this goal
because of several factors, including:</I></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HBV-23was a complex study with over 8,300 adult subjects.</I></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,the size and complexity of HBV-23 is
believed to be the largest US study of an adult hepatitis B vaccine, larger than any done by our large pharmaceutical competitors. Dynavax is a mid-size biotechnology company with a US headcount of 137 and a clinical team of 24 employees as of
December 31, 2015.</I></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>

<TR>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Goal</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighting</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Advance the Pipeline</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Advance clinical development of SD-101 and AZ1419</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Advance early research development</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Progressed and broadened our cancer immunotherapy pipeline,
including:</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completedclinical collaborations with Merck to combine our
SD-101 with Merck&#146;s KEYTRUDA and MK1966</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaboratedon AZ1419 clinical development with AstraZeneca</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuedprogress in advancing early research and
development projects, including identification of our next immuno-oncology clinical candidate</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initiatedand advanced SD-101 clinical
studies</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Quality &#150; Implement quality systems and programs to foster a corporate &#147;<I>Quality</I>&#148; culture</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Complete training in quality and compliance</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Implement quality systems and controls as well as metrics/key performance indicators to enhance quality programs</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completedplanned enhancements and training in quality and
compliance</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completedlaunch of additional modules of electronic quality
management system</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>

<TR>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Goal</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighting</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Execute on the Dynavax business plan</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Manage spending to budget and maintain approximately one-year of cash at year end 2014/Q1 2015</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase market cap by least 10% against appropriate biotech indices</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Implement system and talent strategies to maintain critical path
programs and enable the Company to a successful commercialization of HEPLISAV-B</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Multi-componentfinancing strategy and effective budget
management, resulted in $196 million cash balance at year end, positioning the Company to fund the HEPLISAV-B launch and our research and development programs</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43%increase in market cap significantly exceeded
indices</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successin hiring and retaining key talent allowed the
Company to exceed key business objectives. Talent management assessment completed and follow-on programs designed for 2016.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The Compensation Committee determined we exceeded this goal because we successfully raised more cash than planned through sales of equity at favorable valuations.</I></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Additionally, our corporate communications activities and the positive news flow
from our corporate achievements enabled the performance of our stock price to significantly exceed several indices, as described above under &#147;Corporate Performance Highlights.&#148;</I></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>100</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>109</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As described above, our Chief Executive Officer does not have individual goals separate from
the Company&#146;s corporate objectives. For our other NEOs, their total cash incentive payout for 2015 was based on a weighting of 50% corporate and 50% individual goals. Our CEO recommends individual goals for each NEO, which are aligned with our
business strategy and linked with corporate goals, and our Compensation Committee approves these goals. The 2015 individual goals for the NEOs include those listed below. These specific goals were in addition to the general responsibilities each
officer had for managing his respective functional or operational area. In early 2016, the Compensation Committee evaluated the performance of the NEOs against their individual goals for 2015. Based on the recommendation of our CEO, as well as the
observations by Compensation Committee members of these officers and its own assessment of each NEO&#146;s effectiveness, the Compensation Committee determined the level of achievement of each NEO&#146;s individual performance goals as follows:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015 Individual Goals</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael
S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generate and implement cash generation and conservation
strategies</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase and broaden communication and investor relations
activities</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Develop business development strategies across programs that are
implementable with/for the right opportunities</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retain, develop, and/or hire talent to deliver on our business strategies to commercialize the Company, advance our programs in immuno-oncology, and progress our
scientific platform</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Ostrach exceeded in that his financing strategies allowed the Company to raise $184 million at favorable
valuations and in excess of expectations. The successful equity offerings along with his investor relations outreach created the opportunity for our stock to outperform relevant indices, as described above in &#147;Corporate Performance
Highlights.&#148; Mr.&nbsp;Ostrach also managed completion of clinical collaboration agreements with Merck. Mr. Ostrach met his other goals.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advance preclinical oncology programs to the clinic</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Develop and implement strategies that will continue to broaden our
scientific platform</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retain, develop, and/or hire talent to deliver on our business strategies
to advance programs in immuno-oncology and progress our scientific platform</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Coffman exceeded in generating and advancing multiple oncology preclinical and research programs,
including a clinical candidate. Dr. Coffman met his other goals.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015 Individual Goals</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Complete HBV-23 study for HEPLISAV-B to enable commercialization</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Develop and implement strategies to advance immuno-oncology programs in the
clinic</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Develop and implement inspection readiness strategies to ensure a positive
inspection outcome to commercialize <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retain, develop, and/or hire talent to deliver on our business strategies
to commercialize the Company, advance our programs in immuno-oncology, and progress our scientific platform</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Janssen exceeded in timely completing HBV-23, including data base lock, and BLA preparation enabling BLA
submission for HEPLISAV-B as well as advancing the lymphoma and melanoma clinical trials. Dr. Janssen met his other goals.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David
Novack</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliver on all CMC related activities that enable the Company&#146;s BLA
submission for commercialization of HEPLISAV-B</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Develop and implement manufacturing strategies for commercialization of HEPLISAV-B and to advance our immuno-oncology programs in the clinic</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continue to implement quality assurance strategies required for a
commercial organization</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retain, develop, and/or hire talent to deliver on our business strategies
to commercialize the Company, advance our programs in immuno-oncology, and progress our scientific platform</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Novack exceeded in CMC development and BLA preparation activities that enabled our BLA submission for
HEPLISAV-B and manufacturing preparation to support commercial launch. Mr. Novack met his other goals.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After making these determinations regarding levels of corporate and individual performance
achieved against the pre-established performance goals, the Compensation Committee (and the full Board with respect to Mr.&nbsp;Gray) reviewed and approved the cash incentive payouts noted below. As noted above, for the NEOs other than the CEO,
their cash incentive payouts are based 50% on achievement of corporate goals and 50% on achievement of individual goals. There were no changes to the NEOs&#146; target annual cash incentive percentages between 2014 and 2015. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015&nbsp;Target&nbsp;Annual<BR>Cash Incentive</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015 Actual Annual Cash Incentive Paid</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Achievement&nbsp;of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate
Goals</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Achievement of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual
Goals</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Base<BR>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%&nbsp;of&nbsp;Target<BR>Annual&nbsp;Cash<BR>Incentive</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%&nbsp;of&nbsp;Target<BR>Annual&nbsp;Cash<BR>Incentive</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">339,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">370,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">370,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">228,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">226,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">123,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">253,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,693</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107,813</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">210,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentive Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In making annual long-term equity incentive awards to NEOs in February 2015, the Compensation Committee considered
each NEO&#146;s total options outstanding as of December&nbsp;31, 2014, his performance during 2014, the potential amount that could be realized at different hypothetical stock prices upon exercise of those awards, each NEO&#146;s percentage of
ownership of the Company, and peer company data for similarly situated executives. The Compensation Committee generally targets the value of each NEO&#146;s long-term equity incentive award at approximately the 60</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> percentile of the peer group and makes final determinations based on
its judgment in accordance with our pay-for-performance philosophy, which allows for above-market rewards for exceptional performance. The Compensation Committee determined to grant only stock options as long-term incentive awards in 2015 because of
the ultimate value realized, if any, depends on the appreciation of our common stock price and if our stock price does not appreciate, there is no value realized and therefore there is a direct alignment with the long-term interests of our
stockholders. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Subject<BR>to February<BR>2015 Stock<BR>Option&nbsp;Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2015 the Compensation Committee analyzed the outstanding equity awards held by individuals who
had been employed by the Company for at least seven years. As part of this analysis, the Compensation Committee reviewed each NEO&#146;s outstanding stock options, the potential amount, if any, that could be realized at different hypothetical stock
prices upon exercise of each outstanding stock option and the termination date of each stock option. As a result of this analysis, the Compensation Committee decided to grant Mr.&nbsp;Ostrach a stock option grant for 29,000 shares and
Dr.&nbsp;Coffman a stock option grant for 16,501 shares. The Compensation Committee believes these awards will help retain and motivate these highly experienced and essential members of our management team. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In response to feedback from our stockholders, 20% of each of our NEO&#146;s 2016 annual grants were performance-based restricted stock
unit awards vesting solely upon achievement of a regulatory approval objective. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Equity Compensation Policies</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee
approves equity awards for NEOs and authorizes the CEO to approve equity awards for all other employees based on approved pools for annual and new hire grants. This applies to both new-hire and annual equity awards. Awards are approved either at a <FONT
STYLE="white-space:nowrap">regularly-scheduled</FONT> meeting of the Compensation Committee or by unanimous written consent. The effective date of the grant is generally the date of the meeting, or the date the last person executes the unanimous
written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exercise price of the stock options is not less than the closing price of our common stock on the NASDAQ
Capital Market on the grant date of the stock option. We have no practice of timing grants of stock options or restricted stock awards to coordinate with the release of material non-public information, and we have not timed the release of material
non-public information for purposes of affecting the value of the compensation awarded to our NEOs or any other employee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
encourage our NEOs to hold a significant equity interest in our Company, but we have not set specific stock ownership guidelines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have a policy that prohibits our executive officers, directors and other members of management from engaging in short sales, transactions in put or call options, hedging transactions or other
inherently speculative transactions with respect to our stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Executive Compensation Matters </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax Effects of Executive Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee considers the impact of the deduction limitation imposed by Section&nbsp;162(m) of the Code in establishing and implementing compensation policies and practices. The
Compensation Committee may grant compensation that qualifies as performance-based compensation when it determines that it is in the best interest of the Company, but we have not established a policy that requires all compensation paid to our NEOs to
be fully deductible. Rather, the deductibility of such compensation is one of the factors considered in establishing and implementing our executive compensation programs, along with the need to design compensation programs that appropriately
motivate our senior management and our goal to attract and retain key executives by remaining competitive in our pay practices. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee also considers the impact of Section&nbsp;409A of the Code, and in general, our executive plans and programs
are designed to comply with the requirements of that section so as to avoid possible adverse tax consequences that may result from non-compliance. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounting Considerations </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accounting impact of our compensation
programs is one of many factors that the Compensation Committee considers in determining the structure and size of our executive compensation programs. In general, the Company accounts for equity compensation paid to our employees under the
Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation, or ASC 718, which requires us to estimate and record an expense over the service period of the equity award, and our cash
compensation is recorded as an expense at the time the obligation is accrued. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Recovery Policy </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts paid and awards granted under our Amended 2011 Plan are subject to recoupment in accordance with the Dodd-Frank Wall Street Reform
and Consumer Protection Act and any applicable regulations under the Act, any clawback policy the Company adopts or as is required by applicable law. In addition, as a public company subject to the provisions of Section&nbsp;304 of the
Sarbanes-Oxley Act of 2002, if we are required as a result of misconduct to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws, our chief executive officer and
chief financial officer may be legally required to reimburse </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
us for any bonus or other incentive-based or equity-based compensation they receive. In addition, we will comply&nbsp;with the requirements of the Dodd-Frank Wall Street Reform and Consumer
Protection Act once the SEC final regulations on the subject become effective. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Risk Analysis </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During fiscal 2015, our Compensation Committee reviewed our compensation policies as generally applicable to our employees in order to
determine whether any such programs were likely to present a material risk to the Company. As part of its assessment, the Compensation Committee considered, among other things, the allocation of compensation among base salary and short- and
long-term compensation, our approach to establishing Company-wide and individual financial, operational and other performance targets, and the nature of our key performance metrics. As a result of this review and analysis, the Compensation
Committee&#146;s determined that our policies and programs do not encourage excessive or inappropriate risk taking, and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on the Company.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Compensation Committee of the Board of Directors on Executive Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In early 2016, the Compensation Committee discussed with management the Compensation Discussion and Analysis, contained in this proxy
statement. Based on this review and discussion, the Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this proxy statement and incorporated into our Annual Report on Form 10-K for the
fiscal year ended December&nbsp;31, 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The material in this report is not &#147;soliciting material,&#148; is furnished
to, but not deemed &#147;filed&#148; with, the SEC and is not deemed to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, other than the Company&#146;s Annual Report on Form 10-K, where it shall
be deemed to be &#147;furnished,&#148; whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Peggy&nbsp;V. Phillips, Chairperson </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Francis&nbsp;R. Cano, Ph.D.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Daniel Kisner, M.D. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>UMMARY</SMALL> C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows for the fiscal years ended December&nbsp;31, 2015, 2014 and 2013, compensation awarded to or paid to, or earned
by, NEOs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Non-Equity<BR>Incentive Plan<BR>Compensation<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All
Other<BR>Compensation<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">566,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,004,616</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">370,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,943,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">515,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">855,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,564,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">432,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,367,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">333,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,030,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">200,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,813,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">390,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,420,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">228,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,040,503</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President, Chief<BR>Financial Officer and Chief<BR>Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">354,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">181,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">425,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">221,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,181,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">342,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">561,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">185,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,616</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,092,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">453,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,300,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">253,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,009,623</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President and<BR>Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">440,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">42,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">286,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">768,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">282,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">505,764</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">175,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">963,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">369,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">747,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">206,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,326,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Chief Medical Officer and<BR>Vice President, Clinical<BR>Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">358,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">181,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">283,554</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">246,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,069,945</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">323,878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">175,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">145,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">648,739</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">375,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,001,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">210,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,588,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President,<BR>Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">309,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">362,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">346,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">208,575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,226,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">230,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">587,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">155,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,049,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents for Mr.&nbsp;Gray, the portion of his 2013 annual cash incentive award guaranteed under his employment agreement, and for Mr.&nbsp;Novack, a
signing bonus that was subject to clawback in the event he terminated employment prior to completion of a full year of service. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Represents the aggregate grant date fair value of stock awards granted in
the fiscal year in accordance with ASC 718. See note 13 of our &#147;Notes to Consolidated Financial Statements&#148; in our annual report on Form 10-K filed with the SEC on March&nbsp;8, 2016 for a discussion of assumptions we made in determining
the compensation costs included in this column. With regard to stock awards with performance-based vesting, the grant date fair value assumes the highest level of achievement of related performance conditions. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate grant date fair value of option awards granted in the fiscal year in accordance with ASC 718. See note 13 of our &#147;Notes
to Consolidated Financial Statements&#148; in our annual report on Form 10-K filed with the SEC on March&nbsp;8, 2016 for a discussion of assumptions we made in determining the compensation costs included in this column.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the annual incentive bonuses earned pursuant to our annual incentive bonus plan for services rendered in the fiscal year. For further
discussion see the section entitled &#147;Compensation Discussion and Analysis &#150; 2015 Executive Compensation Decisions &#150; Annual Incentive Plan.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Includes $2,000 401(k) matching contribution for each NEO made by the
Company in 2015. Represents for 2013 the following amounts for each NEO: For Mr.&nbsp;Ostrach, Dr.&nbsp;Coffman, Dr.&nbsp;Janssen and Mr.&nbsp;Novack: premiums and claims paid under the Exec-U-Care medical program (which terminated on
December&nbsp;31, 2013); for Mr.&nbsp;Gray: $200,000 paid pursuant to his employment agreement to cover all relocation expenses and $250 in Exec-U-Care coverage. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>RANTS</SMALL> O<SMALL>F</SMALL> P<SMALL>LAN</SMALL> B<SMALL>ASED</SMALL> A<SMALL>WARDS</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows certain information regarding grants of plan-based awards to NEOs during the fiscal year ended
December&nbsp;31, 2015. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated<BR>Future<BR>Payouts<BR>Under<BR>Non-<BR>Equity<BR>Incentive<BR>Plan<BR>Awards<BR>Target<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP><BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All&nbsp;Other<BR>Option<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Options<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP><BR>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>or
Base<BR>Price&nbsp;of<BR>Option<BR>Awards</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($/Share)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant Date<BR>Fair Value<BR>of Option<BR>Awards<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">339,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,004,616</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">894,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8/27/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">525,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">226,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,001,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8/27/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">299,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">747,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,001,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the target cash incentive award in fiscal year 2015 as further described under &#147;Compensation Discussion and Analysis &#150; Elements of
Executive Compensation&#148;; our Annual Incentive Program does not specify minimum or maximum levels. Cash incentive awards paid to our NEOs on account of fiscal year 2015 performance are reported in the &#147;Non-Equity Incentive Plan
Compensation&#148; column in the &#147;Summary Compensation Table.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>All options were granted under the 2011 Plan and vest as to 25% of the
shares subject to the award 12 months after the vesting commencement date, with the remainder vesting as to 1/48<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP> of the shares each month thereafter. The exercise price of
all options was the closing price of our common stock on the date of grant. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Represents the aggregate grant date fair value of option awards granted in
fiscal year 2015 in accordance with ASC 718. See Note 13 of our &#147;Notes to Consolidated Financial Statements&#148; in our annual report on Form 10-K filed with the SEC on March&nbsp;8, 2016 for a discussion of the assumptions we made in
determining the compensation costs included in this column. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ARRATIVE</SMALL> D<SMALL>ISCLOSURE</SMALL>
<SMALL>TO</SMALL> S<SMALL>UMMARY</SMALL> C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> <SMALL>AND</SMALL> G<SMALL>RANTS</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL> B<SMALL>ASED</SMALL> A<SMALL>WARDS</SMALL> T<SMALL>ABLE</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The material terms of NEOs&#146; annual compensation and the explanations of the amounts of base salary, annual cash-based incentives, and
equity-based awards in proportion to total compensation are described under &#147;Compensation Discussion and Analysis&#148; in this proxy statement. Our severance and change in control benefits are described under &#147;Summary of Change in Control
and Involuntary Termination Arrangements&#148; in this proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As discussed in the &#147;Compensation Discussion and
Analysis,&#148; the fiscal year 2015 cash incentive amounts were paid pursuant to the annual cash incentive compensation program, based on the achievement of certain corporate and individual performance goals. Equity-based awards were granted in
2015 under our 2011 Plan and generally vest over four years from the date of grant, subject to continued employment. The exercise price of all options was set as the closing market price of our common stock on the grant date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>UTSTANDING</SMALL> E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> A<SMALL>T</SMALL>
F<SMALL>ISCAL</SMALL> Y<SMALL>EAR</SMALL> E<SMALL>ND</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows certain information regarding
outstanding equity awards for NEOs as of December&nbsp;31, 2015. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Shares or<BR>Units that<BR>Have Not<BR>Vested (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market&nbsp;Value<BR>of Stock that<BR>Have Not<BR>Vested ($)<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number&nbsp;of<BR>Unearned<BR>Shares
or<BR>Other<BR>Rights<BR>that Have<BR>Not<BR>Vested (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market or<BR>Payout<BR>Value of<BR>Unearned<BR>Shares
or<BR>Other<BR>Rights&nbsp;that<BR>Have Not<BR>Vested ($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">96,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">53,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">22.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4/30/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">35,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">39,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">68,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">81,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">225,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,208,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">61.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10/30/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">53.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/2/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/9/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">34.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">14,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">12,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">14,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">67,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">29,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">28.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/26/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">241,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">58.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/13/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">61.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/1/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">53.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/2/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/9/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">34.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">12,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">28.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/26/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4/6/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">36.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">41.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">56,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">362,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">241,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/24/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">483,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This amount represents the maximum number of shares subject to this stock award. Stock awards will be earned upon achievement of certain performance
conditions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Options vest at the rate of 1/4th of the shares on the first anniversary of the vesting commencement date, with 1/48th of the total number of shares
vesting each month thereafter. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">RSUs vests on the three (3)&nbsp;year anniversary of the grant date. RSUs for Eddie Gray will vest on February&nbsp;4, 2017. The remaining RSUs will
vest on March&nbsp;11, 2017. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Based on the closing price per share on December&nbsp;31, 2015 of $24.16. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>PTION</SMALL> E<SMALL>XERCISES</SMALL> A<SMALL>ND</SMALL> S<SMALL>TOCK</SMALL>
V<SMALL>ESTED</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides information on stock awards that vested, including the number of shares
acquired upon vesting and the value realized, determined as described below, for the named executive officers in the fiscal year ended December&nbsp;31, 2015. There were no option exercises during the fiscal year ended December&nbsp;31, 2015.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Vesting (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value&nbsp;Realized</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>on
Vesting<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,175</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">The value realized on vesting is determined by multiplying the number of shares of stock, or 2,500, by the market value of the underlying shares as
reported by the NASDAQ Capital Market on the vesting date, or $16.47. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ENSION</SMALL> B<SMALL>ENEFITS</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the NEOs participates in or has an account balance under any pension or qualified or non-qualified defined benefit
retirement plans sponsored by the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ON</SMALL>-Q<SMALL>UALIFIED</SMALL> D<SMALL>EFERRED</SMALL> C<SMALL>OMPENSATION</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the NEOs participates in or has an account balance under any non-qualified defined contribution plans or other
non-qualified deferred compensation plans maintained by the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>OTENTIAL</SMALL> P<SMALL>AYMENTS</SMALL>
U<SMALL>PON</SMALL> C<SMALL>HANGE</SMALL> <SMALL>IN</SMALL> C<SMALL>ONTROL</SMALL> <SMALL>OR</SMALL> I<SMALL>NVOLUNTARY</SMALL> T<SMALL>ERMINATION</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of Change in Control and Involuntary Termination Arrangements. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To
promote retention of certain key executives, our Board has authorized the Company to enter into Management Continuity and Severance Agreements with each NEO. We refer to the agreements in effect as of December&nbsp;31, 2015 as the &#147;Management
Agreements.&#148; In order to be eligible to receive benefits under the Management Agreements, our NEOs and other officers must execute a general waiver and release of claims, and such release must become effective in accordance with its terms.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Change in Control. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Immediately prior to the effective date of a Change in Control, each NEO shall receive accelerated vesting (full vesting for Mr.&nbsp;Gray and two years vesting for our other officers) of equity awards
that are held by such NEO on the effective date of such Change in Control. The Management Agreements generally define a Change in Control to mean the occurrence of a change in the majority ownership of the voting securities of the Company, a merger
that results in change in the majority ownership of the voting securities of the Company, or the sale of all or substantially all of the assets (including as part of a liquidation of the Company). The table below outlines the potential payments and
benefits payable to each current NEO in the event of a Change in Control (without termination of employment) of the Company, assuming such event had occurred on December&nbsp;31, 2015. In April 2016, the Management Agreements with Mr.&nbsp;Ostrach,
Dr.&nbsp;Coffman, Dr.&nbsp;Janssen and Mr.&nbsp;Novack were updated to eliminate this benefit and provide for full accelerated vesting in connection with a Change in Control only in the event of a related termination of employment. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Aggregate&nbsp;Number&nbsp;Of<BR>Equity Award Shares<BR>Subject&nbsp;to&nbsp;Accelerated<BR>Vesting
on CIC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value&nbsp;of&nbsp;Accelerated<BR>Equity<BR>Awards<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">448,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,991,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">482,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">433,492</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,895</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">387,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">537,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the value of stock and accelerated stock option and award vesting if the event took place on December&nbsp;31, 2015. The value is calculated based on the
closing price per share on December&nbsp;31, 2015. The value is calculated based on the &#147;spread&#148; between the closing price per share on December&nbsp;31, 2015 of $24.16 and the exercise price of the vested awards, to the extent such vested
awards were &#147;in the money.&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Qualifying Termination in Connection with a Change in Control. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Management Agreements, if, on or during the two-year period following a Change in Control, the NEO&#146;s employment is
involuntarily terminated, the NEO will, subject to the execution of a release of claims, be entitled to receive: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a lump-sum cash payment equal to a specified number of months (ranging from 12 to 24) of the executive&#146;s then-effective annual base salary;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a lump-sum cash payment equal to the NEO&#146;s target annual variable cash compensation (ranging from 100% to 200% of such target) for the year of
termination; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cash payments equal to the applicable COBRA premiums for up to the same number of months as the NEO receives in base salary, as set forth in the first
bullet (the &#147;COBRA Payment&#148;); and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extension of exercisability of all stock options to purchase the Company&#146;s common stock for a period of 3 years following termination of
employment (but in any event not beyond each option&#146;s expiration date). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, if any payments
or benefits would constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code and such payments would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then such payments will either be
(1)&nbsp;provided to the NEO in full or (2)&nbsp;reduced to such lesser amount that would result in no portion of such payments being subject to the excise tax, whichever amount after taking into account all applicable taxes, including the excise
tax, would result in the NEO&#146;s receipt, on an after-tax basis, of the greatest amount of such payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms
of Mr.&nbsp;Gray&#146;s Management Agreement, he will receive 24 months of base salary, 200% of his target annual cash incentive, the COBRA Payment, accelerated vesting of all outstanding time-vesting options and restricted stock awards, and up to 3
years to exercise his vested options. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our other NEOs will receive 12 months of base salary, 100% of the target annual variable
cash compensation, the COBRA Payment, an additional 2 years of accelerated vesting of outstanding time-vesting options (or full acceleration after the April 2016 amendments), and up to 3 years to exercise their vested options. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below outlines the potential payments and benefits payable to each NEO in the event of such executive&#146;s termination in
connection with a Change in Control of the Company, assuming such event had occurred on December&nbsp;31, 2015. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Severance</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payment</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Continuation</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of
Benefits</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value
of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accelerated<BR>Stock</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,812,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,991,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,856,692</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">585,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">482,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,109,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">679,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">433,492</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,142,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">554,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">387,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">971,134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">562,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">537,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,141,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the value of accelerated stock option and award vesting if the event took place on December&nbsp;31, 2015. The value is calculated based on
the &#147;spread&#148; between the closing price per share on December&nbsp;31, 2015 of $24.16 and the exercise price of the vested awards, to the extent such vested awards were &#147;in the money.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Involuntary Termination. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Management Agreements, upon an &#147;involuntary&#148; termination without &#147;cause&#148; or, if applicable, upon a resignation for &#147;good reason&#148; (as defined below),
the NEO will, subject to the execution of a release of claims, be entitled to receive: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a lump-sum cash payment equal to the specified number of months (ranging from 6 to 24) of the executive&#146;s then-effective annual base salary;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the COBRA Payment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">accelerated vesting of all time-vesting options to purchase the Company&#146;s common stock that are held by Mr.&nbsp;Gray (and six additional months
of accelerated vesting for all other NEOs) on the effective date of termination; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">for Mr.&nbsp;Gray, the extension of exercisability of all stock options to purchase the Company&#146;s common stock for a period of 3 years following
termination of employment (but in any event not beyond each option&#146;s expiration date). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms
of the Management Agreements: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gray will receive 24 months of base salary, 200% of his target annual cash incentive, the COBRA Payment, accelerated vesting of his
then-outstanding employee stock options and restricted stock awards, and up to 3 years to exercise the vested options; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our other NEOs will receive 6 months of base salary, the COBRA Payment, and 6 months additional vesting. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below outlines the potential payments and benefits payable to each NEO in the
event of such NEO&#146;s involuntary termination had occurred on December&nbsp;31, 2015. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Severance</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payment</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Continuation</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of
Benefits</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value
of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accelerated<BR>Stock&nbsp;Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,812,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,991,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,856,692</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">399,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">226,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">394,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">329,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">416,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the value of accelerated stock option and award vesting if the event took place on December&nbsp;31, 2015. The value is calculated based on
the &#147;spread&#148; between the closing price per share on December&nbsp;31, 2015 of $24.16 and the exercise price of the vested awards, to the extent such vested awards were &#147;in the money&#148;. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Management Agreements, &#147;cause&#148; generally means (1)&nbsp;gross negligence or willful misconduct in the
performance of duties to the Company, where such gross negligence or willful misconduct has resulted or is likely to result in substantial and material damage to the Company or its subsidiaries; (2)&nbsp;repeated unexplained or unjustified absence
from the Company; (3)&nbsp;a material and willful violation of any federal or state law; (4)&nbsp;commission of any act of fraud with respect to the Company; or (5)&nbsp;conviction of a felony or a crime involving moral turpitude causing material
harm to the standing and reputation of the Company, in each case as determined in good faith by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of
the Management Agreements, &#147;good reason&#148; generally means the NEO&#146;s voluntary termination following (1)&nbsp;a material reduction or change in job duties, responsibilities, and requirements inconsistent with the NEO&#146;s position
with the Company and his or her prior duties, responsibilities, and requirements, or a material change in the level of management to which the NEO reports; (2)&nbsp;any material reduction of base compensation (other than in connection with a general
decrease in base salaries for most officers of the successor corporation); or (3)&nbsp;the refusal to relocate to a facility or location more than 35 miles from the Company&#146;s current location. The NEO must provide 90 days&#146; notice of the
event giving rise to good reason, give the Company 30 days&#146; to cure (if curable), and any resignation for good reason must occur within 180 days after the occurrence of the event giving rise to such resignation right. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DIRECTOR COMPENSATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ON</SMALL>-E<SMALL>MPLOYEE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>HILOSOPHY</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our non-employee director compensation philosophy is based on the following guiding principles: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aligning the long-term interests of stockholders and directors; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensating directors appropriately and adequately for their time, effort and experience </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The elements of director compensation consist of annual cash retainers and equity awards, as well as customary and usual expense
reimbursement in attending Board and committee meetings. In an effort to align the long-term interests of our stockholders and non-employee directors, the mix of cash and equity compensation has historically been, and is currently, weighted more
heavily to equity. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ASH</SMALL> C<SMALL>OMPENSATION</SMALL> A<SMALL>RRANGEMENTS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2015, each member of our Board who was not an employee or officer of the Company received the following cash compensation for Board
services: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $65,000 annual retainer for service as chairman of the Board and a $40,000 annual retainer for service as a member of the Board.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $20,000 annual retainer for the Chair of the Audit Committee and a $7,500 annual retainer for each additional member of the Audit Committee.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $15,000 annual retainer for the Chair of the Compensation Committee and a $7,000 annual retainer for each additional member of the Compensation
Committee. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $10,000 annual retainer for the Chair of the Nominating and Governance Committee and $5,000 annual retainer for each additional member of the
Nominating and Governance Committee. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also reimburse our non-employee directors for their reasonable
expenses incurred in attending meetings of our Board and committees of our Board. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;5, 2015, we amended our compensation program for non-employee directors to provide that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each director and the chairman of the Board automatically receives an initial equity award, or Initial Grant, consisting of a non-qualified stock
option to purchase 15,000 shares and 25,000 shares, respectively, of Dynavax common stock upon the date each such person is elected or appointed to the Board. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On the date of each annual meeting of the Company&#146;s stockholders, each non-employee director also automatically receives a subsequent equity
award, or Subsequent Grant, consisting of a non-qualified stock option to purchase 7,500 shares of Dynavax common stock. Based on the non-employee director&#146;s election date, the first Subsequent Grant shall be reduced to 75% of the Subsequent
Grant if the service period from the election date to the annual meeting is between 7 and 10 months, 50% of the Subsequent Grant if the service period from the election date to the annual meeting is between 4 and 7 months, and 25% of the Subsequent
Grant if the service period from the election date to the annual meeting is between 1 and 4 months. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each
Initial Grant vests in equal annual installments over 4 years on the anniversary of the grant date. Each Subsequent Grant vests in full on the one-year anniversary of the grant date. The exercise price per share of each Initial Grant and Subsequent
Grant shall be one hundred percent of the fair market value per share on the date of grant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board may approve additional cash and equity awards for our non-employee directors.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows for the fiscal year ended December&nbsp;31, 2015, certain information with respect to the compensation of all
non-employee directors of the Company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned<BR>or Paid
in<BR>Cash<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)(3)(4)</SUP></B></FONT>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">294,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">367,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">284,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">191,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Denise M. Gilbert, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">294,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">351,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">294,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">357,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanley A. Plotkin, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">191,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of fees earned or paid in 2015 for Board and committee meeting membership as described above. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate grant date fair value of stock options granted in the fiscal year in accordance with ASC 718. See note 13 of our &#147;Notes
to Consolidated Financial Statements&#148; in our annual report on Form 10-K filed with the SEC on March&nbsp;8, 2016, for a discussion of assumptions we made in determining the compensation costs included in this column.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">As of December&nbsp;31, 2015, each non-employee director held stock options to purchase the following numbers of shares of our common stock:
Dr.&nbsp;Oronsky held options to purchase 32,950 shares of our common stock; Ms.&nbsp;Brege held options to purchase 12,675 shares of our common stock; Dr.&nbsp;Cano held options to purchase 25,050 shares of our common stock; Dr.&nbsp;Carson held
options to purchase 21,750 shares of our common stock; Dr.&nbsp;Gilbert held options to purchase 8,500 shares of our common stock; Dr.&nbsp;Kisner held options to purchase 28,450 shares of our common stock; Ms.&nbsp;Phillips held options to purchase
32,700 shares of our common stock; Dr.&nbsp;Plotkin held options to purchase 20,750 shares of our common stock; and Mr.&nbsp;Ricciardi held options to purchase 12,750 share of our common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Includes a one-time grant made to each non-employee director, except for Dr.&nbsp;Gilbert who resigned from the Board effective March&nbsp;5, 2015, in
October 2015. The one-time grant was made after taking into account the Company&#146;s historical non-employee director compensation structure, the time commitment expected of the Company&#146;s non-employee directors, the existing ownership
position of each non-employee director, the economic position of the Company and the potential dilutive effect of equity awards on the Company&#146;s stockholders. These one-time grants consisted of the following: Dr.&nbsp;Oronsky received a stock
option to purchase 13,200 shares of our common stock, Ms.&nbsp;Brege received a stock option to purchase 8,800 shares of our common stock, Dr.&nbsp;Cano received a stock option to purchase 8,800 shares of our common stock, Dr.&nbsp;Carson received a
stock option to purchase 3,000 shares of our common stock, Dr.&nbsp;Kisner received a stock option to purchase 13,200 shares of our common stock, Ms.&nbsp;Phillips received a stock option to purchase 13,200 shares of our common stock,
Dr.&nbsp;Plotkin received a stock option to purchase 3,000 shares of our common stock and Mr.&nbsp;Ricciardi received a stock option to purchase 1,500 shares of our common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Ms.&nbsp;Brege joined the Board on February&nbsp;5, 2015. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>QUITY</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>LANS</SMALL></B><SMALL></SMALL> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows activity under our equity compensation plans as of the fiscal year ended December&nbsp;31, 2015. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>securities&nbsp;to<BR>be&nbsp;issued&nbsp;upon&nbsp;exercise<BR>of outstanding
options,<BR>warrants and rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding<BR>options,
warrants<BR>and rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of&nbsp;securities&nbsp;remaining<BR>available for future<BR>issuance under<BR>equity
compensation<BR>plans (excluding<BR>securities reflected in<BR>the first column)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by security holders:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2004 Stock Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">292,901</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011 Equity Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,780,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,097,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014 Employee Stock Purchase Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,021</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans not approved by security holders:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010 Employment Inducement Award Plan</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,086,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,125,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">As of December&nbsp;31, 2015, an aggregate of 28,021 shares remained available for future issuance under the 2014 Employee Stock Purchase Plan, and as
of April&nbsp;6, 2016, up to a maximum of 9,330 shares may be purchased in the current purchase period. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">In order to induce qualified individuals to join our Company, our Board adopted the 2010 Employment Inducement Award Plan, or the 2010 Inducement Plan,
effective January&nbsp;8, 2010, which provided for the issuance of up to 150,000 shares of Company common stock to new employees of the Company. Stockholder approval of the 2010 Inducement Plan was not required under NASDAQ Marketplace Rule
5635(c)(4). Upon the effectiveness of the 2011 Plan, no additional awards were granted under either the 2004 Stock Incentive Plan or the 2010 Inducement Plan. All shares currently subject to awards outstanding under the 2004 Stock Incentive Plan or
2010 Inducement Plan, which awards expire or are forfeited, will be included in the reserve for the 2011 Plan to the extent such shares would otherwise return to such plans. Awards granted under the 2010 Inducement Plan have a term of 10 years.
Exercisability, option price and other terms are determined by the plan administrator, but the option price cannot be less than 100% of fair market value of those shares on the date of grant. Stock options granted under the 2010 Inducement Plan
generally vest over a period of four years, with the exception of performance based awards which will vest upon achievement of certain performance conditions. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CORPORATE GOVERNANCE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ORPORATE</SMALL> G<SMALL>OVERNANCE</SMALL> G<SMALL>UIDELINES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2016, our Board adopted Corporate Governance Guidelines that set forth key principles to guide the Board in its exercise of
responsibilities and serve the interests of the Company and our stockholders. Our Corporate Governance Guidelines can be found on the Corporate Governance page under the Investors and Media&nbsp;&#150;&nbsp;Corporate Governance section of our
website at www.dynavax.com. In addition, these guidelines are available in print to any stockholder who requests a copy. Please direct all requests to our Corporate Secretary, Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100,
Berkeley, California 94710. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>AJORITY</SMALL> V<SMALL>OTE</SMALL> P<SMALL>OLICY</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Corporate Governance Guidelines include a provision whereby any nominee for director in an uncontested election would submit an offer
of resignation for consideration by the Nominating and Corporate Governance Committee of the Board, if such nominee receives a greater number of &#147;Withhold&#148; votes than &#147;For&#148; votes. The Nominating and Corporate Governance Committee
would then consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect to such offer of resignation. Promptly following the Board&#146;s decision, we would disclose that decision and an
explanation of such decision in a filing with the SEC or a press release. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I<SMALL>NDEPENDENCE</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL>
B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As required under the NASDAQ Stock Market, or NASDAQ
listing standards, and our Corporate Governance Guidelines, a majority of the members of a listed company&#146;s board of directors must qualify as &#147;independent,&#148; as affirmatively determined by the board of directors. In addition,
applicable NASDAQ rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating committees be independent within the meaning of applicable NASDAQ rules. Audit committee members must
also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consistent with these considerations,
our Board undertook a review of the independence of each director and considered whether any director has a material relationship that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities.
After review of all relevant transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent registered public accounting firm, the Board has affirmatively
determined that the following directors are independent directors within the meaning of the applicable NASDAQ listing standards: Ms.&nbsp;Phillips, Ms.&nbsp;Brege and Mr.&nbsp;Ricciardi as well as Drs. Carson, Cano, Gilbert, Kisner, Oronsky and
Plotkin. In making these determinations, the Board found that none of these directors has a material or other disqualifying relationship with the Company. Dr.&nbsp;Gilbert resigned from the Board in 2015 and was replaced by Ms.&nbsp;Brege.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the independence of Dr.&nbsp;Carson, the Board took into account his role as the university-nominated
representative on the evaluation committee to oversee aspects of the agreement between the Regents of the University of California and Dynavax and determined that this relationship would not interfere with Dr.&nbsp;Carson&#146;s exercise of
independent judgment in carrying out his responsibilities as a director. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By virtue of his employment with the Company, Eddie
Gray, our Chief Executive Officer is not an independent director. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B<SMALL>OARD</SMALL> L<SMALL>EADERSHIP</SMALL> S<SMALL>TRUCTURE</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board is currently chaired by Dr.&nbsp;Oronsky. The duties of the chairman include presiding over all meetings of the
Board; preparing the agenda for Board meetings in consultation with the CEO and other members of our Board; calling and presiding over meetings of non-employee directors; and managing the Board&#146;s process for annual
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
evaluation of the CEO. Accordingly, the chairman has substantial ability to shape the work of our Board. Our Board currently believes that separation of the positions of chairman and CEO
reinforces the independence of our Board in its oversight of our business and affairs. In addition, such separation helps create an environment that is more conducive to objective evaluation and oversight of management&#146;s performance, increasing
management accountability and improving the ability of our Board to monitor whether management&#146;s actions are in the best interests of our Company and its stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Board also believes there may be advantages to having an independent chairman for matters such as communications and relations between our Board, the CEO and other senior management and in assisting
our Board in reaching consensus on particular strategies and policies. Having a chairman separate from the CEO also allows the chairman to focus on assisting the CEO and other senior management in seeking and adopting successful business strategies
and risk management policies and in making successful choices in management succession. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B<SMALL>OARD</SMALL>&#146;<SMALL>S</SMALL>
R<SMALL>OLE</SMALL> I<SMALL>N</SMALL> R<SMALL>ISK</SMALL> O<SMALL>VERSIGHT</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk assessment and oversight are an
integral part of our governance and management processes. Our Board encourages management to promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and
operational risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing the Company. Throughout the year, senior management
reviews these risks with the Board at regular Board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board does not have a standing risk management committee but rather administers this oversight function directly through
our Board as a whole as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure,
including overseeing our healthcare compliance program pertaining to healthcare laws, regulations and industry standards applicable to pharmaceutical companies. Our Audit Committee has the responsibility to oversee our major financial risk exposures
and the steps our management has taken to monitor and control these exposures as well as oversight of our enterprise risk management program. The Audit Committee also monitors compliance with legal and regulatory requirements, oversees the
performance of our internal audit function and approves or disapproves any related-persons transactions. Our Nominating and Governance Committee monitors the effectiveness of our corporate governance guidelines and manages the process for annual
director self-assessment and evaluation of the Board. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>EETINGS</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board met six times during fiscal year 2015. All Board members attended at least 75% or more of the aggregate of the meetings of the
Board and of the committees, on which the member served, held during the period of services as a director or committee member. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OMMITTEES</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL>
D<SMALL>IRECTORS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board has three standing committees: an Audit Committee, a Compensation Committee and a
Nominating and Governance Committee. The following table provides membership and meeting information for fiscal year 2015 for each of the Board committees: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Audit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Compensation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nominating</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Members</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Meetings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Committee Chairperson </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Dr.&nbsp;Gilbert resigned from the Board after the Audit Committee meeting effective March&nbsp;5, 2015, and Ms.&nbsp;Laura Brege became the
chairperson of the Audit Committee thereafter. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">As of December&nbsp;31, 2015. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Below is a description of each committee of our Board. Each of the committees has authority to engage legal counsel or other experts or consultants as it deems appropriate to carry out its
responsibilities. Our Board has determined that each member of each committee meets the applicable NASDAQ listing standards and related rules and regulations regarding &#147;independence&#148; and that each member is free of any relationship that
would impair his or her individual exercise of independent judgment with regard to the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit Committee </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee for 2015 was comprised of three directors: Dr.&nbsp;Gilbert (Chairperson), Dr.&nbsp;Oronsky and Ms.&nbsp;Phillips.
Dr.&nbsp;Gilbert was the Chairperson of the Audit Committee until she resigned from the Board after the Audit Committee meeting effective March&nbsp;5, 2015. Ms.&nbsp;Brege replaced Dr.&nbsp;Gilbert as the Chairperson of the Audit Committee. In
addition to determining that all members of the Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii)&nbsp;of the NASDAQ listing standards), the Board determined that Dr.&nbsp;Gilbert and later
Ms.&nbsp;Brege qualified as an &#147;audit committee financial expert,&#148; as defined in applicable SEC rules. The Board made a qualitative assessment of Dr.&nbsp;Gilbert&#146;s and Ms.&nbsp;Brege&#146;s level of knowledge and experience based on
a number of factors, including each of Dr.&nbsp;Gilbert and Ms.&nbsp;Brege&#146;s formal education and experience as a chief financial officer. The Audit Committee was established by the Board in accordance with Section&nbsp;3(a)(58)(A) of the
Exchange Act to oversee the Company&#146;s corporate accounting and financial reporting processes and audits of its financial statements. The Audit Committee operates under a written charter that is available on the Company&#146;s website at
http://investors.dynavax.com/corporate-governance.cfm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Among other things, the charter specifically requires our Audit
Committee to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and monitor the policies and procedures adopted by the Company to fulfill its responsibilities regarding the fair and accurate presentation of
the Company&#146;s financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appoint, compensate, and oversee the work of the Company&#146;s independent registered public accounting firm; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approve and monitor all audit and non-audit services performed by the Company&#146;s independent registered public accounting firm;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">investigate, review and report the propriety and ethical implications of any transactions between the Company and any related persons;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">consult and discuss with management and the independent registered public accounting firm regarding the effectiveness of the Company&#146;s internal
controls over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding
accounting, internal controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and evaluate the Company&#146;s accounting principles and systems of internal controls; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and discuss the disclosure of the Company&#146;s annual audited financial statements and quarterly financial statements, including reviewing the
Company&#146;s disclosures under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management is responsible for the financial reporting process, including the system of internal controls and for the preparation of consolidated financial statements in accordance with accounting
principles generally accepted in the United States. Ernst&nbsp;&amp; Young, the Company&#146;s independent registered public accounting firm, is responsible for auditing or reviewing those financial statements. The Audit Committee monitors and
reviews these processes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Audit Committee of the Board of Directors </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2015, the Audit Committee met on four occasions. During these meetings the Committee met with Ernst&nbsp;&amp; Young, without the
presence of the Company&#146;s management. During the course of these meetings, we: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discussed with management and Ernst&nbsp;&amp; Young management&#146;s continued testing and evaluation of its system of internal control over
financial reporting. We also reviewed Ernst&nbsp;&amp; Young&#146;s Report of Independent Registered Public Accounting Firm included in the Annual Report on Form 10-K, or Annual Report, related to its audit of the effectiveness of the Company&#146;s
internal control over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and discussed with management and Ernst&nbsp;&amp; Young the annual audited financial statements before filing the Annual Report with the SEC,
addressing the acceptability of the Company&#146;s accounting principles and such other matters as applicable auditing standards require us to discuss; the Audit Committee has discussed with the independent registered public accounting firm the
matters required to be discussed by Auditing Standard No.&nbsp;16, Communications with Audit Committees (&#147;AS 16&#148;) , as adopted by the Public Company Accounting Oversight Board (&#147;PCAOB&#148;) and recommended to the Board that the
financial statements should be included in the Annual Report; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and discussed with management and Ernst&nbsp;&amp; Young the Company&#146;s quarterly unaudited financial statements before the issuance of
its quarterly financial results press releases and the filing of its Quarterly Reports on Form 10-Q with the SEC; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discussed with management and Ernst&nbsp;&amp; Young significant financial reporting matters, including liquidity and capital requirements, and the
accounting for significant transactions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appointed and oversaw the work and compensation of Ernst&nbsp;&amp; Young, including the review of engagement agreement terms;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and provided guidance with respect to the external audit and the Company&#146;s relationship with Ernst&nbsp;&amp; Young by (1)&nbsp;reviewing
Ernst&nbsp;&amp; Young&#146;s proposed audit scope, approach, compensation and independence; (2)&nbsp;obtaining written statements and disclosures from Ernst&nbsp;&amp; Young regarding relationships and services with the Company which may impact
independence as required by Ethics and Independence Rule 3526, &#147;Communications with Audit Committees Concerning Independence&#148;; (3)&nbsp;discussing with Ernst&nbsp;&amp; Young the financial statements and audit findings, including any
significant adjustments, management judgments and accounting estimates, significant new accounting policies and whether there were disagreements with management; and (4)&nbsp;obtaining assurance from Ernst&nbsp;&amp; Young that the requirements of
Section&nbsp;10A of the Exchange Act have been met; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed, in conjunction with the Company&#146;s legal counsel, all legal matters that could have a significant impact on the Company&#146;s financial
statements or compliance policies. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on our reviews and discussions as described above, and based on the report of
Ernst&nbsp;&amp; Young, we recommended to the Board, and the Board approved, that the audited financial statements be included in the Company&#146;s Annual Report for the year ended December&nbsp;31, 2015, filed with the SEC. We also approved,
subject to stockholder ratification, the selection of Ernst&nbsp;&amp; Young as the Company&#146;s independent registered public accounting firm for 2016. In making this recommendation, we considered whether Ernst&nbsp;&amp; Young&#146;s provision
of services other than audit services is compatible with maintaining independence of our independent registered public accounting firm. Although we have the sole authority to appoint the independent registered public accounting firm, we continued
the long-standing practice of recommending that the Board ask the stockholders at their Annual Meeting to ratify the appointment of Ernst&nbsp;&amp; Young as the Company&#146;s independent registered public accounting firm. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The material in this report is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and is not to be
incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing</I>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Laura Brege, Chairperson </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Arnold&nbsp;L. Oronsky, Ph.D. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Peggy&nbsp;V. Phillips </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee is composed of three directors: Ms.&nbsp;Phillips (Chairperson) and Drs. Kisner and Cano. All members of the
Compensation Committee are independent as required by NASDAQ Rule 5605(d) (as independence is currently defined in Rule 5605(a)(2) of the NASDAQ listing standards), are &#147;outside directors&#148; for purposes of Section&nbsp;162(m) of the Code
and are &#147;non-employee directors&#148; for purposes of Rule 16b-3 under the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee acts
on behalf of the Board to review, recommend for adoption, and oversee the Company&#146;s compensation strategy, policies, plans and programs. The Compensation Committee operates under a written charter that is available on the Company&#146;s website
at http://investors.dynavax.com/corporate-governance.cfm. Among other things, the charter specifically requires our Compensation Committee to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annually review and approve the Company&#146;s corporate goals and objectives relevant to CEO compensation, evaluate the CEO&#146;s performance in
light of such goals and objectives, and recommend to the Board the CEO&#146;s compensation level based on this evaluation. In determining the long-term incentive component of the CEO&#146;s compensation, the Compensation Committee will consider the
Company&#146;s performance and relative stockholder return, the value of similar incentive awards to CEOs at comparable companies, and the awards given to the Company&#146;s CEO in past years; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review and make recommendations to the Board with respect to incentive compensation plans and equity-based plans;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">administer the Company&#146;s incentive-compensation plans and equity-based plans as in effect and as adopted from time to time by the Board provided
that the Board shall retain the authority to interpret such plans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review and approve for the Company&#146;s executive officers as defined in Rule 16a-1(f) of the Exchange Act: i) annual base salary levels;
ii) annual incentive compensation levels; iii) long-term incentive compensation levels; and iv) employment agreements, severance agreements, change of control agreements/provisions and any other compensatory arrangements, in each case as, when and
if appropriate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">make regular reports to the Board; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">perform such other functions and have such other powers consistent with the Compensation Committee Charter, the Company&#146;s Bylaws and governing
laws as the Compensation Committee or the Board may deem appropriate. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under its charter, our Compensation Committee may form, and delegate authority to,
subcommittees, as appropriate. Our Compensation Committee has authorized and delegated authority to our CEO to grant stock options to employees and consultants who are not officers of the Company from pre-approved pools and in accordance with
guidelines designated for new hire and annual grants. The purpose of this delegation is to enhance the flexibility of option administration within the Company and to facilitate the timely grant of options to non-executive employees, particularly new
employees, within specified limits and values approved by our Compensation Committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2015, our Compensation Committee
met seven times to review disclosure and certification requirements regarding executive compensation and to discuss our current compensation practices. During the course of these meetings, we: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assessed the achievement of corporate goals as they related to executive compensation during the first quarter of the year;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and approved corporate and NEO annual goals for the new year in the first quarter; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and recommended to the Board annual compensation, cash incentive payment and equity incentive awards for Mr.&nbsp;Gray;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approved performance and related compensation payments to the Company&#146;s other NEOs, including annual compensation, cash incentive payments and
equity incentive awards; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and approved a retention program for key employees critical to the approval of HEPLISAV-B and advancing the Company&#146;s oncology program;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and approved the share request to be added to the Amended 2011 Plan and updates related to Section&nbsp;162(m); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approved an aggregate limit on options subject to grant by Mr.&nbsp;Gray based on approved hiring plans and ranges of grants for prospective hires.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the fiscal year ended December&nbsp;31, 2015, Ms.&nbsp;Phillips and Drs. Cano and Kisner, each served as a member of the
Compensation Committee. None of the members of our Compensation Committee at any time has been one of our officers or employees or an officer or employee of one of our subsidiaries at any time during the fiscal year ended December&nbsp;31, 2015.
None of our executive officers currently serve, or in the past year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers on our Board or Compensation Committee. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nominating and Governance Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Nominating and Governance Committee is composed of three directors: Drs. Kisner (Chairperson) and Cano, and Mr.&nbsp;Ricciardi. All members of the Nominating and Governance Committee are independent
(as independence is currently defined in Rule 5605(a)(2) of the NASDAQ listing standards). The Nominating and Governance Committee is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent
with criteria approved by the Board), reviewing and evaluating incumbent directors and identifying with the CEO candidates for appointment or election to the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In identifying potential director candidates, the Nominating and Governance Committee considers Board candidates through a variety of methods and sources. These include suggestions from current Board
members, senior management, stockholders, professional search firms and other sources. At this time, the Nominating and Governance Committee does not have a policy with regard to the consideration of director candidates recommended by stockholders.
Our Nominating and Corporate Governance Committee reviews all candidates in the same manner </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regardless of the source of the recommendation. In the case of a new director candidate, the Nominating and Governance Committee also determines whether the nominee is independent based upon
applicable NASDAQ listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. Among the qualifications to be considered in the selection of candidates are broad experience in business, finance or administration,
familiarity with the Company&#146;s industry, and prominence and reputation. Since prominence and reputation in a particular profession or field of endeavor are what bring most persons to the Board&#146;s attention, there is further consideration of
whether the individual has the time available to devote to the work of the Board and one or more of its committees. In addition, our Nominating and Governance Committee will consider whether the candidate assists in achieving a mix of members that
represents a diversity of backgrounds and experience, including with respect to age, gender, international background, race and specialized experience. Each year, our Nominating and Governance Committee reviews its Board membership criteria and
assesses the composition of the Board against the criteria. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nominating and Governance Committee discussed committee
business a number of times during the year and held one formal meeting. The Nominating and Governance Committee has adopted a written charter that is available to stockholders on the Company&#146;s website at
http://investors.dynavax.com/corporate-governance.cfm. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>TOCKHOLDER</SMALL> C<SMALL>OMMUNICATIONS</SMALL> W<SMALL>ITH</SMALL>
T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders may communicate with our
Board by directing comments, concerns, and questions to the Corporate Secretary at Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710. Communications will be distributed to the Board, or to any individual
directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, our Board has requested that certain items that are unrelated to the duties and responsibilities of the Board be filtered, including
product complaints or inquiries, new product suggestions, r&eacute;sum&eacute;s and other forms of job inquiries, surveys, or business solicitations or advertisements. In addition, material that is unduly hostile, threatening, illegal or similarly
unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-employee director upon request. Stockholders may also communicate with our Board as a group through our website at
http://investors.dynavax.com/contactBoard.cfm. All communications directed to the Audit Committee in accordance with our whistleblower policy that relate to questionable accounting or auditing matters involving the Company will be promptly and
directly forwarded to the chairperson of the Audit Committee. Every effort has been made to ensure that the views of stockholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to
stockholders in a timely manner. We believe our responsiveness to stockholder communications to the Board has been excellent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTAIN TRANSACTIONS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There has not been, nor is there currently proposed, any transaction or series of similar transactions to which the Company was or is to
be a party in which the amount involved exceeds $120,000 and in which any current director, executive officer, holder of more than 5% of our common stock or any immediate family member of any of the foregoing persons had or will have a direct or
indirect material interest other than compensation arrangements, described under the sections entitled &#147;Executive Compensation&#148; and &#147;Compensation of Directors,&#148; other than with respect to the indemnification agreements described
below, and as described below under &#147;Participation in Public Offering.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Certain Transactions With or Involving Related Persons
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Participation in Public Offering </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;28, 2015, we completed an underwritten public offering of 5,227,273 shares of our common stock at a price to the public of $27.50 per share. Net cash proceeds from the public offering were
approximately $135 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Based on information provided to us, Federated Investors, Inc., which beneficially own more than 5% of our
outstanding common stock, purchased 100,000 shares in the public offering from the underwriters for a total purchase price of $2.8 million (based on the price to the public of $27.50 per share). To our knowledge, no other holder of 5% or more of our
outstanding common stock participated in the offering. None of our directors or executive officers participated in the offering, nor did any of such persons have a direct or indirect material interest in the offering. Since this offering was public,
with the price to the public in the offering determined by a book building process with the underwriters, the offering was not specifically reviewed in advance as a related-party transaction. However, the offering was approved by our Board and a
Pricing Committee of our Board, and consistent with our Audit Committee charter, the Audit Committee subsequently reviewed the offering. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnity Agreements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into indemnity agreements with some of our officers and directors which provide, among other things, that the Company will indemnify such officer or director, under the circumstances and
to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer
or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Policies and Procedures
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee is responsible for reviewing and approving all related party transactions, which would include a
transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#147;related person&#148; are participants involving an amount that exceeds $120,000, not including transactions
involving compensation for services provided to Dynavax as an employee, director, consultant or similar capacity by a related person. Related parties include any of our directors or executive officers, certain of our stockholders and their immediate
family members. This obligation is set forth in writing in the Audit Committee charter. A copy of the Audit Committee charter is available on our website at www.dynavax.com in the Investor Relations section under &#147;Corporate Governance.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where a transaction has been identified as a related-person transaction, management would present information regarding the
proposed related-person transaction to the Audit Committee (or, where Audit Committee approval would be inappropriate, to another independent body of the Board) for consideration and approval or ratification. The presentation would include a
description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to Dynavax of the transaction and whether any alternative transactions were available. To identify related-person
transactions in advance, the Audit Committee relies on information </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
supplied by our executive officers and directors. In considering related-person transactions, the Audit Committee takes into account the relevant available facts and circumstances including, but
not limited to (a)&nbsp;the risks, costs and benefits to Dynavax, (b)&nbsp;the impact on a director&#146;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is
affiliated, (c)&nbsp;the terms of the transaction, (d)&nbsp;the availability of other sources for comparable services or products and (e)&nbsp;the terms available to or from, as the case may be, unrelated third parties or to or from employees
generally. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval. In determining whether to approve, ratify or reject a related-person transaction, the
Audit Committee considers, in light of known circumstances, whether the transaction is in, or is not inconsistent with, the best interests of Dynavax and our stockholders, as the Audit Committee determines in the good faith exercise of its
discretion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>ECTION</SMALL> 16(<SMALL>A</SMALL>) B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERSHIP</SMALL> R<SMALL>EPORTING</SMALL>
C<SMALL>OMPLIANCE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;16(a) of the Exchange Act requires the Company&#146;s directors and executive
officers, and persons who own more than ten percent of a registered class of the Company&#146;s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of
the Company. Officers, directors and greater-than-ten-percent stockholders are required by SEC regulation to furnish the Company with copies of all Section&nbsp;16(a) forms they file. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the Company&#146;s knowledge, based solely on a review of the copies of such reports furnished to the Company and written
representations that no other reports were required, during the fiscal year ended December&nbsp;31, 2015, such SEC filing requirements were satisfied. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ODE</SMALL> O<SMALL>F</SMALL> B<SMALL>USINESS</SMALL> C<SMALL>ONDUCT</SMALL> A<SMALL>ND</SMALL> E<SMALL>THICS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted the Dynavax Code of Business Conduct and Ethics that applies to all officers, directors and employees. Our Code of
Business Conduct and Ethics is available upon written request. We will provide a written copy of the Dynavax Code of Business Conduct and Ethics to anyone without charge, upon request written to Dynavax Technologies Corporation, Attention: Chief
Compliance Officer, 2929 Seventh Street, Suite 100, Berkeley, California 94710-2753, (510)&nbsp;848-5100. If we make any substantive amendments to or grant any waiver from a provision of the Code of Business Conduct and Ethics to any executive
officer or director, we will promptly disclose the nature of the amendment or waiver on our website. There have been no waivers under the Code of Business Conduct and Ethics as of April&nbsp;6, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECURITY OWNERSHIP OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth certain information regarding the ownership of the Company&#146;s common stock as of January&nbsp;29, 2016 by: (i)&nbsp;each director and nominee for director; (ii)&nbsp;the
NEOs; (iii)&nbsp;all executive officers and directors of the Company as a group; and (iv)&nbsp;all those known by the Company to be beneficial owners of more than five percent of its common stock. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:135pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Address of Beneficial Holder</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number
of<BR>Shares<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% Stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BlackRock, Inc.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,240,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 East 52nd Street</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federated Investors, Inc.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,977,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federated Investors Tower</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pittsburgh, Pennsylvania 15222-3779</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FMR, LLC</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,636,982</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">245 Summer Street</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boston, Massachusetts 02210</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">OrbiMed Advisors LLC</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,472,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">601 Lexington Avenue, 54th Floor</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, NY 10022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:75pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>NEOs and
Directors<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">282,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(9)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">134,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(10)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,933</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(11)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(12)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(13)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,756</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(14)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(15)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(16)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(17)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(18)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanley A. Plotkin, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(19)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(20)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All executive officers and directors as a group (13 persons)</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(21)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">768,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Less than one percent. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">The address of each of the NEOs and directors is c/o Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">To our knowledge, except as set forth in the footnotes to this table, and subject to applicable community property laws, each person named in this
table has sole voting and investment power with respect to the shares set forth opposite such person&#146;s name. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to the
securities. Shares of our common stock subject to options currently exercisable or that will become exercisable within 60 days after January&nbsp;29, 2016, are deemed outstanding for computing the percentage of the person holding such options but
are not deemed outstanding for computing the percentage of any other person. Applicable percentages are based on 38,459,964 shares of our common stock outstanding as of January&nbsp;29, 2016, adjusted as required by the rules of the SEC.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on a Schedule 13G/A filed by BlackRock, Inc., on January&nbsp;26, 2016, with the SEC. BlackRock beneficially owns and
has sole dispositive power over 2,240,598 shares of common stock, of which 2,154,041 are held with sole voting power. The </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">
address of the principal business and office of BlackRock, Inc. and its affiliates is BlackRock Inc., 40 East 52nd Street, New York, NY 10022. The Schedule 13G/A provides information only as of
December&nbsp;31, 2015, and, consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2015 and January&nbsp;29, 2016. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on a Schedule 13G/A filed by Federated Investors, Inc., on February&nbsp;11, 2016, with the SEC. Federated Investors,
Inc. (the &#147;Parent&#148;) is the parent holding company of Federated Equity Management Company of Pennsylvania and Federated Global Investment Management Corp. (the &#147;Investment Advisers&#148;), which act as investment advisers to registered
investment companies and separate accounts that own shares of common stock. The Investment Advisers are wholly owned subsidiaries of FII Holdings, Inc., which is wholly owned subsidiary of the Parent. All of the Parent&#146;s outstanding voting
stock is held in the Voting Shares Irrevocable Trust (the &#147;Trust&#148;) for which John F. Donahue, Rhodora J. Donahue and J. Christopher Donahue act as trustees (collectively, the &#147;Trustees&#148;). The Parent and the Trust each have sole
voting power over all 2,977,629 shares of common stock. The Trustees have joined in filing the Schedule 13G because of the collective voting control that they exercise over the Parent. In accordance with Rule 13d-4 under the Securities Act of 1934,
as amended, the Parent, the Trust, and each of the Trustees declare that this statement should not be construed as an admission that they are the beneficial owners, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial
ownership. The address of the principal business and office of Federated Investors, Inc. and its affiliates is Federated Investors Towers, Pittsburgh, PA 15222-3779. The Schedule 13G/A provides information only as of December&nbsp;31, 2015, and,
consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2015 and January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on a Schedule 13G filed by FMR, LLC, on February&nbsp;12, 2016, with the SEC. FMR, LLC beneficially owns and has sole
dispositive power over 2,636,982 shares of common stock, of which 500 are held with sole voting power. Abigail P. Johnson, is a Director, the Vice Chairman, the Chief Executive Officer and President of FMR, LLC. Members of the Johnson family,
including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR, LLC, representing 49% of the voting power of FMR, LLC. The Johnson family group and all other Series B shareholders have
entered into a shareholders&#146; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and
the execution of the shareholders&#146; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR, LLC. Neither FMR, LLC nor Abigail P. Johnson has the
sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (&#147;Fidelity Funds&#148;) advised by Fidelity Management&nbsp;&amp; Research Company, a wholly
owned subsidiary of FMR, LLC, which power resides with the Fidelity Funds&#146; Boards of Trustees. Fidelity Management&nbsp;&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds&#146;
Boards of Trustees. The address of the principal business and office of FMR, LLC. and its affiliates is, 245 Summer Street, Boston, Massachusetts 02210. The Schedule 13G provides information only as of December&nbsp;31, 2015, and, consequently, the
beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2015 and January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on a Schedule 13G filed by OrbiMed Advisors, LLC, on February&nbsp;16, 2016, with the SEC. OrbiMed Advisors, LLC
beneficially owns and has shared dispositive power over 770,800 shares of common stock. OrbiMed Capital, LLC beneficially owns and has shared dispositive power over 1,701,400 shares of common stock. Samuel D. Isaly, as the managing member of OrbiMed
Advisors, LLC and OrbiMed Capital, LLC, beneficially owns and has shared dispositive power over 2,472,200 shares of common stock. The address of the principal business and office of OrbiMed Advisors LLC. and its affiliates is, 601 Lexington Avenue,
54th Floor, New York, NY 10022. The Schedule 13G provides information only as of December&nbsp;31, 2015, and, consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2015 and
January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 2,500 shares of common stock owned directly by Mr.&nbsp;Gray and options to purchase 279,688 shares of common stock exercisable within 60
days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(9)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 8,772 shares of common stock owned directly by Mr.&nbsp;Ostrach and options to purchase 125,348 shares of common stock exercisable within
60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(10)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 6,308 shares of common stock owned directly by Dr.&nbsp;Coffman and options to purchase 109,625 shares of common stock exercisable within
60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(11)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 3,596 shares of common stock owned directly by Dr.&nbsp;Janssen, 948 of which were purchased through the employee stock purchase plan; and
options to purchase 46,625 shares of common stock exercisable within 60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(12)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 1,510 shares of common stock owned directly by Mr.&nbsp;Novack, 1,060 of which were purchased through the employee stock purchase plan; and
options to purchase 53,491 shares of common stock exercisable within 60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(13)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 37,506 shares of common stock owned directly by Dr.&nbsp;Oronsky and options to purchase 11,250 shares of common stock exercisable within
60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(14)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of options to purchase 500 shares of common stock exercisable within 60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(15)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 6,200 shares of common stock owned directly by Dr.&nbsp;Cano and options to purchase 8,750 shares of common stock exercisable within 60
days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(16)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 6,812 shares of common stock owned directly by Dr.&nbsp;Carson and options to purchase 11,250 shares of common stock exercisable within 60
days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(17)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 1,500 shares of common stock owned directly by Dr.&nbsp;Kisner and options to purchase 7,750 shares of common stock exercisable within 60
days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(18)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 13,802 shares of common stock owned directly by Ms.&nbsp;Phillips and options to purchase 12,000 shares of common stock exercisable within
60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(19)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 1,000 shares of common stock owned directly by Dr.&nbsp;Plotkin and options to purchase 10,250 shares of common stock exercisable within 60
days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(20)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of options to purchase 2,750 shares of common stock exercisable within 60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(21)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Total number of shares includes 89,506 shares of common stock in aggregate held as of January&nbsp;29, 2016, by our executive officers and directors
and entities affiliated with such executive officers and directors. Also includes options to purchase 679,277 shares of common stock exercisable within 60 days of January&nbsp;29, 2016. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ERFORMANCE</SMALL> G<SMALL>RAPH</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The chart below compares total stockholder return on an investment of $100 in cash on December&nbsp;31, 2010, for: our common stock, The NASDAQ Stock Market (U.S. companies), and the NASDAQ Pharmaceutical
Preparation Index. All values assume reinvestment of the full amount of all dividends. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note: Dynavax management cautions that
the stock price performance shown in the graph below should not be considered indicative of potential future stock price performance. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g121496g30n33.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Section is not
&#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and is not to be incorporated by reference in any filing of Dynavax Technologies Corporation under the Securities Act, or the Exchange Act, whether made before or after
the date hereof and irrespective of any general incorporation language in any such filing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OTHER MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly
brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael S. Ostrach</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;22, 2016 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A copy of the Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2015, is available without charge upon written request to: Dynavax Technologies Corporation,
Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Appendix A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>YNAVAX</SMALL> T<SMALL>ECHNOLOGIES</SMALL> C<SMALL>ORPORATION</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2011 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
N<SMALL>OVEMBER</SMALL>&nbsp;12, 2010 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
S<SMALL>TOCKHOLDERS</SMALL>: J<SMALL>ANUARY</SMALL>&nbsp;5, 2011 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL>
R<SMALL>ESTATED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;10, 2013 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: M<SMALL>AY</SMALL>&nbsp;29, 2013 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPENSATION</SMALL> C<SMALL>OMMITTEE</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;16, 2015
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: M<SMALL>AY</SMALL>&nbsp;27,
2015 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL> 22, 2016 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL>
<SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016] </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>ERMINATION</SMALL> D<SMALL>ATE</SMALL>: N<SMALL>OVEMBER</SMALL>&nbsp;11, 2020 </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>G<SMALL>ENERAL</SMALL>.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Successor to and Continuation of Prior Plans.</B> The Plan is intended as the successor to and continuation of the Dynavax Technologies Corporation 2004 Stock Incentive Plan (the &#147;<B><I>2004
Plan</I></B>&#148;), the Dynavax Technologies Corporation 2010 Employment Inducement Award Plan (the &#147;<B><I>2010 Inducement Plan</I></B>&#148;), and the Dynavax Technologies Corporation 1997 Equity Incentive Plan (the &#147;<B><I>1997
Plan</I></B>,&#148; and together with the 2004 Plan and the 2010 Inducement Plan, the &#147;<B><I>Prior Plans</I></B>&#148;). Following the Effective Date, no additional stock awards shall be granted under the Prior Plans. Any available shares that,
as of the Effective Date, are reserved under the Prior Plans but not subject to stock awards that have been granted under the Prior Plans as of the Effective Date, <I>less</I> any shares that may be added to the 2004 Plan share reserve on the first
business day in 2011 by operation of the evergreen provision in Section&nbsp;3(a) of the 2004 Plan (such number of available shares, the &#147;<B><I>Prior Plans&#146; Available Reserve</I></B>&#148;) shall become available for issuance pursuant to
Stock Awards granted hereunder. From and after the Effective Date, all outstanding stock awards granted under the Prior Plans shall remain subject to the terms of the applicable Prior Plan; <I>provided, however</I>, any shares subject to outstanding
stock awards granted under the Prior Plans that expire or terminate for any reason prior to exercise or settlement or are forfeited because of the failure to meet a contingency or condition required to vest such shares, to the extent such shares
would have otherwise returned to a Prior Plan in accordance with its terms had such Prior Plan been in active existence at such time, (such shares, the &#147;<B><I>Returning Shares</I></B>&#148;) shall become available for issuance pursuant to
Awards granted hereunder as provided in Section&nbsp;3(a) below. All Awards granted on or after the Effective Date of this Plan shall be subject to the terms of this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Eligible Award Recipients.</B> The persons eligible to receive Awards are Employees and Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Available Awards.</B> The Plan provides for the grant of the following Awards: (i)&nbsp;Incentive Stock Options, (ii)&nbsp;Nonstatutory Stock Options, (iii)&nbsp;Stock Appreciation Rights
(iv)&nbsp;Restricted Stock Awards, (v)&nbsp;Restricted Stock Unit Awards, (vi)&nbsp;Performance Stock Awards, (vii)&nbsp;Performance Cash Awards, and (viii)&nbsp;Other Stock Awards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Purpose.</B> The Company, by means of the Plan, seeks to secure and retain the services of the group of persons eligible to
receive Awards as set forth in Section&nbsp;1(b), to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such eligible recipients may be given an opportunity
to benefit from increases in value of the Common Stock through the granting of Awards. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DMINISTRATION</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Administration by Board.</B> The Board shall administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section&nbsp;2(c).
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Powers of Board.</B> The Board shall have the power, subject to, and within the
limitations of, the express provisions of the Plan: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>To determine from time to time (A)&nbsp;which of the persons
eligible under the Plan shall be granted Awards; (B)&nbsp;when and how each Award shall be granted; (C)&nbsp;what type or combination of types of Award shall be granted; (D)&nbsp;the provisions of each Award granted (which need not be identical),
including the time or times when a person shall be permitted to receive cash or Common Stock pursuant to a Stock Award; (E)&nbsp;the number of shares of Common Stock with respect to which a Stock Award shall be granted to each such person; and
(F)&nbsp;the Fair Market Value applicable to a Stock Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>To construe and interpret the Plan and Awards granted
under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement or in the written
terms of a Performance Cash Award, in a manner and to the extent it shall deem necessary or expedient to make the Plan or Award fully effective. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>To settle all controversies regarding the Plan and Awards granted under it. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) </B>To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in
the Award stating the time at which it may first be exercised or the time during which it will vest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) </B>To suspend or
terminate the Plan at any time. Suspension or termination of the Plan shall not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vi) </B>To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting
amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&nbsp;409A of the Code and/or to bring the Plan or Awards granted under the Plan into compliance therewith, subject to the limitations, if
any, of applicable law. However, except as provided in Section&nbsp;9(a) relating to Capitalization Adjustments, to the extent required by applicable law or listing requirements, stockholder approval shall be required for any amendment of the Plan
that either (A)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&nbsp;materially increases the
benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (D)&nbsp;materially extends the term of the Plan, or (E)&nbsp;expands the types of Awards
available for issuance under the Plan. Except as provided above, rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (1)&nbsp;the Company requests the consent of the affected
Participant, and (2)&nbsp;such Participant consents in writing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vii) </B>To submit any amendment to the Plan for
stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A)&nbsp;Section&nbsp;162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate
deductibility of compensation paid to Covered Employees, (B)&nbsp;Section&nbsp;422 of the Code regarding &#147;incentive stock options&#148; or (C)&nbsp;Rule 16b-3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(viii) </B>To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the
Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; <I>provided however</I>, that except with respect to amendments that disqualify or impair the status
of an Incentive Stock Option, a Participant&#146;s rights under any Award shall not be impaired by any such amendment unless (A)&nbsp;the Company requests the consent of the affected Participant, and (B)&nbsp;such Participant consents in writing.
Notwithstanding the foregoing, subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#146;s consent if necessary to maintain the qualified status of the Award
as an Incentive Stock Option or to bring the Award into compliance with Section&nbsp;409A of the Code. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ix) </B>Generally, to exercise such powers and to perform such acts as the Board deems
necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(x) </B>To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees or Directors who are foreign nationals or employed outside the United
States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Delegation to Committee.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee shall have,
in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the
Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time
to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Section&nbsp;162(m) and Rule 16b-3 Compliance.</B> The Committee may consist solely of two or more Outside Directors, in
accordance with Section&nbsp;162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Delegation to an Officer. </B>The Board may delegate to one (1)&nbsp;or more Officers the authority to do one or both of the following (i)&nbsp;designate Employees who are providing Continuous
Service to the Company or any of its Subsidiaries who are not Officers to be recipients of Options and Stock Appreciation Rights (and, to the extent permitted by applicable law, other Stock Awards) and the terms thereof, and (ii)&nbsp;determine the
number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; <I>provided, however</I>, that the Board resolutions regarding such delegation shall specify the total number of shares of Common Stock that may be
subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Notwithstanding the foregoing, the Board may not delegate authority to an Officer to determine the Fair Market Value
pursuant to Section&nbsp;13(w)(iii) below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Effect of Board&#146;s Decision.</B> All determinations, interpretations
and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(f) Cancellation and Re-Grant of Stock Awards.</B> Neither the Board nor any Committee shall have the authority to: (i)&nbsp;reduce the exercise price of any outstanding Options or Stock Appreciation
Rights under the Plan, or (ii)&nbsp;cancel any outstanding Options or Stock Appreciation Rights that have an exercise price or strike price greater than the current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards
under the Plan, unless the stockholders of the Company have approved such an action within twelve (12)&nbsp;months prior to such an event. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Share Reserve.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>Subject to Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date
shall not exceed 8,743,442 shares (the &#147;<B><I>Share Reserve</I></B>&#148;), which number is the sum of (i)&nbsp;60,889 shares (which is the number of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shares subject to the Prior Plans&#146; Available
Reserve),</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (ii)&nbsp;an additional 1,500,000 shares that
were approved at the Company&#146;s 2011 Special Meeting of Stockholders,</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> (iii)&nbsp;an additional 1,000,000 shares that were approved at the Company&#146;s 2013 Annual Meeting of Stockholders,</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (iv)&nbsp;an additional 2,250,000 shares that were approved at the Company&#146;s 2015 Annual Meeting of Stockholders,
(v)&nbsp;an additional 3,200,000 shares that were approved at the Company&#146;s 2016 Annual Meeting of Stockholders, and (vi)&nbsp;an additional number of shares in an amount not to exceed 732,553 shares (which number consists of the Returning
Shares, if any, as such shares become available from time to time).</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">4</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>Subject to Section&nbsp;3(b), the number of shares of Common Stock
available for issuance under the Plan will be reduced by: (A)&nbsp;one share for each share of Common Stock issued pursuant to an Appreciation Award granted under the Plan; (B)&nbsp;one share for each share of Common Stock issued pursuant to a Full
Value Award granted under the Plan prior to May&nbsp;27, 2015; (C)&nbsp;1.33 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan on or after May&nbsp;27, 2015 but prior to May&nbsp;31, 2016; and
(D)&nbsp;1.60 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan on or after May&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>Subject to Section&nbsp;3(b), the number of shares of Common Stock available for issuance under the Plan will be increased by: (A)&nbsp;one share for each Returning Share or 2011 Plan
Returning Share (as defined in Section&nbsp;3(b)(i)) subject to an Appreciation Award; (B)&nbsp;one share for each Returning Share or 2011 Plan Returning Share subject to a Full Value Award that returns to the Plan prior to May&nbsp;27, 2015;
(C)&nbsp;1.33 shares for each Returning Share or 2011 Plan Returning Share subject to a Full Value Award that returns to the Plan on or after May&nbsp;27, 2015 but prior to May&nbsp;31, 2016; and (D)&nbsp;1.60 shares for each Returning Share or 2011
Plan Returning Share subject to a Full Value Award that returns to the Plan on or after May&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) </B>For
clarity, the limitation in this Section&nbsp;3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section&nbsp;3(a) does not limit the granting of Stock Awards except as provided in
Section&nbsp;7(a). Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section&nbsp;303A.08, AMEX Company Guide Section&nbsp;711 or other
applicable rule, and such issuance shall not reduce the number of shares available for issuance under the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)
Reversion of Shares to the Share Reserve.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Shares Available For Subsequent Issuance. </B>The following shares of
Common Stock (collectively, the &#147;<B><I>2011 Plan Returning Shares</I></B>&#148;) will become available again for issuance under the Plan: (A)&nbsp;any shares subject to a Stock Award that are not issued because such Stock Award or any portion
thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued; (B)&nbsp;any shares subject to a Stock Award that are not issued because such Stock Award or any portion thereof is settled in cash;
and (C)&nbsp;any shares issued pursuant to a Stock Award that are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Shares Not Available For Subsequent Issuance. </B>The following shares of Common Stock will not become available again for
issuance under the Plan: (A)&nbsp;any shares that are reacquired or withheld (or not issued) by </FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 608,892 shares that were originally subject to the Prior Plans&#146; Available Reserve were adjusted to 60,889 shares pursuant to a 1-for-10 reverse stock split
effective November 7, 2014. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 15,000,000 shares approved at the Company&#146;s 2011 Special Meeting of Stockholders were adjusted to 1,500,000 shares pursuant to a 1-for-10 reverse stock split
effective November 7, 2014. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 10,000,000 shares approved at the Company&#146;s 2013 Annual Meeting of Stockholders were adjusted to 1,000,000 shares pursuant to a 1-for-10 reverse stock split
effective November 7, 2014. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">4</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 7,325,537 shares that were originally Returning Shares were adjusted to 732,553 shares pursuant to a 1-for-10 reverse stock split effective November 7, 2014.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Company to satisfy the exercise or purchase price of a Stock Award granted under the Plan or a stock award granted under any of the Prior Plans (including any shares subject to such award
that are not delivered because such award is exercised through a reduction of shares subject to such award (<I>i.e</I>., &#147;net exercised&#148;)); (B)&nbsp;any shares that are reacquired or withheld (or not issued) by the Company to satisfy a tax
withholding obligation in connection with a Stock Award granted under the Plan or a stock award granted under any of the Prior Plans; and (C)&nbsp;any shares repurchased by the Company on the open market with the proceeds of the exercise or purchase
price of a Stock Award granted under the Plan or a stock award granted under any of the Prior Plans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Incentive Stock
Option Limit. </B>Subject to the Share Reserve and the provisions of Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock
Options shall be eleven million (11,000,000)&nbsp;shares of Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Section&nbsp;162(m) Limitations.</B> Subject
to the Share Reserve and the provisions of Section&nbsp;9(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section&nbsp;162(m) of the Code, the following limitations will apply.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>A maximum of one million (1,000,000)&nbsp;shares of Common Stock subject to Options, Stock Appreciation Rights and
Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least one hundred percent (100%)&nbsp;of the Fair Market Value on the date the Stock Award is granted may be granted to any Participant
during any calendar year. Notwithstanding the foregoing, if any additional Options, Stock Appreciation Rights or Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least one hundred
percent (100%)&nbsp;of the Fair Market Value on the date the Stock Award is granted are granted to any Participant during any calendar year, compensation attributable to the exercise of such additional Stock Awards shall not satisfy the requirements
to be considered &#147;qualified performance-based compensation&#148; under Section&nbsp;162(m) of the Code unless such additional Stock Awards are approved by the Company&#146;s stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>A maximum of one million (1,000,000)&nbsp;shares of Common Stock subject to Performance Stock Awards may be granted to any
Participant during any calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>A maximum of five million dollars ($5,000,000) subject to Performance Cash Awards may be granted to any Participant during any calendar year. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Non-Employee Director Compensation Limit.</B> The aggregate value of all cash and equity-based compensation granted or paid, as
applicable, by the Company to any individual for service as a Non-Employee Director with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total of two hundred thousand dollars ($200,000) with respect to any such cash compensation
and (ii)&nbsp;eight hundred thousand dollars ($800,000) in total value with respect to any such equity-based compensation (including Awards and any other equity-based awards), calculating the value of any such awards based on the grant date fair
value of such awards for financial reporting purposes. The Board may make an exception to the applicable limit in this Section&nbsp;3(e) for any Non-Employee Director in extraordinary circumstances, as the Board may determine in its discretion,
provided that any Non-Employee Director who is granted or paid such additional compensation may not participate in the decision to grant or pay such additional compensation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(f) Source of Shares.</B> The stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or
otherwise. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>LIGIBILITY</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Eligibility for Specific Stock Awards.</B> Incentive Stock Options may be granted only to employees of the Company or a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof
(as such terms are defined in Sections 424(e) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and (f)&nbsp;of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees and Directors; <I>provided, however</I>, that Nonstatutory Stock Options and SARs may not be
granted to Employees and Directors who are providing Continuous Service only to any &#147;parent&#148; of the Company, as such term is defined in Rule 405, unless the stock underlying such Stock Awards is treated as &#147;service recipient
stock&#148; under Section&nbsp;409A of the Code because the Stock Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Stock Awards comply with the distribution requirements of Section&nbsp;409A of
the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Ten Percent Stockholders.</B> A Ten Percent Stockholder shall not be granted an Incentive Stock Option
unless the exercise price of such Option is at least one hundred ten percent (110%)&nbsp;of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five (5)&nbsp;years from the date of grant. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ROVISIONS</SMALL> <SMALL>RELATING</SMALL> <SMALL>TO</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL>
R<SMALL>IGHTS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Option or SAR shall be in such form and shall contain such terms and conditions
as the Board shall deem appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates shall be issued for
shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, then the Option shall be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not
be identical; <I>provided, however</I>, that each Option Agreement or Stock Appreciation Right Agreement shall conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each
of the following provisions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Term.</B> Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent
Stockholders, no Option or SAR shall be exercisable after the expiration of seven (7)&nbsp;years from the date of its grant or such shorter period specified in the Award Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Exercise Price.</B> Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, the exercise price (or
strike price) of each Option or SAR shall be not less than one hundred percent (100%)&nbsp;of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Option or SAR is granted. Notwithstanding the foregoing, an Option
or SAR may be granted with an exercise price (or strike price) lower than one hundred percent (100%)&nbsp;of the Fair Market Value of the Common Stock subject to the Option or SAR if such Option or SAR is granted pursuant to an assumption of or
substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code. Each SAR will be denominated in shares of Common
Stock equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Purchase Price for Options.</B> The purchase price of Common Stock acquired pursuant to the
exercise of an Option shall be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board shall have the authority to grant Options
that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The permitted methods of
payment are as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>by cash, check, bank draft or money order payable to the Company; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of
the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) </B>if the option is a Nonstatutory Stock Option, by a &#147;net exercise&#148; arrangement pursuant to which the Company will
reduce the number of shares of Common Stock issuable upon exercise by the largest whole number </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of shares with a Fair Market Value that does not exceed the aggregate exercise price; <I>provided, however</I>, that the Company shall accept a cash or other payment from the Participant to the
extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued; <I>provided, further,</I> that shares of Common Stock will no longer be subject to an Option and will not be
exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are reduced to pay the exercise price pursuant to the &#147;net exercise,&#148; (B)&nbsp;shares are delivered to the Participant as a result of such exercise, and
(C)&nbsp;shares are withheld to satisfy tax withholding obligations; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) </B>in any other form of legal consideration
that may be acceptable to the Board and specified in the applicable award agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Exercise and Payment of a
SAR.</B> To exercise any outstanding Stock Appreciation Right, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such Stock Appreciation
Right. The appreciation distribution payable on the exercise of a Stock Appreciation Right will be not greater than an amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on the date of the exercise of the Stock Appreciation
Right) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such Stock Appreciation Right, and with respect to which the Participant is exercising the Stock Appreciation Right
on such date, over (B)&nbsp;the strike price that will be determined by the Board at the time of grant of the Stock Appreciation Right. The appreciation distribution in respect to a Stock Appreciation Right may be paid in Common Stock, in cash, in
any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Transferability of Options and SARs.</B> The Board may, in its sole discretion, impose such limitations on the transferability of
Options and SARs as the Board shall determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs shall apply: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Restrictions on Transfer.</B> An Option or SAR shall not be transferable except by will or by the laws of descent and distribution
and shall be exercisable during the lifetime of the Participant only by the Participant; <I>provided, however</I>, that the Board may, in its sole discretion, permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax
and securities laws upon the Participant&#146;s request. Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Domestic Relations Orders.</B> Notwithstanding the foregoing, an Option or SAR may be transferred pursuant to a domestic relations order; <I>provided, however</I>, that if an Option is an
Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)
Beneficiary Designation.</B> Notwithstanding the foregoing, the Participant may, by delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company and any broker designated by the Company to effect Option
exercises, designate a third party who, in the event of the death of the Participant, shall thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such
a designation, the executor or administrator of the Participant&#146;s estate shall be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f) Vesting.</B> <B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) General.</B> The total number of shares of Common Stock subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or
SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions
of individual Options or SARs may vary. The provisions of this Section&nbsp;5(f)(i) are subject to Section&nbsp;5(f)(ii) and any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be
exercised. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Minimum Vesting Requirements.</B> No Option or SAR granted on or after May&nbsp;31,
2016 may vest or be exercisable until at least twelve (12)&nbsp;months following the date of grant of the Option or SAR; <I>provided, however</I>, that up to 5% of the Share Reserve (as defined in Section&nbsp;3(a)(i)) may be subject to Options or
SARs granted on or after May&nbsp;31, 2016 that do not meet such vesting and exercisability requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g) Termination
of Continuous Service.</B> Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates (other than for Cause or upon the
Participant&#146;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) but only within such period
of time ending on the earlier of (i)&nbsp;the date three (3)&nbsp;months following the termination of the Participant&#146;s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement), or (ii)&nbsp;the
expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the time specified herein or in the Award Agreement (as
applicable), the Option or SAR shall terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h) Extension of Termination Date.</B> If the exercise of an Option or SAR
following the termination of the Participant&#146;s Continuous Service (other than for Cause or upon the Participant&#146;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the
registration requirements under the Securities Act, then the Option or SAR shall terminate on the earlier of (i)&nbsp;the expiration of a total period of three (3)&nbsp;months (that need not be consecutive) after the termination of the
Participant&#146;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award
Agreement. In addition, unless otherwise provided in a Participant&#146;s Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than
for Cause) would violate the Company&#146;s insider trading policy, then the Option or SAR shall terminate on the earlier of (i)&nbsp;the expiration of a period equal to the applicable post-termination exercise period after the termination of the
Participant&#146;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#146;s insider trading policy, or (ii)&nbsp;the expiration of the term of the Option
or SAR as set forth in the applicable Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Disability of Participant.</B> Except as otherwise provided in
the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or her Option or SAR
(to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&nbsp;the date twelve (12)&nbsp;months following
such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous
Service, the Participant does not exercise his or her Option or SAR within the time specified herein or in the Award Agreement (as applicable), the Option or SAR (as applicable) shall terminate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j) Death of Participant.</B> Except as otherwise provided in the applicable Award Agreement or other agreement between the
Participant and the Company, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s death, or (ii)&nbsp;the Participant dies within the period (if any) specified in the Award Agreement after the
termination of the Participant&#146;s Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the
Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#146;s death, but only within the period ending on the
earlier of (i)&nbsp;the date eighteen (18)&nbsp;months following the date of death (or such longer or shorter period specified in the Award Agreement), or (ii)&nbsp;the expiration of the term of such Option or SAR as set forth in the Award
Agreement. If, after the Participant&#146;s death, the Option or SAR is not exercised within the time specified herein or in the Award Agreement (as applicable), the Option or SAR shall terminate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k) Termination for Cause.</B> Except as explicitly provided otherwise in a
Participant&#146;s Award Agreement, if a Participant&#146;s Continuous Service is terminated for Cause, the Option or SAR shall terminate upon the date on which the event giving rise to the termination occurred, and the Participant shall be
prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l)
Non-Exempt Employees.</B> Subject to Section&nbsp;5(f)(ii), no Option or SAR granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable for any shares of Common
Stock until at least six (6)&nbsp;months following the date of grant of the Option or SAR. Notwithstanding the foregoing, consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;in the event of the Participant&#146;s death or
Disability, (ii)&nbsp;upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be defined in the
Participant&#146;s Award Agreement or in another applicable agreement or in accordance with the Company&#146;s then current employment policies and guidelines), any such vested Options and SARs may be exercised earlier than six months following the
date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ROVISIONS</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL> <SMALL>OTHER</SMALL> <SMALL>THAN</SMALL> O<SMALL>PTIONS</SMALL>
<SMALL>AND</SMALL> SAR<SMALL>S</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Restricted Stock Awards.</B> Each Restricted Stock Award
Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. To the extent consistent with the Company&#146;s Bylaws, at the Board&#146;s election, shares of Common Stock may be (x)&nbsp;held in
book entry form subject to the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (y)&nbsp;evidenced by a certificate, which certificate shall be held in such form and manner as determined by the
Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical; <I>provided, however</I>, that each Restricted Stock
Award Agreement shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Consideration.</B> A Restricted Stock Award may be awarded in consideration for (A)&nbsp;cash, check, bank draft or money order payable to the Company, (B)&nbsp;past services to the Company or an
Affiliate, or (C)&nbsp;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Vesting. </B>Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the
Company in accordance with a vesting schedule to be determined by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) Termination of Participant&#146;s
Continuous Service.</B> If a Participant&#146;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of
the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)
Transferability.</B> Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the
Board shall determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) Dividends. </B>A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the
same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Restricted Stock Unit Awards. </B>Each Restricted Stock Unit Award Agreement shall be
in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock
Unit Award Agreements need not be identical; <I>provided, however</I>, that each Restricted Stock Unit Award Agreement shall conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each
of the following provisions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Consideration.</B> At the time of grant of a Restricted Stock Unit Award, the Board will
determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock
subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Vesting. </B>At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions
to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) Payment.</B> A
Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) Additional Restrictions. </B>At the time of the grant of a Restricted Stock Unit Award, the Board, as it
deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) Dividend Equivalents. </B>Dividend equivalents may be credited in respect of shares of Common Stock covered by a
Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the
Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the
underlying Restricted Stock Unit Award Agreement to which they relate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vi) Termination of Participant&#146;s Continuous
Service. </B>Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#146;s termination of Continuous Service.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Performance Awards. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Performance Stock Awards.</B> A Performance Stock Award is a Stock Award that may vest or may be exercised contingent upon the attainment during a Performance Period of certain Performance Goals. A
Performance Stock Award may, but need not, require the completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and
to what degree such Performance Goals have been attained shall be conclusively determined by the Committee, in its sole discretion. The Board may provide for or, subject to such terms and conditions as the Board may specify, may permit a Participant
to elect for, the payment of any Performance Stock Award to be deferred to a specified date or event. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment
of Performance Stock Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Performance Cash Awards.</B> A Performance Cash Award is a cash award that may be paid
contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Cash Award may </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
also require the completion of a specified period of Continuous Service. At the time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be
achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained shall be conclusively determined by the Committee, in its sole discretion. The Board may provide for or, subject to such
terms and conditions as the Board may specify, may permit a Participant to elect for, the payment of any Performance Cash Award to be deferred to a specified date or event. The Board may specify the form of payment of Performance Cash Awards, which
may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) Section&nbsp;162(m) Compliance.</B> Unless otherwise permitted in compliance with the requirements of Section&nbsp;162(m) of the
Code with respect to an Award intended to qualify as &#147;performance-based compensation&#148; thereunder, the Committee shall establish the Performance Goals applicable to, and the formula for calculating the amount payable under, the Award no
later than the earlier of (a)&nbsp;the date ninety (90)&nbsp;days after the commencement of the applicable Performance Period, or (b)&nbsp;the date on which twenty-five percent (25%)&nbsp;of the Performance Period has elapsed, and in any event at a
time when the achievement of the applicable Performance Goals remains substantially uncertain. Prior to the payment of any compensation under an Award intended to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the
Code, the Committee shall certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where such relate solely to the increase in the value of the Common Stock).
Notwithstanding satisfaction of any completion of any Performance Goals, to the extent specified at the time of grant of an Award to &#147;covered employees&#148; within the meaning of Section&nbsp;162(m) of the Code, the number of shares of Common
Stock, Options, cash or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of such further considerations as the Committee, in its
sole discretion, shall determine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Other Stock Awards.</B> Other forms of Stock Awards valued in whole or in part by
reference to, or otherwise based on, Common Stock, including the appreciation in value thereof may be granted either alone or in addition to Stock Awards provided for under Section&nbsp;5 and the preceding provisions of this Section&nbsp;6. Subject
to the provisions of the Plan, the Board shall have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent
thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Availability of Shares.</B> During the terms of the Stock Awards, the Company shall keep available at all times the number of
shares of Common Stock reasonably required to satisfy such Stock Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Securities Law Compliance.</B> The Company
shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; <I>provided,
however</I>, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is
unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure
to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant shall not be eligible for the grant of a Stock Award or the subsequent issuance of Common Stock pursuant to the Stock Award
if such grant or issuance would be in violation of any applicable securities law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) No Obligation to Notify or Minimize
Taxes. </B>The Company shall have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Company shall have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be
exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Use of Proceeds from Sales of Common Stock. </B>Proceeds from the sale of shares of Common Stock pursuant to Stock Awards shall constitute general funds of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Corporate Action Constituting Grant of Stock Awards.</B> Corporate action constituting a grant by the Company of a Stock Award to
any Participant shall be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually
received or accepted by, the Participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Stockholder Rights.</B> No Participant shall be deemed to be the holder of,
or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms, if
applicable, and (ii)&nbsp;the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d) No Employment or Other Service Rights.</B> Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto shall
confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the right of the Company or an Affiliate to terminate (i)&nbsp;the employment of
an Employee with or without notice and with or without cause, or (ii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the
Affiliate is incorporated, as the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Incentive Stock Option $100,000 Limitation.</B> To the extent that the
aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any
Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options, notwithstanding any contrary
provision of the applicable Option Agreement(s). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f) Investment Assurances.</B> The Company may require a Participant, as
a condition of exercising or acquiring Common Stock under any Stock Award, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and experience in financial and business matters and/or to employ a
purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and
risks of exercising the Stock Award; and (ii)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#146;s own account and not with any
present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (A)&nbsp;the issuance of the shares upon the exercise or acquisition
of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that such
requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or
appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(g) Withholding Obligations.</B> Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation
relating to an Award by any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock
issued or otherwise issuable to the Participant in connection with the Award; <I>provided, however</I>, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser
amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to
the Participant; or (v)&nbsp;by such other method as may be set forth in the Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h) Electronic Delivery.</B>
Any reference herein to a &#147;written&#148; agreement or document shall include any agreement or document delivered electronically, filed publicly with at www.sec.gov (or any successor website thereto) or posted on the Company&#146;s intranet.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Deferrals.</B> To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the
delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by
Participants will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the
Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#146;s termination of Continuous Service, and
implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j) Compliance with Section&nbsp;409A. </B>To the extent that the Board determines that any Award granted hereunder is subject to
Section&nbsp;409A of the Code, the Award Agreement evidencing such Award shall incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code. To the extent applicable, the Plan and Award
Agreements shall be interpreted in accordance with Section&nbsp;409A of the Code. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly
traded and a Participant holding an Award that constitutes &#147;deferred compensation&#148; under Section&nbsp;409A of the Code is a &#147;specified employee&#148; for purposes of Section&nbsp;409A of the Code, no distribution or payment of any
amount shall be made upon a &#147;separation from service&#148; before a date that is six (6)&nbsp;months following the date of such Participant&#146;s &#147;separation from service&#148; (as defined in Section&nbsp;409A of the Code without regard
to alternative definitions thereunder) or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A of the Code. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k) Clawback/Recovery.</B> All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that
the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer
Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including, but not limited to, a reacquisition
right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#147;good
reason&#148; or &#147;constructive termination&#148; (or similar term) under any agreement with the Company. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL>
C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Capitalization Adjustments.</B> In the event of a
Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii)&nbsp;the class(es) and maximum number of securities
that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;3(c), (iii)&nbsp;the class(es) and maximum number of securities that may be awarded to any Participant pursuant to Section&nbsp;3(d), and (iv)&nbsp;the
class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Dissolution or Liquidation. </B>Except as otherwise provided in the Stock Award
Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s
right of repurchase) shall terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or
reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, <I>provided, however</I>, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested,
exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Corporate Transaction.</B> The following provisions shall apply to Stock Awards in the event of a Corporate Transaction unless
otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the holder of the Stock Award or unless otherwise expressly provided by the Board at the time of grant of a Stock
Award. In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board shall take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate
Transaction: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring
corporation&#146;s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company
pursuant to the Corporate Transaction); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>arrange for the assignment of any reacquisition or repurchase rights held
by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>accelerate the vesting of the Stock Award (and, if applicable, the time at which the Stock Award may be exercised) to a date
prior to the effective time of such Corporate Transaction as the Board shall determine (or, if the Board shall not determine such a date, to the date that is five (5)&nbsp;days prior to the effective date of the Corporate Transaction), with such
Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) </B>arrange for the lapse of any reacquisition or repurchase rights held by the Company with respect to the Stock Award;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) </B>cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the
effective time of the Corporate Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(vi) </B>make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A)&nbsp;the value of the property the Participant would have received upon the exercise of the
Stock Award immediately prior to the effective time of the Corporate Transaction, over (B)&nbsp;any exercise price payable by such holder in connection with such exercise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Change in Control.</B> In the event of a Change in Control, the Board shall have the discretion to take any one or more of the
actions set forth in Section&nbsp;9(c)(i)-(vi)&nbsp;with respect to Stock Awards, contingent upon the closing or completion of the Change in Control; <I>provided, however</I>, that for such purpose, the term &#147;Corporate Transaction&#148; in
Section&nbsp;9(c)(i)-(vi)&nbsp;will mean &#147;Change In Control.&#148; A Stock Award may be subject to additional acceleration of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the
Company or any Affiliate and the Participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Parachute Payments. </B>Unless otherwise provided in an agreement
between a Participant and the Company, if any payment or benefit the Participant would receive pursuant to a Change in Control from the Company or otherwise (&#147;<B><I>Payment</I></B>&#148;) would (i)&nbsp;constitute a &#147;parachute
payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<B><I>Excise Tax</I></B>&#148;), then such Payment shall be
equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; shall be either (x)&nbsp;the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y)&nbsp;the largest portion, up
to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the
Participant&#146;s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute
payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order: (A)&nbsp;reduction of cash payments; (B)&nbsp;cancellation of accelerated vesting of equity awards other than stock options;
(C)&nbsp;cancellation of accelerated vesting of stock options; and (D)&nbsp;reduction of other benefits paid to Employee. Within any such category of payments and benefits (that is, (A), (B), (C)&nbsp;or (D)), a reduction shall occur first with
respect to amounts that are not &#147;deferred compensation&#148; within the meaning of Section&nbsp;409A and then with respect to amounts that are. In the event that acceleration of compensation from a Participant&#146;s equity awards is to be
reduced, such acceleration of vesting shall be canceled, subject to the immediately preceding sentence, in the reverse order of the date of grant. The accounting firm engaged by the Company for general audit purposes as of the day prior to the
effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company
shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The accounting firm
engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Participant and the Company within fifteen (15)&nbsp;calendar days after the date on which the Participant&#146;s
right to a Payment is triggered (if requested at that time by the Participant or the Company) or such other time as reasonably requested by the Participant or the Company. Any good faith determinations of the accounting firm made hereunder shall be
final, binding and conclusive upon the Participant and the Company. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Plan Term.</B> The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan shall
automatically terminate on the day before the tenth (10th)&nbsp;anniversary of the date the Plan is adopted by the Board. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) No Impairment of Rights.</B> Suspension or termination of the Plan shall not impair rights and obligations under any Award granted
while the Plan is in effect except with the written consent of the affected Participant. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Plan became effective on January&nbsp;5, 2011, which is the date on which the Company filed a Certificate of Amendment of the
Company&#146;s Sixth Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware following the approval of the Plan by the stockholders of the Company. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The law of the State of Delaware shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#146;s conflict of laws rules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>EFINITIONS</SMALL>. </B>As used in the Plan, the following definitions shall apply to the capitalized terms indicated below: </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>&#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any &#147;parent&#148; or &#147;subsidiary&#148; of
the Company as such terms are defined in Rule 405 of the Securities Act. The Board shall have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the foregoing definition.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>&#147;<B><I>Appreciation Award</I></B>&#148; means (i)&nbsp;a stock option or stock appreciation right granted
under any of the Prior Plans or (ii)&nbsp;an Option or Stock Appreciation Right, in each case with respect to which the exercise or strike price is at least one hundred percent (100%)&nbsp;of the Fair Market Value of the Common Stock subject to the
stock option or stock appreciation right, or Option or Stock Appreciation Right, as applicable, on the date of grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)
</B>&#147;<B><I>Award</I></B>&#148; means a Stock Award or a Performance Cash Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>&#147;<B><I>Award
Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(e) </B>&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(f) </B>&#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock
Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash
dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards No.&nbsp;123
(revised). Notwithstanding the foregoing, the conversion of any convertible securities of the Company shall not be treated as a Capitalization Adjustment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(g) </B>&#147;<B><I>Cause</I></B>&#148; shall have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such
agreement, such term shall mean, with respect to a Participant, the occurrence of any of the following events: (i)&nbsp;the Participant&#146;s theft, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or falsification of
any Company or Affiliate documents or records; (ii)&nbsp;the Participant&#146;s material failure to abide by the code of conduct or other policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct)
of the Company or an Affiliate; (iii)&nbsp;the Participant&#146;s unauthorized use, misappropriation, destruction or diversion of any tangible or intangible asset or corporate opportunity of a the Company or an Affiliate (including, without
limitation, the Participant&#146;s improper use or disclosure of confidential or proprietary information of the Company or an Affiliate); (iv)&nbsp;any intentional act by the Participant which has a material detrimental effect on the reputation or
business of the Company or an Affiliate; (v)&nbsp;the Participant&#146;s repeated failure or inability to perform any reasonable assigned duties after written notice from the Company or an Affiliate, and a reasonable opportunity to cure, such
failure or inability; (vi)&nbsp;any material breach by the Participant of any employment or service agreement between the Participant and the Company or an Affiliate, which breach is not cured pursuant to the terms of such agreement; or
(vii)&nbsp;the Participant&#146;s conviction (including any plea of guilty or nolo contendere) of any criminal act involving fraud, dishonesty, misappropriation or moral turpitude, or which impairs the Participant&#146;s ability to perform his or
her duties. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant shall have no effect upon any determination of the rights
or obligations of the Company or such Participant for any other purpose. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h) </B>&#147;<B><I>Change in
Control</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%)&nbsp;of the combined voting power of the
Company&#146;s then outstanding </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of the
acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s
securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act
Person (the &#147;<I>Subject Person</I>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares
outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change
in Control shall be deemed to occur; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>there is consummated a merger, consolidation or similar transaction
involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either
(A)&nbsp;outstanding voting securities representing more than fifty percent (50%)&nbsp;of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than fifty percent
(50%)&nbsp;of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting
securities of the Company immediately prior to such transaction; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>there is consummated a sale, lease, exclusive
license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and
its Subsidiaries to an Entity, more than fifty percent (50%)&nbsp;of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding
voting securities of the Company immediately prior to such sale, lease, license or other disposition; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) </B>over a
period of twelve (12)&nbsp;months or less, individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#147;<B><I>Incumbent Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members
of the Board; <I>provided, however</I>, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new
member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing or
any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B)&nbsp;the definition of Change
in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; <I>provided, however</I>, that
if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j) </B>&#147;<B><I>Committee</I></B>&#148; means a committee of one (1)&nbsp;or more Directors to whom authority has been delegated
by the Board in accordance with Section&nbsp;2(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k) </B>&#147;<B><I>Common Stock</I></B>&#148; means the common stock
of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l) </B>&#147;<B><I>Company</I></B>&#148; means Dynavax Technologies Corporation, a Delaware corporation.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(m) </B>&#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s
service with the Company or an Affiliate, whether as an Employee or Director, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee or Director or a change
in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, shall not terminate a Participant&#146;s Continuous Service;
<I>provided, however, </I>if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#146;s Continuous Service shall be considered to have
terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service shall be
considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or
their successors. Notwithstanding the foregoing, a leave of absence shall be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms
of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(n)
</B>&#147;<B><I>Corporate Transaction</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>the consummation of a sale or other disposition of all or substantially all, as determined by the Board, in its sole
discretion, of the consolidated assets of the Company and its Subsidiaries; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>the consummation of a sale or other
disposition of at least ninety percent (90%)&nbsp;of the outstanding securities of the Company; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>the consummation
of a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)
</B>the consummation of a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are
converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(o) </B>&#147;<B><I>Covered Employee</I></B>&#148; shall have the meaning provided in Section&nbsp;162(m)(3) of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(p) </B>&#147;<B><I>Director</I></B>&#148; means a member of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(q) </B>&#147;<B><I>Disability</I></B>&#148; means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve
(12)&nbsp;months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and shall be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(r) </B>&#147;<B><I>Effective Date</I></B>&#148; means the effective date of the Plan as set forth in Section&nbsp;11. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(s) </B>&#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely as a
Director, or payment of a fee for such services, shall not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(t) </B>&#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(u) </B>&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) </B>&#147;<B><I>Exchange Act Person</I></B>&#148; means any natural person, Entity or
&#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; shall not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of
the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v)&nbsp;any natural person,
Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%)&nbsp;of
the combined voting power of the Company&#146;s then outstanding securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(w) </B>&#147;<B><I>Fair Market
Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>If the Common
Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock shall be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such
exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination,
then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>In the absence of such markets for the Common Stock, the Fair Market Value shall be determined by the Board in good faith
and in a manner that complies with Sections 409A and 422 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(x) </B>&#147;<B><I>Full Value Award</I></B>&#148;
means (i)&nbsp;a stock award granted under any of the Prior Plans or (ii)&nbsp;a Stock Award, in each case that is not an Appreciation Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(y) </B>&#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 of the Plan that is intended to be, and qualifies as, an &#147;incentive stock option&#148;
within the meaning of Section&nbsp;422 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(z) </B>&#147;<B><I>Non-Employee Director</I></B>&#148; means a
Director who either (i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity
other than as a Director (except for an amount as to which disclosure would not be required under Item&nbsp;404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#147;<B><I>Regulation S-K</I></B>&#148;)), does not possess an interest
in any other transaction for which disclosure would be required under Item&nbsp;404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation S-K; or
(ii)&nbsp;is otherwise considered a &#147;non-employee director&#148; for purposes of Rule 16b-3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(aa)
</B>&#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any option granted pursuant to Section&nbsp;5 of the Plan that does not qualify as an Incentive Stock Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(bb) </B>&#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(cc) </B>&#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common
Stock granted pursuant to the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(dd) </B>&#147;<B><I>Option Agreement</I></B>&#148; means a written agreement between
the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ee) </B>&#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is
granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ff)
</B>&#147;<B><I>Other Stock Award</I></B>&#148; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(d). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(gg) </B>&#147;<B><I>Other Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a holder of an Other
Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement shall be subject to the terms and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(hh) </B>&#147;<B><I>Outside Director</I></B>&#148; means a Director who either (i)&nbsp;is not a current employee of the Company or an &#147;affiliated corporation&#148; (within the meaning of
Treasury Regulations promulgated under Section&nbsp;162(m) of the Code), is not a former employee of the Company or an &#147;affiliated corporation&#148; who receives compensation for prior services (other than benefits under a tax-qualified
retirement plan) during the taxable year, has not been an officer of the Company or an &#147;affiliated corporation,&#148; and does not receive remuneration from the Company or an &#147;affiliated corporation,&#148; either directly or indirectly, in
any capacity other than as a Director, or (ii)&nbsp;is otherwise considered an &#147;outside director&#148; for purposes of Section&nbsp;162(m) of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>&#147;<B><I>Own,</I></B>&#148; &#147;<B><I>Owned,</I></B>&#148; &#147;<B><I>Owner,</I></B>&#148; &#147;<B><I>Ownership</I></B>&#148; A person or Entity shall be deemed to &#147;Own,&#148; to
have &#147;Owned,&#148; to be the &#147;Owner&#148; of, or to have acquired &#147;Ownership&#148; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or
shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(jj)
</B>&#147;<B><I>Participant</I></B>&#148; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(kk) </B>&#147;<B><I>Performance Cash Award</I></B>&#148; means an award of cash granted pursuant to the terms and conditions of
Section&nbsp;6(c)(ii). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ll) </B>&#147;<B><I>Performance Criteria</I></B>&#148; means the one or more criteria that the
Board shall select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that shall be used to establish such Performance Goals may be based on any one of, or combination of, the following as
determined by the Board: (i)&nbsp;earnings (including earnings per share and net earnings); (ii)&nbsp;earnings before interest, taxes and depreciation; (iii)&nbsp;earnings before interest, taxes, depreciation and amortization (EBITDA);
(iv)&nbsp;total stockholder return; (v)&nbsp;return on equity or average stockholder&#146;s equity; (vi)&nbsp;return on assets, investment, or capital employed; (vii)&nbsp;stock price or stock price performance; (viii)&nbsp;margin (including gross
margin); (ix)&nbsp;net income (before or after taxes); (x)&nbsp;operating income; (xi)&nbsp;operating income after taxes; (xii)&nbsp;pre-tax profit; (xiii)&nbsp;operating cash flow; (xiv)&nbsp;sales or revenue targets; (xv)&nbsp;increases in revenue
or product revenue; (xvi)&nbsp;expenses and cost reduction goals; (xvii)&nbsp;improvement in or attainment of working capital levels; (xviii)&nbsp;economic value added (or an equivalent metric); (xix)&nbsp;market share; (xx)&nbsp;cash flow;
(xxi)&nbsp;cash flow per share; (xxii)&nbsp;share price performance; (xxiii)&nbsp;debt reduction; (xxiv)&nbsp;implementation or completion of projects or processes; (xxv)&nbsp;customer satisfaction; (xxvi)&nbsp;stockholders&#146; equity;
(xxvii)&nbsp;capital expenditures; (xxviii)&nbsp;debt levels; (xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income; (xxxii)&nbsp;billings; (xxxiii)&nbsp;submission
to, or approval by, a regulatory body (including but not limited to the U.S. Food and Drug Administration) of an applicable filing for a product candidate or other product development milestones; (xxxiv)&nbsp;acquisitions, divestitures, joint
ventures, strategic alliances, licenses or collaborations; (xxxv)&nbsp;spin-offs, split-ups, reorganizations, recapitalizations, restructurings, financings (debt or equity) or refinancings; (xxxvi)&nbsp;manufacturing or process development, clinical
trial or research objectives; and (xxxvii)&nbsp;to the extent that an Award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of performance selected by the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(mm) </B>&#147;<B><I>Performance Goals</I></B>&#148; means, for a Performance Period, the one or more goals established by the Board
for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable
companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the
time the Performance Goals are established, the Board shall appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to exclude restructuring and/or other
nonrecurring charges; (2)&nbsp;to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated Performance Goals; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the
effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (6)&nbsp;to
exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture;
(8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or
exchange of shares or other similar corporate change, or any distributions to common shareholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based compensation and/or the award of an annual cash incentive under the
Company&#146;s Annual Incentive Program; and (10)&nbsp;to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item. In addition, the Board retains the discretion to reduce or eliminate the compensation or
economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or
vesting corresponding to the degree of achievement as specified in the Stock Award Agreement or the written terms of a Performance Cash Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(nn) </B>&#147;<B><I>Performance Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of
determining a Participant&#146;s right to and the payment of a Stock Award or a Performance Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(oo) </B>&#147;<B><I>Performance Stock Award</I></B>&#148; means a Stock Award granted under the terms and conditions of
Section&nbsp;6(c)(i). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(pp) </B>&#147;<B><I>Plan</I></B>&#148; means this Dynavax Technologies Corporation 2011 Equity
Incentive Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(qq) </B>&#147;<B><I>Resignation for Good Reason</I></B>&#148; means voluntary termination by a
Participant from all positions he or she then holds with the Company, which resignation results in a &#147;separation from service&#148; with the Company within the meaning of Treasury Regulation Section&nbsp;1.409A-1(h), effective within a period
of ninety (90)&nbsp;days after the Participant provides written notice to the Company after the initial occurrence of one of the following actions taken without his or her written consent, which written notice must be provided within thirty
(30)&nbsp;days after the initial occurrence of one of the following actions, and must reasonably specify the particulars of the action; <I>provided, however</I>, that following the receipt of notice by the Company, the Company shall have a period of
thirty (30)&nbsp;days during which to remedy the action giving rise to a Resignation for Good Reason and if such action is materially remedied by the Company during such period, no event giving rise to a right for a Resignation for Good Reason shall
be deemed to have occurred: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>the assignment to the Participant of any duties or responsibilities that results in a
material diminution in the Participant&#146;s employment role in the Company as in effect immediately prior to the date of such actions;<I> provided, however, </I>that mere changes in the Participant&#146;s title or reporting relationships alone
shall not constitute a basis for Resignation for Good Reason;<I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>a greater than twenty percent
(20%)&nbsp;aggregate reduction by the Company in the Participant&#146;s annual base salary (that is, a material reduction in base compensation), as in effect immediately prior to the date of such actions; <I>provided that</I> an across-the-board
reduction in the salary level of substantially all other individuals in positions similar to the participant&#146;s by the same percentage amount shall not constitute such a salary reduction; or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>a non-temporary relocation of the Participant&#146;s business office to a
location that increases Participant&#146;s one way commute by more than thirty-five (35)&nbsp;miles from the location at which the Participant performs duties as of immediately prior to the date of such action. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(rr) </B>&#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of shares of Common Stock which is granted pursuant to the
terms and conditions of Section&nbsp;6(a). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ss) </B>&#147;<B><I>Restricted Stock Award Agreement</I></B>&#148; means a
written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement shall be subject to the terms and conditions of the Plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(tt) </B>&#147;<B><I>Restricted Stock Unit Award</I></B>&#148; means a right to receive shares of Common Stock which is
granted pursuant to the terms and conditions of Section&nbsp;6(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(uu) </B>&#147;<B><I>Restricted Stock Unit Award
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement shall be
subject to the terms and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vv) </B>&#147;<B><I>Rule 16b-3</I></B>&#148; means Rule 16b-3
promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ww)
</B>&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(xx) </B>&#147;<B><I>Stock
Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;5. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(yy) </B>&#147;<B><I>Stock Appreciation Right Agreement</I></B>&#148; means a written agreement between the Company and a holder of a
Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement shall be subject to the terms and conditions of the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(zz) </B>&#147;<B><I>Stock Award</I></B>&#148; means any right to receive Common Stock granted under the Plan, including an Incentive
Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance Stock Award or any Other Stock Award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(aaa) </B>&#147;<B><I>Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing
the terms and conditions of a Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(bbb) </B>&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than fifty percent (50%)&nbsp;of the outstanding capital stock having ordinary
voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any
contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or
participation in profits or capital contribution) of more than fifty percent (50%). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ccc) </B>&#147;<B><I>Ten Percent
Stockholder</I></B>&#148; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than ten percent (10%)&nbsp;of the total combined voting power of all classes of stock of the Company or any
Affiliate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-22
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Appendix B </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>YNAVAX</SMALL> T<SMALL>ECHNOLOGIES</SMALL> C<SMALL>ORPORATION</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2014 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;10, 2014 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: M<SMALL>AY</SMALL>&nbsp;28, 2014
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL> 22, 2016 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL>
<SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016] </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits
the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>The
Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related
Corporations. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DMINISTRATION</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section&nbsp;2(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>To designate from time to time which Related Corporations of the Company will be eligible to participate in the
Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and
regulations for the administration of the Plan. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) </B>To settle all controversies regarding the Plan and Purchase Rights granted under the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) </B>To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vi) </B>To amend the Plan at any time as provided in Section&nbsp;12. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vii) </B>Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests
of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(viii) </B>To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or
subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and
may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and
expediency that may arise in the administration of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>All determinations, interpretations and constructions
made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>Subject to the provisions of Section&nbsp;11(a) relating to Capitalization Adjustments, the
maximum number of shares of Common Stock that may be issued under the Plan will not exceed 250,000 shares of Common Stock, which number is the sum of (i)&nbsp;50,000 shares that were approved at the Company&#146;s 2014 Annual Meeting of
Stockholders,</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> and (ii)&nbsp;an additional 200,000 shares
that were approved at the Company&#146;s 2016 Annual Meeting of Stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>If any Purchase Right granted under
the Plan terminates without having been exercised in full, the shares of Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares
repurchased by the Company on the open market. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; O<SMALL>FFERING</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering
(consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate and will comply with the
requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering will be incorporated by reference into the Plan and treated as part of the
Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the
Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms
delivered to the Company: (i)&nbsp;each form will apply to all of his or her Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have
identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common
Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that Offering will terminate immediately as
of that first Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. </FONT></P>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 500,000 shares approved at the Company&#146;s 2014 Annual Meeting of Stockholders were adjusted to 50,000 shares pursuant to a 1-for-10 reverse stock split
effective November&nbsp;7, 2014. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>LIGIBILITY</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b), to Employees of a Related Corporation. Except as provided in
Section&nbsp;5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding
such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights
under the Plan unless, on the Offering Date, such Employee&#146;s customary employment with the Company or the Related Corporation is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may
determine consistent with Section&nbsp;423 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>The Board may provide that each person who, during the
course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under
that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>the date on which such Purchase Right is granted will be the &#147;Offering Date&#148; of such Purchase Right for
all purposes, including determination of the exercise price of such Purchase Right; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>the period of the Offering
with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the
end of the Offering, he or she will not receive any Purchase Right under that Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>No Employee will be
eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing 5% or more of the total combined voting power or value of all classes of stock of the Company or of any
Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights
and options will be treated as stock owned by such Employee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>As specified by Section&nbsp;423(b)(8) of the Code,
an Eligible Employee may be granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#146;s
rights to purchase stock of the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined
as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)
</B>Officers of the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that
Employees who are highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will not be eligible to participate. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to
purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 10% of such Employee&#146;s earnings (as defined by the Board in
each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>The Board will establish one or more Purchase Dates during an Offering on which
Purchase Rights granted for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>In connection with each Offering made under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant pursuant to such
Offering, (ii)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date pursuant to such Offering, (iii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all
Participants pursuant to such Offering, and/or (iv)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date pursuant to such Offering. If the aggregate purchase of shares of Common
Stock issuable upon exercise of Purchase Rights granted under such Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#146;s accumulated Contributions)
allocation of the shares of Common Stock available will be made in as nearly a uniform manner as will be practicable and equitable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by completing and
delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each
Participant&#146;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a
third party. If permitted in the Offering, a Participant may begin such Contributions with the first full payroll period beginning on the Offering Date. If permitted in the Offering, a Participant may thereafter decrease (including to zero) or
increase his or her Contributions. If specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through payment by cash or check prior to a Purchase Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a
withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#146;s Purchase Right in that Offering will immediately terminate and the Company will
distribute to such Participant all of his or her accumulated but unused Contributions without interest. A Participant&#146;s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under
the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>Upon either (i)&nbsp;termination of a Participant&#146;s employment relationship with the Company or a Related Corporation
that has been designated as eligible to participate in the Plan or (ii)&nbsp;any other circumstance or event that causes a Participant to no longer be eligible to participate in an Offering, the Company will distribute to such individual all of his
or her accumulated but unused Contributions without interest and such individual&#146;s outstanding Purchase Rights under such Offering will terminate immediately (subject to any post-employment participation period required by law). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Plan, the employment relationship will be treated as continuing intact while an individual is on military leave, sick
leave or other bona fide leave of absence approved by the Company or a Related </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Corporation, if applicable, if the period of such leave does not exceed three months, or if longer, so long as the individual&#146;s right to reemployment with the Company or a Related
Corporation, if applicable, is provided either by statute or by contract. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>During a Participant&#146;s lifetime,
Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described
in Section&nbsp;10. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) </B>Unless otherwise specified in the Offering, the Company will have no obligation to pay
interest on Contributions. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>On each Purchase Date, each Participant&#146;s accumulated Contributions will be applied to the purchase of shares of Common
Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>If any amount of accumulated Contributions remains in a Participant&#146;s account after the purchase of shares of
Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant&#146;s account for the purchase of
shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such Offering, in which case such amount will be distributed to such Participant after the final Purchase Date
without interest. If the amount of Contributions remaining in a Participant&#146;s account after the purchase of shares of Common Stock is at least equal to the amount required to purchase one whole share of Common Stock on the final Purchase Date
of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such Offering without interest. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the
Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws applicable to the Plan. If, on a Purchase
Date, the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an
effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 6 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares
of Common Stock are not registered and the Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the
Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems
necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue
and sell Common Stock upon exercise of such Purchase Rights. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares of Common Stock and/or Contributions from the
Participant&#146;s account under the Plan if </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Participant dies before such shares and/or Contributions are delivered to the Participant. If a Participant is married and the designated beneficiary is not the Participant&#146;s spouse, the
Company may require spousal consent for such designation to be effective. The Company may, but is not obligated to, permit the Participant (subject to spousal consent, if applicable and required by the Company) to change such designation of
beneficiary. Any such designation and/or change must be on a form approved by the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>If a Participant dies,
and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to
the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or Contributions to the Participant&#146;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the
Company, then to such other person as the Company may designate. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL>
T<SMALL>RANSACTIONS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>In the event of a Capitalization Adjustment, the Board will
appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a); (ii)&nbsp;the class(es) and number of securities subject to, and the purchase price applicable to
outstanding Offerings and Purchase Rights; and (iii)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final,
binding and conclusive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>In the event of a Corporate Transaction, the surviving or acquiring corporation (or the
surviving or acquiring corporation&#146;s parent or subsidiary company) will assume or continue outstanding Purchase Rights or will substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the
Corporate Transaction) for outstanding Purchase Rights, unless the Board determines, in the exercise of its sole discretion and in lieu of such assumption, continuation or substitution, to shorten any Offerings then in progress by setting a new
Purchase Date prior to the Corporate Transaction (the &#147;<B><I>New Purchase Date</I></B>&#148;). If the Board sets a New Purchase Date pursuant to the preceding sentence, then the Board will notify each Participant in writing, at least ten
(10)&nbsp;business days prior to the New Purchase Date, that the Purchase Date for the Participant&#146;s outstanding Purchase Rights has been changed to the New Purchase Date and that either: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>the Participant&#146;s outstanding Purchase Rights will be exercised automatically on the New Purchase Date, unless the
Participant withdraws from the applicable Offering prior to the New Purchase Date in accordance with Section&nbsp;7(b), and such Purchase Rights will terminate immediately after such exercise; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>in lieu of such exercise, the Company will pay to the Participant on the New Purchase Date an amount in cash, cash
equivalents, or property as determined by the Board that is equal to the difference in the Fair Market Value of the shares of Common Stock subject to the Participant&#146;s outstanding Purchase Rights on the New Purchase Date and the applicable
exercise price due had such Purchase Rights been exercised automatically under Section&nbsp;11(b)(i) above, and such Purchase Rights will terminate immediately after such payment. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDMENT</SMALL>, T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>The Board may amend the Plan at any time in any respect the Board deems necessary or advisable.
However, except as provided in Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing requirements,
including any amendment that either (i)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (ii)&nbsp;materially expands the class of individuals eligible to become Participants and receive Purchase
Rights, (iii)&nbsp;materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be purchased under the Plan, (iv)&nbsp;materially extends the term of the Plan, or
(v)&nbsp;expands the types of awards available for issuance under the Plan, but in each of (i)&nbsp;through (v)&nbsp;above only to the extent stockholder approval is required by applicable law or listing requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>The Board may suspend or terminate the Plan at any time. No Purchase Rights may
be granted under the Plan while the Plan is suspended or after it is terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>Any benefits, privileges,
entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent
of the person to whom such Purchase Rights were granted, (ii)&nbsp;as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the
regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including, without limitation, any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the
Board, or (iii)&nbsp;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#146;s consent if such amendment is necessary to ensure that
the Purchase Right and/or the Plan complies with the requirements of Section&nbsp;423 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding anything
in the Plan or any Offering Document to the contrary, the Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of the amount
designated by a Participant in order to adjust for mistakes in the Company&#146;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to
ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#146;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any ambiguities
regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section&nbsp;423 of the Code; and (v)&nbsp;establish other limitations or procedures as the Board determines in its sole discretion advisable that
are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights
granted under each Offering. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Plan will become effective on the date of the annual meeting of stockholders of the Company held in 2014, provided the Plan is
approved by the Company&#146;s stockholders at such meeting. No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the
Plan is adopted (or if required under Section&nbsp;12(a), materially amended) by the Board. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of
Common Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter
the at will nature of a Participant&#146;s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a
Related Corporation to continue the employment of a Participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>The provisions of the Plan will be governed by
the laws of the State of California without resort to that state&#146;s conflicts of laws rules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>EFINITIONS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>&#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase
Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large
nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board
Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder<I>.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>&#147;<B><I>Committee</I></B>&#148; means a committee of one or more members of the
Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) </B>&#147;<B><I>Common
Stock</I></B>&#148; means the common stock of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f) </B>&#147;<B><I>Company</I></B>&#148; means Dynavax
Technologies Corporation, a Delaware corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g) </B><B><I>&#147;Contributions</I></B>&#148; means the payroll
deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided
for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(h) </B>&#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of
which is to change the state in which the Company is incorporated; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>the sale, transfer or other disposition of all
or substantially all of the assets of the Company (including the capital stock of the Company&#146;s subsidiary corporations); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) </B>the complete liquidation or dissolution of the Company; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) </B>any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited to, a tender
offer followed by a reverse merger) in which the Company is the surviving entity but in which securities possessing more than forty percent (40%)&nbsp;of the total combined voting power of the Company&#146;s outstanding securities are transferred to
a person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger but excluding any such transaction or series of related transactions that the Board determines
will not be a Corporate Transaction; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) </B>acquisition in a single or series of related transactions by any person or
related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%)&nbsp;of the total
combined voting power of the Company&#146;s outstanding securities but excluding any such transaction or series of related transactions that the Board determines will not be a Corporate Transaction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>&#147;<B><I>Director</I></B>&#148; means a member of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j) </B>&#147;<B><I>Eligible Employee</I></B>&#148; means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k) </B>&#147;<B><I>Employee</I></B>&#148; means any person, including an Officer or Director, who is &#147;employed&#148; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of
the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l) </B>&#147;<B><I>Employee Stock Purchase Plan</I></B>&#148; means a plan that grants Purchase Rights intended
to be options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(m) </B>&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(n) </B>&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) </B>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair
Market Value of a share of Common Stock will be the <B><U>closing sales price</U></B> for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) <B><U>on the date of
determination</U></B>, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing sales price on the last preceding date for which such quotation exists. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) </B>In the absence of such markets
for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Section&nbsp;409A of the Code. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(o) </B>&#147;<B><I>Offering</I></B>&#148; means the grant to Eligible Employees of Purchase Rights, with the exercise of those
Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#147;<B><I>Offering Document</I></B>&#148; approved by the Board for that Offering.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(p) </B>&#147;<B><I>Offering Date</I></B>&#148; means a date selected by the Board for an Offering to commence.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(q) </B>&#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company or a Related Corporation within
the meaning of Section&nbsp;16 of the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(r) </B>&#147;<B><I>Participant</I></B>&#148; means an Eligible
Employee who holds an outstanding Purchase Right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(s) </B>&#147;<B><I>Plan</I></B>&#148; means this Dynavax Technologies
Corporation 2014 Employee Stock Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(t) </B>&#147;<B><I>Purchase Date</I></B>&#148; means one or more dates
during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(u) </B>&#147;<B><I>Purchase Period</I></B>&#148; means a period of time specified within an Offering, generally beginning on the
Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(v) </B>&#147;<B><I>Purchase Right</I></B>&#148; means an option to purchase shares of Common Stock granted pursuant to the Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(w) </B>&#147;<B><I>Related Corporation</I></B>&#148; means any &#147;parent
corporation&#148; or &#147;subsidiary corporation&#148; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(x) </B>&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(y) </B>&#147;<B><I>Trading Day</I></B>&#148; means any day on which the exchange(s) or market(s) on which shares of Common Stock are
listed, including but not limited to the NYSE, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g121496pcpg001.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">DYNAVAX TECHNOLOGIES CORPORATION </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">VOTE BY INTERNET - www.proxyvote.com </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">ATTN: STEVEN N. GERSTEN </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">2929 SEVENTH STREET,
SUITE 100 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">BERKELEY, CA 94710 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your
proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">If
you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic
delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">VOTE BY PHONE - 1-800-690-6903 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you
call and then follow the instructions. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">VOTE BY MAIL </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote
Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK
INK AS FOLLOWS: </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">E09657-P72330 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">KEEP THIS PORTION FOR YOUR RECORDS </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">THIS PROXY
CARD IS VALID ONLY WHEN SIGNED AND DATED. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">DETACH AND RETURN THIS PORTION ONLY </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">DYNAVAX TECHNOLOGIES CORPORATION </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">For All Withhold All For All Except </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">To withhold
authority to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the number(s) of the nominee(s) on the line below. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">The Board of Directors recommends a vote FOR the listed nominees: </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">1. Election of Directors </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Nominees: </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">01) Dennis A. Carson, M.D. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">02) Eddie Gray </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">03) Laura Brege </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">The Board of Directors recommends a vote FOR proposals 2, 3, 4 and 5. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">For Against Abstain </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">2. To amend and restate the Dynavax Technologies Corporation 2011 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for
issuance under that plan by 3,200,000, and to approve the award limits and other terms applicable to awards intended to qualify as &#147;performance-based compensation&#148; for purposes of Section 162(m) of the Internal Revenue Code. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">3. To amend and restate the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to increase the aggregate
number of shares of common stock authorized for issuance under that plan by 200,000. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">4. To approve, on an
advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in the proxy statement. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">5. To ratify the selection of Ernst &amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">NOTE: To conduct any other business properly brought before the meeting or any adjournment thereof. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">For address changes and/or comments, please check this box and write them on the back where indicated. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other
fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Signature [PLEASE SIGN WITHIN BOX] </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Date Signature (Joint Owners) Date </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">


<IMG SRC="g121496pcpg002.jpg" ALT="LOGO">
] </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Annual
Meeting: </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">The Combined 10-K with Proxy Statement is available at www.proxyvote.com. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">E09658-P72330 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">DYNAVAX TECHNOLOGIES CORPORATION </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">THIS PROXY IS
SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF DYNAVAX TECHNOLOGIES CORPORATION </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">FOR THE 2016 ANNUAL MEETING
OF STOCKHOLDERS </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">May 31, 2016 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">The undersigned stockholder of DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (the &#147;Company&#148;), hereby acknowledges receipt of the Notice of Annual Meeting of
Stockholders and Proxy Statement, each dated April 26, 2016 and the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2015 and hereby appoints Eddie Gray and Michael Ostrach, or either of them, proxies, with full power to
each of substitution, on behalf and in the name of the undersigned, to represent the undersigned at the 2016 Annual Meeting of Stockholders of the Company to be held on May 31, 2016 at 9:00 a.m., Pacific Time, at the Company&#146;s offices at 2929
Seventh Street, Suite 100, Berkeley, California, and at any postponement or adjournment thereof, and to vote all shares of common stock of the Company which the undersigned would be entitled to vote if then and there personally present, on the
matters set on the reverse side. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">THE PROXY WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY DIRECTION IS
INDICATED, WILL BE VOTED IN FAVOR OF THE COMPANY&#146;S PROPOSALS AS LISTED ON THE REVERSE SIDE, AND AS SAID PROXIES DEEM ADVISABLE ON SUCH MATTERS AS MAY PROPERLY COME BEFORE THE MEETING. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Address Changes/Comments: </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">(If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.) </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Continued and to be signed on reverse side </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g121496g30n33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g121496g30n33.jpg
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M9\%3CUK V>-_$N@Y?([NBK*=S?DV99B+<N#@GG?/PK/>=ES9JU(Z@(-FUA#
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MUBD\N=&ER1KHU2,^4]6CC8$HKKT3HNV0K0Y!T-:?UAE,2Q:08RU(Q?#[@?\
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MY%=X*[F3RHI?(NG+!MSKZRLX&4\(KY":4!\$[ F6L& &*MG':C7,JQ1>,MM
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MOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1
M_DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W
M*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]
MVCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ
M1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M
M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.Q
MY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBX
MNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2
M<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI
M.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOW
MBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _D
MI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*Q
MGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VC
MOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1
M_DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W
M*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]
MVCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ
M1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M
M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.Q
MY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBX
MNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2
M<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI
M.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOW
MBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.QY]VCOWBXNZ1 _D
MI2<M8W*QGI.QY]VCOWBXNZ1 _DI2<M8W*QGI.SYBZ\]&P 0@P^I"*@00L,A!
M1A7*6#""#PM?+,003.V.&&&&-KY99Y7MCC:U[WO:UJ4G+6-RL9Z3LMH&)@*'
M@*'E;,,3#$3#.WW989VMECE;_P LL;VO;_RO45^Z!01Y+OJGD_X>/7Y;4J##
MA'U,1%\,&#\J)-!)]!URNEE%Q)5$10\K\@6$XZEG?(%%02#WDB@6%*&?(E9(
M-$55+-^)&S\G44PZ34"0W@&21HN9""%P"O86D#3GFG!D5>,$-TFL7XU9-%<3
MLN;<#N-/EDGV<HM==,.I0,"KN=TK./F83LEX'@T4XCM\DAJ":;1\S1(P*^_;
MM%K2]"SE0[H+G;BTZ L\5$ PL.9]OUPNXXFJS5<#'4T,^]E=RG':>;QUI.MR
M(HZ";6ADK+!;4%'$IBLCY*5%K-_XAI6ND$$OHLU,ERX08  $'OP$  '#$($$
M$)NF\ P@@\+8X!AAX8XX8888VQPQM;'&UK6M:M<'ZHZ^)9F[K'F%M;?=;^JW
M]U95S0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"K>N#]S;51_R^RY\C+=6
M+X^X\I-W6/,+*I7\EIO]@)_X<.HK/H%!'DN^J>3_ (>/7Y;4J##A'U,1%\,&
M#\J)-!)] H% H*FZ\/W,=3WP3D#Y?.5K@_5'7Q*3=UCS"V-ONM_5;^ZLJYH%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H%!5O7!^YMJH_Y?9<^1ENK%\?<>4F
M[K'F%E4K^2TW^P$_\.'45GT"@CR7?5/)_P /'K\MJ5!APCZF(B^&#!^5$F@D
M^@UEZ''*G,YV*#,(HZH\"+97CC437"H"I* HN4LEFAD(BN*@(0PR:CFU3 J7
M4U ($44F2$',!A"9!VQN'F.5V0XRGL.,KN$ZU$F57#.\31K(S/>;07V&IQTE
M.^38G9#L;!Y&P=SI(K,A%TN1KNIJ+S7=:Y'*VRKICZ3U-:1#[?"=QKXWX4K%
M+>4T\4G-II39&9844EH>*93&3E1[Z2F9K)+*JHG.(-MM=M/B%I[DPI#"U?%R
M8CGWXA*L/I@*J[ #283-M9:55,%E)YI/+^.'QMZT[Q$\L[%IM<+[3S.A&;5X
MXDN<E=YZ?W6H%4XLUG(O&DH14:&1_P C7LF^D*0*+D4L:Q+F#*MF1*6'"&QL
M-MAYVQUP_JCWDQ/YCGG'.Y9JTNM3:M_T3)_W6_W)3/V!K*N>%UJ>R9/ZD9G[
M T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9
M^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1
MF?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/Z
MD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3
M^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)
MD_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>
MR9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:
MGLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X7
M6I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.
M%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T
M#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P
M- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?
ML#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9
MG[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I
M&9^P- X76I[)D_J1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_
MJ1F?L#0.%UJ>R9/ZD9G[ T#A=:GLF3^I&9^P- X76I[)D_J1F?L#0.%UJ>R9
M/ZD9G[ T%9-:DI-D]I!U/D@$R1L!C<"RL6"S.0]+:<4P$&9*T'AD94%!D%2!
M(OCEE:XIHX9 *E\/"%'&#"QRSM8OC[A)_,>87;2OY+3?[ 3_ ,.'45GT"@CR
M7?5/)_P\>ORVI4&'"/J8B+X8,'Y42:"3Z#!5$M-6TU115E/(JZ.KD3:6K)2F
M4 /IJFFGRXA0\GJ!$T&*5.D3I444L;*&0A #)<40$8/,//+&X:>CQ7&J WP6
MJD,1IDVX OI3K#1[(2<,1NZ4)33%I#<PH)@ 6P[B15A$151)6QKB*::?1TDV
M2- #II+, 58(T+Q 83CJ0/%T?#):DL#.!03A6@@"$3JV93#J(95#17(A<$<Z
M:1%)21#0XN&69E%4E%('N(G'S988(9UX?N8ZGO@G('R^<K7!^J.OB4F[K'F%
ML;?=;^JW]U95S0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"K>N#]S;51_R
M^RY\C+=6+X^X\I-W6/,+*I7\EIO]@)_X<.HK/H%!'DN^J>3_ (>/7Y;4J##A
M'U,1%\,&#\J)-!)] H% H*FZ\/W,=3WP3D#Y?.5K@_5'7Q*3=UCS"V-ONM_5
M;^ZLJYH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H%!5O7!^YMJH_Y?9<^1EN
MK%\?<>4F[K'F%E4K^2TW^P$_\.'45GT"@CR7?5/)_P /'K\MJ5!APCZF(B^&
M#!^5$F@D^@TR1CJLFQZ_%%!<+>:2XGLQT'49UNX*X[4;*L51#PZ<X7.#B.5R
M&;R*<#!4EH+$T6N(FEC.%AP;W\9B'FLQ]14JKD=14JG'P^B4GH6I>-XLEZ._
M$P.Y@U!$=CGBU =!U/4"[;;)^1XN)I;_ $AP(#YC;>"]FJ6=0IR06T;7F*OQ
M1<U3ZFL3,7X3XSK=?2UJ3TU.:B&B5?ES+Y2AB6*K.#T0).:2A'DG1)O:;NGZ
M0)5B6.V:H)\5LI2)JQHR@[HOIKO T^7?@E-8N;0)#,I;\3Q4X4C>M<;9SPOC
MZJL_K@<[B$T(38I'6(OBJSAT_NLTOI28:;>&] \<9^1D\65<G X$$8P$0-#C
M$\MR@%(YED6SRR*8[>'AZX?U1[R8G\QYA9JS^=>U;_0E)_W6_P#6T,=[M95S
MO^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_ )U\B,G\[0QWNT#?\Z^1&3^=H8[W
M:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_G7R(R?SM#'>[0-_P Z^1&3^=H8
M[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_ )U\B,G\[0QWNT#?\Z^1&3^=
MH8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_G7R(R?SM#'>[0-_P Z^1&3
M^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_ )U\B,G\[0QWNT#?\Z^1
M&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_G7R(R?SM#'>[0-_P Z
M^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_ )U\B,G\[0QWNT#?
M\Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_G7R(R?SM#'>[0-
M_P Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_ )U\B,G\[0QW
MNT#?\Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_G7R(R?SM#'
M>[0-_P Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_ )U\B,G\
M[0QWNT#?\Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_G7R(R?
MSM#'>[0-_P Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_ )U\
MB,G\[0QWNT#?\Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_G7
MR(R?SM#'>[0-_P Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@;_
M )U\B,G\[0QWNT#?\Z^1&3^=H8[W:!O^=?(C)_.T,=[M W_.OD1D_G:&.]V@
M;_G7R(R?SM#'>[0-_P Z^1&3^=H8[W:"LFM1[N8UI!U/EAX>D9.!'@65@15
MXIQ)F4)!B,E:PS-&<$^4CQ_,N7QO<47$F2-FLL,<K %AA?!#RL7Q]PD_F/,+
MMI7\EIO]@)_X<.HK/H%!'DN^J>3_ (>/7Y;4J##A'U,1%\,&#\J)-!)]!QEC
MCEC?'*ULL<K7QRQRM:^.6-[;5[7M?T7M>WHO:_HO;T7H.E(-IN)0:8$EM]$3
M0D4(V C!D$H@3#20#^=A#P*9@7 #Q(!'!+6S-AE;!8&,[6R&MG>VW096".DA
M% R :6G!D0C6)T(E@2+8% CF!S=' V&7Q"L#@:Q4/\^Q'QPL+B<_SFV=A_VZ
M"KVO#]S'4]\$Y ^7SE:X/U1U\2DW=8\PMC;[K?U6_NK*N:!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!05;UP?N;:J/^7V7/D9;JQ?'W'E)NZQYA95*_DM-_
ML!/_  X=16?0*"/)=]4\G_#QZ_+:E08<(^IB(OA@P?E1)H)/H% H%!4W7A^Y
MCJ>^"<@?+YRM<'ZHZ^)2;NL>86QM]UOZK?W5E7- H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H*MZX/W-M5'_+[+GR,MU8OC[CRDW=8\PLJE?R6F_P!@)_X<
M.HK/H%!'DN^J>3_AX]?EM2H,.$?4Q$7PP8/RHDT$GT&ER1<]C';]R3'4,Q5*
MS+=-T][ET7!R&&<>LAGKE'4 W10Q@UX9O&/%JX2*($+@J9D\2.8>>(]\;AY?
M1S)TCN".(9PLO.G.6V]J283>6DA$F]87$"3HW'=,6)4HR)$UW CN)3F.,2+<
M=PIAX-U_&L344G,97)(SO*KL>MA;,%LK/7E;7\=/X0P#,^L2[8;HZTIR"G)(
MNF)I/"3%U,3CIEP(.NH[ FHA>?4-)92Q0P*GHJ(_4.)3"7'Q4MDA9/@1NL ,
ML=!>!IM+A?[;;>=(Y65BV;KXKSQK2R5\M<!^0<]",VF##>;>:^=T_NL5[DSC
MD/HX"(HBM#(15"1/(6XYL%CR=0S-@ @&328%D$$%G8^)XR]\-</ZH]Y,3^8\
MPLU96F?:M_U!C#[K?[W77W)5E7.ZTS\08PZW77W(T#=:9^(,8=;KK[D:!NM,
M_$&,.MUU]R- W6F?B#&'6ZZ^Y&@;K3/Q!C#K==?<C0-UIGX@QAUNNON1H&ZT
MS\08PZW77W(T#=:9^(,8=;KK[D:!NM,_$&,.MUU]R- W6F?B#&'6ZZ^Y&@;K
M3/Q!C#K==?<C0-UIGX@QAUNNON1H&ZTS\08PZW77W(T#=:9^(,8=;KK[D:!N
MM,_$&,.MUU]R- W6F?B#&'6ZZ^Y&@;K3/Q!C#K==?<C0-UIGX@QAUNNON1H&
MZTS\08PZW77W(T#=:9^(,8=;KK[D:!NM,_$&,.MUU]R- W6F?B#&'6ZZ^Y&@
M;K3/Q!C#K==?<C0-UIGX@QAUNNON1H&ZTS\08PZW77W(T#=:9^(,8=;KK[D:
M!NM,_$&,.MUU]R- W6F?B#&'6ZZ^Y&@;K3/Q!C#K==?<C0-UIGX@QAUNNON1
MH&ZTS\08PZW77W(T#=:9^(,8=;KK[D:!NM,_$&,.MUU]R- W6F?B#&'6ZZ^Y
M&@;K3/Q!C#K==?<C0-UIGX@QAUNNON1H&ZTS\08PZW77W(T#=:9^(,8=;KK[
MD:!NM,_$&,.MUU]R- W6F?B#&'6ZZ^Y&@;K3/Q!C#K==?<C0-UIGX@QAUNNO
MN1H&ZTS\08PZW77W(T#=:9^(,8=;KK[D:!NM,_$&,.MUU]R- W6F?B#&'6ZZ
M^Y&@;K3/Q!C#K==?<C0-UIGX@QAUNNON1H&ZTS\08PZW77W(T#=:9^(,8=;K
MK[D:!NM,_$&,.MUU]R- W6F?B#&'6ZZ^Y&@;K3/Q!C#K==?<C0-UIGX@QAUN
MNON1H&ZTS\08PZW77W(T#=:9^(,8=;KK[D:!NM,_$&,.MUU]R- W6F?B#&'6
MZZ^Y&@;K3/Q!C#K==?<C0-UIGX@QAUNNON1H&ZTS\08PZW77W(T#=:9^(,8=
M;KK[D:!NM,_$&,.MUU]R- W6F?B#&'6ZZ^Y&@K)K44Y;ST@ZG\%!D1R5(9P+
M*V)PR3E)S'C8!7)DK5AQBQ(>'DX$V8#"\+,(L*H$@QL[8AYFB^.5Q<;%\?<)
M/YCS"[:5_):;_8"?^'#J*SZ!01Y+OJGD_P"'CU^6U*@PX1]3$1?#!@_*B302
M?0*#BUK8VM;&UL;6^ZUK6M:W]5K>B@YH*FZ\/W,=3WP3D#Y?.5K@_5'7Q*3=
MUCS"V-ONM_5;^ZLJYH% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!5O7!^YM
MJH_Y?9<^1ENK%\?<>4F[K'F%E4K^2TW^P$_\.'45GT"@CR7?5/)_P\>ORVI4
M&'"/J8B+X8,'Y42:"3Z!0*!05-UX?N8ZGO@G('R^<K7!^J.OB4F[K'F%L;?=
M;^JW]U95S0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"K>N#]S;51_R^RY\
MC+=6+X^X\I-W6/,+*I7\EIO]@)_X<.HK/H%!'DN^J>3_ (>/7Y;4J##A'U,1
M%\,&#\J)-!)]!I<D)^Z\=OU)\O=Z5NFRW2G[IQ\)F$_DWRU#/%O+V0*&&-F&
M[R?C?*&T)@$+G@M!DLL0\[VMC</*V.FZXKLJ%67(D?2ZD/9KSNWEEHRU&# G
M!#;2NUF0O18Y3S@48_3R@B5#AJ81BZC#S];3R,)+),():7)"P6+-5TDT=TFK
ML[/8KSI?MRZMX1;/824]SS*'EN0F$Z5^;7@DJJLUW%'4X'Y&><%2 5CQ-=*
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M4RH\?8^0A$8$T;;3R/I"0)F5W;4TS \3S''M[FR9/R@)'IE(5WFF)CA#$-R
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M<V2T!BY7(7,/(RQ&5(S>9)HUE<;.QD^9;XI\YA8(,V9'P !Q#+7ZTB?++D*
M8*EQ1(*\KPS%<GJ:41W-2STAL!JO4RG$+CB&;E" CE2E.Y0'(P,*-G@7\7;,
M3/+/+;O>A68NF6\69K0L$@@V:K;L"U26*:V K(:78)N)V )0O@000_)?!1R6
M(! B!B53[%P,0210.P=L"X..!&R6M:UK6M;:M;T6M;T6M:WW6M:@4$1OW3_
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M$_)17,."*4RI)7#L5'-XEF"N*#/)M^3E 3 OF%B0CM6<YK$UF 4%##,& 0Q
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M8$Q)BE P5N/$1-2Y86%)Y2#8H]$4\,L9GY+?I!,:)$B14!,QF7DV5Y%56 &
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MM6]%MJU')M= H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MB:GM:3^NZ9^WU X(FI[6D_KNF?M]0.")J>UI/Z[IG[?4#@B:GM:3^NZ9^WU
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M-!)] H% H*FZ\/W,=3WP3D#Y?.5K@_5'7Q*3=UCS"V-ONM_5;^ZLJYH% H%
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MW@;+,SOX-#U+Z'IL)X[>5L9*TN2_$"]GM?Q0LUZ.M1CX1,;W^X0Q@Q;6O?\
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M0*"F@^AB&E/?"><)Y[.%U.DLK)"\^CBRF)[O5&LMH,B-94:Y]104)(+'BAY
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M4F[UT;5>H,W!R&#+.$T[H3N)-O'<W)-!7Q)%6TLRO%1@2F*D,.=2=SRHUAU
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MKE=;?$4OZ<J84:9*$%Z@EEWR,<;T9++Q9CV=C6=^9-WF8J3I,;AE(U30*['
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M1Y+OJGD_X>/7Y;4J##A'U,1%\,&#\J)-!)] H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H(\EWU3R?\/'K\MJ5!APCZF(B^&#!^5$F@D^
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$>2[ZIY/\
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M+P(;3X;X2\+;,[(M^OX]A]QM1&DME6N#F$ V<H<:K^9R0"6B!YI]VFT&3C'
M,@M%D9$F;@'9*22RA&PRBVFF(+B<3R"6;)D#91M&!4PGYM=(,KZ)FNKM>,3\
M=-MJFC::SF4WT%0A!S(J,G(;I>"Q$C'9I@R*S 4-!;;A=*"?9R*W5,R10%($
M8@4P*"I2^EW4"VS76?>;?Y'6=-#:.RKC([+) W;:&'J0D9548H<JDF*X49HR
M02QD$LM%6N;(/-UL-#3&T0!$0S2NYT4F112!,(/<C  @+?QK7W_+OW8TM/L(
MIJC+:A%2"0S;68*\97&9$QUXNPB,CM\=%Q7"2:S&VN.?,VDM/ XFYJ:>2$.%
M4"QDA8;R4;(N*+9Y]WV#U0P</8YF6>V!P HHH:4&;(H;B/%%,VOOA"C0#<,R
M421@5LJE/US(;5=1]+R-$6:K* 0+J,(^& H@9*>]_P#&/)O;+E5BR&NO]O,U
M9$7#T8N/%H/,P72E@)&3G3B7\I.M\HX#1 !#6U9&QO@"X22&H*([>."A$5K$
MB<%# R"1*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"/)=]4\G_#QZ
M_+:E08<(^IB(OA@P?E1)H)/H% H% H% H% H% H% H% H% H% H% H% H% H
M% H(A>L+M)_23&$EN3#= _%!5V!-U%.)Z,H(N:@Z3S-5 UX;!03C1XJNMM38
MR*>;BBE'4\4B/F=S%L8R$+Y%@K*Y=CQAY[MY":SU7G<OI*$VI,:9<Y@&U4)V
MV09;*2,1?*(7>[>;:8Z2K<<(4CBFE=KXJ8C?.++(CI=Q3RZJ@*)I=+6=?\^4
MTR%IR3I>9H['E9_/9Y(IMJ/%L', Q4=I"&QW<W,VEDZ!<V6EM_.SB3D XO%@
M<0LPF\..Z5T41OX@8H11$)<[6-80.1NYWDY@Y2?#F%D%UHSV>1%=(,8,LN.1
M%AR/86".BC([12SI0$ZB1HWG(?*)YDH#F[!%$P5L401P6^6#5'3I09#JPF+
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M88XLR?S*U.VM ^T)ACBS)_,K4[:T#[0F&.+,G\RM3MK0/M"88XLR?S*U.VM
M^T)ACBS)_,K4[:T&BRAK^AP_&DB$06U)F(IQBNTJ%D(C-:P>(AA 4 <,A+XO
6//*V%LL[7ROCAEE;';O;'*_HN'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g121496pcpg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g121496pcpg001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#*@)R P$1  (1 0,1 ?_$ -0  0 " P$! 0$!
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M7IP'I#2\L=?_ !(E_;7CR#!42K'P0<T=85\C<KQ@-UF&JULR1MR$W&&*<.!
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M 8AI#SL4GK3J)9*CJH6]3[[.I6SK!:J!75BC.VH@IV98;))NIL=?I(ZQ176
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M!'T98I:$.SHQKMTF)# ".B"W12I1Q%9&;T,MB:A J^P&9_Q;<H' #1-OKV%
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MTR48?B>#\L44!1CQ->PODNU(#U)DA/-)>+FVUW*]N0:,-]S9#%=ES.\GRNZ
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MHQNA;<G"6AXZ:9(W+<1:0G?%,T7ZEBGY1? 0OSL2?N9JBROPV*\/C$L68FX
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M;GD)&A\F*YM22Z5;$L53Q8L^0C^.X*0M\YHH*[/$&,!L2%'[:N+/+7ZD)O\
MGO%Q=SQ4-B>!(=LT"-8\I!1\4[6%V\A,+SSW%5^*&.%0\;2%#"]^^Z=W"UR<
ML^BJYORQV*9J'<':*MRNS%#Z]ZPMDO9-?UA4M3!=:#=A@GJ^]J_7P-CL-MEJ
MJV2T1&!(UE,!><+CNJ5Y>=XH6_W!'1L^.BC6]8J<(H2Q%>U:G\Y)X^C(\S,6
MABM4Z=R9$63<DO'M<@8QG1OUJOAYYZUN1Y:ZSU7D=5W/5@'B9O(>1C6)01-+
M7+4V0%2R13$R[$4C'<Z[^Y[M2+WBZI=5$;1U75"0<QJ_2_;RJB((8\<M^_\
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M.C?[C%#<EE!;95B3OBTBM[8AF:42SH><<=679'HL%RE- ^_H&DBKP-QUR64
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M0L'Y<=$*D,GX5WQ@BXK"%CT,@V.N_4S<A%4R#O5J[F="$+Y*N#Z2.MCT$/\
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MKW.Y#7@E5D6$I"K*J'3YS;$7'P]?Q;1,\$UFZM:L./<E:(TOE31GD%"RO8K
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MS4?Y>ZZX*R_EQQ+.%^'EWO;G:[8NL1\B8N?0?CCGF2S(@^I$CH2'?DX5R$8
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M2R]E26\.(RG+F?H/(^5EM_N[R'[FKIVII/$VJ=>,^[XYLM53N/T'-4JP/!Q
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M[:F--KW.+*1!NP;81BV> (:EH@ R29"TMN9DY<3[YUX?,T9O#(I@\&_D9YX
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M$DBVWE2X+#S;CV$(6G.3_CK_ "Y/;5^.9^9Z)V%8(TW(].TKLJ&3? ,P4G9
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MR+'C)7Z.8$Y6<9;=QCPKMO)Y*"]#Y)%E-[QL561B[\G^)/>GJ,S=& 'S!$_
MJT4<$0A/M SE0Q&C=H7O&S2Q3>/\@+4>PITTE:C5L-L^KE:*3H2")+$DCR[Y
M$GISTYTWL_0NBJ]K+;&PHVQ#X(F<^3R8#IN>-J-,?(+54=>"C]I>D6VT"Z6&
MPW$CD"RUD'FDX2ZI>484KI>0N_.[,LI>7R AU/.X57L3%W=IG5 $5BK+&>('
M/M]Q@'=AF2C3%)YXX0D7CVF!@A3D4KQ"*-!$A8EBO-'D )/#N=M?8BYM'SG9
MOQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,^,AGX
MB._']5UGUV76?685A#[7JH4CU65J2M*76_-XISG&<8SC]C/,URLEVI+3D++'
M-&R$J=, RE25/73 '8.CHY9#)V9DFXJW!@=-U4Z.]$;&P?0]1T^N<<AOL?=4
MQ^N+3K=S9?9DI'L%=KE,#VLEL:HN6V@TBN;7B;L;J%.?BZWB 5""VQX#,Z<L
ML/*S7\-X:P^EO*DJW1SSP+6-9S'8JV:4ZR*!R9O'025Z2N""G"O'+)P"HNV;
MDY;2ZD9FDLV+%@"5;,=]61B2H?R9W=F4@A^[-Z;9V51]J@DG+Z-^V5I&WE<6
MN_[ W?L#8C0/0P.)LRSVJH(NHW'7?;!?<U'*"Y%?H(((-*DKB8<^;K8@H:FP
MVVV4MM>&5*LJV?A74OTT2.POD(;AT#IY(:1H!'!)W$\#RF1.G*2:5M@$*N*Q
M76WX]_&62SU'\?=IZ/\ +%>FCGD*Z U+&\,(AD^Y%AC#<RN\B9WVCNL)H);A
M$>Q[JKDO8E$[':WV-9:W> \"R7^I]G+Q(V+=X%KFOU*9%).5JW2W9-==PPVL
M7AYQO.7D.+2KFQU8HO%IX:/8\='3\;7">H_]JF,U68[!!G/)XIG])(I'0J/:
M5ZK>1M-Y9O.,1_DCY"S;5]=8WM5A5FB37VP%$A=8^O&6"*0':D-G(7MG4\?8
M]#W.-V@[<MW3KQ7+52J1:T734K)0A1;B5K9,S3+-'CZ49#3@JV*D/A(7&B0Y
MR84?",R%+RIS/6^?,?,3^:<*UFY##'94[X6!#--85I1L-R:6=V?MLBGV@*.(
MSCFG"/"1> A!BI5I3)7*_?78UDJCM%N0TL2=!(K^YF)WO0FVC?;]U_H&N;VI
ME2W%V"-4K?<G9Q$S5;;;*3/'4@YMTY8K!=K#KV<*UT$L XQ-(61WT5DII5N.
MAEG"$8\JLKY%JG#<_:<?[/L\F\?%42LDF]3+ B,G:##2:;F[L>'(NQ/+6@.M
M'>EB_<I_=484>1:W\EUT3&\H[04LI).D2&.-5# !!K6^N6=UTZQ1NO(8]3(F
MQ[?>-;-UC7.N]8Z[LJ82*WJS6NM:$,I ^MBXT3&$&B]C<B/D#)20A#LZ0_A.
M&VVVDISUO,7/\_#;7R\<<MB]<M33MK09+&E6NB[(C@@C7@B [/)V8DD:Y=*L
MOC)J[^.9XHZU:-%&_<9EDDFELNP"\IIGD!)X@($55^N:QP_:9ZZXJ(/4EDO>
M_-@=<JM=QUTK/5Z_WX%9-$!HX>86)AZ(FMOTMJPE]="2Q;,F.*)%IJ&U1H[>
M%^@REGF5&+-6F\AJ[:J1\(I+ $CC4'QXW.@H:6&+VQ2,I8$\R6?W9KD=N=PT
MC\2*\VY4@_&A+3BQ+Q V4$\@_,B$(RLP55Y$Y?FI^D&H.O\ K+=&I^OI&YZ-
MJFY[V;V*IK6DRL!UZOL=@!5D"2SJ.#-J9.OU88XU5VI"8LF$0:3*??7X9PYA
M*5J6S;\55\3)-)VJG<$;[W)PDM2VC&68,"BO,Z(..UB(3>P&Q7,%?RTOEQ#$
MTLT<2O&01$3%#V5DXJ5/<*A6=N7N=5)&AHT(<]GWHQ<-8PM=;!U9!V68SLAC
M:UGW-L,+1+;O&^V]VUA[;9%VS8)6ENOX!W>2!BPRXP;''#Y QK$5MEEK&,8N
MKSI2O^.O4(HH!XQD,,: B,]MIG59027F7O6);!$CD]YN>^FLKF,]BO>ALS2R
M2WXFC>0G\D0*1Q*8" %A:.*)(T95Z*"3R=F8[+T#I[J?6U;[# :W*MR9_9P_
M:#VS+A++#W+<A)^LM4H* K$^.&BCZ_5M<4^,P-K0]$5<<7%83CP<4IQ:^?=K
MCR'[?7]MVG=J6I^XV_RS26I&ELSS.0><T[-J1]#V*B*%5% U5++4?/+^X:RQ
MK<B^,L2!0(HHZB@00QH-<8D(9]$DM))([,2V4JOVP.LBB6C9&/O";":.UOJG
M53%*;M41%/VA4]&61RZZB8VX,2#^)LTBBW:0\7C_  D@:S*EOK3,;DQ_*PGM
M?Y6U_G;'[@]OS)YX[ 77XX;,4#U8K,*[VLT==S#&2S*H6-PHEC20<GX,'^$7
MP77XW&RC/T[LD-R2.6U [ZT8IY(E:0*%;1=58+)(K=$^<W-N.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&:F]O])V3>^O1=-KK
M33R?G,IXNTNSEZDXX+D@B@UUEDN">C%&\/KFX0XAMUOSM*5A6<ISG&>?8JM-
MY"M8(!@B#\@3Z\N&@5]&&@=AMCTV#FM+';\?/#&=67>,J=#IP+'8/\I!*D$=
M?T.:];RUKOLMN6H4?3AZV"M;A-!1#=PK(BZ7:BBW;/0S/U5I5' W.#AH<"7L
M.N7@P_.D1I"IC#M3'..H2E:',]<RBW=\CY"WN:JEZM(B;,<DALLPN#ER7<:5
MJL7;12%BGLR.&61R<P1US6_;U+QU22*KYAX)HFD*&4(L4<4E>4#3(&CM[CD#
MISL5[#J0Z0KVY-IK67:BNWVIPKQ(+OZV=LIFWD9LO=ANU$:I696H)U'!:HEL
MD,.EKD0$6M3)-PPN3EI]_'Q6?-*QE>40#U)ZGD).5L>*>OWT0)WK4D_CY/D(
MBA>QPCCMQKH!EWI0%E89&=I5GJ34D B6RS,C'?"(2>3=%;9?O'4U)"&9ND>B
MQ$29K\&ZU=]HULNA&[;)/W>@+*5<V&I('?\ =J89/)KEF(4E%?@V8<D?-J X
MAJ00-.$?"2OYA8YLO"UX5X/<HA=FHQ/:4?.Y/[%/2,6* 5^3].Z*GDHH)H"0
M":[6(F#+(R/;=5Y9GCH2=FB@"1EU#RE8++RL[D#3'R5:W9KL#[JCUZCHX"(T
M69O6@>\MI% *3$/I;;$LP+*G89+;A&6W&L;!O29$")^KJX+\Z?/H[5/,K23<
M5CXF2O+Z,)<F.YQ=^,2--*2\T36@"GXS.+%.["S(5 -;G)*BJJC\*2G@ L(!
MNJM#"@$ZF1);WCY&4Z(C@JRR/-&=[[AE#1$Z.I&A!D)8*<R:NJV\B^AK548U
M;Q5[(<[!WK8PL%:]TG-F%8%6-Z:/T@<X1V,<03,$",BRST.>@Z](S%CK\<.9
MPC",=$6JRWO%3[!AJSQO* @72KY(62NA_4(@&MG7(Z3J!RQ/)W/$^2ICD;=C
MPU>JK%B1)/%\<R2=?Z:,4<@  ;'+@"YSYU/K/W!!$*K#G["+014'>^PKJ4E4
MN^D8XQFB']IJME%$M5!XU712HX&IKE0C$9Y,]!)\FZ_EMQ;;/H8/&2K"?'_.
M]_QO%5X9-CDIL10)'(P]=Q21*E>-2K&)XFL($,FSEOJ9/E&D D$LTA1.H8)(
M).+EQHF:*R[6R5,:R(8JT@D2-N4TN?7OL$QN6^6.@9.0ZQ<]LB+O!*P-[W&N
MQ14QP3J@>0LYJH-S7H9X4.$TTP-S7EMN#Y/S!IU+2<H\[57BF[#P)8]L,4DO
M5ORC@\S3."C?<9E?MJS$F IR4 $9T_)V*EB+8B:6;_'I$=,8CW%6TL14C7%8
M9)(;#<2G>".C\RS!\KNW0'9NU;#-V/7>S;?51AS:$(A%<$[%LCD<!5Q^LZ$'
M!DXE+FVH)4FH R[0#C\X4EEYHG\6EZ0U(5A&&\4<4Z))'&_%WKVRK-MNW8DD
M7LL2>1,?QU,00*RQ.YE1!)[\32U":LI3N1Q0P)/&-Q]\"2Z9.++HK(K2U91(
M'1I%A$#L8MHU&P^O/=FO(V%)I+)8 >OU;%TO)LWV4L]PD#;9%':R0YNQ]T^B
M?)R+C2JN4;8 Q\I<;:FK0VEIJ2\C'0BEC#-$B=JC)Y-[2IT8PPB*O'\=FZM*
M\QC?\C%@BK&&+!$48"7CKQFT1<\E%7J122@"$6#'+Y-YF55 $*$6H"(T5%+J
MS  KMK]U[ISLA%W#K"S'#=TJM#K]:@Q;%7'=P'=CQR%KA2[QFX%3*3]I0T4%
M;"C&A68;?P4M03Y<G$9$3\++GM-H(VF,XW&R.$0_2-H>$<1?9;N5['.SWUXO
M*)(H7D:.,QBFXLTM58HSJR+7-I%Z%AW*S'2Z5%C>*-XNWK2;F=5+RJXJF%U%
M[!5^?>3^MS96B6MQAZN5 T_NN]6(//$2[COJP$S)6M3"D@=+=DL; $YB-3D/
MR!KC>?A7(V6<*5RZL=FO^VZGC"VIPK+.J_[(_%PUX1&_3C(;D(8RIPD[84.[
M("F=)I:\GGK5^=.55[J3QZT&*R>0CFG5^G4+3$B!&Y(79RJAI.>7.#U!V'$Z
M\U$&GFKG:) <S?)5F#3]M&J_8*^^>CM9H!"9=8%F.%]BU_7SK<IIP<1)R5$O
MCFWGL+S%0WCJ>0=9YT^(%C<>/>,2_1;!DC99'AT$<\ Z[ZA0NM,9&9>=2#P^
M.DBM[DN->B=NNN<"PS)+'&WK%W)FAE''AQ",HXCVMK4:ZM=NK)4S%?,/6LI"
M/4JP5@C6K#VBV'/#H+_=[.C3KC"*C3, PZ6O^S&&)#$&=F8%$B)2VVXD1;7D
M7H6?QR^0@NPP2QU8;5>PL?/D\:07ZL\=82'[Y$KI.KV'!=W$9[Q&7V4[\<\
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MQ/\ [-J"6/KTT$L;!2N$TIZ*N(WCQ5^W5?M@+6?QM:_KM0T 95?\@C>G5KR
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M"1E4X_)/QYLJCVR/(-N2%,N(+08JQ><8C37&4<FN)U6(.R\(DC5U(ZS&-X)
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MY(K9KEK!>2:4<NY*T2!6]\FTLM6TM(JMN2QR3BH"A3-'S*%ME5:'NA8^*K&
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M(ZQBPLX,Y-;]!YSQD7M9KQ+%<>-HJT8GD:,[E908**P1N5'*8Q7(I[C ,>]
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MG<5K+"5HZUN,,J=OD\\ 6*0(&8(8WCT?<Q622.1&81\D_HO07<,@A^40LNU
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MLBM'2D?Q[2RHRO)%)(%68)'/)7$;PA8^,DU9J]\;0D3+/"L?;U$FQ?8PKV)
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MGDU.WRI"([ZHPTB8BQITE3++0Z>I:LM\FI)R\A-%<9D\<%C//C[E?O5E"Q=
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M+PSGEUF(J0+;YF23QL3NX&GCLO1MS..(5E_';CK1<>VQ =E*N[J5WR#OR1&
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M>Z9FVN0T7L;M39M4[&$G8AANSZFOVA=?,$@];!QS5\+$K+KJZ;AMI <$86]
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M@\6+AQQXZ#%:QY6HT.%$;9C18[2?H2A"4I3C]C'+&=W/)R2V@.IWT T!_H
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M)KW=$GCB1(F])93%(9Y40,T!AFBDC3\4DD;\E>#<M=P:4K,(I3LJ%$?=$DH
MVD18+7C=BJS-9JRQN0TD:;2]I^V\K0%MH=2!L4HX?MXV=(<J5@)3Q%@PJ7&+
M-5XP-D-K^$(AV"H9Y)!B*U+FML(4YY6F_!S/S\EIQ8GK0A7>.L\BG>@K1PV)
MOR#UX2+#Q0J-!N7([X*VA(?[*M=G#(LUE(BIT2><U2)@I'0-%\D,W(Z8E FP
M)"L9TYVXVC<]WU_0]VU]4H-AG1[H?)6BI3[1,JKM3UTHA7+C)%O%13*XYN!?
M"]88;B2W$*>'F%O(\RF%)QWUIPO)>0,X%)-G8'7N2QPUM]=?G>+R9 7D46C[
M]=U">7)/+!7H3RA&_P C!7>,*WN1I:PNRAU(V8X*TM2,R#H]FR  $0[@9ONO
MM&F["OU-,1-/&WJYMHC70@!HP<#76PU>=;*I5P5:K0;PGK-[ "P#JSA+&4(8
M4)<8<0E#:EO(XRS$T>^ )+"02%@A)VZFY[@-=(85KI\@DEU'>.@517[WDJ<5
M:QQB=4A-595YGKM:]>4QD]!W;<DK04U'1I@J>\[ P1_W![-8J9;9VL).C(!H
M/JDI;PQJTW"65KECO477X6P2-;UE(EZ)DQ;:M8"V,%87K8D,05LYRVEQ2L)Z
M8JF7S:T*C+)6;SB5(SU)GKMY!*JV4*[!A>/D6EC+A3LKL $\=I5KU.]Y /$Z
MU1)* /=#(*YFDC96UJ0-[(T<H69&#:/07-;^SNV >NX!O-5JHJPUS;H^DWZQ
M2?BW]7E146Y2:X4$TXC)*P+'"MAQ'PS4!,^)B,F5(PC*UY4C&>/9O(D=+R%=
M)#2L1VF[1UWI6@K^0*I$5Y DST@>HY<9$4*S%M:(XI'6_3E:-+U9JRB3>XHS
M-)XTL\P.B(UANOLJ3H0O(2J@ U"![[;3+S&'X=1U#:ZX" U>VW$O1+39C:"4
M&XG-?5Z+3*0]D<F,]?JF0NV<%F9F4MI5AAM*4..J2WT[,+5>_(?RP02685*=
M?DO!7FLK/7]0U681&&-ML3*DVF8)D(";=:.95:M+-+7]D_M-=9Y'1HK&NJV(
M.(,JZ4*&&POUMJH=HMJ;#ZI[7W1 KE I-OJ2)+M9DE3\&TT=<)FOUD_,G6%5
M6L).>,77UF)<.:S(=BOI7"]=33;+B<<J\M'_ (^*DZ2(W=MP1R-KV-&]Q8&D
MB.RI5XCM3R8*X8$GB-^T76Y+8!CE14HS3*AZ2QS)!.ZUI5(!,R/&A<!%#"54
M4!@VM;SGN.;7BNM38&O:4@%]>"-/8+*LH&:,QCX/8,:.3N"F;BU.I@T0]4H9
M61(GH@,O02'HMJ\[*W,E;=?OF-@\E82JC$*4+3408V8^TRQ">6"1"0>\8VX@
M;3(1 M((V8,8Q-W.(.W[$3L'B!ZF.X1WJQ4-J*-N3-W$;,R*[W[WO+C(.K5K
M1H"Z%+N&JL>K3[83N!BB+3L+555E9VLQ5),D>/&W(9>Y4@/)&RW\*PPVI&9&
M,N^2?#[WC(DABEG+L P41P278VB)(#+:(K+(BE>!"S;]H1FU5HU<R"8J'6HC
M*O(;=Y?'K=6=-$AJD;GL2,.O.2(;5FXYG07?G:%Q7%'UFE:ICV*P%8%7%5LO
M:;&\;J)7&T-9:U7:]@#APY4F)1;I]>I!*N.-80_+C16TY\^5NJ9L:NQ#&(@J
M"KD]=)'QG=HI"/2R4BVB@%#PF)/%5+^Q0 QEY'0,E>1N(/ND84GMB2/?K7B=
M!7L-IBDLT(Z$\3</5WM[=NP&P[%4RNN0]:$  QQ,HA$LHR04BV&KFQ@)V8^
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MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,90O9:WVN@ZA-V^F$ 8\R%-4M:U6$
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MT(E*!)9F<=#R52S8N^0I^.56N4)C6HB32HT\_D?'5WC:3V]94E@2=^/X&[#
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MF\A,Z"H)Z59B 3VI;/C:MU[$G'?]K TD@EZ"1/8H!UR:_=Q[\"22I[6NP U
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M!D31NJXP^-%.P6(3%'KS<9N'9R*"]BC8:3 PC+)HJVF3)3G&<.OXPM7BKZ>
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MJ_EH6X2F)*<GN&PE9K5:*!QU4F%%E*H.3P1SIS$9F -%RP;K/6O!W$UJ>;;
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MP!?7]K-BZ+RZ(/&,*V:*KV(&QJ7+;,UW<&5!8)G.L/O0FG+%&$3P[=>K,T6
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MH2$<Y"I;.H([,%P^0C2-_G7?(64C"KQCC%E+<W<#Z4@AHN\=GN]MVX(IXY#
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M&T;,7H!.UZZB%[.'BQ=9RYNQ9Q%B0E[,Q^'X2H<=]/PJ7?(JLM*:E6L Q6K
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M3G-B64H;7B.P3;,R8TWR_3(B/*;SX8^GE*(J2F4]6-F"?J3_ %*[<XC].@8
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MO$M:031<U,C*I/ /-8B*R'7$)$Z10=Y#Q:Q)%&2K,5.+USW=MF=AGQ^R[Y2
M=$";N*4X^<LL>H5H76P4;[]6HXG)R!:R,87G#>OQ3N%GLCB\A:GEMP_A'&W<
MY/&S5F\5_D/(,%A6E8E#[ +M$E-_0;0\.[, L3.2H'=X2*4SH^;K6*_[A/B_
M&(SQ[K^T*6($J#9WH'3.PZD !B%7D#O/!4>ZFRK?)GA[+;@VGPEPOXFZ4[:]
MOUJ9KP&IZ M\8UBB#)3=[2##FCI@F B1Y!UQ[Y6B0?;CM96\AG#ED=><)6@O
M?@OPK.EI& 1OD=J.Q# 1(?9)&LMB&1%V\C>->1-K*_#%;L1AI+7C3'8\9,T
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M%@2W)-M11"-+L':Q/"M@3  '<8B="?YCR7BK;S"X[E:[:/R:N1IVTA!T*?\
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M'QGO'^(RZ;+OXA7-25':K?7[L/8Y=LDCH[VJ*U3:Q.VW4\$(1.8J3;J[+O$
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MC.<8S]'&>\?XC+BJ&_B%LU;=]F/=?NP]2E4Q95#&L;?3:P-VE=/E@B"60ND
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M^WI^*LW_ &';O'6-='33<5#M)87B>17@C$GEQ4Z;$=>+Q<5Y6<SOY&O49=
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MLFI'4 J4)V=Y'Q)'E/'5)B#%Y&[YI/&JITT<<IBOR2/(ZDLT:-19!VT8N'#
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MF:-L8R[+0VPVW)A!&)27F\./1V\<EY*M"?"S>-H!G:K1LT*P?B%FIVE0.I(
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MHR@XYIBFEAL0VXR18AEBE#?[IH(?CPV)?I-8BB]D<\O.5?N#\NN9]KK7[?\
M%INQM=C8VM@=!VN2U>9NU+KVVB%?K$TMIQ-710"0H(&ND$?6)PUNEBD2G1:(
M:RB(+29V9&$^&=S7K3V(+<CEK%7R<GD(B='A:E<2.XWTX-(.?9_HAF9EC!=M
MY(JT,,;11#2OXQO'MU.WJ-'+"8W.]LW;GE03,3, W23VKJQMUTCJ?V!14'=C
MW.N?/-?%)IFA76C;O,ZKV-22!4>L08<JFQ]8W:HW@ R<$N9C3F8T]MF;'_ >
M2M.,8Q@$86U\V-G2R8VC+(S+SC8JS1R!2!)&656X.&4,JL & .;!*PJM18(]
M1G1^+*K /'OMR+R!XR)R8*ZZ8!F&],0=9:K[?WM64B0T3JM%U&%LRQ&U 9V\
MQ-O',;%O4#=@0O7MG_>=L1R^KNNT)MI%G)"5RK#.)28[OINQW&G66EHL(7X,
MOBXE6+Q<U)*CPQ@1Q&"-HG1>VG% RO"C]P 2EN3%R9'+3AMVH+\7E>X[^3AO
M+<260F619U+D,'DY-P_(R]K?:*:0H550/L<Z'^VJ=*,&5OQ 9%F @4Y(IG:W
M;5%Q/%*UQ6=1D19=FG;?!L&!MCUU31@LNQ*2ZV79B)5,P^YE2U6RS23V9[-@
M]PVFG,R. T4HLV([<Z/"VXFB>S$D_:*&-9>;JH,C\LT*BO#7B@VAJ+7$+KTD
MB-5+,==XY1^19(H[<\:RANYVV5"Q6*()?-VU+TQO@G4P4B>J%>A:)@&ANG'-
M;[J,:I(ZWBGJ1.US/Q4BVM;O52@I]%-(O0XSJ'O5A^;#K"FWDI<Q[8L6;-Z?
MR<TDAOVH'AEDY$,T;S0SNI((T&EKPDZT=+PWP9E/E1(J5*/QM>./X$4\4RQL
MBNO<A$@C8APW+CW7.FV&8\F!8 C%1M$=&(_7*]]4'95")Z.VA"O$38];.[A)
MGCMY?V5,FDKT<M.P3-UG;#-6NS$B#LF27?*K)JD*PYA_"TISC/Y!(_)U:]*T
MB?#J)"D,:*(DB6NP>%8UC"A CJ&T-;.RV]G>KQ]JQXOR+^6JNW^1ED9W=SW2
M[,@C//N<PR]L",*05" *   ,I@?[?_M4C#@FV0]=Z6;NU?.ZQL-<V"O:!%_8
MM9F:;C@XNMX=:O[]W<N  !6X]?80D7$FLCI&%R/78=^*D^KL%RPELWHVXVGG
ML3.R@+W'M(\<_=  $J/%(T0CD#1I$%C151$"\\58!2_QO'=$54KJA)(2)&Y*
M(][[;\_R&6/C(TGO9RW7/$OV_?;-?!2JM/F+,55T/M>OCJJ>[?[J.UFJAMX.
M^OM$=1 );=$P70H]JD?MB\!VH68[GX4?TE?3S+$TD"1K&\@DBAJQ))R8RK'1
MEKS5%$Q)EU#)4KLGOW^, DJ6!WO9FDL2V6/OFL23N  $::6*U#)(4 "<FCNV
M5)X_]3?JB%=@J'IKI-KRA[.UP*)4.PUS=:)K6XI&RMOD-M6K:;$\"FK.Q]@7
MK9MRMETMD9BM(3 C-S9[R(D1.&F<-HQX<6]7:">,F"BBDC2*J 1@2NXE><%.
M)[[2*LAFWW>:HW+:KJBD6\=>'D:;,MQ4CC5MEN,<*E8HE#;58D4L%B $>F;V
M^YMP6N]5/;^K:!ZF2 $\2&7_ %YLJ+8[SV,O6PK=]8]2PRX_6D23;KQLL_99
MU/I$(]-:'5]Z4X"CIDN>$3\+/+WLRR%6EXNZM99BRJQE>Y :MF2<D$SR2UR8
MF>;FP704C0R 15ADKI[:\D$< 1?:L<,-B.W'% HT*Z+8BCEXPB,%E'+8V,B6
MK.COMO:/LP>V:<EP]7D L6Q#6QU&[4[6K=4*AK39C5P+U^STL9MQBHVVMYL=
MAER8X\G"EPX>5I1';:0VVE&01)_C)?#2<I/%STDJR1R,9%>**.:*/8<M^5([
M$RK/_7',GN<@"-,L\DM__*MH>2^;):$J@*XFF:LTI5E *HYJ5^40U$>WKAIG
M#;"0]?=/(/7)/4Q@OKM6@$:V>U$FAR=GYF8^[]X4X%6#S8Y5I>M:G$CG,H1+
MS.^-0K&%I>PO&%8E^X%7]TK*OG1WQ/PY_P F^WQX?9QUK@OIK>NOUQXN>;PM
MD6_&,8K EDD!]??,SO(=-L:9I']NN(!T !H90$3HW[8\""7'0:WK6'&.Z5U5
MUX)_"[JLD>0_J'2AL58M;U1$MK8*9<90,N#ANNSVEH)$,16D3)#Z$)3CI_Y;
MR'^3G\QW/_<;/F*_E9&TONO58S#!-QUQ'",D=I5$3$EF1FZYS8*%:O6KTX@W
MQZOCK5&,%F;5:XS/90EB2S2,['NL6E7D0CJ#K)=:^K_1"W["<VO*M*:_LA[8
MY?;#MTH':;9VM3Z[L?I-3UR<F9G4#:U<<^4&*52!@^2*_P#Q6\U'SE4?*W7E
M+YU GQG;%(E(XH[,87>T9+=T>0G21&VLJO<"SA9 P1E4)Q10HZ%R1KX;Y>G9
MEK#D0.2_$KS5:[(P')&2"Q-'S0JSB0ERQT1ZJ?UC]OJA[*UGN"JQ=<#-E:@F
M;BFT"VYV\4FDA#N^RDXWM-J7@A=I48]"L)8G)D-1R#<I@:[(<5"1'\ZO&=*1
MO'(T=+4:/XR#QY  T:E>83PQ=0?Z<@!$G]4J A<H..9[D:^0;E=+2-_D6O[)
M._EO *[S;WZO" K+]C$!RI<!L\I#J[T(.;&?VU:3(F[;"<ME-N,*R7SLC?;Q
M(K\V@6 M::F"J<6U[-+P*C0Q5@.RI7U;&M10#SCO[;#7A*<8IJ11TH5A@4%0
M9B2_Y&D[]6>E()7?DTP^-9GB02EQ$)&:,*VF%UUVO\A8/XV55XK[$7C/5L\H
MT3BL;M/2JO(Z!7D[*JY92P,-!='/;6KEL!7$8W7\DJD5K!6CC2'978QBH:]^
MIUR?V#7@VNJ*6VI-IE"J<*X25S5AQ$"&+D+SY'8ZV\81B^"66OP(8O(B! TA
M[KF,5+%%8V>3D[QI5M3PQHQ*H'VH#*K#R\?\A&\-G^A(TKLB?C0R36*]J:7A
M'Q42RV*L$LDH =RFF8AG#?VA]'_;AU2>J]DU3.C:M)5$I>28E&N.UFV*.+D-
M[)N\/8ES 'P=:VZ-"VFF&+; 9D?(R4>4(CMHPPS&;C^+7*454IKX_7*@OCHZ
M/;?WH:T*3I$C*_(,\:VI^$S;F4OR#\E4B=B5[4TUF;7R9[\EUW "O\F58DEE
M5UTR=Q88PZH51BNRNR29GI7J_P!".OL4O&U@8#CW2VNWM1QRMD['WR_V&JZN
M?D2IB]?Z]LE^V993NMZDDA+7*1" R!S")>$/)3AUM"DRN?\ N'BK'AK>WHVT
M1)NNGE6*(P1+)*-2NL4),<0+D1J2$ULY)+$D?EH_-)KYT5J6PG0=M9YY>]/*
ML.NR'FDTTK<-R:TVUZ96M>]O?VHJ=!R-I&M]*4.$_4P%++,439Y&F8LP6L7B
ML[(!O7%59NXM=QL,.\5""1R6*9EE7GTN^I(6F0^ES?!Y.[6MK<KN$=+4%E%5
M5$235A*L#QPZ[4?!9Y4XH@5D;@P*JH&-X(Y:YKS;D#0V(F9R6D>.U&(IU>5B
M9'#H!]SDJP#H5;KGU*=!O;)(E[$=B1P=4*6[8FT-I6:1K[L]L_7*3EMW4%!U
M[:V"$>B[9K\9^M7H+78D>>$\GR9U"%^$7&77<KYM>..K4A\?$ ?'04WJK"WO
MB-9[(N-!)&VTEC%A5D5)%<)Q5$T@"YOL6Y[-DWI&U>,L$HE4!)5EK13012I(
MH#QRB.Q,K2(5>0R%I&9M,+9VKUXZ+;C"ZIKUJ,UT,&TB!.U/64'6/8"VZ;;K
M=2M%>A5.Q5'S:FV)3'"M5-UH>U!DCIN9$1V-C*,M^"E>-MAFN>3G\M<)FN6H
M&AGY^^.:%I8YS%-$VXI4,L,;\70C: :UTS-4U0HQ>.I 15H+"3Q%0 \4T<<T
M22Q2C\D<@2>9>2L">9)).B*VC=$/:OA6^#L,?K;1 W8(>YZ_O=?OHR^Y'76K
M&=6,!XNOX%2M,*W,'*M4*S#!,,, (#\<'EA3S:XBD2'\.6PV;$$WR879;!DL
MR.WUE:XLJ6.\?682)*\?&7FJ1A$0*L<86IX(I:QIR#=4UXX I]$CBXE.W_Y;
M\E$C2Q\9'E+2.[.S,9>[U:Z&I&:<%A;1BEMZ#F['G:KG:[[4;0UT<KN=N'XU
MGV-!E6&D;7 G+&&M1F&TY(@E)$R&E",-MMH:_ Y"M-)4MI=@/YDHUZ>C[D:M
M5X=B*2-MQRJAC0_D5BS*&<L>N73$3QV8Y0"+=]KLAT.7RF69&F1A[HF*6)EU
M$4 61@!K68>I]._;UI!$X7KAEB(2,*NN8,N3VHVF4=HJ-DW1C86PF=2Y*[:F
MXT]&N]NC-RBK=7P)1.2C#+N%,?M?/*,C>.AB@J:5(154$CDQCI/SK0.[;:2O
M&W7X\A:%]D.C G/;KMY&>6Q;):28RL^O:K2S5_BR3\5THLF#V+9 $Z?<DBM[
MLWFQMG56,8QC9FOOHQX?3=*YG]C_ ..27CGD/7KD  H"CT&?W[VM5?SF:^^V
M=<_A+C/<?>UJK^<S7WVSKG\)<8Q][6JOYS-??;.N?PEQC'WM:J_G,U]]LZY_
M"7&,?>UJK^<S7WVSKG\)<8Q][6JOYS-??;.N?PEQC'WM:J_G,U]]LZY_"7&,
M?>UJK^<S7WVSKG\)<8Q][6JOYS-??;.N?PEQC'WM:J_G,U]]LZY_"7&,?>UJ
MK^<S7WVSKG\)<8Q][6JOYS-??;.N?PEQC'WM:J_G,U]]LZY_"7&,?>UJK^<S
M7WVSKG\)<8Q][6JOYS-??;.N?PEQC'WM:J_G,U]]LZY_"7&,?>UJK^<S7WVS
MKG\)<8Q][6JOYS-??;.N?PEQC'WM:J_G,U]]LZY_"7&,?>UJK^<S7WVSKG\)
M<8S/@[A4K.I]%:M%=L*XR4JDH!FQA94=*L^"5/I@29&6DJSGPQE7AX\8R1<8
MQQC'&,<8QQC/\ZG=;5T[W$O=IH/0?;5^V*!Z>:4ZER^RNR=6:\O!_7;FY]EV
M2^L4ZGQ;58:A*&V-^M5X8IU[TFYD9QE]O'HJQB0_GC+%/%>0^[>838GMT>PU
MJ3<<70USZL'8MO2/H[TXU%@=DSE!!2-CD20#6X>T;*'&YE2"V/8!X0[ %1)<
MQ$F=.4AI.,N.HPK/7L1VGLQP<FEK%U*Z/*22.JUUX8!ZS3+55IS''R;@K:&Q
MK)6N5..&6PZ*L\?='4$I#\A*IGE _I0"PZQM*^E!.R0H)%2-]9_U;5PWK "G
M3T#$G;I . J<Y6.Q^ D>X&ZQ8[;$H%J.?./E=.V P+JLQN4%)NQ2$.:A$5YI
MN0ZVVJZ5DB[YY!HH:EBR'4\DF@JU8KD\E9EV+ 2M-'+^+D2K: )! L$-DJ[$
M:,5F*"53H-#+/=?QT2S*>L8DMQO&K. I53*#VO?F:B=1?U<^>HHW"T:S*>":
M-U%V.+,,L]D5O#]1[N-# =&L4I&"_BW*2^9BR"D#_P"N#07DRIK3#'[9SI/X
MRS%>L>.D[:V:GF(O&2[==+<F53''RWHJQ>./N@F,2RQQ%@[JIQ)9$D,4Z':2
MT[=I?U[-+NF=B/4$+!.\:GW2I#*T8948B=!_;^_5^3^]P?6T3H09,VU92&V!
M8$(V0W_@85G:36*C[#8B69=@375Y&$"N8<?.9.,3YD.8Q&]5R'(2WSJN[M6>
MW5!=*U3Y+J/O[1LV*BE$^YV>2K,R(H+- HL &%U<VV9#3=$LL$[D\42DD %I
MJL%Q#OT"&&U7V_VK+-'"2)6XXIWMZ>PUL2E;4O5 ZGV:Z#-+ 8QG9(JN NS)
M"UUT@[(-L3:.[54%DG)6R@*0+SQ.O,LN%1\=UAQ]E")#.5U6YZ]/PX_<$LBG
MPI90)E/)"IABL&4$;W#'',G=E'LC</&Y$D;JNF&"S8\P/ 1=?+EI%[>P&!CF
M>  _0&:2-Q7V?SJO.+DA5C7E5Z@_J_5L9#SV.H6S00(GJ)&^9]IN&N^V52JM
M/U#,F7&""O=\L!Z7"&TT-:WJ$3R)S/6RZ1;92ME"DN-Y5IMQ&B++62%%7M+)
MUV1+,B215U V7LNLB 0+N3FP37(ZS/4=O()6DH'O"W-+'%PT2WQS$+$FOI#!
MWH^[*=(@)).E;4C&]&/8.E0+#.,]0]@49RKU6BW@N*V)2.U5(.MU#9FR9NIZ
M-86 Q^=#GR1MAN8]UIE2$94F,GXA>$LYPOEIJS+(L+ "<^0KT2NQR2U:!:*&
M0;]C$*>1;2H>C$$Y2]J-*/\ DPX;QYJV[*R+[ED@HPPSV)(R/O"Q3Q,NNK[(
M0$J=0T)UA_5P+0(P5JVCLV=]XI<JZ-K@"#V6)V\W<*-ME&D3-&!U:.54:*W6
M3L5Q,6"-:95)GQ\_%,)7&QEW&2$FS%!-65Y19IU+404$L\%R*W/&X4=1PAHV
MI;"G35TB)F";7=\[&K=FH6W6*Q!8LP2<R JR5?AAP6]-.U^HD# ZL/,J1<V!
M GM>Z+_J]EC&[ )M:$B!TZGUL[M'9L"SO]AJV8H82-:#E+F@[.(+G8I ;?(%
MHKTB&\ 4WDLEU37[1G#[65Z'@?X(\E7_ #TWM5J\;0_D[T]P+\>. +LRM(["
M(< 0)MQ-IP0(12F2R*DA[4_;L2,)-((XZH1IY)2VA'&D;K-S<@-">ZI*#>8Q
M?2'V#$BXBD]/]B.WV;;9=*:T2Q1NU+O89!J#7&;C+=D:300S?XH2/4I31)1%
MR&F#\&ZA?J_A8QROCS[9K_F21)6+1^]8Q#(D4O>9=K$4DDB0JY!+2(%!Y#)(
MS-WN9[?9,7W^SGWQ(8>URT9.X(9B.&]"&7EK@<\^>EGZO]FYJH;/4R]R[".;
MV%*M[<.E=JI4#6PO5;8%5]-[,*-3E0:,$KSMDB,N29ZVFUR%J;;RI:%X37))
M%%4F\@[K_C8*\LSS;_%PBFNUSI_0LTGC[0C4;:18PZ@JZDVU(KEXQQUHY&MS
M6Z]9(N)[IFLP5;$:]O[@!%<KM(Q 6,N5<AE8"P,^W![%#>AJIV+E]2K$/H>P
M"X8!KD3.&=C6-C;&-69_+-2&T36OSY5RL\NW-8^(&)BQ%_%Q/VY'[7C*L:+U
M>QX^U%0GCD/D90Q[* O*O;#M+W$79C[2(SR\M!$')CHC=%&9/(Q3V:LB&C7&
MVF+ 1%24561SH.'>1(TX[Y2'@!R! KBR=-_U?&F2"#=TZMVVGP0(V&Y;S]EJ
MO:,36J):R-(8V*/U3>;!)))%5?<4ZH3(\IJL2G4%EYE,-89]5YM"HO&09>WJ
M58VD5#&>8L-"W"9:I7?R6B<,KB+EQ:.4>L;\;TCLO)%"%83RJKE2--%')(T<
M4TX]88970B.23BK@JP/%E)A:.O/ZN(U&K$PUUPME1BG\6!\Q(NE,[6U-C60N
MLSM?CB1_<;QN7#:U7752=JUWT)QI42/(0684A64JSG%DE=H9"DS(B+I2Y8!!
M*T]RJ*Q??'Y)LT+< @WW.["R\=E=XQ;#5VLQ\G17 TJEF*FO#;$JJ 6:'XT\
M<_= *=LEM^TZ]AKK-^KNU^ S,)=4]C-RB<L2JK 6M<=N)%GOE5.![@?&[,H5
M>8?64MVJGP]!+2%6&$VZ-;;B9RMU/G;\^??$)WMQR,',BO[6KJD?=9K2G1KK
MVPS!I>(/"0#W1N!NAAFL]QJI66%>B.C!DF?Y->F8J[#I-*+%JM&T<>V!GC)'
M%@<EL[IO^KQ-8W4D'UWGWJ7U^UEJ_<FS1FO1G9>ZE!>L]NA<62IVT3! E9;]
ME@1JZK$XLD?B0\%BJ2N:AC"D^,O(J?%06;5[V5Z?E)?'SMZB*S"I+JVMZC!#
M1B;^DTRO$KET91339KTM.O6938OT?E0(2 TD7<6/0!UJ7DZ'M'4G!T?CQ92<
M&WU/_5[7W<BHO4O9$RZMC0YZ3J^'KOMI*VI!JYBICKQBW3M?LREV2)51-7,P
M91"<MC#$'XUA#N4N.I1G9=\?9\<\JW0$CKRRI8<L.W6,++'(;+@E855VX!G(
M#,L@4G@VJZ<X\C6@MT6$L%N.)ZQ71^2)N[VA7'K*SB&1@J;(1>1 !7<JH/2[
M]72VCLG&IJ!I^N6F[+OU'US&@"R^_784X[L?49'>-+GCRZK D9-JIS78E^2V
M7;=4/3)1\*MU,G.&LJ_C;EDRK$AYP/>20$Z*/XYZZ6E;9Z%39A,8_P"LC%XN
M:JQ$;5D4XXI;!*I-6JSIT.S'<FFKPG6MAN]!+'*A :%EU*$V-[T_] KVF/T1
MZ_\ ;S:G\N.8LLYM^N/^@5[3'Z(]?^WFU/Y<<8YM^N/^@5[3'Z(]?^WFU/Y<
M<8YM^N/^@5[3'Z(]?^WFU/Y<<8YM^N/^@5[3'Z(]?^WFU/Y<<8YM^N/^@5[3
M'Z(]?^WFU/Y<<8YM^N/^@5[3'Z(]?^WFU/Y<<8YM^N/^@5[3'Z(]?^WFU/Y<
M<8YM^N?&1["7M)Q8[\I[J2 2S&9=?=5B][65E+3*%..9PE-WRI6<)3GZ,?3G
MF>W:AHU);MDD5X8V=CHG2H"S'0ZG0!Z#J?IEL*S3S)!%UD=@H]!U)T.O^N<_
M0W57]6WET^MWFX:LK&F %T#MV>EKWT8WYIB?;J=+7#9#W:O#=@6()-(5&R2)
MJ6A<[",-$G4.)C^IEM>,:9@L#=J5D%@(C-'R!DCY[X+(@/)78 L$(Y%>NM9)
MHK(LRUP"W9L30,Z]8^Y7++842#V$0%2)6!XH>(8@LN]JK-[/_LE5;2TOL))Z
MS@2^I(E.A[ Q:ZM:]S6AF92Y\6-/C6,;!"6Z80(C%#9:)2EM-*\L;"G,^"4Y
MSB=V";QMU?'7E:*ZUN*MQ8=1--,D$:-_MW*ZJ2?:N]L0 3F:E83R%9K=1U>L
MM>6;EL &.&-Y9"-^I"(VE'N9M*H+$#-/#/7#]6O Q+B0(:?B?+M?[6N>F[C/
MA1NS!**#M] AUN;:),A8\E)4]5(2+; ;;,,X<&R7WO29>6XE2<4=R/LUIRP$
M5J)Y(R3K:I:%,@CU5FG9>"MIGC=9E!B8/D[#25G,;[:01P/I?<>-BM+;3TWU
M$,,ID7UB:-HW"N..1(7K#]5T+U<U;(U0J3(X'2X%_?B3Y/9(<;(5N>^<8RZ
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M0DK,T,A#4/);?PL\T8*>0B@3M]-M*Q\7-;[A0CVN;<$59X@-(UEXM"41</.
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MOP2\YC'T+5XE 5>"]$Y%M#TY,"&;7^XAB"?4@D'H3GC$NRL_5E"A2>I 0H5
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MT@Y;_P!VHXQOUU&@_D74 BA2@ X-ZCZ'3,PV/K[G=NO\S,?5COS2=9ZWFC9
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MA(=6^\MGT%O.*5YX]1X\58_ZU:C.):\<G5(F6RUQ O#@Q6.TS3HKLWN/ [B
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MSPZ^F6_QGF.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&?XO?<,SC_-@^VA]/\
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M0!V7R=8M .P?*XDH.T7=:BSX;KR\JCH>9QG#R?;4SS=AX0$GK))P.VXEWO\
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M?#2>5@LRNK<9*TDW&AS4H.[!8<N!H)SXX[U;Q%?YBE_,)<%:P?L1I5\C2H/
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MS*BEW(" ;)/0 #U)/T RU59V"("7)T .I)/H /J3D/IFR==;'B2B&O+]2KY
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MS-1Q+*1FOF49+D/U)#2?4\SB,9ODK6(I)H98W6:N4$JE2#&9.7 2 C:%^#\
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MJ#*!R2ZQ2IL9)% I<G,)!)</+F)"(*Y:<M)=RG",N8RG&?'&<<\7W\^'7ME
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MYE\G=\MVY!"]4 J%+,H5H)2QX@D@H\1&AL]Z(C?<3E.9U\I&D-<C8\J;6R0
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M3&Z0WJ$PF"Z+-&AI2K8F3<4!DC[CQ\3RR>*E,9\9(%'8CLV;DJA@6Y6J122
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M:A#%"\B$'^XJ-;[JCB1T26;49#+P9U"$%MKD<Z^U#5.NZ%O6"#[:=<MAVO9
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M^5[+6NG=,DLT=8#B:=J+9?82,WO'OQ=VVW=B9D VR"6&7N!.B%Z9:D_D?))
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M*$BE_D(:_D;$>EF9YRZB%IB12!B:AZ6B.J/CUT>6^JRTO*4?.0Q_V5$0P1Q
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MC/G&R6.,9S>[%;!U=J7O%UQON\KM0]::ZSUW[%UH/==JV(!4:2W>"-VT1.;
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MU);&(='S12X154A>794J2M+66Y=Z8$R!V%QFE=IAI93--)8D>;F -.6L/[%
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M-3OD1$T2:9V>1QL2N^SFO0KVV:?*UJ"I%JW)N9AUG7H^GV"#4S5$;JTD@_2
MM.MA.,/LFLS4HQ'L> C$I<8RHA$;E,MO-,-+1CPT69HY[SV@@,3 (J'[4B%F
M2V(E"Z*A9I92DH/R$5RJ3+TUMCMO#Y ^0B ,XOV+08_<\DTF^Y+K0+F)8TD1
M D#<3^+W'=B67H[2&JG=XM'+6'ZU6*E[#JXI5HL"6 ,>1L*+=V)DV:Y7Z^R8
M9^6O7V6]&7&6AUI;+'E5A2,KSD\ES\E4FI.>"6."LZ[YQ@21-W8COI-$8UDB
M).NXJ[('47>,NQ47K+8ACL4JPB!B=0R3+#!% (I0P*M'-' J3 J0RO)[2"$S
M/E^EE#.5WK]6W;KL4(+Z[5^MA:F("3ZK/ E)%9&0APXT>&WBH7+$DTTB'_\
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M] TRLLC!3M5VS-)I0%[C,Q4\B#$-H!2 0&<G?JW-*T;!V^YO94B4$GDJ[4,
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MQUQ4!F+$L!H!0?0$L=]-*1ZD Y*B6V%?Z33[T,B$( ZYU@#:H$$LQB*4APK
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M2)P_2KA% ](,; &$\GY!-2/@F14^&52N+G*_6?0R^K#?D8=4F^6)H(;-B?\
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M)DV )2T;(\U6R7.W]MV3\C<P=<7"RO+3^%JRWFKBO)XQK-K4(:7Q[ C;$/\
M*LCQ\/,>Y5$VR%3E74R.)2L:AGC;F#7[#Q\9'C6_+)TX&0V*_<\E,4UQ9C'
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M5D"D!%0GCTVG:&6RJZCY1R EA[[+4*%WL#EKBPB,*QG?8*Q'WJQD1? P!Z\
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M,KD\T(3B1P3CC8_4O23%@^L[H6RD2S<TB1A+,;!O9>&)GF@Q\'8)04<1L4B
M'>L<.S2UD<QVV_C9*T/O>=YIM:<Q@@-.:@$45IX3"X T3">1$(8>Y8D+NT:
MA8VD<H 6.X12-#/\F/0F+!B=#W.)*\O<;]9&>I7Y.?<RQ*C$IL')"^K^E@Q1
MTR.J\Q@B])"2W'\V>T/84_713X42OTGC#C./AATE:,XPGP<SGS+\RL8SR^\[
M>22Q'<]R6IYII/IRDL120RMTUKE'*ZA1I5WR4!@"*8$6M'%%"-)#1K4T^NJ]
M2:.Q G7U*2Q(Q<[=P.+LRD@QNM],^OU3>'NAJJ;;;"PU#J]!F7N\DA=:'OAR
M(6?"K8PA89,$%&+QRTAZ:B,VWB9-=S)=\[_@YA:8W$MI9]WS8K$4Q]&:.RQ>
M6/D.JIR.T52!'Z1\0!ET4DD,U:=&;E3FAFB!)*K+!&D4<I4^UI!$B1EF!+(H
M5MC-E XJ"!$BP8MI4<:&'0A0YA3KKZF8(Z,U$B-*??6X^\IN.RG&5+4I:O#Q
MSG.?IY99L2V[$EN<[GE=G8Z VS$DG0T!LGT U^F9*E:&E5CIUAQKQ1JBC9.E
M4!5&SLG0 ZDDGZY[UIPM"D9^C"TJ3G./V<85C./H_P#S\P7:J7:<M*0D1S1,
MA(]0'4J2-_4;Z9I5N+!AZ@[SD6#ZD]MHVD-7=/)\+KG%T9K&XT);>ZX>T=F$
M]L':)K6_0[F&RO2;VCP]/%6X]$%L0Y6,7B5#AN+<?;R_C"6.=>*_)=\]XS]Q
M^758[GCIH)VCAVZ2S5X#$JAGX-%'(VG8D2M&NT'</OSS]Q)'Y2KYNI3+=OS+
M6NKZ0P"Y8[[]%[@E,/(HO6(2Z#'M;*CKMS#C'&,TXWOJS>*]WZI[!Z%%ZIN%
MDI.OMEZLL%$V]>[?K$'/ ;!,T*R,6,-=*9K';T]DP$)4-+*X+X7+$MB;E>)+
M"V,)>C3>:E/?XJKU_(05%8EBK1M2DMO&57BP=91=E#[9"ACC*\PS!?;4-:[#
M3:5I$M4+$[QZ *.MJ**.57V05937A:,KL$&56&RC+ENIFF]D:J$;@L.VWZ0U
ML#=^Z[5N(Y7-<ECUDIU,2;$UT /K FVV:NTTW;<Q1]:;>>GO!A/J//J0F,E*
M,*7K)KP^.J^.K,[B!96=V4)RDGGEG<*H9](G<"+MBS<>1X\N*RN6)_(>4?R,
MZH@^+6KHJDM[*T? .Q(7WN68E0-*- ,QV<VQYFR&0O9%-8V+KR^:^E37AL:]
M4RT4Z01CMH>?@,68)."NS667,X;==BMS<K2E6<85E/AGZ.<SS7CV\KX>UXQ&
M"/8KR1AB-A2Z%02-C8!.R-C8Z;'KG2\-Y$^(\Q4\L$YFK9BEX[UR[;J_'?76
M]:WHZ_3.=X;KSV\NF.IVOMMA>M]/UMU>ONOKX[>-<[6V=>[QL.3JNGF*I7AS
M>N[-HW7H&DL69PFF5-<S9C2AZ499:Q*SG#V/K(_+";]QV?W1:0QV9ZMU! I[
MBA[R\&W,1$>$(+%3V=RGB"(NISYN+QY\?X&/]NT7[T"&LAFD';;M5I8Y0>TI
ME'<D[2*1W0J;9@7Z+G43G&SI9QN_6"O[F[OO^)2;^_@7C))]V=&>K']6+KE^
M(?4'Y/J]QGA]3E\<9YCC&.,8XQG#2G_ZAO<7^&C0?RSKXR9^P?ZYW+XR&.,8
MXQGS>:;?:=8>3A;3S:VG49\?!;;B<H6G/AG&?!2<YQR$D:2QM%(-QL""/U!&
MB/\ LR<<CQ2++&=2*00?T(.P?^W->Y?4OK9/BNPIFF:/)8D8<Q)]87YWI7JG
M)ED<S*E9=^*DJ<-$9#ZLN+5G.7W$Y_ 6I.9K["C)T,90KKZ%!(%(_CJ639]6
MYL6V3O(EF9>+$D$L?4^K+"A/^O&O  ?Y1%'QUP76<SUOT/DV_8_NHI23C\]@
MKDD@,PV^P4C(9;;)0O)Y6QQ#+<=&%O1TMN.XQ^'E7CGQG%(\$JSQ,5F5G8-O
MW R2+*^CZZ>1%=E^TE1L:&5RQI/"M>8<X%15"GJ %B,"]/U6(F-3ZJIZ$9XK
M-U?Z^7*Q62W6C4=+-6:X06AUE-S!:5$3$1F=723:)4A"T*]5,ZHBW?53Y7<J
M@,>*OVM/A1'#%%7>I&H6M)*)&4= 7'>/(C]3\B??T;O2<M\CES2.UA;3$FPD
M90-]0K(L9'_!$55)ZJ%'$C/8*ZVZ%!I>0)U/28+;X.%6GFF0L?T7 (]D Q$%
M*:7A3>8;356'8RGP_#^":RKQRC&>7M([JRL=J\\<S#Z&6)S)$^O]T;L63_:Q
M)&4=F(DGB-F&2(_QCF!65#^JR*Q##Z@Z], ^MNAJW!E# 6IZ4,@S9#$J5'BA
MF$I>>BFA=CAY6I7F<]. ;"0Y,=O&<-QW(S?IX3A&,<K(!A$!V8A&$U_RKS !
M/J?ZC]3U/(DD[R\R.UAK9)-ES+R;ZGOIVYM__M(_8X]"O3,.'ZH=<J^-;#A=
M04X:*:KSU32.BP740E5QY'IY$.Q_B,M/Q&L8\6L+PK+"OPF\I5]/)NS."'.P
M>'_\HHT>OTX&-..M<>*@= !AI'>8SL3WC)*Y/ZM-S,Q/Z]TRR&0>CEV+ DG)
M2+T+ID+2QFNA>M:G$HP;-G6,K"13+@F(Y=5&%VUUN.]ZGB_8W+!-5,6K.5OJ
ME.*5G.59SR-C^Z=)+'NDC@$*D^JQ*(PJ*?HJB*/B!Z<%UU PLCH[2 GDTZ3'
M?7<J A'.]@E5)4;Z<3QUKIGHJ^C]14L*<KU5UY5P@6S!G:]8A\(:TEDZ$>DG
MICHTME?G=(1G)-G(+SAU2LYS+<_V*Y8\LDB")SN-=:'T&@%!U^NE&SZD]3LD
MG$$DE:6.:!BDT+ET8'JK'M[(/J#J*(?P$: =% R)-]5.N;<F5,^YZE.2)J9R
M)3D@9\5A_!$2V!DY6B2ZZWE?R9E,9M7AYF&<>5O*,<IXJ(S$/L( /Z]"#Z^N
MR0 6WR90%)*@ 1#$2"4'3J3H_IMF?7^@=F<#T#,S  L2?%6.H?62EEH)ZK:2
MH(0R-4Z[#)0@R$RVI#\EB6],4ZM:\OD'9$5M2I#GF?SY<8\_A]')HQC8-'[2
M%C4:Z:$1B,8'Z!#!"0!KK$A_E&42UH)H37F16@/<VI&P>]W^[O\ \?RK'+]>
M])_O.9E76/0*GY<E&J*A'D3G1DB4]"@*@..2@SK+HR9A4)V/EN=$S'0G#Z/*
M[EO'D4K*,Y3GQ/QJ$CZ*K\P!Z!N+(2/TVKL"!T/(D@GKFJS+)<FDL6B7GE4A
MV/4N&<2'F?YO>JL"=E2J\2-#7ON'7C2&P+(,M]VUC4K19@X>17QQDR-3-F1@
M\L0<K\B#A;JLI=;="68A$RI>%+PQ->1C/E6K&;(99*\\MF \)YSN0CH6/*)M
MG7UW#$?_ -VGT49Y'))$L21L0L)0IHGV]MN::/KI7]ZCT#^[7+KF(L75GKK;
M;#]:[)IRB&+'\49GJ+S C"YBR%A$D@1@DZM/E2Z2FAC$J+F0K&7D,OK2A2<9
MSRM/Q*RQ[4-&$.NGM#K* ->FI$5]C1Y*#O8&>([1Q"%.D(*GC]/:00"/0J"
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MG*\*=7X9QA6<<OJSS4I#+49HY"X8D'1Y#MZ;_7\4?7UTBC^49GM0Q70%M*)
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M.,.-.I1;)#+$TJ2*PEAFCB=2/<'EM?"C 7[F#6?QAE!7J')X$,<PLPD AO\
M^G><_P#+''6^8_/_ &.*WY>VVI"- *6(&5Q%[]]=FXEG(6HI<->P:H*,'"4J
M\T.SA<.B0=VMM%)2H45(^41>7%(4V5*6TIA#B8"L/>7RMR/0C&IEBA>/J\\-
M:14&RW]W%%+"FAZR-W50("2S_9R1D=];1,LD4>U_-8M0H=@*7ILB2GF=*$8R
M((W)XNQ[>Q+[,LU[M1I)FAP]C_60U(K<X\5K3+4&AWTA9D%P4:5/-LRJ5"K,
MBX0HX83"<GRI#T%$>./QB4M:6%)<R=3')#&^MSJ[*=@KJ-VCD+./:G:E1XI.
M97MR*R-I@1E=8/<[HK*[O"T:LH4\^<RQO"BIKD[S)+&T2*"T@=>(.\IYOW!-
M+KL"1#U6W' #*-V41]?2^O'PU"S'J]OK]%FG6SQ4E#=DAI5GL3<:-Z3#DMS+
M+BLL)2IC+R)2\+S2?B5$C8AP0VYGL+"@4;8O**LKHH!)3CO3DH+'C*RM$A5R
ME=IR5/M$258;<CECH*L<<\09FTO-M!BJLPGQ;NCU[!/LPS%EM8\G)'Q"$8+)
MU3M9!Z0H@T[+'"8X+ZEY+/64D+85/CBTLY(O#<?&(9S&_;>>\'[[5M?W"2QQ
MLOU5Y&KH%8?R\7MUUE)T(6E E*$-K-)/%#5%Z1@*AADE#?1HHQ.6D7_<C?&G
M[;+M92FHBY90;AH>V*9LRHRKS37SQ.MQ9!:+\3(IUN#S9CX1UZ.10+"F0@\R
M6]*5'6RC,:.[AUY&4-^96,XY&P&JUULRANVT?,  LQ4^A"+M_</<GM]ZD,NU
M()N0%[#51H2HX4[Z*&T"1S.E]N],=Z5@5;3*0(11.S^F-DO'F*G8C,E=4 R;
M%;%$Z->ZZS5(4-:T285F?L-;%L@; TEI:\C)2FB/IH4OT?+C.<5S21049?)R
M.G^/B4,9 P964JS<HR">Z %/(Q\@I]K:) Q&KR6HZ**WRY6=531!Y(P1@P(]
MA#$#W:]>F5K7^]FA[#8Y%::3LH5+3,!#ARSVJ[P(D')MDBS9XEL96Y(?%U1&
MD#Q[TCXJ4+C0_01YL.YQG'C>L3\':4=MXYYXG5B 8S6*K.TNB5B6,NO/NLA0
M';JHZYY(46+Y$;++6*(RNAY+()$61.T1_6YJXX&(.'Z\"P!.9E[NIHB-A<B4
M0O$<4H,Q8QQ96L=@.LG:XY%GD9-I!BHU>?LI"FCA,#,V0=3 P$1#<;=Q+4A>
M,\C&CO.]9P8[,<D:.K^TH9%!'=W_ $.)8+()^TR-L$>UB+9:\\=A:R(\DS*Q
M C!?DRR-$(H^.S-+(R-VTA$A<#IU90?S*[P]9H+<.1.V!-AQ".3V!TZ51=@L
M0)Z:]+ECY+L.:[5DQ9+!,E!=C"W$*R@Q)1EJ#F0OP3GR,-*%[88EXX'4:/(_
M)T:ZA?7N3 [CBUW& 8A=(VJ!)$0[*Z&.(2%V# JB0GC-*[;XK# VA-,Q$41>
M,2,O<3E[)7<+4(ZB9V06C[!"U5%_.ZX>47UW:!]C8/@)3D&0IVBOP4WK#$Z<
MA+,1K W,V0IQ&4Q_(K"N5AP7J1 $RW4G:,*.9_!++"ZL$Y$.7B;V]2HZ2]M@
MZK8$9FLJ@V:LL"/Z*#\BM':1E+<046&0%FZ;(/;Y@H6^EV[=:JI%3IUUD0-B
M' -TDWV'#4"UW:G"8:;K4)8S5L@6L&4'"R]6)P<U:7$Q%GLQW\S4>GE./!64
MIW^/HN"4:K'85E]RO%,T"Q%&&U9G^1&RH#S*\M*6'$RK1_+JS6X6';@F[3 [
M!#<V0^HZ*I0[<Z3T]VF!.3I7;+15_M%>I-?M1-%OLK4KX*MG:9=:T4@D(*+*
M[*K]@:/U\<W6[0TQ3BCN!LY4>:XS"<<0VIORJSJ>O(K3@%62N"78$<?:(F8
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M=KL$ @\'6100=@@.BL-_50?49^=<:Z ZKJPZEU:0<56@D(2+ CS9J<=4$$A
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M*XTX.@S#4=@I4%_$)*2WJV:'0(<J+)F6/SD?,K"DM/J\K:4MIPGD'*R5ZT)
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M?HS;!VZJWW#9@(KICI<5*=F8Q=2#V(2 HSYI<R\U%?JT68F:)IU?;6M*!E7
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M!NU9^7"C<B2R0S\6C4GVA$3950,C)&DJ2AP#)-7,+-Z-Q:L:;LNNBO)7)1V
M&_NT&VV?([T1Z\VE]UVTA+)8T+M9.VMQ"]L+R(4:085LE1 *S%0ZTVJL2%;8
M,Y5 <]1G.76LY\?0;\M2#@D*J?=7K]F-O5E"Q111/UV#+72"(0.03&4!'4MO
M1)-))":V^-9INXR+T5B98IY%;ZE)9H5DE78#,7] VLEDSJ;JV7K4#K!N1;1(
MFME"906=KAIBLVU#AN!-#&XSQJOC1N'XIFOD'1\GQ:]5R)G"<K\R4KQ9-(;$
M\4TH!$:LO#_INCL7=73[65W/-AH M[O4DGRI-/1[IJ.T<DKQR<@=,LD(012*
MWKSC,:E2>74:(*^W/,6Z<Z+-B$ 9P(PH.V^??;@,V(HRRVJQWP/L@@E&4/8<
M2ANT@HSK'X7BRVCR)SY<YYY*S2JZM_.8#TZ$&L+(A*_H4^7*?XGAO[!GD;F)
MF8 $/3>JP/HT,D%>M(I'ZO#6C5CT.R[#1<YXX7333\8XS99KMPL!],:OLRS5
MC/,ES1*35_28!E)IR0-^=8)PQ<9B#EQF0REZ$PEIQ*_%>5V=^3Y)M]!8,\<Q
M( 'Y8C"P<@:!Y- C.IVI8L0HV-9IH(YZ(\=)LTA6EK*OT6"4S$Q+O>E0SR&,
MCW+L>X\1DBK_ %KK=?\ O9@LW/84NN[DBDUVH&_84QEQ[&==(-G+:$-"X@\P
M)-3A+T2$E3+J4--P&W<8R^MYU>9HD?Q*>(.^Q&?8P.F52S2,H/Z-*[NVP?7B
M $ 7-T<_9\F/+0JJW"_)NFT;C'#%&"C; $:P^T#6S(Y;?MU@-==-]0:U?8>$
MNW,PB/4KO2FXEDL[Q&%\CV*5AF;<VN-'C06W7B4^"A:<J\41\Y6II*%NN*7*
M<+9\?-XN8 TYZ\<##6B(XC,452.HZSN=^HZ!=*-9FK;IS)/7)61+;60=[)F9
M%0N2=D^U -; ;[GY,%*QAOH=I90^RCB)K:QY-RC@QMHEG]B%2A R KDIN6'K
MC\R0UEV,)@NLMY:S']&2TII"VWDN)PODW;NA1. X^6UIN0_J6'8,TLFM;+:*
MD#2E&>,J49E(*D=9J==1%6-<P*J>T10F$0"./_:%C XD[8, ^^0WGO>Z/:=?
M$0Q#AG:>4C ?U/$D4[%,I,B: L=)#2->#R:<8DM4Z8&D_".QU94\MIIO]M\Z
M,+Y+NR-9>Y.>[8F='G+^[Y+(!UL#TDY$;?8 8L^Q[B#?\B=)A/6<P2)OM=OV
M"!N;R*\('1&C9SV^A55"J%XJ!G@>Z"]>Y=D/VV>-L9([:<D/GTTB9CS%S42H
M+, ?B/ZXU60TBN(82Z/DP,Q9;4C&'''75XQG%4(,$1CB)#,Z2%M^_OQR"5)^
M7J) ^VZ:C)9R8R7<MG=(I"H=%,:0F )_)\9E96K%?1H60A"&V_!(U#@1H!.5
M=3=72J/#H1N=?+..B;"E[/67L5S*$;-.MLPN@TY*(&OVI^3#:DM(0W'\N&FV
M$);QCRXY9 WQK-.U %66BDRQ:'3^X>629G'\S.\TC$GT+=-  9-69?D=2?E/
M$S[_ /D5TJQ!?]JK#&BZ'KKD=GKF=M'6S6UL "ZX0^LT0>(NMWOD=8FR3Q\Q
MTOL659Y5OB2Y3>5.2 I;-NFMYBY_ ;:6E*,I\B<\I* I7B.^S6JQ5T7Z&.!8
MEB#?[F7L1L&/4LNSZG/8G:"M8JQ'4=ERSGZ\BY?:G^7W$^GTZ9X*KU7U'2]H
M3]NU\9/C7 K,,DB;\J3%)1II(W*/2I$[Q(P))"$^Q]8Y#37PLB.A+'D;4E24
M^&;"\BPV88] 6>1;IZ.RQJSC6CMEBC1@20570 ))R$RI8,#2C9KP00+_ !BK
M(J0(P]#V]%U.N7<=W))(U4VM^ANL*K4LA[F:M^P+#+K%@IT^P$;(7CHB5D],
M/3$UZLPTRG%@0P618I3T!O#KKL:0ZI>',_@X3IFLR%TDJO+'/&B!9.6Y0Z&B
MPE#Z_J*_CZY0Z]H4C1+N6U7;'S;[7954H;1G$1 ,7)DM1$&/[2'CMR+(-:?4
M9T."ZP&RO;OU1=:9>PHXY=&[AL*F6'7IZ]6FY6H\1=K5W(P2%RDJAP2X6(Y8
MI)*&DM#EXPA44VRS(QXMH4RNE'3Y<,DJ(]);-226,C8D2E/'8A0$[*E&1U4G
MD MFSM6,I(KCFDA D7WSQQSB/GMD+30S0.LHZ%H7255EC4KS2"N-CLH1?&PN
MKFL]DD:V1-R+<-S3*[#K=1B5BQOUV'6F!QJMGQQ 2D>PA]DE )5* IK*G%LI
MPQC]JSGPSB,DDLOD)_*2NS7[+JSN2=G3\V7_ ,,A)Y[V=,X4KS;>>M&E3QL'
MB( !0KPO&J^OMDKRU6))ZENS,Z[Z;TA8$HA%61_;[T&R)E!WG]B$F)AF8=DR
M#%WF%IDJ=(;K/POQ[L^,^@L@5.J$"9'S+2^Y\6SZCJG?,K&8P$UH8X(/:D?4
M=!ZD[+$$:V5+Q[ 'LED'W-R$W_);FO2=;5C7)MG>N,HT-$:!,O(@=-QQ:TL8
M7)YGIWI%P%*KDD07D"9\A^21B8,.P8\YZ8U0F9^78@ID?!9;(8UP-4\AEII"
MEY?5X8R^OQ\G5+*213*##+7$#+].T'>0(/T +L!KT72C2@ 713S06X+T3<;5
M99EC8 #CWTL1N= :+<;,NF()#<6)+#>>6N],='UH1@+!%F5P<#XXG.%$VH;C
MHR&2#%(D24H/!%IG9CO@HZ$O/X<DY9PI"G%)S]$KA:]7>O:)99)%D<^A9UAM
MP<^G0$QW)@W$ $\#K:+F2O!%4D$E4< B!$ ZA(Q-#.J+O9XI)!&5!)T.0_G;
M=ZZ]H<'7%=C5@8<M)P=!9'QH"[8:<.S8,,8''!HT*-+=99<3&]$;AY>%>;*I
M#KJ\Y_#\,7V+,EI^Y*%[I))(&BQ)))/ZGK_V9Y!7BK1)# .,*)Q51Z !G8?\
M1RXC_D5!_+UG/,^78XQCC&.,8XQCC&.,9_,XQG&<9QXXSCPSC/[&<9_9QGD7
M1)4,<@#1L""#U!!Z$$?4$>N ='8]<T'%^W3I@63!L)ON_P";K"L6^'=*WU\(
M;<+/Z(!D1)[ZT5X; HR(;+V*W6K"EN7 '.3'(K"V6T^13:$HY=1EDI3UK18S
MW*:J())B9)(F2,Q1NK'J9(HSP1VY,!HDENN2\JW^72U'9 6.\6-D(.(F[C]V
M;F.O2>3;RA>(9F;6@=9OSRO(XXQFN6\^LM.WJ7IUIFW#:FLKU1(EA$U_8.FK
MQ+H5P;K=L4(?LE4GD&8L^*3K9B=7ATIR.^PORR8++C:D9PKS5)&T4\D\+NG>
MC1)5!]LJQLSQ<QKJ86DE,9&BO=D'HYRUI0]=:\J1NL<O<0LNVC<H48QMZJ)$
M(60#H_%"P)12,_H;0-'Z\5,M5Z9,MAV39K47O5TN5^LLVWWF\7(ZF*R1LEIL
M$["%32+D*!&C(PVVRRU'CMH0VG"?IVS66EBBKA4CKP(514&@.3M(['U+/)([
MR.S$EF8]=: SE6>S)<F=Y+,@12S'9"1*$CC7Z*D:C2J/3J>I))N[F?)YCC @
M98!!0";@QB88V.FB"PV8WAZ(0&$HSL.?!E-*_!=CRXKRVUIS]"DJSCF:Y4K^
M0J2T;BAZDT;(Z]1R1P58;&B-@D;!!'T.7U;,]*S'<JL4M1.KHP]592&5A_$$
M C-**)T U72;1KD_-V7V'V*$U 5B'-5ZWV?M\O;M;4(R(%S 59)A*V]#BN/3
M*B$GO11BYDB5F,TOQ_"7C"\=2"]:ALR>0D<S>5EADB:>332E9]"<[&EY3@:D
M;CL@MK6SF":K6D@6G"@@\>DB,(8]K'J-@\2:V6[<3JK(G+B"B;!"@9O1S)FC
M.-WZP5_<W=]_Q*3?W\"\9)/NSHSU8_JQ=<OQ#Z@_)]7N,\/J<OCC/,<8QQC'
M&,X:4_\ U#>XO\-&@_EG7QDS]@_USN7QD,J_<6VJUI&B3M@VV.1E!H).OB'&
M!;@1B4N993D"OCO&59#5>!0XZ9Q)O+KLF:PVVWXY\<Y\,9K[@-NO24$SVI3&
MGIKD(I)>I)&MK$P'J2W%0"3A])7EM/\ TH4#-T).BZ1C0 )/N<;^@7;$@ Y8
M DA@L+&E,1I$))*!$GIARUPW)47$MAM_$>0X.ESQ[C[.'/*K+#[S.58SE"U)
M\%9T31F&5HB02K$;&]'1U]0#_P!H!_4#*XI!+&L@&@PW]#_]A(_["<]4AU3$
M=]Y##TI;++KJ8T?TOB)"FT*6EACUW6&?6=SCRI\ZT)\V<>*L8^GE+L54L 20
M-Z'J?X#>AL_Q(RY%#,%)"@G6SO0_B= G0_@"?X9K'0>W.K;P>CU2</N] M4V
MR%:O!!W:N)\)!$98[)4FLRK!3R%OJ %)VQ4\G$%-$R,&45=A.XBLN^7/-%:%
M[D$4]?W=ZLDX7J#VWKK:'4@*SK XEDC1G>)"'D559"U,TJP<FDV(!,T0?U5G
M600L ![@!(R*&954EP%)(8++[5V1T_2C5G V(^=BS*61K@FVRH>O=CF@-;G6
MP3\\!-&;0$J1&M#VY0M3;KCKDM+47UV4OJ;6^RE=,&[+!(02S3F%=@CE( AX
M+O08_D0 KL%B5!Y*P%\\;UDYS#0-7Y U[B8>Z\/,*NV/Y(Y!Q YZ1GX\ 6RF
ML]_-!M0ZP1EL;/'CK.9D!TSIVK[;'8K[<$;;"Q(W:O-!RZ!KX^#39:URG4^5
MQ'E6SAUO#JVK*41O6EJ0E1(R!ML>*@,E-T#,=!&8WZT>GX\)'U)P4<BNQO1L
M2U6#26(G"\8P7:0F6Q%^)0.4H'Q9Y/8IW&H*\F95-UVCL'K2KT41L9<XX?JA
MR\B->#IU5J]@L#CMA,6W-*;4N+"'J?9$0SJ%H>FK3B+A*/%"UY4WA=!?C+!"
MX97L12R)R4K[(JTMMBW( IN*%BH8#9*DZ3;+X5*B8]"(&C5M$'9DDBB7AK?<
M'*9#^/EL;X\B-9!Z-W-Z]7^/2EA[>6@$;XH*T( V*CW@";@NV),!(!5DBD*Z
MTS6QM@EDV(PPE,=:%%Y+F&H$F2K.,9TI7DEF6"'3R-&SC7385'D8:.BKK'&[
MF)@)0JL2@ .0M%:;SK.0/CV&A8^H+K*(CQ_WJ'9067:J&4N5!R;W#L7I^AF[
M'7+-9I\8W5(E>F'8 VFWBQ.1OK8Z^W7!\=RN5LLP3.%TQ7761T53\_,=IQ[+
M.&D*7C+WHQ$9V(6 2F/D>B\UC,K@$Z![<2EY2"5B71D*[&[Q!*2H ^Y.?J-!
M>XL0+G>DYRNL<?/B9'/&/D0=0D3W.ZYEY$Z,S?L,KA1IT_UE@C\J!+'1F5R8
M$F(6%#2(E<NSQ6E.AAZGT%2Z4*Q%BNJ3E.+BDBH6=660/(A0@\^<5EZDB*O_
M %'29/R+%W#&DD3R\!(N9U<,1K^DQ4*YZ(>5:*WLDZX*(9E+&3@ RR ;X$Y\
M7NY6DXI\I7R#U_$/")$2))E'-6["!I?E3Z_'L<.&*%EZ["L9R?*ARVVD184&
M1*5)5Y/3_P!O(P?W$4DD>R8Y6CX@<G9U-<<41.3L?[E#KB" KL=  MY+(D,R
M0R%5YUQ-R)"QK&384,TC%47K6<#9]Q9%3DQ(67T3LYI/95I:I=,MTTG8GHR'
MVXLJF7L'#4^H%"L[P;YT?K(L(FT0 )%J5+$9DX*0F\Y]>.WE"\)MAB>PLDD'
M%XHDYEE964Q[B421L"5EB)GB EB+QDN &/72=Q6>**QM)92P52"&Y*]B-E==
M;C8/4L*5D"G<3=.J[CMP[>Z5J$TB'^86RSV ;< =%6"J5"MY:5-L)JY0*"XT
M&).B(==.0J[:B340S)B37F!#ZDM2E-/+;;7"HCW9(4@!XSRJ@9O:JAUG=)'+
M:*PNE>9HY=<)1&3$7Z;NGC:LLQFZ-!4DL%1[F:.-(G8(%WR?C/$>'J.8+<5#
M%95<NP-,H5JMM=LHRU11=!UW"V==KO&%PR%6KE;)/6IB"V_&@DW[B4+27*?+
MPF..$3,YSEO'CXK\,5(ZO6FMG8AALBOZ,Q>4I7?@BH&8^VS$=D ?<-['6<,$
MMFU#1KCG;F7D%! TNW')BQ50"48=&)Z;( (.12-W&Z^3)LX8Q;++DK!.MUGY
M2YJC;T<N1L"ED&GQ%?%2*&T0L\X:L7(Q.0.;E9'^DKXGTOHY8ZLB@ZV6!8 :
M)XA96[A ZB(B&4+*VHG:-E5RPUF8.AA%C?X#&'Y?3B6KH!_XN5NL"GWKWD)4
M [S)R.T&MH_7XCV45&MC>NQD<A)DM$P"JS8FF1MH=J4EZ8-MTJOQ0L-HFRIQ
MR40DQ(<:'C,A]YII"U)7E- UQ/K^Y%4IHCH+:QM%RV1H@2KR7JQ;VQAV9 UE
M,&Z9UAWNN+);8/7XJR-+QUOEL1-PX[#'0Z==2DEN^GA]3!]U%HEA'48E KA@
MC*EBVV9M3 V%^&RY8;5%5+\@T#76IN))26VX^S$A-N2?,MA"G.>VU%&TE:TR
MIS<)R;VJC,A9!)RXLC.X6$(RAUG=8Y%0\RM=5C=KR3U%,G;5VXKHF18VT[1$
M'C(H0-,A5B)HEW#W&>-'@NONW^BMD+8CA+$8@3)I1(L7&/U&SBV3:I)9H6*E
MU\RH6]73T4PU,B36\0YCST:%.87,;C*4I"10JB.VU9U!X,"LBGMRNX:-@'':
M,$\,K:X)8ADK\S*O#%B6"N9=R(\41TSH>2;Y1IH,N^I,T3!?N:*1)U!@=)6^
M _N?UP+9(8&7LI/R/^5-HQ$UQM%_)J6:'UPJ/%5+#=+5F['5#+:/D.CP_P =
M-C,R/.\TWAMS*(.>W")WV$/(@:/(JCRQO($'O,2R0R(9>/;#KPY\BH.J>O+6
MLR5)P%GB=T?W+I'C;BZ,P/$,#_*3LJ0P!4@FQQ&[]?6.N:FM];(3SE8W6L;F
M@EXP@A 1.C%P<JPCYI ><9$F!#+PZ(K.42(R)#;F<(6VG/CX7V8)J?D_\197
MC=$<SD;5E AC[C^Y20=K]NB03]1ZYFF;L59;4H95AM)7=2I5UE>8U^)5@".,
MH(?>M:) .5ROMKKC$O3C#86[OQMUC62M<)MBPB(06+*LU=J,'%F:D6)@FS(G
M'+/%;;;@1R"L(\ZUX0A'CGV*N\MJ2H-!XTA8D[T3/%9EC4:!.RE2;9("(0O)
MP#O+[L+T3.LNB]:6PCA>I JR)%,X] 45I$T >XX/M0G8R<7KL-J76AR36[O8
M"P,PP*9,,1E4>^SVC,5\L !-L5><+K$Z!;B_S>T0(ZH MV9.0Y)3A3./!7ES
M1,)I#%%UE$L<?'^;E+]A /4Q[Z/* 8HSTD=#GDD3Q0_(D&J_:>0MT*A8TED?
MD1T5Q'!*XC;3LB%E4KHG"[H[-:TT,,#%[VQ=U0CE<MEJB+KU#M)]QD32PT<Z
M9P2:A#LK%$509*<1XDG#4F0]XM(1ES'EY*/\OE5\.-_+8)Z LOOM5Z8T4Y%S
MW;,9(C#G@"0"2@>!5OA+>4;B>;M@;"GD:\]GKS*A!VZ\FRY4!M;TH=DR5,[(
MZ8V!:8E)JEP=(6F9 E3L!I58N 61"7";0_+#&5G:^-C@+7'AKQ)6&G+CE\1,
M^O\ #>C^'RQ(FE5GB*O&J<^2LK*Z!E1GB8$K*D;ND<K1%UBD98Y2CD+E;R+$
ML;2[42OP78(//3MQ8$;1BL4C*&"EU1F78&\B1KN+H"L6$_5[7;2=;*UJ4?8,
M.$*=;Y02"Q7<3/C)\^SA@A6LB(TMP<^W#1-F1I,UYK+;+2UJ0E5<7YZ\=F$%
MEE4<% )=F8R!8D76Y9V$3NL,7<D*#EQ]=6JC,Q4:&I FR5 ')H5#-U]D?.>)
M#(_% S:+=#F 3WKZU,P3) S;[#6(X,A:Q\UNRZWV,*(M*IL'X\N[*"KJSAH,
MN0RAW ^*1CPYY13#GP;#^,)RJ:QL\<+Q>\SJA4+MB3):>I''[0099)D/&)2T
M@0\V50'XYTGB=9G# 1U^1D+$*$1(8YWE;EHK B2H&G8"$2,L7/FRJ<[.[F]<
M!D1$PE?YL!'P)B=(CS*!LJ,2&*"2)L64)."'J>@J L\QT<_D>(G,QRI5#2EP
MH\A&/-R.ML40AV';^TA]]V7L*%*[#L)OQNJ[:)P1*$XG5I("<W(5?=OE[=!(
M5L.Q#:*HL+I(7.ETRC>V .*-=X>N(-5>3)MI]W%A)-BU.M:\V!'9KDMPA:Q*
M8]T>)5J U4";Q>DDXC V?E@M-DQLMQHKRLXQF2H6G[!Z'LF0-U*L!''+P1EV
M))>,L7**/D\9D7NK'O(R/VXTD<,.Y($ (TPV P9E;12,HPD65PL;Q^]&9>N"
M/>+KC!@F)D>TVDP\$ 2[!,&"-6[1?(Y;@13,V<#::D4^+'Q<X,6O35R ;CK9
M>-B*YZL9'ARJ1C'$T^BT2R0H2-$;G%0HRG>G3A=JNSH65$E!8C3:MC7NR&)2
M.0C=S^@5&L1^XC83G)5GCB+E1*Z:0L&4FS[_ -@=5:N&U$I?#Q,%'O$:7+KC
M;=.NAR9):@BVC$O$R%7*\8EB%LQ'T)\LM#&5R'$,(\SRTMYLG7L7Y/&-[KL:
MLQ506V%EB@/'B#S)EFB1$7;N7'!3HZSPV(IJ$7D]B.E,R*&D(0 O%)..98@(
MHBAD=W8A$5"78=-UP3[L]<!K@QE-V(D'B[<=<',"DWC(_P!5\0U8G1L^P3*]
M#K04_ K;N2$@7.FQB;41"E9C^;'ERXGO]CZ\E'+8*%6GKUNXCCVRQI/:@B=H
M3)Q=RI')'"SL2?%B[DZNCZD]A4K)RBBLS-&T; -'(8ZD[*LH0L$!'1T+?W/=
M30*".(3IJYLQ'JH"N(TT[JK9Z19P58[ ;K@M !/U2R4-2WY%?DRL)CQG&U#6
MU3$+7&;>=;\Z! [D)LH &]I]\#V 3RUQ"PQLTA;7:(XR<6(&:'A=(Q(>JF6>
M,Z]%>O+!#(K'[=F:Q'''HDNYTN]KR^RNZ_6-#;DAS9R&H#>"KN2SU0OK0-4,
M/&E29!1HZY5DAWPDWX%YF!.0^J&4EM+C0W7Y"<M8][<GM 1S(_(*H4EW=9)(
MS$B <WG+12%8%4S/&AE5#%I\JB_,"8_L$J1ECT57=8&4,QTJC5F ,S$*C2JC
MLK[42 ;VCU"0UM;-M/3[6&I%,N^=>%Y)O7MY@V-5H6<!UF&/AT'ZONW]Y\E8
M+%$B1F5"T27G'<*PUZ>4KS8\$B14Y1[A?0M"%]Y(62:([X[ T8)&;9TJC;E=
M$"%.1;\UB&KU>J&,F_:%"5ULN=MK86%@W\>H79UO!VCN5U^JM.<O$JVE"0AH
MO5 3D,-3;A.L*2MQL&:R+'9K:@C!OYK'*LOMRH/H?'QW(SK*F?B,)95&.)I+
M%:LO5[A<1$ L&[<$-ER. 8\1#8@?EK1$@.]*Y6<6IFE5#IH0W,-[=%18.CRU
MU/Q9]?0\-[TR%O/GN=HC!:(+P9L:T3T1DP)C--LC[LTC(S8VE5Z-6F1[EY=M
M4.;5)T60+^5?'LR6%(4UC*',H1QF2$S#7'0*Z]W-62I(K)QY JT=R%PV]<>9
M;7'K7W5,IB]"O+D3[0G%I4;F7XA0&A90?1BR<2W,9<ENVS1:)&J<ZVD2H6!=
M"<$.&(R*G;W1L8@20E<%JSD(H*1"H[4A2TMX>-.#V</*PUE>',X1RMRL=KX<
MC(LW%SU90IX=6"R;X,VML%5BS*&9055B)!@U4W &[ X[]IY#ET7::YC9TO5>
MC%5.F8 UY)[6Z,BP4$GK-8?@7(#Q5N2UK+:<A#@I$Y@9$*HQ'I3JEBSI*1B.
M*D8QEDP\AQ$%4A3+N$/=S6/B_?81Z3BW<W*9!&G;US$LG;<K"5$K <@G%E)]
M+1*ID:2(0!Y%[G-.V>T$,KK+R[;11B2/G,K&)2ZAG!8#/W*[6Z#@UMVV3+YF
M,%CL+>DK>JUT02B*:KMAM;T*8!57,'HA=@'5"#CD)R,F8VY&RPIK#ZD-J\9E
M5#(I$D88 &,]T-M*\@X&/D) 4M0,&3DI[G0[5PM]>O-:F:O$I^0JJ65O8RAK
M,E0<@_$J?D1/$5;14KR8!2&,(F=Y>OD%X]F27NC VKBP):PFYNLK^)'B&3LV
MWP/@Y<<S7AQE)P/)I,Q,X<F(H@PK*$X94O*TH]](UE;81[#PKH%B[)3-W:!.
M1=6A!"E WY-*P4,K-GKGYCB.J#([",@#0WW;<5-022 I[TJ??Q!CY.I8*=3,
M5VPT0;.U.LCK:9=.W,JR!$CGM=;,A.P3LE9MN*$MZYU.C,Z_,2U5R9Z44\H:
M^[AK&4ISAQKSV)$\DP@31<JQ'4<6X1-.P5]\6=84:0HI+\%)X],K%B%JIN!A
MV%X;_P!P$DL4"/P^_MM--'&LG'MEV*AMJ_'$7'M[J&@[ N&O;6B\C)-##C3%
MELJ*%9"%48P6$2SD,6*G#(<PE9C2QL7SYC#(DQ>%.H1_OYRE-$$BV&X*"':?
MLH""#))W:D("+]Q!ENP('("$LQY<5)S3>1O'P16;&NQ+$\G('HD<:69&9V.E
M&HZD[$ EM*.FV4'V5?M[H"XW2'KX%;3R[40+30<*(4UCM6NCY)8?,-CI4-JP
MV*DBJXI:"5;GQ4Y^+\CDJ&ZRC*G$*3BZM&]Q&DKCDBH6)V!T&_3>ME@"Z ;+
MQCNH&C]V56&^+((9PRS<58KHEE5UA96< $HO]Q"I9^(621(F(D/'/YLKMMI;
M5SMS@&BEG-'Z,F$@K7*E1+A82,XE.D5UAH!7YT8,BNG;'&Q;!KTN!'G+DP8T
MUIZ2AEI:5YA7#VB@KJS<YTB'30V\O9[GNU^%9.2/,-QJZ/'R[BE,TFNZN$E(
M0FO+,-]=I#%),X'$$\S'$[*GW,!L#CUSW[C[/:TT4\%8OL6]I<. 95CC_5V@
MV>U(CCX9FN@7V9CH$?.:;+9(VB,EJ$E2Y<C'G]%MQ2<)4AU/Y,^*CV;("'8!
M*GN2=M>/$%F]PV>"MQ71;0(S,6848O(%2(IF90"55@4A:=N?)@% C4]2=%AH
M;ZZSE$[%Z;V79,5&E7'YO8<BOFZA[E?M(GT6DQ!9"2,DRS8,=!BV@= -Q'Y@
M9QU!:$Q(0X_&;0K&>6)$TL;2Q<7B50W)65E:,E0)8V!(EAY,J&:,O$)"(RXD
M]N>2N(&C6;:/([(H8$'FC3*R$$;5P:\_L;3ZB=@.(WD?5V=H4?%N*$0=]'T:
MIV.734;%S6L%J];;C /1*K*JU&K];GF]EV@S]9WWH#*6 'IRWXCV8ZW6_2<=
MJ1@U2&XVU2P@>(:)9XF5Y!-[ RK%VD,S.[($B/<?BH;CH[3-,\$)65X@>YQ8
M$1,HVR.21^13I&1>3+(>V1S#*L<E]W^LD(KD0_L,CEU,&.2>(Q]<;2F5J)!?
MKX6TN29]NATE^JCVQH&Q0GY_KS&\COB$HE89<\48L,;B3M,-2<F4 ].16582
M4WT=>\Z1ADVI=E4$E@#0645UL[W"P!&NIZB5@I4;97*P3.(V <I&SA> WF=%
M]N-!F0[%@A6TZD,^?#5I<^?K/:8AF 3LF!JJXZ9P6I4)P"%L*2\;, G-3'&S
M,.?M+Z_*KPKY#MPRDZ2>-W3?381 Y4CU60HRLD+:EEY#MHY(R95@91HGLD\B
M!L:5I4=U(Z211O!*LLJ%HHF1ED=3H8K';KKW<$B_D=[DJ?./ F \ M2M@5LJ
M3S9S%<!@'H0>QU424D0RLZW#5,R$LY85$EHE>?$7"GDW003665(5)=AL#T_D
MGD(.]<65*T[,K:91&W( Z!KL21U)I(+#*DD3R*VR-!HF1' /HQYR)&O$GN2,
ML<?)SQSXVWMMINAWZWZ\M\NX!2-(%@"ILUG7]Q*UO+1\<5-)0/) @Y1Z<T#!
MAW9I:8AGY<*C*0J5(;RKRXJK:MGC'T<V.RH;V\F BVP+:"Q*TT2&1RJ%WTI(
M#$:IZT\"PL49^_$SJ$!<G3,BQA5!9YI"C]N&,/(X0Z794-+\[_UF[2K%L$82
M+EZO5[MC7I6=#K1^+Y[.BXP:)+CB$F1PI-A@0;+/PPY,@*DQ%Y;<PTXXI&4\
MDBL\<,H!"3[X;!Y:4LI)37<'5#Q!7;C3(&5E)A%$T]B:K&5,T%?O-U''A\87
M 0_V$M 5<:;0Y .5.]>/4/8W5^\'),6B2[0X1@#&RY0:>H=UK3PF&^4)"8:"
M4PV!A"(Y"<\*==:A_$YEJC>5[T_34E6?(U,M%/(QZ-5TB;8(.C+7ALA- G;K
M%8B+A>04L!L[!-#R)'9>F_2=)98R/K^&:6!GZ=1&TD$BHS<>14KH.K**^JG=
MC1MI.SJ\J1=ZT08LA6LCD6K7]I%J/2 AF_!"I4;%9'S24.MP)&LR[KQ$BQ!B
ML1X^''5HPKPQY%J:E%?7I#+56SUZ%(&C259)3]L89)(RO)AR,B*-LP!TR5YH
MY.T%+M\B2 </?SEB,"ND879D*O85#VPPVDIWP0MF?-=M]+!!C!200N2FB 6:
M?!(DZRV)7VK*.'_%.3/JX7MU9KM>+3&H4)Z7B.W,]=R"CXA"%,J0M5L,$L\G
M:0:D 4D'VLJO+'"&*G3:$DT:MTV.74=#I!";$BQQ,I#R.@8'DG*.)IB.2<E
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M/!937>KDE">OKRWT.P-AV!90&*GB6(  Q5NZD:RN,8S$FD[H/9L),\2,?*C
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M&2:O+WZ\CI85TDC<';QS1N[I.DC N9%+E?>SHR@!T;;\L_L*LDBH\<DW<=6
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M:D/;KM&T:@E(U!+>KNL9C$C$:(?CH$H4601QK*KJNCZ99GCL12D&.;Y"*/\
MRX9Y+$C1+^HY6)']_,K(>490!0)C(Z:4EG9NBKH)>D-C-,%6["R@D2)2C4\H
M!U.SJ"ICT+BJACG038/PGSVI*'O6*P8;[:4*:\4WU[<T5V2V_$J:UJ-!KTDN
M3022RG9UN..%X8"!R1+5E>061@U?D%:_#)&7938OP6)P-<7%<V)(TUK8'R)U
ME.CK\* @_2>;+ZMZ]V>;/60H8O  [98\<87*5,_'%2GZ_P#5TA52];:5(&$$
MQ@]E"D,MSO3PF3E;+3C+K*T85G.FD=20&B#$LC=4E!,3%)%_F3\*C70Z:0;T
MY&;CY"V(XEA<QRU]&)UZ/&X:1DD7>U+HTC%>2LGIR5@,ES>BJ(SKA_5;""[-
M3?MSUT])LCX3F2SNQ_O2])B7EC/D'MV;&$H:\N?")CTO-_\ I<N^1+WH9V.Y
M80O$GZ\1H%OU)^OZG,T3]EI3$%59JQ@('H(S46EI?T(A4:.S[_=_#(]KCK=3
MM9W7-Y%6.\&"+-?-587 L!,*^,# #EG>MCPN)D77A)6=$@$7U(AHGRIF(K6<
M^3P6I;BJ*@%.G\.+JG8K0DG>RE2)88=@:4L$4 R<>YU8!@C%35846)Q._0BQ
M//H=!W++O).?UXN[EBF^&U1N/)%(AMDZ6Z@M6"+!67<\C3AIDU81+!N"B(;4
MS<-CWA,!Z2X'=+BHJCFTRGBZ-E09OP^6V</X0E>'(QKVHZ\2D\*L$<4?71 B
MJQTT;8T2PAB4'9XLVV93T O,TAB[:GB1--*&'0AYYX;#Z^A'<@CX@@\1O74@
MB-SNB&LC9X.?M&P-S6U\!6Y=4#0K#;0,F",#2@Q( F- Q%J,.;!] 84<3X,O
M-HD.);<DI?<:0M.FI.].6:>,!I[!4NS=6)62M*#OITY58_;]@Y2LJAY78P5V
MCEADB/!8"2JCJNBLRZ(;9_Z['F")"$B0N8D"9)=Y]3:9V%V11[+L./#FU2DZ
MSVM28PZ.[/:,RR6U&*\'FS9*5K< 28(@ (D8C8DQ9#C<F6O*?!&7$N9:Z&"W
M:O(S):GAKQJ5XD*8+(M+*0X93)'(BK">)';FLJ^PX&>\^%*M2C'XX+7=)).V
M0020]C:E6[4C2)/*O( S5*<@'.)66,B>@^F1-UK5Y0:OSY&JLB<"Q6)U0%5M
MN8(LE$MB"+02N4L)&%O$36O83TQB!\'!E.O27EQ\OO9=QLKV6JNSPJHV.*^I
MX)[CP7KO@.6D5BPC50L7!2P:+'E5:F=")S*6( !9IH+%=V/TY&.U+M@ S-P9
MRW!=6MMGK%J[<UL"72XPI#AP("DUM#S,*LSD3!#T[YI$:6JQUT])%3 Y12Y,
M28,<@3&GU^;+JO*WY.<]:-^_LL!8KF%M'B0K)-&2K#3@\9G!'+B>@92.0;2M
MR=$@CV"E:QWD!&QS)B+;!Z,'[,8(() 'M*DDY7UIZ/ZDM4R9+</[+"(,E A*
MTP0%KC0X-N;K<H,1 "C[4D+-<6+%% ;,EM,9<9U;F58<<6WG",:K3O<DF:<[
MCG:R[(.B=VU!9K2R@>O,06Y439*KI#Q++O,<*)!#2BC #T(:<43_ ,_;HR12
MPHS?52\2F3T+AI!L!R,B.V^D@H[4XT?4ED,TZ_C ]HK-?N!&RSVG*^&NS,]%
ME>C(@")J)TR0J4C&&GFO24VGP\R%X2O&>]%_D2\5@@5["31S: ),-FQ)8G0*
M>AY/*Q'52 J*& Y$Z?%R1>+BAB5.XE6W!;A!)&K-6I#2@<L.H"P0 'HPY.[E
M22 -UZJ"15ZQ7*RW)<F-UT"'!-RW4I0[*0('QX"9+J$YRE#CZ8_F5C'T8SGG
M1\A;-^_/>*A3-,\FAZ#FQ;7_  WK.5XRG_CO&U_'\N78@CCY>F^"A=Z^F];S
M-.X5EIS"?'S9;7A/A]&?-E.?#PS_ -OCSA^72>7Q-J.KR-EJ\@3B='D48+H]
M-'>M'8ZYT8R!(I;TV,_SKUS<^D"/MW]:.L;.TM8$^T(+86A 9GK]%N%9)[X"
M[$K.\PDZWQRNKHT^3?1EB N1)<LC(>A-KCMH<DNN8;SEW/U32U/)_OK]M^0\
M$4E\-#>H2\X1^**M'2(D9N("Q11KM'#<!&?Q,%;VY5^](YH/&?O**0&.Q9;R
M@C#>UIFGOLT/;WHRF8%7BX<NZI5TY*0<_P!%G.-DL<8SG%V'V7K32O>'KELG
M=M^H^J==9Z\=BJB*O^T+."I5*9O!6[:*)LUN/:K1-' H-G,@!$EYF+F0W)FQ
M8;V6TN(8<\GOAYXH9_.PS.B3SU/$F)68!I%AG\K\CM@D%Q$9JQE"[X]R)F&N
M)$/*U[<\'AYJR.]."]>[Y795&EK5A5,@'^X1VUB8C2_E4%3)I_5[>IVLW+'<
M&_T(H'LNN[YW&V-8Z1<ZN_&(TZ["E5#7HZ;9*D?'9<#6<1(-CY3*B$)U^,])
M8=QAQ2D*\-*5[%3]O>.KVD>.0"VRHP*D1/>LO$0IT51U/-!H JP=1Q8$Z_,S
MUK/[DDEJ,CHGB_'1R,A! FCKD2(Q'0R("@<;Y+T5M$:'1/F7,^5%V!'FBVAM
MV"ZW&GS+"2U'LB !B"_4^9RC,RG&8XN,.])2'?CGYKB$L^7.%>IG'AGQY\[^
M[D:3]J^2C52Q-&<: ))W$W0 ;)WZ: )/IHY]#^T988/W7XR:RRI73R%=F9B
MH43(26)Z  =23TUG(N5O;KSMBE>UOJ?36VM1[%VA0]W]=BA_66N+A5;-L"@
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MZ+$#U9K5>;0FIS21RC>RK1QB5]:^X"/;;7?16_3*X=STJWD8@34ML5B;1]S
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MWD<,0D)E( +'@O>V0!LD_P!O,.(]VXW&MC)Q1//*L,>N;3+&.HUS;M$;/H%
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M$SB@:DC2A_Y*1"IC,R23TR7\+(?\SN7W5/<D'8410/\ 0!).O:&)JM4)XKI
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MK"-76ZZ5G_"3B\:?B')BLK3Z3SKN%83G\5LKOR 8,+49C#:.@S63-\@KU>
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M;/0R-).K*TI(DX.6# 'AG1D[,M62O)ME?REJP >H6-[U&:LJ[WQ$4-=]1@<
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MS$JA69W*\ P8'-,(:8W(PI%FD%YQ^KN6$+\8P-\BL<PE8;'%$D)ZKHT/CW"
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MTF5'RJ6RRXPEA[G2VEA_;MR5DW6K>/EB,*]0\-*W3[%0= 22?(/:2-4=$96
M9W9S%UF@G;S%.(,2MFQ!(LY!'&;XDL+2?71@C5:K.S(626,@=LQEH)'W#1+4
M3H6P8'6C2S]*V37]D$+NI6R)>;Z.K(ZUZTH3ZK$%A45L$_9):[],R\"F.NM_
M#,M+^9QUJ4SSZ7XLU'ST]>Q-JRMOQFIH_<OR;MV;XTFR0'X300R2..#UY%=5
M%@JN?-SV(9O"Q2\-QP>*FD6%U*D5JM#N21*3U5%A_#$I4K*) VHEV6V;[7VK
M6NO*/3:_)UWKV_5#9E\(H+U$V3P'!%YE@@DL+L1,G#3/CP*\Y8";2CI)^$0C
M1AKK[BV',^5.?GZA_P#=:GC(PJQPUN]"2>(B<7*:1$$@@*3:ED10.4DH14(9
MNO4F=ZU:?R,99999W$Q4'DZPT;=F0 @J>]JA%$GN''Z^FQH S:J))['C=G0=
M%:_*XHE0GQ8]6@7<& J-5:KEUAB+':*_8 NIB17;4I\W5H4H&J=D1'82SXJR
MTYX8;Z'B'>I7F>L6"R_X]59EXO&;ACH5XUC&@J R%'F+,S5&#1H_)4-GF(8J
M]2*E.5XJOD++H@#QR? B;R#.)&"L&X3DF(*%6V74OQ3N-LG/O>MZGU_J.PS/
M7S1;EGV>UL-VU"85K8!:_CQ=?NRK65C*M9RCF?F=GEJUZ.S#%3!S;<HI&2VZ
M\TVSESF$HK5?'4869*TWAZLP*JI:,24X8^-: \N[P2V\<4>S[/8Q;>SLHI;\
MA;M[>/N0>=FK())"BM)\ZUPDGD&C$ID5Y9ID#,#(94CVW!=6-2]B=/4T/O7K
MB)Z]KO,DZ43LFW@MAW.LUZO6:TA[76=5WH0N!5M9-0*L-U@T.HLAEYL7E1#Y
M^RZA"7FUJ<Z21V/,>/JPHJGXDD*=6;2?-::7N"7KS,?D1Y#QT@0!HY:;; #Z
M'.BE!\BC!G%JQ3F8#@H"P5HN]'$>/M[T]"5?(-"^GCALJO)E727/0^P- I!V
MRT+6O3.JBR@A]OKY:'H=T.MTN#/%%LUV56GK9*U+*AHU<^Q&;:C3<-HG$"7E
MCO"FO(J2G(D_^5IJ"2:/D34/%P%[JS00R %=\2\2W9A&G+@461NY$LB@U6[,
MOC__ 'K1/D*L%JRK*=LO]W81FY %E:6>G'),>.TYHR]TH1E@BE:$#Z0F71KJ
MUJ0*NK;2)ZXO5-:N4U\;K]BR&Z@Y;RYBPQ]?.3"RL,!@Y#$4..)1)#$>(XS*
M3'2IYGPR0QKXV1I /'V@2)2#PC:":U+&.+ .6%WN(QD6/M3RS,Y[8:1YO&.?
MDXE3G/7(+HH'.4-6AC+,.@4?#=2$5I&>)$1$:8K$M/5#>NLZF#EPRO5/1@XC
M;:!==CD) ?8F0]?MFHBMA?KA.# ^=T6>[G8=J=UY!6Q54R'H$J/$R\DFC+*V
ML6+)-6KA'$D<E9D$L2[>19E6C.HB4 -,4-Y=DA3$R)&.8>(GJ&*4^;E@H2H#
M\V-(97;@G+M^3X22.%_'&J0V!W%0EC:8F)27QLS=.G[^0GU:LZEH ,ANRA'
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M"+VG7!Q)%:'6:^67KG/&#A\5%KJR'+D#S.J[5;B+M%))K>GP")%4P01S+:S
MCMPO.JFG#):C[MHI6?MPR.@96,<W883U%8L1)%\A6:*>/O<HQ'N4&0(>JZ0+
M%*ZMR;N6TB_YHEFG-6=ET&$AB6(-&PB!)!$9+$B/0-B]^JO0 9&'(V!?"D:
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M1_[?^_'YD/NX_P#KA%?_ &X.I_\ "'&.4?\ M_[\?F0^[C_ZX17_ -N#J?\
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M5JL"Y!0-,9<4A^&^I<=Y.?!:,\CP7Y$5DC;PR*Z@]5YJ0R%E/M;BRAEY Z8
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KQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g121496pcpg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g121496pcpg002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#*@)R P$1  (1 0,1 ?_$ ,P  0 " P$! 0$!
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M?PZWKX=;UO\ XZQ],X!##8\@Y$IS/(5647=)O8<J885#V0*83Q)I,YI&9D;
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MV\KK'+O7!R%/G-C4ZM*KT=M*I3J=)SS$JC:<XL[1"HGP]LF.]F(7LCRO-KS
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MDZ=YD 8!I29 J.9)3&'AEE<\FSYBW/=@I3SUHE-R<=,3&29?5(UFQ#V:QM\
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MZNNJ=:7 ,PNR2I9%J./?"588JRUI%=XU8V702#9.7(GA'X]2ZCLN$Q[&VO\
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MB&KGK*+=49"NCM["N 3\VL^\.>1;?Q<'OZ_\7@3KX_\ [4@Z3K8^++RXV_\
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M/PI$2NH/.6,M(0@ 7<@M65$$<:H0]R6)I NP$50S(HE;9=&=E)0")P4#,6!
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M1DMKDI;QK=A='AU5%G*!@"?[()8 R3S^_P"3J/<7<EAOR&8E5UO0$:Z0$#;
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MAUIE<_\ 0TF5RX]L(.JN+PV,+[8B&G)N<G 1\QCRR;MS*VD-HF[2=3LAR5;
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M-[\[1DV<$,*="6!'I:(8'4T6D1Q8_+L8MEA9YKSK8RDS.XWTLL9FN%^\S/(
M0_9EU+7.S!^4.]^0&MW('6QB\/#6M[U\.,]X_P!QEWW!?;A4J>(*$E ]"6WN
M6(W!6<GI^'1F1J(EM !I&%)+P/DVC 6U8X?&FPIPD"5!&)*?YA!\@?.SP#?Z
M96\.Z_>)=+(Y%CN/>S(@5(7A$TF2J8UG!&V)QX"PW10G>1N"&U'1:B9T>M^8
MXPI,>,(?AT 7\&,]X_W&2"U.H76L)HOAR7EOJRT"4*1N5!F55U_#7^%K]N"4
M*D21 YO%CQU><K;MB]DI")( (#=;T$0M?#C/ -_U&9&GNDG.VY6HBRSFOINH
MRD[&M>M2FX8+$HW%% T:QN2!94[@QV!*%HWQ9IPV<25M,$L1*<[>S ["$(F"
M-?U&5^^]G/3(^OC(#B[MM\ RO3LS@>V*KH K8GL#6X*$ 'AC5J+:1J%3*ZA3
MZ4)#3"23#$Y@!"+ +>PZ9[Q_N,M2N+^<+#AT]ERGG[H>NSH*E4J2(A8\-C#+
M,9WM,SJ'?26!-K5.'U"[JE(R/<R@J52+0EA@ ;WH.]CTSPC7]1E+:[A?=ZUO
M[#7>&O'7CX;J:N?'7_X;_P#UQ_PXSWC_ '&74OOYP0TLV7$'G_H9<M<5P$0J
M;00V,'72VA$_JV+WYSC!DX)82$("TFE^Q@=C!?%YI9GE\^]EA9YKSK8RDC.X
MWTLLPS7"_>9GD (?LRZEKG9@_*'8O(7K=R!UL8O#PUK>]?#C/>/]QEX6[?;A
M5"*&K4E!=!VR*7I%ZLY%44.C,C6Q#:$EH-"DF13W-HR6VJU^W78$X2!J@C&D
M4:V(.@!V-G@&\K6']@/,ME<<BYW'?9L2*D+R@9S)3,*S@C;%(\!<H 0)XD;@
MAM1T6(F9!H?M%!I28\P!>M[T 6_@QGO'^XR16KU Z5?-%L.2\N=5VB2C0MRT
M,RJJ 0Z00M8)P(V<)$B<WFQHXO-7-V]>12 20 0#WX!$+7PXSP#?]1GBK;JQ
MVL2;,4,4\H=<5T0]F+BS)I9-=PIDA+'[DUKG,)CZZ-5F/S@D+7"1:2D;+2';
M&J/*#O00BV,+!&OZC(](.S'IA?WYB+XP[9?BV-[=F8M^C]7P!8P/@&IP4( /
M3"L4VTB4JV1U"GTH2&F$DF&)S "$6 6]ATSWC_<9-ZWZ8<[#3S@]3S)U%7>X
M5%5$G((LB!Q!D438U.!6/47@X&JPWX+K*E'NN@EIU D9(A&E^)VO'?@SPC7]
M1E8:[B?=ZUO[#/>.O'6M^&ZFKGQUXZ\?#?\ ^N/?PZQGO'^XRT$O2[FIJ-WM
M;?,O4*56U2I/& 5.J@<0+MQV*4?%/C*&B.@L,QD415/\:[]HH&YE'!]U/\"=
M^0/G9YKSK8RL/MPOOW&N\/T35U_]X\9[Q_N,W&@TH-FL/C<M/BTJA)TB:$3L
M9$9RWHVJ81T:PH)HFF2-K<Y/"%$[H][\AQ92H\ 1ZWK0Q:^'&<GQDJQC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC*DNRV4-+0
M?4U7M.WDHR4PJ*$HMOK!&2-+9O+&B)(E2U]DZYM96Y"B5/ 33AFFZWLL&P@T
M(>PAWXA,EVO177.PTH!)  ]5:>RV]_4E(&5%&RSLJ@><[XCTRSMOC$@8Z4L3
MRD2,?0> "X+,=*BAF8@ YJW+^^8Y#%Y"-XK5Z0I7]U?&:!2-WG-;,$0F"N'(
MUZR;FCE3Q)$C-&&]DTWB+2*'(T@MW.,* D\^S ^,"VX&BDEV1ZJ[664@AOMA
M+)"KJI\O,\L3 55W,(PTI 1)"L:-&\XK _R\Q$?!TLW"O(5)^GK$=F,B?_;9
M_P"('FR!O@U^H5 94W/#]!H1(Y1'&UTA#.G<_C5A:E*T^81YJDQ[H:S*E0W1
M!%XRWOB4"YS&7M,4>9L(MAUKS;T+E:6C.L%@H"]N>$-R^(6![,32R,=")&EJ
M2QH9./(\?(V0.()4L5VG0@R1UDD>,'DX=VKCT(%W[942S'*XCY<8]L-C6YY%
M>TH#(I79<96-I#"77+6K6B=E4Z@"PE\<4GL-%,*5"BD!C@B<WW2@)S3[8O13
MHB$%02+8!ZUE"U.*O1V^[*LPJF;^+6I'$!M!] ^%=?M)"R-ID!!;0!U:IPBY
MV=7K4>,&UZ?F6^*^Y:[*W_SQ?]RB>U-J9%=!LCS@(WVBX3!' 5$9HR4O!U@R
MIQB#.0EGE:C).7-L*+G2ES;'$$A&WR*.(VI040L7(##RD:[VI!GX9!GAJ249
M8K?VCZ!-:>8-YXZ@L/7=6.OCS9.4+-I9E>,H3S7="M;BL];_ )-.1@YPKH#D
MP-B.-XPX'[3\V#@_[?K);0/C-)NPDZA+6*G=9NQ8K1D4VAC(B^6T",<!RJ%/
MDB85(&U$!Z]O)(DK-CPE.WY!HYM3(#RU!HPE[\<K+'[)1%$R'GUR74)8#<30
M&=N6_P!G! -,^E=F55.SK+3JT7+W?'UW16?>]+(SQQH@.OE*6=D:$?R))%*A
M&US%P3M^/SI[9&Q)7$E(;#Y2TPF52I'(88_1J+RF33R:US$T*1P9GI3\KT3S
M)8*K 8L; G$(RS"A&[\!"\MBK2DMA)8R!6E1S&Y\!WBJ+=D4#R0OV[PO%+_M
MS^Y.!^I'-@/ \D" 2VX67V(A#,D3F)5E;R  "\HD3?.)JTZ.H95#;QY3SW&,
M8QC&,8QC/D>>0E)-4*3BDZ<@L1IQYY@"B22@:V(9AIIFP@++ '7CO>]ZUK6,
M9 _K:JK\IM??/..?C+&,?6U57Y3*^^><<_&6,8^MJJORF5]\\XY^,L8Q];55
M?E,K[YYQS\98QCZVJJ_*97WSSCGXRQC'UM55^4ROOGG'/QEC&/K:JK\IE??/
M..?C+&,?6U57Y3*^^><<_&6,8^MJJORF5]\\XY^,L8Q];55?E,K[YYQS\98Q
MCZVJJ_*97WSSCGXRQC'UM55^4ROOGG'/QEC&/K:JK\IE??/..?C+&,?6U57Y
M3*^^><<_&6,8^MJJORF5]\\XY^,L8Q];55?E,K[YYQS\98QCZVJJ_*97WSSC
MGXRQC'UM55^4ROOGG'/QEC&/K:JK\IE??/..?C+&,?6U57Y3*^^><<_&6,8^
MMJJORF5]\\XY^,L8Q];55?E,K[YYQS\98QCZVJJ_*97WSSCGXRQC'UM55^4R
MOOGG'/QEC&/K:JK\IE??/..?C+&,?6U57Y3*^^><<_&6,8^MJJORF5]\\XY^
M,L8Q];55?E,K[YYQS\98QCZVJJ_*97WSSCGXRQC'UM55^4ROOGG'/QEC&/K:
MJK\IE??/..?C+&,?6U57Y3*^^><<_&6,8^MJJORF5]\\XY^,L8Q];55?E,K[
MYYQS\98QCZVJJ_*97WSSCGXRQC'UM55^4ROOGG'/QEC&/K:JK\IE??/..?C+
M&,?6U57Y3*^^><<_&6,8^MJJORF5]\\XY^,L8Q];55?E,K[YYQS\98QCZVJJ
M_*97WSSCGXRQC'UM55^4ROOGG'/QEC&/K:JK\IE??/..?C+&,?6U57Y3*^^>
M<<_&6,8^MJJORF5]\\XY^,L8Q];55?E,K[YYQS\98QCZVJJ_*97WSSCGXRQC
M'UM55^4ROOGG'/QEC&/K:JK\IE??/..?C+&,?6U57Y3*^^><<_&6,8^MJJOR
MF5]\\XY^,L8Q];55?E,K[YYQS\98QCZVJJ_*97WSSCGXRQC'UM55^4ROOGG'
M/QEC&/K:JK\IE??/..?C+&,?6U57Y3*^^><<_&6,8^MJJORF5]\\XY^,L8Q]
M;55?E,K[YYQS\98QCZVJJ_*97WSSCGXRQC'UM55^4ROOGG'/QEC&/K:JK\IE
M??/..?C+&,?6U57Y3*^^><<_&6,8^MJJORF5]\\XY^,L8Q];55?E,K[YYQS\
M98QCZVJJ_*97WSSCGXRQC'UM55^4ROOGG'/QEC&0:Q'3GZTXWN)S.P8:L9OC
MB//Y8&NT28TX)WB*O:"1,2Y*\1N1M+NE-0O#:2;X%GA"9Y/(/0@"$'?@ 6Q%
M:78GA+E""?!DBD@?Q]"&BED0@[&FWK8!'8<A'C\%'4!@0#L!E<?7Z$,JD$>0
M1E1+*AXZ7#D0SIHW@%*2AD.^DW1,Q2%[)4[]HYE-I2:Q"BF0#^HT$YSTC"1\
M9'@ :I]J8 (M>!(O7ZF1&AV/BRAE*AG<1,I!#0!I92("#$/=+I-2/RX722>Z
M/2S -\AX;DPB5I-CS[BL,*F;_<XQ1KRTH ]6ZLX^+6.:YKF#+&C'-!MK]A#K
M]DT.;VEO,1-S<L21AKC$^:FZ)D.B%G1E+0MI272T*0G1_M/9@\.YR;4<L5LF
M:.=F]@D/,2*TDLS1ORWRA:6>:4PG<1DED?AR8DQUX8*DD,M6...6NBK&54 K
MQ5(U<$#_ '1''''[3_+P0)SXC6?2(5;QE!%;PKB[K7Z #TQKXT-M/M=0YL30
MQNAX%;BWQ6/NDM6LL/*6+ :.,VUD)![-\1^/FWO><VU%ZK8J7/Y([7,2D^78
M.92R^S_<"GW2?%6"C8  "KJ>M(]2>M8KGC)4,9B'U53%'%%&W [5F6.").3
MDJNB3MMREV8^6WE&UH5,OA:8ABK]_K!AVSVP8Q*&&(R=&C;WLAD5LLJ0*FAZ
M5HD!96G9.,MU)!YM%J ><?FZN$WWLR6B6>XJK,1\?8BR>WUMQU_&7 +1C2.
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M/IQC'-OUQ_@%>DQ]T>/_ #\M3Z<8QS;]<?X!7I,?='C_ ,_+4^G&,<V_7'^
M5Z3'W1X_\_+4^G&,<V_7'^ 5Z3'W1X_\_+4^G&,<V_7'^ 5Z3'W1X_\ /RU/
MIQC'-OUQ_@%>DQ]T>/\ S\M3Z<8QS;]<?X!7I,?='C_S\M3Z<8QS;]<?X!7I
M,?='C_S\M3Z<8QS;]<?X!7I,?='C_P _+4^G&,<V_7'^ 5Z3'W1X_P#/RU/I
MQC'-OUQ_@%>DQ]T>/_/RU/IQC'-OUQ_@%>DQ]T>/_/RU/IQC'-OUQ_@%>DQ]
MT>/_ #\M3Z<8QS;]<?X!7I,?='C_ ,_+4^G&,<V_7'^ 5Z3'W1X_\_+4^G&,
M<V_7'^ 5Z3'W1X_\_+4^G&,<V_7'^ 5Z3'W1X_\ /RU/IQC'-OUQ_@%>DQ]T
M>/\ S\M3Z<8QS;]<?X!7I,?='C_S\M3Z<8QS;]<?X!7I,?='C_S\M3Z<8QS;
M]<?X!7I,?='C_P _+4^G&,<V_7'^ 5Z3'W1X_P#/RU/IQC'-OUQ_@%>DQ]T>
M/_/RU/IQC'-OUQ_@%>DQ]T>/_/RU/IQC'-OUQ_@%>DQ]T>/_ #\M3Z<8QS;]
M<?X!7I,?='C_ ,_+4^G&,<V_7'^ 5Z3'W1X_\_+4^G&,<V_7'^ 5Z3'W1X_\
M_+4^G&,<V_7'^ 5Z3'W1X_\ /RU/IQC'-OUQ_@%>DQ]T>/\ S\M3Z<8QS;]<
M?X!7I,?='C_S\M3Z<8QS;]<?X!7I,?='C_S\M3Z<8QS;]<?X!7I,?='C_P _
M+4^G&,<V_7'^ 5Z3'W1X_P#/RU/IQC'-OUQ_@%>DQ]T>/_/RU/IQC'-OUQ_@
M%>DQ]T>/_/RU/IQC'-OUQ_@%>DQ]T>/_ #\M3Z<8QS;]<?X!7I,?='C_ ,_+
M4^G&,<V_7'^ 5Z3'W1X_\_+4^G&,<V_7'^ 5Z3'W1X_\_+4^G&,<V_7'^ 5Z
M3'W1X_\ /RU/IQC'-OUQ_@%>DQ]T>/\ S\M3Z<8QS;]<?X!7I,?='C_S\M3Z
M<8QS;]<?X!7I,?='C_S\M3Z<8QS;]<?X!7I,?='C_P _+4^G&,<V_7'^ 5Z3
M'W1X_P#/RU/IQC'-OUQ_@%>DQ]T>/_/RU/IQC'-OUQ_@%>DQ]T>/_/RU/IQC
M'-OUQ_@%>DQ]T>/_ #\M3Z<8QS;]<?X!7I,?='C_ ,_+4^G&,<V_7'^ 5Z3'
MW1X_\_+4^G&,<V_7'^ 5Z3'W1X_\_+4^G&,<V_7'^ 5Z3'W1X_\ /RU/IQC'
M-OUQ_@%>DQ]T>/\ S\M3Z<8QS;]<?X!7I,?='C_S\M3Z<8QS;]<?X!7I,?='
MC_S\M3Z<8QS;]<?X!7I,?='C_P _+4^G&,<V_7'^ 5Z3'W1X_P#/RU/IQC'-
MOUSF[ZI'I?<P^G=RA8WJ%<&-LYYBZ+Y.2,-FQ]PA%HV0LB$Y96>1HBI'!)M"
MI%*'J-N39+&9R/2'*=)M*-%B"$0C"P:+QG2NQ^)\C/\ 354TR-L:JZTL(],6
MC/G=?PV9')"?/LE*;*(XVO9B8K9GB9LL@:[80^;X?#7P_#C(SX.LL#&,8QC&
M,8QG#2'_ /<-W%_TT8#^N<>,[/[!_P <[EXSC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9QN_U!7_)N[W_,HM_KQEQG2?NS
MHSRQ_=BYR_,/4'ZOH]C/#]3E\8SS&,8QC&,9PTA__<-W%_TT8#^N<>,[/[!_
MQSN7C.,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,Y?7
M'WS=,*Z=N'GRH..E]_(*&IJOKJL.0,5X1F%S58QS\^7%)62 5W*8>%HED@1!
MAZ@6B5$D;-*-C" &_/O014X+L?V'8]Q?5XNGZV^E61T'M?;5(K9E]0XG@B2$
M,%+O\-JK;XBW-4(N]=U5=T;L^RJ23QJ^T0".R:I1I 'T6;B02H7Y'D0%Y&+C
M]7FB&Q14,YEK$OAO,=^\W3>]JGZ#D+R!O3.,OK%,>[6%0TKA2QG3'Q.RV:/)
MC5*,KXR6?&9R8].27[0K?FO=@C==)VM60K)V%&K6M5DB/,=C5L\$62LP )<3
M2UU,7%B(YTF9E&U$%&&;L11>NA$=CL9J%GEH&C:B+@+/KDGJ<13 2\U_DB*!
M&!#Y"E7J]ZA5G\%5Q=O,\GJ77;\-<)FI>EL_3/OU#HW23MD4J]-8;>5"VLLP
MR=.LF9DZLSWE*4R+7,! ]J-@V,6E7ZN6;\LM_A[LH[2IUU>8E?FCW)18+T$;
MQMT^UG2*37\\J!%C7D#E"U;C@_%T_+H?Y.HD[&>%3Y5OM(1$PO$$?%&CE$S1
MGS'""Y<GXY8SOZHC.S\J]-](F4RZJWRA^D; Y<A-2(YLD,?+KLZ-3YJK>&-3
M&]CC)1,=5V!(WDD(21I%WQ>5H8QC."#>\^=%R27I.A[6I$TUKOD1HX%/R0&>
M=)/E]'$4%:6P3I=JI3P?EFW-2AJ]YV_5W)ECH]/7$TU@CX\#4BLCX [!9Y4K
MJ S%G92/KQS*1;U.(K*(GP#8)%7N2*!]NSMXI]\?5<M3 44%=#<Q/QJ.NI2V
M[CX-2-8Y3>)N<?T> YN$6K3@,]B/1N@!^@^QAD_(UZ.M,LM:STLG8TIU!XVH
MHXX;)0+_ *&-25IM\G\Q21ZV.68CV)H.DM]K;C$5KKNVCHVX"P+PF2Q)5]G)
M058+,(@P^(X3HX<_0UE?'JZ(J@B?34EC'/+_ &JLICIF*\F5!'&*?H6QTZ0M
M]9$T,OL)JC?M8DY%Q1+6J ]06H-,^,=*CT9@/XG>]:SY^.]$>LZSM) 1%V-C
ML6XK\GBZ[K!)]QV)!X\X]PS!8AHG@-.2VAN/01.RL]>\G'[2G0DD=E*K]UV4
MJ15:2_T,CB6!RY("B0[72,V7[;?J&Q*LZ"YCZQ;8*JF?,UYO=:D6+9Z"2EH3
M:$AMKH$H(U8DD8?B%PT_1EHE#@F;7T7O;=MH";M0/9@2Q@UM]C43J/RL?C79
MRI%7D]R16=CU/,B&6NC;(XQVXU)AF!8<S&A74@88O73S=I^-S=Y4B=KU9%>6
MK_ZH1)/7<"G_ %RU&!+Q !I%20H=KHVMRUU(Z=6U9.[FA=6JF6OPS2<,%!.[
MY*BRQWW$(B88UM=GIT^H^7N#Q&<2)(H+:A&[<#3FXL"[>M . 5E6S7NU>FJW
M)HBG<V:IG-5SQ:%7):LDSZ/"66+A+(G ^@2*I9V#:MH]5^\L=:)0W65ITA:R
M@YJT@ ^Y]2['L2O(3$'#@2NC@!  3IM7'J0]+26?=9Q&?<20^!-'%T<4O-T2
M)IZR23=0%P65 LM^)-448P4-&Q/Q3\UDE)5*D2I/IO--V+V9^@;"+/M7X*GX
MA8_,)=_:12VX$0#Y/8IM"LL9/^A/YE*R:;>C\!ER&B]C\HJ?B\1'W-I:DO,^
M%2O<EGBCDUYY.#7<M%L?4?/SO)55_J3S WD5S[:Z9YT::)I-75\!LFNB8+>"
M>^)]/SK'$C)C$)+B2:LJXTR2QX7NZ!(D*VJ5%GJU7D$(H)8A[W.]Z^?HKO\
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MM*@(C:#W53M>TONR%U,&6/$/D HQ/'JH8$[,;^Y3J+Q)Y3J2!K5ZU@+7')3
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M ,^<V23JEEJU):K#-X3<M61T:Q$M5P2W&N,(-IG%I?4Q:%V3+6 DYO-4%F
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MOT'MJU:G>9M&^B[*?)6[MDJI5#8I[ZP0.KG9B8T"0:8"Q0%R7J7 .R F #H
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M8G C3PJLIA3DP)V)?H-#,KHK<-SHNW[;L$X]A0_'1>^U#::*8E"!(?+%3MT
M('E"=_TSH3S;T'T;'>O)_P .]1N5?6/)&NCF'H:J+QKB,K8$7,H0HEQT"D\>
MG< 5/,A21^7,,BT0:2<@5[1*T:CX  , +69U%ZO:=;?G1#!V7678(I4#%XY(
MK<4LM>:,D JP,$L4L;$_(*ZGB<7XI^MFH2LZR];V:6!&=<9(IZOJ,L3 ;5XV
MCF5XY!Q8:9'!.CE*N71O='0\J[&E_*\II"MJSXTL^94W'X79D">9H]=#V15L
M4:I'82>42=%*& =7P\;B\%MC6>WIE:L1A8U!OB7Y0;Q&O2=9^)Q_G-]%GI3B
MU,E924;[*K/+7:4S:;_N96KSO''Q]:*(Q)LL2-EJ$-C\EC_#X',5HUZ3/9US
M"S7XEGBC$7C^**.2(RMR+L6;AKCQS5I!ZQ-QOO4O$DA1Q6,LW%M\\?U;<E](
M'!N$IFU.3*X[:>Z<CTHW,0K"4ZB#1JP/BQ Y>9)H 49XU?GUK7AKZJOU<2_D
M?=]-/+SHH]2'KIM<=SVZ4O85DF7SLV8J\D">1QL/&OD',*])8A_%.O[01A>[
MCO=FMZ-6+H8.L>I!9:$ZY?P-8>SX!:2&,KH'-^^).KKEO/@RS^@;$51A79D3
MF'7+*T'L<?\ BIA]RINQ[%C,' >T:<5GO)I;5&DFE0]'!TJ,T(>M \WAKYC\
MIGEZG\$H]_3&NSG_ !FK=?D-K]Q+7]CZ7QI.?T3?@>-Y]%5I59__ "'?_'"=
M]1!W_P!I&0?EZ/X=;?Z,VI&(?6B->,Y.<G>J[U[9--6#,CKGH3I)Q1>FQ8/6
M\I>Z^K(,2#RW?,?1[^2-0SE(W2Y[:)<FE&PJC](S3$CL1IM&(S023"Q"U/R^
M./I.D[NQ0<,G7/UHKW#YBL/;Y&S!P^A:JH5S(C< '"/\_I2_%H$[C\CZ.E?!
MB;L>TN5[%/R)8J]>0+':$GU42DK&%==L6YIM5;+4;?4DNE@]-BQ^P6CN#GSH
MZ?L .35$F;8M3C+&6"@%UISF!-]F1B7D-,V=37E42P2=84G&I&F,1#2^UV$>
M_$.:O95^LZK\IZKJ9&Y_CUG\H%26X6XI)357Y\/'%& 42^P;TKZX^,^>I/V'
M8]7V5J$<>Y@_'+5J&J%VWW,:R&%SO3,C,H0QZ 8J2&T<V\AGJI5A8O9ES1NN
M+NJBR>2J2X;6=#3>20G:=Y71^=,DZ=DSV!?*4Z[904@(6WZ, A]AH7M-Z'Y_
M'?ESY8VIJ/X]^0]]?C9HNOGHI4 \>WWP6&DC'UYN\R1(GTXEN/G?C<:LUONO
MQ[I.N9?N^S-U9^7GB8GJB%OZ<%"RR,Y.]@;\ 9$_3?[_ .D;]KZ]DG3;1#XW
M; :E:.O.?T\<83VIL7\S7 RR!RK1"YICEZL+W(H$Y,/N3PJ 85I2-42+99?F
MUXVORF&WT'X'V%WDO_N_HXI*]_Q_%]W]BEV&5(R>2QOREB*$G3U9!R\Z#J&K
M=I^9TZR*X_%.UL/]IOQ+ZJ_824K"2N"1[>(@G70\)./KQR'W%Z@_143]&SF[
MM!).*X@]T6L?S2EGMA/D% Z0"*-UK3YFC4YE0(8<^I2B4;&R+SE998UNP%>Q
M\1;WKQS6_(*=2C^8=3T:3BKU=RS7261]-Q63KGLMHG0!:955?T#:\_7(/Q8O
MVG1]WV-B,SW*%7LI(40\>3U;CPPJ?KOX !OIR/GQ],WL@W4K97_!MA=5R6_H
M=V&R5C";4L%1:=5Q1L@D>FJ2"ENZK4;:F9I=I(W(UB%2V[;C5 3S-;-UL8@Z
M\-ZS&_*;4O2=7';BJLMIH80BLQU-)/*(H7V0.$;,Z ZWH L#YRS^-4&[SNO\
M89EXM8TVE\PHL22.I\_)@O*0;XD\U0ZUO-1V_JGO*DF+D7HOH]\HB9TWUG9E
M.UO-:>K^%OL;D7.RCH DLFMW.)6&KD3P9:A+&^+T:-]+7-Z,1H3AG)-@"#R[
MWQUL-'\N3\%N.T]Z;[J**RH" W*L$D[1&$DZKRB"9(Y.7L1O67V"0/GY>VBM
M?B=C\UJJ:].K'%.8'_D9ZDMB.'D9!QXV%6:.0J 8SIU&CHY\N .TK2Z+ZFON
M"V9V%2JAPK:^.C:W9./&"JFIHLHB!5G)U##$IPX3G<M6/"@K231:@\7Q>$H_
MQ\/$/CK,7\58]I^%4N]F_P"ZO6NK2>9D^"U96M&+Y*-[!154 D?*96W\=9K?
MD>NO_*[/40G[>C!?$4//Y-:0TUG(4G6BCLY)7?B!E(&R1(NG9OWW%^_.;J!K
M#JVMHA5O4*&]9,W-CQS.S2Q_KAMI*,1)^"R$R ^?-NY,.4&OAH#%)Y! DP=:
MV (O#X>OQU&N=GV5.^?9'UW71WOB.!D26_'5$']>/!).7L\DL/(\Y)WDL%7K
M*5VG&4>UV"43MN0#_96K+3CP/)>N%]?[0'/R\9JM;OK++J@KOU2XK+KVHN-=
M,\X7=+(!RM 'UI3I'N0QUMB,!7,1KG%1O.CI@J<'QW<? PLQ/H6M!+\->3Q%
M!6G'8_CG1WNOT_;7.X:&TB_+A7'<_;>!_I9:.V+DG9!EU_IR<4Y*GY%=HW]K
MU$72UYX9"./LL/U;3N=_0J;@4! /B#Z]GZY:3+W/<4O]1V>\VR;M.C* BT--
MY7,KVDY#4#,_6#?0[3@R*5SIH8I6Y3)N6-YJIR\Z%,8F1G"2;.T+RCV#X=CJ
M*\5B]VBL#:>IW_:5$KH>+K6J0H\4C,-L2O)Y&;0#+$0=;SYR6_,O3=79EXP?
M>_C].T]EO,8M69I(N 4Z&B1'Q3EO;@;R[/52Z_M3F:P^*X1!^B*EY:A=\S>X
M62S;EMZ!MT\8HZ@@M:"EL:3I4CK)8PA1J'=]!I+L0CA#-]KH(->;P\<"M/[.
M[M5)I42O7Z2:W&I!)FGCL01K""OS(9)';2*7/#X@GQGTDD9CZ8788'GL-VM.
ML2K:$4,Z66DE.QKXM%&H+$*.7G*;J+O;M#IUEXIH^$(ZMIN^.AZ4MR_[3N5^
MAKW*(M&ZAK6P U]"937-5N;XS*UC]=(UR!U3I'5=HEI;SQ^T",>R]:WYNMEL
M]I;CB#4ZW6]1UENU"^I)EM]BFQ1Y#2A8&2;W2Z+?%44<^1S,:Y3Z^L$:1;]B
MUW=VE3E3<<4M>B.<UQAY8$\DBBC'B1]R[]6L^ME^J';_ #WS-WJUW&GKYQZM
MY!LBO:,@\DBK0XHJ^N&7=#LD?<.?92"(+G%:M9W!3\I/,],P%IP &-YNB3=%
MF \,F?[GN>HZ:;H0M;N.X[R3J>#[ECAL5IXUGF!^+-7^VD$XV.2':MO6:D55
M>K[+L#W'LGZ&AT7^7$D?%)9*QCL 0E22!,MJL\'(:5U9'5?KO+SSO;IV!^DK
MT3><M5P"*=N<JF.]77&J%%QN%=MMGQJ51M$;-D,1.=$QAD0EL"DR&0H"!*@A
MTF7 UY]Z#O)N\FJ&3H[W5,:_3]M>IP2&3Y& FT:781DG6S7L13JK?U14;R&&
M\_J1:,G9U+Z":_3I6+4*Q[431O3-Z@1O9^<;QQ/_ /Q4E7P00-:'3U..MB>0
M>R+#KJW:5NXJEK-Y9KRENPHO5*EMK^=/ESRB),ULQ597!LG.:7AUJ ,C)*$L
M0+](SS5H "_C23 ZT3UKW+70T4)J2=I^3OU_(CF)Z2A0MR-6T4+R^Z#SM&:!
MGCVA!,_5F&1[CSD3BO\ BT_8R1+\6JW$BGDCJR.-B0,D<<V@ Z(_"73,-=,J
M'OSIFONQA\3]1O\ 75M&S"A'&_Z;O.OH@LK=Q=FZ)S!IADZA-B0 Q\D;4WO"
M!3($*QO7-RD*90F&8687HT.LAH_;]E5[-0AA[/JY*K, W*.:M<,Z12KL;26.
M:O)'(A)#!D=-#D,IVEL4XNM['DLG6]D\\.B.,D-F"*.<KX\/"\3DHYXNKJ58
M,"&R(R2]>R>C^F^G:8Y/FM/4K#./MP*/2"3V97[M9KU<%NS:&@GPHEMN2R2+
MD0>NF)C7H2%#B1M4Y*%*@8B=! 7X;Q:DUE^AL?E159($OVJL%;]OM^R"">26
M8;*%I7X0JJZ 0O(2& S5NQUJG:5>AE$BS3]?%;FG&CZDL2R)"D4?TD;A"[RE
MR .2HHV"V<\9+ZM=Q6/*.*"EG1%'<#Q*Z:1OU[M]]L. H+5:4U[T1<C;43K!
M(<[R"2Q4GXB>W IQ4HC!Z&>-,2#QWL>A>.U4AHW^[E%"9WZV7I^GOTH&4">=
M>S:<O&Q4GYPJB(>(T6/( !@,CEC-;H"[I[.VK?DO8=79E7D(E6G721)50[($
MA93\F\<^/^G9Z@^HW>]^4S5W+*'G^P8A$)Y?/6%$T"[6)):_)G;4@CEDHY$%
MZ?VV('/;.G$N$>VDG$!$IV L.]AWX^/CE=();WYQ4_'HMUJD\792,I'-U^SJ
M2V4CY'7]8_6QUYWOQK,Y+453\1N=[+JU/7KTRC*>"NUB[4JF30WXXSLZKOZZ
M&]9I%>WJ&]A\WQ+LBE)^NJ-_Z&YJ;^4K(K^Y(O#'-%#+*ISH.ZV>L5QLIK9Q
MD"SY,3UA/(<4II:9Q-1&>T)4$ZUH(@;FZH1]Q9ZEQ'Z4?\QJ]1=CY<@T=F#[
MF.2!R R\XMJP?D8Y%\<E8:X[O[GI*EN79EBE_&.Q[&I(0%*6* X2Q3("0ZAV
MCD0KQ#H_$Z93E?1_U-NHU7=,PI1EMBE[*5H.]1\U-W&Z*LU+5:B+GDF*Q]_D
MG0N[,;Y(IVF*@P7)4<?\8(2T"HM+LD.]'##K<7X<B]U#3-L^V*P.W:U,GQ%!
M:-FW#6+KY#B8PP1%20[M,&C'AM3?E<C=0D[5%X314^HDKJY!^]GO10-8@7Z%
M3&KR3*PVJ*G%SHC=J\I^H%85D=']1M]M]J4HC;J O/K2,(..&*H69):SW3]$
MB<CV>8?+<R9'/1B@AJ2#//,"W^S4;3[UX \V_#-H75B_\>Q_F-A&O3#I'N65
MB^ KR+/-$JG]PTZQQD!M>9E\Z&:UOK;-O\Q_]KT5^T#]A3KP-)M_>)ZM:9R-
MZU_)+(@*[XB(^"<V,YDEGJ%=?T_$>GTU[4M0<$OB"K);5U0ME(&6:\U]%).G
M-6UM)9+/7B=LX)3- MAB92YH"T2=K\QHBB]ZV'S[V^PZ>WT3GJ>SE63NE2(S
M,BZCBE(5Y(8@23(BAO49'(8L"Z@ @9F0=A3O3R3TXB.MBM31IR<EYHXI&A+O
MI0(RS(TB*@.E*J^SRS3JL^[^UZJY<ZTZNO.V:XOD5/7U8_)E55 PTNCJ=!(K
M5;+HC515U-I3-6^6R%Q2,CFXO&AN2$I.$)9)@A%FZ$ /C0ZYINYZ/\<7KHD'
MY!^4O66%G8^JK[)[,4O)1YE58X3*/*L67@/W[%V6M'!^0]W2LR,.I_'HYIIR
MH'LGBBH1V^*[V(W+R",'3#QLC6;(3KI/N'C^P:X@O1\XIBZFWI*M;Z/@LIK^
MMG2O%E/7I4E4NUJH(FJ9U,ID)4^K%_:F=600M.$D<RE*8.S_ , WPUG]S>CJ
M]7W=;KRW^3Z_I9^PJ3N!JPE:6&*=)H1\8W3[B*6,HY5E#QG; -DG549[LW6]
MC:58Z%CMZE*W &),/WG,0O#+Y,FGB:.4.HUS21"0&4:=<&>J+V5>,+E3FPOE
M2=TOS=P0MZ8?4-25^KK19472AA/FA?,3^)#(WUIE"J=Z J&4 DPIU2Z0"]H'
M03BMB^A_)JHZKJ.XM=:#+'1L4HZUG3,E@V%+7%]2CDQH1\)F,1(=9!$?Y? R
M_P ?9.RO]-'VD@JR7Y[:V:QT'KP0.$AL^T_%%L/N(+*/W'V#^-3OI]Z972<F
MZ9JV13":=,5I>4R3J8\&8U]#ZE=*6EW.\M7LP%DBJNP(3)WI=,REC2YB,*2*
MG1(B-5DD",#[4&]#R?L*52K K=>_W?7&:58KJL#'9C4@*P5=K&_]6CY<E#*'
M4$>:<%FW+<,5Z/[.\(%:2FP)>%R3O4C:,J :3V*"C.K%6T="DU717=O1LQ[!
ME?+,GHVLZPX[LF4U!%X;9,%>9L]]%V-742:)-.R)7)T<FCXZJAXU[P6V-AS>
ME6K-F &I.V(ORE[^5_R!Z_\ $4_.KRB>G+]W*M5=HPITYY8'E,WRW8F:"9HD
MXB-0$$GEBV?2?90V?RA/PN)GAM"&F9+) <+->02QHD6P#%%&\?M8MS9BP30
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M5[^O8$>HYH\ E _.(P\?CK*?'7XO6_&%\0P):4R#PTGW5F:R2X^A,9F*+_\
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MH[I^W^:6+I8#9KHV%0)IA4A03I<VQ<F%&RR'.LP9W-QJZ>O$42)T2YU0[/\
M> IBC-DZ.!HW(!5BFI2]-V'*?\>ELSSFN24T]I@]E%E73K!.^WEA'CD\AC:/
MF1G26'K2U;]("/N:=2"M',=N/36!%8/&QX-) "5BD\?'0</H9$9+Z82B+V-S
M[87)'1<@Y7WSOS:JY:B\=1UE#;;:7.M5DI9Y8H&XBG"HI4%^/<F(C9BH(A",
M%YQ[UYA[S8D[3L;'<]AVMIU>+LQ366(*%4+1,_I2,CRB!+#1@#Z*%\[&5_7
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M5KFP4@$$)HOA4"+T,SX1;SW\K<_EG3IU%@+"J]5'2+(/J(XO69 I\ MY;C]
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M[+%B!U>E[N M0K5ITY[XX""'WE0:'6M9H??6KG8VP',G9]BL#3* "\B4HS%
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M5%R*95/14@F;E%ZW^,_>C@JW*.,3=LS1@]#,WK>]9WUTLM>.6'KV8F&NL,C
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M\7IT[[H*0@0A)=%Z^'.;QBD@CZ.[Q2);"V!%XC+3PO&XF<+Q:61&2/D[\F(
M5R5.BHEUG_S-';R+ 8!(/FJ0R*ZF*/?)(XV!?2(%7>V Y#8DK_QCPG>T8D,Z
M<(3$9U#+.HJ%4M(9A'+.F 8O,:.K"1$RZ$M![_$YPD:7%%%7UM]N0\ -VX!
M$PH2O9(S"Q:%FY>IWY^SN,T5V;LZW:2,XX@W*XYU[7!@$4A6!TJB.5.'-755
MU#UK1I2I]?U9#4Z5*U0@5#SXU[2?;V:^_+/R5>!YEGC<$H4DV<E-P6!PA;M-
M&Q>[;2YGF5'3-R^2@ S.T:^.ACU(HV,EP"U-3ZJD9284KCAR4M2#W12%P1&E
MA-#L @Z%K-MQQV9H9K._N2WW$+ E'VI_WH64JPXEM>R,C7+6]'1GHB2C#+6I
M@BO%&()5UR4(Z\1%,K<@0ZC]D@/+6]$C>4Y .;_3*2T)>X(.;4$BH^VV-7 >
MA+.,OQYGYDE8$K=[H9%)QT ^63()FB1,K8[Z"G2CD!&FXM0'9(2M"#O<O9?+
MK(:?9:CZM[,=A ?XEEGCD4I,6''W2"2$#FQ=F*%&)'('OKYK$';_ 'W7DGMH
M860:',Q1.&Y(D9Y+%&P+'BJJGC8&U!$Q>N&^#+R=H!>RZ 16?AB45K!KB$P9
M;0FZN".L2I%]42FK?CUOCL[+@%BH(*^C,5(U#RF<]@'X^<8@Z\-6WLV^N[:Q
MW<Q,7:36C;E=P /N#7DK&P$8<(Y/MY7CYHJD(1H_%2,Y(*MWJ(>BB"R=9#7:
MJBJ=L(7DBE:#V*?8R&6&-S&SD<@3K;ORSR:)<'V!:C?T*QO]*/=F'1E[Y<33
MF&6NWIRG=HF:X;PXU"M01.7IHW(9 N<$(U"5*I3*'9,8 P2797X?C12HLU.W
M0C1FI=U6X3(-E;$5<.Q9 /H8DD?G-%Q<1GB[\  -![,RRUY'8B;I[!LQ[T#7
MEG"P\W_M)Q1567<9< JO,[S'H*%X.CT$I*ET>JX;X7QG;$!55#$C+@=]J*DN
M%O2.26O&ES5JIT-^<90J2RA1I&TOQZT2[2D._8&[T7O6B+]VWV\'>HQD[9H;
M%.*10#R0U_M[$**!P=UKIP?2F2,*6VK MD5@F&I>I6?A5M%+=D-\=AK:VTG8
MG1CC:TJNK*5C8C@-H>&> _A;@!]O!]F9E55ROMMHD;1<$LAR>9/VX\DF2U4<
MK8K:E=#)98&M=S!:M;C#4LB71_;@:<0(8%.Q WO5+K'/3PBQUI]4%5W1&'E:
MS.I=UA9MBJS)(798C&2K\B-'>2=B)>Q/K[ ,[VXQRV.+64C*IJ0KHV40JJ:D
M]B@@+_;/89SIP/T1'NL&U.V5?;D:Z66-#;U<5'[0<)0W2)TAK$E8&=._',$S
M4@KYWCS0TE:+VUB:5))J?1_CH\/M=4Y:E0='%7F4#HDNR7HV)(06&=))9EEW
MO]T:%@']84%>(1F!L)=NIW2V$8_YN.FM,#0YBN?8%B,>M$'W2 %E+GE^XZ75
M\P-SY^I6@X2.%S" 1'G6OH7'([#)2IGR!5 6B$LJ=)'8X6"P']]7)5Z$HLDE
M,6J4N!QAQGAH1@S-^.];MKUJ>\USN'U>G8,2X"%BZ\E(72CY+IEXCROD>/.9
M?74X8X36ZQ"T2/*2%V^F#L9=^205?GS!_800=:T)<R6_4TEA2VR8Y:%=O]=-
MJ94L<9\R3:-.L*0)$ -F+E2V4H7,]B2ID9>O,:,9X0EA^$6]:RI9_P"SC$MO
M^*)M:9_B#R("Z+:!Y$@#7U) 'DY- 19D,5;^25=["_(C0).P-D: )/Z $GZ9
M"4'57+[K&'V;-?2%"N4,BZUM;9-+4%P5ZLC$=<7GVOQ.@?7Y/(C&IH6NOL!^
M[%*#2S#_ ""\FA>&\]D4PQ1SS I!*Y1&/A7=0"RJ3X9E!!*C9 ()&LDCCDF=
MXXE9I(TYL "2J;US8#R%WXY'QOQO)Z5:M7GP05I$61 CJR A&Z#L8J81XR"!
M;2Q^S,<12X#CN/A0@,UY=G;4>ST+X-[\<\M?]EK[S^'>M<_COE^W7+7U_I^O
M],XK_P#>,5J?RL-["?(C0V=\=_0>3^@\G,_&)3&)LPMLIADC89=&'E/I6T2.
M,.[>_,+JEV(0-*6UW:E"MO7)]B#O7G*,$'QUOX<DEAE@?USJR/H'3 @Z(V#H
M_P!"""/U'G(XY8IEYQ,K+LC8((V#HCQ_4'P1_0YGLCR3&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,9QN_P!05_R;N]_S*+?Z\9<9TG[LZ,\L?W8N<OS#
MU!^KZ/8SP_4Y?&,\QC&,8QC&<-(?_P!PW<7_ $T8#^N<>,[/[!_QSN7C.,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,_S#T375_23JGUFY=0E=\QO
M#NR]!V8@8+(E9;\/I2'6N=R3%"((16QJ&'+V AN.D"]%H8E+RC."68?_ !>_
M$'FRF2W'_P"&1)![$:5^]6(UM^^4CLS[8Y">(UZQ((N!=O9Z]@>=:XEZ]O\
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MG1:IA8"UJ(2T *^:3&\_8C $; X;"(7X6M;SXZ]/M?RSK^G[")[/15B]^\J
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M\HM4Y'^9-2:I1EJ\R=AGKM%)5G'D&2LY/AAFSK0SSF*=CL_I_/:)_F$PYO\
M32[QB-%R%Q*&M=;5Y^N&(UXZ43[HK/\ $YU?XYI NBCCK7CYEC+H>][]J'*7
M?SW/R#\=_.[]A2_Y%%T-.E=51Y>Q2[9F%@*/J+=26O9T/I*\L?[E.4*$-;K.
MV_!36XQ]!:_(6OUMG2PK8ZMA8KDGZ"M;CG5//_TS0.=!LMV =*4+.ZK]"R&0
M^>L;[,>75R6SNA8BE*/+D-!0VE.5+ CED.UN-2@@E16?R=?E $/D==)#%)PO
M*1HS7PY]9^2=U1B_\C=K^<PNL_XS7_%^WD-E#N)ONXJ:58UD^ADG<%%C&W!!
MY*-9\_TW1]DO_CZG^%RQ&/\ )9/R;JHEKMXD+079GF<+]3'%'_(TH^'$@ACO
M->>'^C9; .M:=]0>WJ5Z K'7J"](V=5-EVK-X/MJI"24-=)[</A,31-3G8S8
M5<=4Q1$4E+/3% "E?U6@B#X:T91_%NKEZJ*O^"6P8NV[#J'FLQ2 )(>^ADFO
MLJ*"0[O3FLT] AF,$'@\3QW?RN[4[)KOY=UK_<=7U-^!:\J%6C3IQ%'UULNP
MUJ,7$AN@Z)+%][+@CKSZ6%\44Q6KWQ1[E;M8M5S23U(NE%[-5"J9QU)8CRG^
M+8PX"6((@8N+?5Q6T+<>=L99 M>R(&+>_ .]YC_C -S_ ,<]"E,&4UZEYI G
MR]:_Y6YLOK?$#FNR=#Y+^N2]\#7_ #WN;-@<()1U@1F\!R>NK* I/[CR^( _
MKXSG_P"H*Z-M.>KI9O<  '&.7"O-/(UKS ML!L]V54+/;5MBK;R1:2$B"<J)
M2Q>0$NV@"_!\S3XZ^'61?CMZ'\?K]WWTH!JV>ZCZRQ_^3;Z99*>_T([*&J@/
MU F;^F?1?D/53?D'3=#TU<#[]*78WJY)T!+1NU7E\_H])[:'7G94?38/-*PH
MEN.5EZI5GS@#*CL/J'AGCGKNS0RHX!2-$XWOVH\RF,-$F&=H\U,S1>O@,K8=
MK81A*+2#T'6_#PS<Z_K3^,]55_$G,//IO_(705YC*?X3<- SWGE(!(C:[+8Y
M'1/J'T.LQ^PMP=]?C_)ZHE]':?C'Y6U?TC<QHP)#4H^D$@%VJQ)+&-@&2;R?
M).=+^SY_"W;CCD*1IUWIB^[-'J6TP2X'TS-S'+CL)Y$0>QH]W5)!PMO7MKD8
M28+XP#\6*!%D;3;UYO,+RYDI]?YW^/S*/BU3NO$^EAY_9RAEKL.0)X\.)(7^
M8@'2Z;**+&_XAW=?;>T1]3LQ#=GA]]%Q,B^#PV&)\GX"70)\&^N_8M2=C<)\
M76"JA/'<@<G#N3DJ(FR+G!$P2^FA-R_HK:1^B\!E:^/M2Y?'URHXX#@E$02
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MU?Z;8:V/C4?YFZ53=8.="-J9'7*.DCZW0$TY&K//CB9.P!G1=CZ+,:43A_\
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MC&,8QC&?S>]!UL0MZUK6M[WO>_#6M:^'>][W\&M:UC'U\#ZY_ # 8 (RQ!&
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M1-FYC4SR"P)!=T5F$V4RU'7*E@C=:GR5656:Y\:VR6[9ERR.[/+0:<7!PD8
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M6*1>LERW<:F:IJ+ T.K6PO2:.O"*.*6J<.;"_/25"X(V,YQ5H%IOL%!99H1
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MXU"ZO72!,O3O%<P[G<\M:98$C)&K8;%AB9\>8+(9Q#4K,0N=53/&[0BSJPJ
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MC9VF.=6#>M>\^\' ",>@$A#N&@?L*;UDVSR]3%3=MZ#2U_9#!<XC0$\77N*
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M.^,S$:RI_3Q?37RIED@OA+)V*HW&IS8XU/-/LZQT9FBFI&4\1=NA#ZMF"TN
MN4@;TY:61N2)&)4\"!H>O=R]:(U:HS?:=A!V<BA[<2/R9=J9'DZ^>@^R>16
M"8S)732B4;=GWM:_=I_FJ%B@P6)9[KV-@$ZY]G%V9#+R"R2*\9@69P66%M*H
M8;/[4^G:L526-OBF[5K@W,QXV9SBRV/SAMCLBKE'9RBS(U&7AHA%SPMJ=I&Q
MJW)8F$[N2=Q3J-&%&?%Y>RA -BZH1=<T/L7VI'6ZY&V?W2]76^UJS(&YQH0B
MQ.ZF-R98^2NH;BOER)+!G:$O'[G[ @;!TO9S-/;1F 61D:1V"J)$"Q$QL')Y
MY:IO$[*8V:; V [@ &FK0IT!NF)N$(**S;.;[+4/GEVJT':IH4-^DA9'_P"6
M<6+SB%H6O#/59EZVKUY\_;?X33'ZM_A514V/Z?<<-O\ _F]_'>7?N-===ZX*
M.%RYVDY/_0>T6TK(!_40_=$J3Y?@.6MG58)O3B:$[K-=&6N^.$8?GR426(-C
MPGF[X\5Z[S6Q6VQI2%C,>;57UZ2V.*XI8C"6BB[<H"C5 T-0884,P^WU5U^L
MGJV H:2I]NBG9VT%9@8H79N;D )%R*,BEX@P0#2+0M5X;#<U4(S"0MKZ>V:N
MT$DJJ.(5GYNYY<R/8Z A3XN66<V31MD2RS:HL%N;Y^BG]G60UM4MBP':+NZF
M?5XV1 $0<#4;TV+VM$0ZQ]"JVYE;.."5HTO1 O,$0<NF)^MK"&KQ<_9W*QY>
M/C<[4=H9!K^L,FD"_215\E2VQ//%5NW6MW ^C=IV0%8#B:O6KUA7R#R$L'-A
MO7"1U/R5--Z+QYHE/0,"ILJ166?![<JYQ32DZ70H$V:8TY29U@;U!YHC$T0^
MQ8#+ODXY)9(K&E) _DC)&$G9NSP:&6.S=AJGLYIJ/(]?)!/6*R;)>O++#+I@
MK*O/G6A8\@ZZ#KQV0Z]4YW%,17$4S^V.92IT8I8^8'%B#L".62(G0+!N0XD
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MTR[D6,.?>R_["*[;A9)JU-TC()(+V+U.M-0A+1B4(D5PST;<K#8DDK;CB/L
MN7K3KJ44C<-<P6'22#Z-5JZL,F4)F3,S-ZV0,=E6<&#)U,)E;K:D8=W!]3$(
ME@A-S1') 8F\A9ZD110]:%GTY&LWFC4!ZPL)7(!U(DLD9<2!1R>2,"2%BW!(
MMI)'[>1<PR652'JWG)XW8ZMBQL@^MT@0-Q)/%$+,KKH2/*>:D1>$$VJ"7U#+
MKU!T\GU;G+T@-D:A&4_*VB'R5.T<T:#UI7=%#U;>A6HL6.FGN'3->H(VJU'1
ME.+(>8$)Z;S:!H5JT4[0UWG18Y(NJ<6?_39K_76;,T"#? R0RPIPW-^V8+.L
M0XRGB(LUJ=7AD!AK=ZP@8_S,>L29Z\H**^HGX*LRA23R7T,Y+*EBI.W;85"?
MV)?<O-D:;86"Q'!AOYVB#ONK>CSHDY-B=!!ZS:]VNF+:I(4!:(EP,;WB3CV9
MY-I$QPO:E%U+LGVU-NQBAD:S%7YK1V?N+6I)U$L#!21#+Z5CC CDD]LA)'K]
M+3WXZ,#2Q5ONHC'/.B/.  E3E!%(RR@MZV9#*7)>:!?7&1X/L,>+,Z]Z*/';
M[[%#8! T5;PBT+REL+L*/3N>2)7J%1"HG[ZLR'!7:3.D@ P:D2]&K4)41B)(
MIT XIM\^S]':CTXZW:U*1D6QUAMP5>2:5I/N>]O=?[UD^>U6&))(U;V%F/ 2
M)$J*N-%-8N]%6O1Q>CM+:J>,A/&%O\5#;X,@522)I.+G:'@I^)D8MGV>>I+H
MJQRO=9(.@Z6.:8]U"<WNC5*8TB#/J_J933L"EC6U02NG*[V!;/SEJ]S%H):5
M00N-\BE2B0K##=)2ZU..%X>FJRDRSS2689FC +//_E9ZT,4BAG:'E&%;GQD]
M$+0ET,2F9[MH<Z5R_ ICE6C7GA1M>M8VAY22ESP#\6!1%_C6>973V(WP6[.I
MI:N#TAS@Q"LF/P^+O5>SI_6-,PZ/M7F]FD+BDF%6)D)[<57#JVFSN4)$+H>!
M.SNFAI-EGCT+P\PO&M00#\CFAD\^N&+2!O8X)G<$I ?XI >(5G(V?BG[7(SJ
MV5?\0BMQZ#R=AQ+ZX;0T;+\6D'SB7D%?XG8*\OJ@.:HVMUG9)5F16>%V!2[O
M)H LZSTRT&A97PB<U03!RW2!-DHMY65-7)VD3&%A$%Y7!TSL8=Z&':,\]+O:
MO77X\YL!I972,W_Q^DTT[#^*F;G9]2TL<B ZYUF9JY+21M[(G]D<>V2/.[&!
M).YH42DBP0=[:2- P,EQ:_4]HT4L+/Q'&R$69 !(/58B^32*HEP#?UG,ZI?^
MJK'9Y_7/1:YHLN4N(I/5"24(X4\FQ7CCG]R1"30^/69*FAR)83EXCEQ)BYSU
MY2A")-1FB&,NS">='KJK@P1SU+NY7'-4+?DE*G]QQ?UC@D<[DG:,&!59_0[B
M73[!C-:ZU25FXI"GJB^$K**_Y'<]'(D*TSO"@3?.,H59H3.B&/>* ]$W=/\
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ML2  \A]G?NT])K9^:4O<5 ^ 8K\@G,J;3WFNQHG\%6O7FE._B(Y>OJ7G=]Z
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M%U!+ \0P\KNHG*U?3IB<)B=5N,XK=LB#\5#+68&CW^0&B=B&2QOEG"GMY>2
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MRXY83?9BB*I$T1*@4VA3BFLI=&9K%B)6CE11!I%;W13II2_1Q1Y(OC+;TWF
M.#L:,6R_ ='K5CI=A-9G!EIV)*<CQ[((DHM8:%E+<X@=V6)YP2,"J\64%U;N
MR[S5XEA8Q6X8K<:NNA\+J0),K$!9?_U= .$J JSAE+%'CC#IPXY*V26Q5!;*
M%-&)U"54-D:)SKM0[KP!2V],K:BZ]C6AL!N0(--BF<*T*\I2C7;<"RRC2C$8
MM#"9/TT[]7)1>?\ F-'_ !;*1\"\G7((V9C\@$G0>$4 PO\ +G*NDR*52P(@
MU&IM=M+H;.D[40;C'D'<!KIIR3[%+*54D,,5;G!#A8EA/%C,%SKXHXR%SL0I
M^8S6NQ2HZ\0RR6RL$;U&',%7W;3[^XJ"E-7IA!/4.!J TA4:4<@,& DXNCUU
M>.C4_P ?*JS4W=FD5@=,?OKUV/2DF,<1?FB?G'+STCCUCFCV+3BU8FM?))W,
M/ J=%/51KTG!.MMS-:.9"IC:(\D5B&8FYFWE-G:>>9%0""4#1(')Z<G]A?DC
M"1L,=7;E)$NC99K(XN3D4_HF)Q0IP'EJ5'BXDEB":(.S-BU;FL6I/\;.'WV'
M6RUYD=P2)):]DVE:1$,9"N_AUC=#K91D.N.=4H5J\?8567_L.PCGB=$^)2*Q
M6^U=(V?V?)8]^MG5]'CR5P#OQP?F.2M%F$W+.+.:9+8*^<;F$L^24 7P:&NA
M*&K%55L#.R1QSL*=NK'I UJMJ5*E4Z.ABL[\$.B"_*$/<4JP>M(P3$E2[$0Q
M!)>[:HV&D!55 6,4$C5.)9N9=Y20!EBZ)KZ0I,R@5[,$D?%0-1PPWHS&Q_<[
MR27GD,C-I%01)&%).>ASYE>72["[..L1MW%DMK1.X$$,-@RD]]2RB/U9,JK<
M$FYH9-_BX3*YMLH)4D%EL92E(<E&$1YX#P^PXZE_\77EA&WD<7PK \>(O&FS
M ^"6,;5#Q(*@K*5(^.VXMUTLVFMIM)9(:L<@^JL*DCR1E1H%22_SY%P6 9>.
MM9K\T^G,)GL%GE1=QK'.*B^1"F8P)U:K*2-#V[UW)Y7)XJ\,:2&WI#HBWJDB
MR1D[&%\9),7LU$$0-%A'LL-..#AU"=1L<(:?JA?6VBE;J(>IDE57+Q@/%"'"
M(B.H=X_:QXR+-86.R9'D7<DMV69_)"NC]I+V:1L%(8F-Y63GS"R$([1Z!C:S
M"N)$A<%:(5NP@"TU5+S;56G/4+3@$<FYXFJ"8E.@4FI%O1!<J-1;)]TT9L#>
M(S9FC#]Z\N]H=B5_*;/Y*$U]QV4=LQ _3UP6H1'SUY_^IY!^(UPX\?EM:UBM
M]Q##&Q^<->_%R(V6^^DAD+'S_H,(!&S[-[)77G[W%6W2MKP2D#BSZWBEIP[I
M)GL9Q5IV)1*H9&H"PO\ +=,9+DPN<R87.4NY<.6("'$;>ZMQIKB,XY)H@K02
M=4>N=Z_9T;_)8Y5Z>Q'8)!=/NK'7F*1(E5D81&RS+$S%BL84R<MG/.RC,]>S
M56/VP'LX6A ?UM]O#<1TE=B"ID]*>QX^/';>L;90YP[7PU[@PS0DZT='2Z:-
M<><5<C3P-(F:D=ELMW6+?:B4DQ8^2+RSH>X3.?[*U'S%>QE(D@0[<!G#T<7&
MH6L*8H@J.ODZ]H/8>7QZ^M]M&LWJ]',NA9BT?I",QX*!XRQ/&ERO)6N@%)QV
MBR^L!3P[(TR5BYB7AZ1350S^UI>1,I+<B\9>N"I3+[&9+DF%Z-QUFQVU&^\F
M@^*U../08BTVR,0^LDK@?%'6R96\K(GNGXH8RC:S7H1HESFH<]*]*"6\"*UU
M]@=;8@F@!(@AG@TQ'RANS2S=@GA0H:9FA6"3@6K"#9][S2NTE^2QV-"3KY65
M86"<2@*E36#O28D-N3TV9I[$PDY"P6B@_AKP^J3 -/IN[8YE\?)[?T^Q9SD$
M2E\JKZ6L-H*8H\2F!.YCM$7--'H?T!!H:,AM-2-PS"7EG??;*40C-#+";HHJ
ME4$E6K]KM)$2&58N:\^#S5#4D8JQ*E7!/)5"2&-GA$P'!X]#MNQE[2Z]T#TO
M*SK($\<H9++V&CY@!^8]LR([,RH61Q$2KB78B@:ENJE'-NA#A*X%*ZG$W2I[
M6B98K*(@GB+VI51E#":^J:)/EF6,HB5=L;2B<U"E.K<G(OVRD@I"%$24,H=W
M[A9XI([?M>6..(12NX>21FEL-,)FX+M(8OMHZY.Y3_(99'TH7&DA=)UGK>M4
ME=O;&J\(XU2*((T:@G<EB9II9VV%7B L>W+#6];Z8[*LM1GLG=ON!*9CO:5S
MYMBY<$:MI4U%3YO;W&>\QEKQ/FS-PZ8V:TD2)<XC*&:9L1R72;03MG!K].[=
M4*P):7TU987V2#.R6!8ZJ63Z_/J&&JQ71;2[*J.!M=Q)+VZ68Y&U'8>%QL*Y
MC8P25;X4E1\+]>5D=2-PMQDC8E5U/U?"SH,M(@16ZA+95#:[-DF0N-<'N2AT
M*4]-*.DFDQG4EV"WHV4Q$K6G,ZKWA*Y:6$;">#2<01%#OP=E+"L,+*&K0IU6
MAY#>WJZ\==7#>0$E5.? )RC<@B5@NC/).K+,474T\?91,2=KZNQ@DA8!= \X
MF=7#%BKJK1F,%PZ7,]<TZ=HA>D5+FQB(=U7"S6R)S+C^AF1L;035Q&F(*<+V
M3MWTH!6NO_5;,3;#I9X>RW[+^,JI/PK==7 \4)&;>_\ <Y=A8OZU_I\S^O?R
MV5]GU;B/8K(BGLSA=FS2EKG^WLI&GSWKY<00_'QL )R ^64_/N*)A.)A+%6K
MN:FFN)&Y7;)$\/U5 UTJ12F[*?,JEQ4+9Z.QTZ%QCT?,4&NB5$4QHU1I@_8&
MK1%AT+(J+"K7B@F42&L9/21M.*R]J>U?F-MS?V,\"L."+$5)C:12S<I/ZFL-
M&#NW+2EFY'9YTJT55/7H+P1XX8F8/[&]@<A^#A$_%K\M6.76S+%ZHD[.ME0^
MKZANT3[(HVF/:(NS1)=#B7HQ;'#I6U&R@E(@BPC?8IW% J.V?Y2A &7H8K-:
MPZ7*KAEC2!^S=BR\PWWTW96A'Q!5AIKP@YJV_A[? 8H/.L6O4K]NLS,7O=;'
M @  (DAI4J:'9#J0WVGN(9>(Y^OSH.?&CX<F+25/E3+=D=22"]6>2,/03BKI
MLQ<V2)MDL^GL].W4[*&STOU7+D!]F.Z,HUS42X!Q DYBHM0H(]J96<1R5TZM
M^?\ AE:O)QV/<9H-%G]W#CQE*@F+TE(M?]OZN4G/VU;L7"MF?@;\8F2,\2(Q
M'-6IU0K(I61FCCHUR'69 S>TNK<D]=<R?TMV%[?I2ZM%S/L<1.%FPV30MN(B
M"-:H@-8::9&UW?4;>ZG2$E0X)[T^7<@.5NNP$&-ABY-LM,?[@3YIJU@K)#)?
M5;""S9:PA552Q4D*25>O8!25K4[$,,Z#;-(R."4]K$5) Z4FJ46]+IU]>*N_
M%':O<A$4<G9+M=-9M5X8X)]Z#*'.]2,N2"+>G EC+V::.V#GJ,LDCV[UFU/+
M39;LZP!D77E!+L?XDD \WHZUEMH>%,$2MWF;(DS&E%ED&^(_9#*/\Z^U8J1Q
M&TYGMQS57:0Z#2BJ)PGL+<VY_P H(9'158.?6>:B.?L)!=>VD2)%0MU+41B
M^,;V*34D>/CP'")))6,<@D:3FH,H92[;(]'<U*;_ %C*(N=AA[877EMU?*46
MXN*0J7F+VRCBP5:AD5;DC*B8W]C<X>C/)-6)'A$>3LTDU(+SA,!%4EGHVVMU
MV7F9:4RAAL+/UUDVZC_4!H_<?YXR-RQ@(DD)VYYD6O/6-:=&96+*VG9 T,T4
ME>Q'M.,BN\,K"*9)%:!]2<9-!1$'?DR23Z'W\W6K;2)UG5\1&.0M5+*V@"RL
MV2)M4-3JAQI2UQM78$Y?USH!W7&J5IQS_K1X-A)3@2!UO8H9XD]""ERBMKV5
M>\7+NP,U66"2%556C:.("NB,$D$K;9O<&X%.O89&5+7\E1.MLT5&EY^FVLJS
M,Q96B:74I*'T")2!N)@6!U[EOIOS>80]\B[KT(R+A334@W/-R.NK=G;(^N;D
MAC36Q3E&US[JF3/*>RXLT1_W!*XN+H[MQ: 8"R&U.85LXRW7>O6OTK<48$=2
MY6M:''G[8+J6W];\2L:V%BCBE)CDE'%G24*YBRM?C/8=1=ZZ4_\ <VZ<U;VD
MN=12U9ZZHZ!P'CA>Q)8CC!C0R$\P_@B_V'DN4LB"/PG=JQY;54+O 5XPUB-J
MU25/$3NNGTAL9X87^= LC; _MAC[*5@$1Y<<1+4Q&B?;FJSBQG&HY]"FTZAI
MJ,"01E?B###4:G$'!Y$RB$H'D4H)&5F]:\SJ<E$KWJU9>,?8Q,)>1+ZE>6*>
M22/>B$:6,N(F+B,/ZXF2*.-%D:SF%V2PN.-<1L1O:)S"+SLN\H?*'^"BDT9)
M=+*G4\E;BP22$IIA'5SVW)&N?*$.CTKTV*Q'% 5 &3O8B<K+[(9.MF@XB7K^
MK2C\@Q5XUII3=]*R%&8()%')U4_!A(N<2QP6(K=>93]O:MQ6-+Q4K)#(DJ#9
M1@5Y)\]*K,"=,K -F1I7F@VHY*9+5,ZW*'AV8[#!*"@QO;(SN4QM"UG.VY3(
M&=MW('<3$Q!>W<Y.C:QG+#24WE]HM.,T(8YV=5IST(%_[>2IUM=/9IRJ]=%=
MB4R!1&LAF^\+,$6)$X<44*X"1V%FN=E7[2TR_<0_=["($4K8'7HBJ-DKZ8NO
MC3FQD>9G,DC%P2]&#XEM%&C6G1>^(%$'<IXFAL28F>B)(=3\(CL_@;G#),W1
MZM7/H!<Z-KTXKG +N8H1OZ-J$X%;%MK\3U&S:ZIQKFNS,XDI3U)68[8032T9
MA' W@QK$]!> E^XXK-*B\5$(BLAU'9P]EQ4-7NP6T10%5[$(NHTEC0W(TL-Y
MHV,?I.X8').I%D_D=X3E[$(<?579&'^M%,BHZ<N,6=:3#\HG":T17<-B#"<?
M+DEG)D HE(I!!$#HYMHF<2H2?9R A<049HP%ZQ;]XUZX^,4O:/ K LB_Y1+,
M3K,I.YDBBMS*O%H7=_6SN45HWIK7XV)K*LRRV?M1,5^I6M,DP]7+D(F=HU7D
M0ZHNV1!.?</R7PQ/-Q(J,G7K&TY9D,O.MSFIIJ.2)H-&Z_NECA3;\F:QB[Q>
M+^\0E%$'*#IE20A4\/#?HL\Y.2E2@V6(N.28R1/"[22":.$2O(W.9VK3S35S
M[.*_&,3M$P=9)714_F!&SI=;97KNRA[..-!+!=AG1$'"(!$X3J4&SSL$F3FK
M*J2,S>IP>.3YZY3L8$J>)9"+HBS M^LPZT(D1)ZA=9B0S.SY6(ZQE[7(-(;=
MB&Y(T+D)296V:2_%!S:>2()YB\LSR@H/ 9&DD+:EEBOP$@?2M>G@LLJ@[_GB
MF@'&9N431L4-;D/9E%8S]I2IRGE#2@ZX)KQRFZ^*Q761_K_%+#9D#Q+Q<2!'
M$_$&,QEAX<>V=JAD;57(F=XXRP+GJ*2LM171R1]DKWS\H/$AD#*Z(; (:XD@
ME:5<H"J0;;G :<X8#"56@@V4/N_6J]C9E>9"M)II6CC1B"BS]98ZV5&D8,7^
M$R21L A1HV#^SF&CMV[EVS&0K(DS36)6/$L"TW<0=NNE+:'KDA:$\BW-'#?
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M'S'E&:8W^Y&*P.",W>A[."  ]:#E6*>>O)2FA*^RI[A\AR$BSBRK ^05T+)
M*MR^.P1OQO2]@LT_832(VK_6I4\,-Q\*4%-9 65E;_8$G!EU\O620.1H9W].
M!Q?)(LE[K=NEKM/=OP+R828S9T7KJPTK[8KY8)B!CAM=]"0<]A1)AR5:AT6^
MN$M"<0(L9VC# F;.EHV?L+<3Q<S1B>M)P9N3^^NSO[@Y4Q*S._-%]!6%E!C
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ML71JGJAY2J)C(&(C*\'N]S .L[+LQ$I?KJ$O;1JA;4KMU\\<,>W$;*/:&=Y
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M/=%!LB5R$M,->E(\I@=&*,O=3%!VEVH23%1LUNN=E)W)%]] TSR^PJL<D4!
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MK*2RQ@L(R [,\DD"#K>VC51&]*[&5*2F?PW94ZXC$[ &2,1RR?0+LR%'Y>I
MO452Y,ZEJ=E.WE(0W(R7$AS=$SDG)+:?<RC-.!A[@$WV;>>V@T(0Q#$'9.P^
M(O#PSYJVT(I/-/)ZJAB8F3EQ 31!</\ 0<='Y;\$'],XK\S95(5$DZR <-<M
MMX(0K]23L?'ZD'^^<:XK/7%P0G*H9T/8JWEFU^B*O@4<GKY<KA+9ZD@R."6
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M7GUK?-FTM".:[8+()-^UM,6DXD$\] L_$H"=[UP!.N/CF&O]P8JT2J0IW&/
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M''QE=!L*"Y8J[*/&V)<[^OR)_P!6S)/OA%>L>5>0UXW/GY*I8Q _4<5C\KX
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MG$8K;N+,C.WW"_*2+?8=Q:,:[T[+.G80M(1+&!)'('274;C%N53),\U=4^V
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M!1'QT[?N:@1A*TDP8@9ESTU::P89#NWUYKB0KIJLGO5Q-'H\VY(HY>J2M("
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M-6$?A6UVHKARWGBH*D=#Z6IVGU\1K9D02>$FN3ZV.O3@B[-AL[-BW0[:?6Z
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MKKBX.>FRT'Z<L\6FU=K[6Z](@ F]=.WBP&]UKZS7D:$N1E""]%'PPH2L:,A
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MU5R7'M /)D =2.:ZF+#U=<R9Z0BD#54[E$HE8M74=8"1K/E".PI5.;$8(BZ
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M=F5W*+N9GE>LG08&RU]$DD1.6PYP="W72AVGJ\R:IS"UA&R$)*-"J/$G'K0
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M.##'Q,KN9X$)?9$"/.,!Y/PA;W[3L26S/=@9A)(98I6)(:05!4C97/U=56Q
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M80KD3XQR>0*B8NQEJ'V2QE(V((W(7D\"$)KF^1Y RHR$*L_8U"0E(2 H8 E
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M8K(I56JE AAM>-,?21=Q?V.LGAI=)FPL</>']8?*YPXJ2@.!YX@KW$U$0:,
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M%V87^KAK&Y8K/$#U=@T8S#S6(&I!)W8LPAU$:Q?]G?ACB*!-$D1A/6HS.O\
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M8RFEF"29JZ,#,BHQ']>,@)1O[JX!XL-JVCHG1R&W%VYR;S^X2YIN:^(!7KK
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M:\*^C3324L9H'::IU>RB-PZ;2)G:Y P1%>G\HE2F2O3*]I%*5$F >I/*/#L
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MQY 4O6-\7B+4S.BQD=ESI*7=$WQW2=M=T!R<_9:H?LS2]A%X;RF)8SU*]YR
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M^LD<<L;,H\Z=?UR>RK4Z\UNR"E:"D+DC'Z)5:<U1.WZ1FP##R_ZQK,#9/?\
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MGQ4EZ[\>GZ&*1+;U^MZ=(G<,L5J6GW-GLYZO$@O'52.1*\1D'E&_8-%,V?\
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M(S5H=STPNL+HR9V2:_C#939U99$-DUC0Z*H673Z%(I@AC$PDLZL[3<,]/('
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M*.8("#\1(&922K%3Q;1T09[MBIU_X[+WDH>0KV'7UE"E0-7K'V_,[!WPVK@
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MUB@0%8]A,*UHL0<C_)KE?H.F/:HAD:.E[67VHW.3;:4%1_"#\05DVR>78\2
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M]CWO><]U*>]I34^UTXF]R3/^V61K')I/9(-,7(9BNSM5_;H#(>JKIU$\4_6
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M7GEK"]"-5:$.QU+I6_-QV$W". _B]LA_<)!]VD-*.H>?(A+($3>B+8DA"^I
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MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG&[_4%?\
M)N[W_,HM_KQEQG2?NSHSRQ_=BYR_,/4'ZOH]C/#]3E\8SS&,8QC&,9PTA_\
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M?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\
M]]^F/V)SOWG,8VOZ?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._
M><QC:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?4[W_ /??IC]B<[]YS&-K^G_/
M'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?4[W_ /??
MIC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\ ]]^F/V)SOWG,
M8VOZ?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3
MO?\ ]]^F/V)SOWG,8VOZ?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_
M8G._><QC:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?4[W_ /??IC]B<[]YS&-K
M^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?4[W_
M /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\ ]]^F/V)S
MOWG,8VOZ?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_
MSQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#W
MWZ8_8G._><QC:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?4[W_ /??IC]B<[]Y
MS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?
M4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\ ]]^F
M/V)SOWG,8VOZ?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC
M:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]
M_P#WWZ8_8G._><QC:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ?\\?4[W_ /??IC]B
M<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\ ]]^F/V)SOWG,8VOZ
M?\\?4[W_ /??IC]B<[]YS&-K^G_/'U.]_P#WWZ8_8G._><QC:_I_SQ]3O?\
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M0O%(S1QC[B'9YY'6*F[*-$P40+."S!3+-9["U);(VQ5)8J_J:&(<XU,K-PF
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MG[>DZQ<F$#U'I54EB+@DU%AG]PGY#G(L:,DT<[2O9[:"Z&IBMH_!VJYKR@<
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M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&:9=W?_ +&J\_\
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M.,<?[C'VO[._R]>X/Y/D/][G&./]QC[7]G?Y>O<'\GR'^]SC''^XQ]K^SO\
M+U[@_D^0_P![G&./]QC[7]G?Y>O<'\GR'^]SC''^XQ]K^SO\O7N#^3Y#_>YQ
MCC_<8^U_9W^7KW!_)\A_O<XQQ_N,?:_L[_+U[@_D^0_WN<8X_P!QC[7]G?Y>
MO<'\GR'^]SC''^XQ]K^SO\O7N#^3Y#_>YQCC_<8^U_9W^7KW!_)\A_O<XQQ_
MN,?:_L[_ "]>X/Y/D/\ >YQCC_<8^U_9W^7KW!_)\A_O<XQQ_N,?:_L[_+U[
M@_D^0_WN<8X_W&/M?V=_EZ]P?R?(?[W.,<?[C'VO[._R]>X/Y/D/][G&./\
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MM].\?3UUE]@G<P(H=&XE475=-VQ.'E[/B_3$LD>R6^&PI>844B;%JE0H"64
MO>Q^.F>@ >=CZ9U%QG&,8QC&,8QC&<;O]05_R;N]_P RBW^O&7&=)^[.C/+'
M]V+G+\P]0?J^CV,\/U.7QC/,8QC&,8QG#2'_ /<-W%_TT8#^N<>,[/[!_P <
M[EXSC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC(S-'TZ,1"4R1,D$O4,$>
M>'@A$'6][5'-K>H6%)_ .]"\#1DZUOP^'PWE'L[3TNOFMQCD\<98#]2!EJC
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M99+4F<5Q0U^ER4\A2H+V< KB$&Q]OP5E>Q]N_$D?QI/0>XD1;P&L2/') B@
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M3X9D9E174'R59W158>"S*H.V /J?RJ[Q?)(WX.1Y"OHMQ8C]K<5+<3HZ!.M
MY4'6/<M'\E52JLN42)AF#B-'$G:,UO%YK""9].F&6R]@B*>0PQF>W]M'(&1
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MEZ)Z'=VNBF!^YKSI$IT0)B]6O:W"#IG"K85&T/#JW]-$[(0NRZXLAD5R:N[
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MHJM_Z"XQZW_3'^X%])[[SN_T56_]!<8];_IC_<"^D]]YW?Z*K?\ H+C'K?\
M3'^X%])[[SN_T56_]!<8];_IC_<"^D]]YW?Z*K?^@N,>M_TQ_N!?2>^\[O\
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88QC&,8QC&,8QC&,8QC&,8QC&,8QC&?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
